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Abstract 
This Thesis describes the development of novel catalytic dearomatisation methodologies of 
indolyl and pyridyl systems for the synthesis of spirocyclic and annulated products. Chapter  1 
provides an introduction to this area of research and reviews related reactions, as well as 
setting out the research objectives. 
Chapter 2 describes the cyclisation of indole-alkyne systems I, using Ag(I) or Au(I) catalysis, 
to selectively form either spirocyclic indolenines III or carbazoles IV in high yield through a 
common vinyl metal intermediate II. An efficient and reusable heterogeneous catalyst system 
was also found for the synthesis of indolenines III. A high-yielding asymmetric 
spirocyclisation methodology was later developed by using the silver salt of a BINOL-derived 
chiral phosphoric acid V to furnish spirocycles in up to 89:11 er. Finally, these methodologies 
were applied in brief studies towards the natural product spirobacillene B VI and in an 
accidental synthesis of actinopolymorphol B VII.  
 
Chapter 3 details the cyclisation of indole α-diazocarbonyls VIII, using Rh(II)-, Pd(II)-, 
Cu(II)- and SiO2-based catalysts to selectively form 6 different products, namely spirocyclic 
indolenines IX, oxindoles X and XI, as well as annulated indole isomers XII, XIII and XIV. 
This work is, to the best of our knowledge, a record number products prepared through 
catalyst-selective synthesis. A number of diverse mechanistic pathways were proposed in this 
work, including a surprising reaction involving atmospheric oxygen. 
Abstract 
 
 
III 
 
Finally, Chapter 4 describes the cyclisation of pyridine-, pyrazine- and isoquinoline-ynones 
XV to generate annulated products XVII, which are presumed to form via a vinyl silver 
species such as XVI. This work ultimately led to a high-yielding 5 step dearomative synthesis 
of the alkaloid (±)-lasubine II XVIII. 
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Chapter 1. Introduction  
1.1 Dearomatisation reactions 
Dearomatisation reactions are important transformations that provide access to high value 
spiro-, bridged- and fused-compounds from relatively simple and inexpensive aromatic 
precursors.
1–4
 The more complex three-dimensional structures typically obtained from these 
reactions are often found in a number of natural product systems, further extending their 
synthetic value.
5
 A prominent early example demonstrating the synthetic power of 
dearomatisation reactions can be found in Woodward and co-workers‟ seminal total synthesis 
of strychnine 3 (Scheme 1).
6,7
 In this work, indole 1 was dearomatised in a Pictet–Spengler 
type spirocyclisation process to afford spirocyclic indolenine 2 in good yield, which was 
subsequently elaborated to produce strychnine 3. 
 
Scheme 1. The dearomatisation of indole 1 in the total synthesis of strychnine 3. 
Following this pioneering work, dearomatisation reactions have been employed in a number 
of natural product syntheses.
5
 However, perhaps the greatest advancement in this area has 
come with the development of new catalytic asymmetric dearomatisation (CADA) reactions.
8–
10
 A number of CADA reaction strategies have been developed, with arguably the leading 
work in this area performed by You and co-workers, who have used an intramolecular allylic 
alkylation approach to great effect (Scheme 2).
11
 In this approach allylic carbonates are 
tethered to aromatic systems (such as phenols 4, indoles 7 or pyridines 10) and then reacted 
with a chiral catalyst (usually an iridium complex) to form a highly electrophilic π-allyl 
species, which is then nucleophilically attacked by the aromatic system to form the 
dearomatised product in typically high yield and with excellent enantioselectivity.
12–14
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Scheme 2. CADA reactions through an intramolecular allylic alkylation approach. 
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1.2 Spirobacillenes A & B 
1.2.1 Isolation and previous syntheses 
The Taylor group became interested in dearomatisation reactions following the reported 
isolation of two unusual natural products, spirobacillenes A 12 & B 13 (Scheme 4).
15
 Both 
natural products were isolated from a culture of Lysinibacillus fusiformis KMC003, which 
was obtained from acidic coal-mine drainage; a somewhat unusual source of natural 
products!
15
 Biosynthetically, both spirobacillene A 12 & B 13 were proposed to be derived 
from a common intermediate, diketone 14, which was also isolated from the same culture. 
Diketone 14 was presumed to form either spirobacillene A 12 or spirobacillene B 13 
following oxidation and the dearomative spirocyclisation of either the phenol or indole ring, 
respectively. 
 
Scheme 3. Spirobacillenes A & B and their proposed biosynthetic precursor. 
Mechanistically, it was proposed by Tang and co-workers that both natural products were 
formed by two aromatic-enol oxidative coupling processes (Scheme 4).
16
 Here, spirobacillene 
A 12 was proposed to form via an electrophilic oxidative dearomatisation reaction, in which 
the enol of 14 nucleophilically attacks the activated phenol ring 15 (Scheme 4, path a). 
Conversely, spirobacillene B 13 was proposed to form via a nucleophilic dearomatisation 
reaction, in which the indole ring of 17 nucleophilically attacks the activated enol tautomer of 
16 (Scheme 4, path b).  
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Scheme 4. Proposed biosynthetic pathways. 
Tang and co-workers successfully applied a biomimetic strategy to complete the total 
synthesis of both spirobacillene A 12 and B 13.
16
 The synthesis of spirobacillene A 12 began 
with Weinreb amide 19, which was prepared in 6 steps from indole 18 according to literature 
methods (Scheme 5). The α-keto hydroxyl group of amide 19 was then protected with a TES 
group before reaction with benzyl Grignard 20 to form indole 21. Subsequent cleavage of the 
TES protecting group and oxidation with DMP afforded diketone 22, which gradually formed 
the enol tautomer 23 following column chromatography. The proposed biosynthetic precursor 
14 was then prepared in good yield following cleavage of the TBS protecting group with 
TBAF. Finally, diketone 14 was reacted with an excess of Ag2O to form spirobacillene A 12 
in modest yield and in 12 overall steps.  
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Scheme 5. Tang and co-workers‟ synthesis of spirobacillene A 12. 
For the synthesis of spirobacillene B 13, Tang and co-workers reacted benzyl ketone 21 with 
LHMDS, followed by iodine to promote the formation of spirocyclic indolenine 24 (Scheme 
6). Interestingly, indolenine 24 appeared to be unstable and formed only spirocyclic oxindole 
26 (with ambiguous stereochemistry) upon quenching the reaction with sat. aq. Na2S2O3. 
Mechanistically, oxindole 26 was proposed to form via the Kornblum–DeLaMare 
rearrangement of an intermediate endoperoxide 25 formed by an autoxidation process. 
Fortunately, this reaction pathway could be supressed by treating the unstable indolenine 24 
with PPTS, which promoted both the deprotection and autoxidation of the TES-protected 
hydroxyl group to form a low-yielding mixture of spirobacillene B 13 and the TBS-protected 
analogue 27. Finally, the TBS-protected analogue 27 was also converted into spirobacillene B 
13 by cleavage of the TBS protecting group by reaction with TBAF. 
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Scheme 6. Tang and co-workers synthesis‟ of spirobacillene B 13. 
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1.2.2 Taylor group synthesis and methodology 
In contrast to the biomimetic approach to spirobacillenes A 12 & B 13 employed by Tang and 
co-workers, the Taylor group devised an alternative strategy, which focused on using ynones 
28 and 30 as precursors to spirocyclic enones 29 and 31, respectively (Scheme 8).
17
 
Subsequent oxidation of the enone framework was envisaged to provide access to the desired 
natural products in a concise and high-yielding fashion. 
 
Scheme 7. Alternative retrosynthetic analysis of spirobacillene A 12 and spirobacillene B 13.  
Unsworth, Taylor and co-workers succesfully applied this strategy in the total synthesis of 
spirobacillene A 12 (Scheme 8).
17
 The synthesis began with the preparation of alkyne 34 from 
indole 32 in 4 steps according to literature methods. Alkyne 34 was then deprotonated with n-
BuLi and reacted with Weinreb amide 35 to afford the anisole-based spirocyclisation 
precursor 36, which upon reaction with SnCl2·H2O, afforded the desired spirocycle 37 in 
excellent yield. Unfortunately, selective oxidation of this framework proved difficult and 
could only be achieved by first reducing the cyclopentenone moiety under Luche conditions to 
form allylic alcohol 38; allylic alcohol 38 was then epoxidised with m-CPBA and re-oxidised 
with DMP to form α-keto epoxide 39, which upon reaction with TsOH and then TFA afforded 
spirobacillene 12 in just 11 steps and 14% overall yield. 
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Scheme 8. Unsworth, Taylor and co-workers synthesis of spirobacillene A 12. 
Unsworth, Taylor and co-workers also conducted preliminary studies towards spirobacillene 
B 13 by applying the same strategy. Unfortunately, when model ynone 40 was reacted under 
the same SnCl2·H2O-mediated conditions the desired spirocyclic indolenine 41 was obtained 
in only 40% yield, confirming the viability of this approach, but suggesting that improved 
spirocyclisation conditions were needed. 
 
Scheme 9. Preliminary SnCl2·H2O-mediated spirocyclisation of indole-ynone 40. 
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1.3 Spirocyclic indolenine synthesis via indole-alkyne spirocyclisation  
At the time this research commenced, only a few indole-alkyne systems had ever been used to 
prepare spirocyclic indolenines, which were typically formed in low yield upon reaction with 
a gold catalyst. Inspiration for the majority of reactions of this type came from the pioneering 
work of Echavarren and co-workers in 2007 (Scheme 10).
18
 In this work the authors describe 
a single spirocyclisation reaction, in which 2-methyl substituted indole-alkyne 42 was reacted 
with gold catalyst 43 to form indoline 44 (Scheme 10a). Interestingly, when the analogous 
indole 45 (without a substituent on the indole C2-position) was reacted with the same catalyst 
43 only the annulated indole 46 was formed (Scheme 10b). From these results it was 
hypothesised that all reactions of this type may proceed via a spirocyclic vinyl gold 
intermediate (48, Scheme 11) but rapidly undergo a 1,2-migration process in the absence of a 
steric blocking group at the indole C2-position. The 1,2-migration was proposed to proceed 
either directly (48 → 50) or via a cyclopropanation-ring-opening sequence (48 → 49 → 50).  
 
Scheme 10. The first Au(I)-catalysed cyclisations of indole-alkynes. 
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Scheme 11. Proposed mechanism for the formation of annulated indoles. 
Later, in 2012, Van der Eycken and co-workers reported the first synthesis of a spirocyclic 
indolenine using this approach.
19
 Again, a Au(I) catalyst was used with alkyne 53 to form a 
low yielding mixture of spirocyclic indolenine 54 and annulated indole 55 (Scheme 12). In 
agreement with Echavarren and co-workers, the authors suggest that this is further evidence of 
a 1,2-migration process. Next, Carbery and co-workers reported a single example of 
spirocyclic indolenine synthesis when indole-ynone 56 was reacted with AuCl3 to form 
another low yielding mixture of spirocyclic indolenine 57 and annulated indole 58.
20
 
However, it is important to note that both of these reactions were only performed as part of 
mechanistic studies in the synthesis of other annulated indoles. Finally, a recent report by 
Wang and co-workers described the first high yielding Au(I)-catalysed approach to form 
tetracyclic spirocyclic indolenines 60.
21
 However, as the substrates 59 are substituted on the 2-
position the synthetic challenge is somewhat diminished as this substitution inhibits the 
problematic 1,2-migration pathway (as demonstrated by Echavarren and co-workers, Scheme 
10). 
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Scheme 12. Au(I/III)-catalysed synthesis of spirocyclic indolenines. 
Finally, the only example to not use a Au-based catalyst was reported by Toste and co-
workers, who instead utilised a chiral Pd(II)-catalyst in their studies towards the synthesis of 
the kopsifoline (Scheme 13).
22
 Here, indole-alkyne 61 was reacted with a Pd(II)-complex to 
afford the spirocycle 63 in only moderate yield but with promising enantioselectivity.  
 
Scheme 13. Pd(II)-catalysed synthesis of a spirocyclic indolenine.  
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1.4 Spirocyclic indolenines 
Aside from their presence in natural products, spirocyclic indolenines are also potentially 
valuable compounds for drug discovery when considering the dominant presence of N-
heterocycles in small-molecule drugs and the rising interest in spirocyclic scaffolds.
23–28
 
Interest in spirocycles stems from their ability to occupy areas of 3D chemical space, which 
are typically under-represented in medicinal chemistry drug discovery programs and screening 
libraries.
29–32
 The exploration of new chemical space in drug discovery is important to help 
find new lead compounds and also to ensure their commercial viability.
33–35
 Drugs containing 
spirocyclic heterocycles have also been shown to exhibit enhanced physicochemical and 
pharmaco-kinetic properties.
25
 Considering all of this, the synthesis of novel spirocyclic 
heterocycles is an area of interest at all levels of drug discovery.  
Indolenines 64 are also highly reactive and useful intermediates that can be converted into a 
range of other privileged scaffolds such as indolines 65, oxindoles 66, carbazoles 67 and 
polycycles 68 (Figure 1).
23,36
 However, their inherent reactivity also provides some substrate 
specific synthetic challenges with regards to their isolation and handling (Figure 2). 
Spirocyclic indolenines are known for their sensitivity to acids due to their well-documented 
propensity to undergo 1,2-migrations (69 → 70 → 71), a process driven by the reformation of 
the aromatic indole ring.
37–39
 Another complication lies in their tendency to exist  in 
equilibrium between the imine 72 and imine trimer 73, which can hamper their 
characterisation and further manipulation.
40–45
 The equilibrium between imine and imine 
trimer can be manipulated to favour the free imine/iminium species 74 by employing acidic 
conditions;
43
 however, this solution may subsequently promote the aforementioned 1,2-
migrations. Overall, these properties have most likely hindered the development of new 
strategies for the synthesis of spirocyclic indolenines, an area of synthesis we have 
comprehensively reviewed (see Appendix I).
46
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Figure 1. Synthetic utility of spirocyclic indolenines. 
 
 
Figure 2. Reactivity of spirocyclic indolenines: a) 1,2-Migrations; b) Imine trimer formation. 
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1.5 Project aims 
The initial goal of this project was to improve upon the preliminary SnCl2·2H2O-mediated 
spirocyclisation of an indole-alkyne system and to extend this work into a general 
methodology for the synthesis of spirocyclic indolenines (Scheme 14a). Full scoping studies 
of this methodology and the development of an enantioselective variant were also planned. If 
successful, this work was envisaged to potentially enable the total synthesis of spirobacillene 
B 13. Following these initial goals, the development of other novel catalytic methods for the 
synthesis of spirocyclic indolenines was planned by pairing indole with other electrophilic 
systems (Scheme 14b). Furthermore, the application of these dearomative methods to other 
heterocyclic systems, such as pyridine, was planned (Scheme 14c). 
 
Scheme 14. Project aims overview. 
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Chapter 2. Indole-alkyne cyclisations 
2.1 Indole-ynone cyclisations 
2.1.1 Reaction discovery & optimisation studies 
Studies towards the synthesis of spirobacillene B 13 began with the preparation of PMP-based 
model substrate 83a, which was prepared in a two-step sequence from 3-indoleacetic acid 80a 
(Scheme 15). Acid 80a was converted into Weinreb amide 81a in quantitative yield using 
propyl phosphonic anhydride (T3P) as an activating agent.
47,48
 Amide 81a was then reacted 
with the lithium acetylide generated from the reaction of n-BuLi with alkyne 82 to afford 
ynone 83a in excellent yield. 
 
Scheme 15. Two step synthesis of model ynone 83a. 
Ynone 83a was then reacted with a variety of potential catalysts in an attempt to improve 
upon the preliminary SnCl2·H2O-catalyzed spirocyclisation conditions; dichloromethane was 
retained as the solvent due its compatibility with a wide range of acids and metal catalysts 
(Table 1). These experiments were carried out on a small scale (0.1–0.2 mmol of ynone 83a) 
and examined by analysis of the 
1
H NMR spectra of the unpurified reaction mixtures.  
First, a number of strong Brønsted acid catalysts were examined (entries 1–3), which 
promoted varying levels of conversion into the desired spirocycle 84a. Next, Lewis acids, 
such as BF3·OEt2, SnCl2·2H2O and in particular anhydrous SnCl4 were also identified as 
effective catalysts (entries 4–12). Investigations into π-acid catalysts (entries 14–20) began 
with Ph3PAuCl, which without an activating silver co-catalyst displayed minimal reactivity 
(entry 14); the combination of AgOTf and Ph3PAuCl promoted a dramatically different 
reaction profile, affording primarily carbazole 85a (entry 14). Investigating common copper 
catalysts used in related reactions (entries 15–17) revealed Cu(OTf)2 as a comparable catalyst 
to SnCl4. Finally, Ag(I) catalysts, AgOTf and AgNO3 were examined, which again promoted 
full conversion into the spirocycle. Following these results, the more easily handled Ag(I) and 
Cu(II) catalysts were examined further at reduced catalyst loading (1 mol%, entries 20–23). 
After 30 minutes, it was evident that the Ag(I) catalysts, particularly AgOTf, were most 
effective. The potency of AgOTf was demonstrated further when the catalyst loading was 
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dropped to just 0.1 mol%, which still promoted 85% conversion into spirocycle 84a after a 
prolonged reaction time (entry 23).  
 
Entry Catalyst (mol%)
a
 Time (h) Ratio 83a:84a:85a
b
 
1 aq. 12 M HCl (10) 24 82:18:0 
2 TFA (10) 24 40:60:0 
3 TfOH (10) 24 10:90:0 
4 AlCl3 (10) 24 91:9:0 
5 PdCl2PPh3 (10) 24 84:16:0 
6 Sc(OTf)3 (10) 24 69:31:0 
7 Yb(OTf)3 (10) 24 54:46:0 
8 ZnCl2 (10) 24 45:55:0 
9 FeCl3 (10) 24 40:60:0 
10 BF3·OEt2 (10) 24 10:90:0 
11 SnCl2·2H2O (10) 24 9:91:0 
12 SnCl4 (10) 24 0:100:0 
13 Ph3PAuCl (10) 24 88:12:0 
14 Ph3PAuCl/AgOTf (10) 24 0:17:83 
15 CuCl (10) 24 52:48:0 
16 Cu(OAc)2 (10) 24 99:1:0 
17 Cu(OTf)2 (10) 24 0:100:0 
18 AgOTf (10) 24 0:100:0 
19 AgNO3 (10) 24 0:100:0 
20 Cu(OTf)2 (1) 0.5 63:37:0 
21 AgNO3 (1) 0.5 7:93:0 
22 AgOTf (1) 0.5 0:100:0 
23 AgOTf (0.1) 120 15:85:0 
a
All reactions performed with 0.1–0.3 mmol of ynone at RT; 
b
Calculated by  
1
H NMR spectroscopic analysis of the unpurified reaction mixture. 
Table 1. Acid catalyst optimisation results. 
Solvent screening studies were also carried out with both Cu(OTf)2 and AgOTf (Table 2), 
which revealed that both catalysts were compatible with a wide range of solvents. However, 
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CH2Cl2 was retained as the standard solvent due to its potential compatibility with a wider 
range of substrates. 
 
Entry Catalyst Solvent
 
Time (h) Ratio 83a:84a
a 
1 Cu(OTf)2 
CH2Cl2 
24 0:100 
2 AgOTf 0.5 0:100 
3 Cu(OTf)2 
CHCl3 
24 0:100 
4 AgOTf 0.5 0:100 
5 Cu(OTf)2 
PhMe 
24 3:97 
6 AgOTf 0.5 1:99 
7 Cu(OTf)2 
MeCN 
24 42:58 
8 AgOTf 0.5 37:63 
9 Cu(OTf)2 
THF 
24 37:63 
10 AgOTf 0.5 11:89 
11 Cu(OTf)2 
Et2O 
24 41:59 
12 AgOTf 0.5 69:31 
13 Cu(OTf)2 
EtOH 
24 0:100 
14 AgOTf 0.5 Complex mixture 
a
Calculated by  
1
H NMR spectroscopy, ratio of starting material to product. 
Table 2. Solvent screening results with AgOTf and Cu(OTf)2. 
The variety of catalysts capable of forming the spirocycle 84a suggests that a number of 
mechanistic pathways are possible (Scheme 16). For example, a 5-endo-dig spirocyclisation 
(86/87 → 88) could be induced by either (i) co-ordination of a Lewis acid to the ynone 
carbonyl, increasing the electrophilicity of the β-position or (ii) co-ordination of a π-acid 
directly to the alkyne. Following this cyclisation, the vinyl metal intermediate 88 could either 
undergo protodemetallation to afford the spirocycle 84a, or react via a 1,2-migration and 
rearomatisiation pathway to afford the carbazole 85a formed under Au(I) catalysis (Table 1, 
entry 14). Alternatively, it is also possible that the electron-rich anisole, which is in direct 
conjugation to the ynone, could react with a Lewis acid (90 → 91) to afford an electrophilic 
allenyl intermediate 92, which could undergo a 5-exo-dig spirocyclisation as shown to afford 
spirocycle 84a.  
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Scheme 16. Potential mechanisms for the spirocyclisation of 83a: a) Direct 5-endo-dig cyclisation of 
the alkyne; b) Alternative allenolate formation and 5-exo-dig cyclisation.   
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2.1.2 Substrate Synthesis 
To fully explore the scope and limitations of the reaction conditions, a wider range of 
substrates were prepared using the same reaction sequence demonstrated previously (Scheme 
15). First, a number of Weinreb amides were prepared from commercially available 
carboxylic acids using the same T3P-mediated conditions (Scheme 17). 
 
Scheme 17. Scope of Weinreb amides synthesised using T3P. 
More functionalised amides were also prepared, such as amide 81g, which was prepared in 2 
steps via a modified literature procedure for the alkylation of acid 80a with benzyl chloride 
(Scheme 18).
49
 This reaction presumably proceeds through a trianion intermediate to 
chemoselectively alkylate α- to the carboxylic acid. Amide 81h was synthesised via a Suzuki 
cross-coupling of a previously prepared bromide 93,
50
 with phenyl boronic acid.  
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Scheme 18. Synthesis of other functionalised Weinreb amides: a) Chemoselective α-alkylation of 80a; 
b) Suzuki cross-coupling of 93. 
Next, the prepared Weinreb amides were reacted with a number of lithium acetylides 
(generated by the reaction of n-BuLi with the corresponding alkyne) furnishing ynones 83a–r, 
generally in excellent yields (Scheme 19).  
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Scheme 19. Scope of indole-ynones prepared. 
Alternatively, the requisite alkynes were made from dibromide precursors. For example, 
ynone 83e was prepared using the lithium acetylide generated by a Corey-Fuchs reaction (94 
→ 95) and ynone 83g was prepared using the lithium acetylide generated from the reaction of 
1,2-dibromopropane 96 with LDA.
51
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Scheme 20. Alternative ynone formations from dibromide precursors: a) Corey-Fuchs reaction of 95; b) 
Sequential elimination of dibromide 96. 
Interestingly, the attempted formation of a methoxy ynone resulted in the unexpected 
formation of spirocycle 84s (Scheme 21). The reaction of amide 81a with lithium acetylide 98 
(generated by a literature procedure from 2-chloro-1,1-dimethoxyethane 97)
52
 afforded only a 
modest yield of spirocycle 84s. This spontaneous spirocyclisation is suggested to proceed via 
allenolate intermediate 100, which following protonation would afford an electrophilic 
intermediate 101 that could readily spirocyclise via a 5-exo-dig cyclisation. 
 
Scheme 21. a) Formation of spirocycle 84s; b) Proposed mechanism for the formation of spirocycle 
84s. 
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2.1.3 Indole-ynones: scope & limitations 
With a range of ynones prepared, the scope of the optimised reaction conditions using AgOTf 
(1 mol%) in  CH2Cl2 (0.1 M) was investigated (Scheme 22). First, ynones with different 
electronic and steric properties, including different aromatics 83a–f, aliphatics 83g–h and 
heteroaromatics 83i were examined, which pleasingly, were all converted into the 
corresponding spirocycles 84a–i in typically less than 4 h and in quantitative or near-
quantitative yield. The structure of spirocycle 84a was also definitively proven by X-ray 
crystallography (Figure 3). Next, ynones bearing a benzyl group α to the ynone carbonyl 
83ej–k were converted into spirocycles 84j–k in similarly excellent yield but with no 
observable diastereoselectivity. Finally, ynones with substituents at the 2- and 5-positions on 
the indole ring 83l–n were converted into spirocycles 84l–n, again in excellent/quantitative 
yield. Interestingly substitution on the indole 2-position appeared to significantly increase the 
rate of reaction, for example 2-phenyl substituted ynone 83m underwent full conversion to the 
spirocycle 84m in just 6 minutes. This could be attributed to a more favourable pre-
organisation of the substrate caused by the sterics of the phenyl ring forcing the alkyne moiety 
perpendicular to the indole ring. 
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Scheme 22. Indole-ynone 5-endo-dig spirocyclisation substrate scope. 
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Figure 3. X-ray structure of spirocycle 84a with thermal ellipsoids shown at 50% (CCDC 1023667). 
For a brief demonstration of complementary Cu(II)-catalysis, selected ynones were also 
reacted with Cu(OTf)2 (1 mol%) (Scheme 22, conditions B). These Cu(II)-catalysed reactions, 
as observed previously, were generally slower (typically 16 h vs. <4 h) and slightly lower 
yielding than the Ag(I)-catalysed conditions. Aside from the differences in yield and reaction 
times, another interesting difference was also observed when using Cu(OTf)2 in the degree of 
trimer formation observed in the product. Trimer formation, which is a well-documented 
phenomenon of indolenines,
53
 occurred in almost every spirocycle formed when using 
Cu(OTf)2, but was drastically reduced when using AgOTf. An illustrative example is 
demonstrated in the comparison of the 
1
H NMR spectra of spirocycle 84g formed using 
Cu(OTf)2 after column chromatography (Figure 4a) and the same compound formed using 
AgOTf after column chromatography (Figure 4b); note the three key diagnostic singlets 
(highlighted in red at 4.62, 4.84 and 5.24 ppm), which are tentatively assigned to protons 
alpha to two aniline nitrogen atoms (101, highlighted in red). It is somewhat surprising that 
there are only three major distinct chemical environments found in the imine trimer, which 
suggests it is formed with good diastereocontrol. As proof that this sample was genuinely 
spirocycle 84g, treatment of sample (a) with catalytic TFA drastically changed the 
1
H NMR 
spectrum (Figure 4c),
41
  which closely aligns with the sample afforded from the AgOTf 
reaction (Figure 4b). Two possible rationales for this difference could be attributed to either: 
(i) potential leaching of the Lewis acidic AgOTf into the final products, which in a similar 
fashion to TFA could change the trimer equilibrium in favour of the monomer; (ii) the 
multivalent Cu(OTf)2 catalyst could act as a nucleation centre for trimer formation by binding 
the indolenines and thus accelerating intermolecular reactions.  
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Figure 4. 
1
H NMR spectra: a) Spirocycle 84g made using Cu(OTf)2; b) Spirocycle 84g made using 
AgOTf; c) Spirocycle 84g made with Cu(OTf)2 and with the addition of TFA. 
One substrate which failed to undergo any reaction with either AgOTf or Cu(OTf)2 was TMS 
ynone 83o (Table 3). This lack of reaction was attributed to the β-silicon effect,54 which 
effectively inverts the electronics of the ynone system, inhibiting a 5-endo-dig reaction 
pathway. Attempts to cleave the TMS group (TBAF etc.) and isolate the terminal ynone 
product were unsuccessful and led only to decomposition. However, a one-pot desilylation-
spirocyclisation process was identified based upon literature precedent for Ag(I)-catalysed 
desilylation reactions.
55
 Pleasingly, the application of these literature conditions (AgNO3 in 
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acetone) to the TMS ynone 83o readily afforded the desired unsubstituted spirocycle 84o in 
excellent yield.  
 
Entry Catalyst
 
Solvent Yield (%) 
1 AgOTf (10 mol%) CH2Cl2 - 
2 Cu(OTf)2 (10 mol%) CH2Cl2 -
 
3 AgNO3 (20 mol%) Me2CO 93 
Table 3. Optimisation of the tandem desilylation-spirocyclisation protocol. 
Finally, the only substrate which failed to form a 5-membered enone spirocycle under the 
standard reaction conditions was N-methylated ynone 83p, which when reacted with AgOTf 
in CH2Cl2 afforded only a complex mixture (Scheme 23). This decomposition is presumed to 
be due to the instability of cationic intermediate 103. 
 
Scheme 23. Reactivity of N-methylated substrate 163. 
Whilst the formation of the 5-membered enone spirocycles was relatively simple, larger ring 
sizes proved more problematic. For example, the extended ynone 83q required elevated 
catalyst loading (10 mol%, AgOTf) and careful temperature control (35 °C) to effectively 
form the desired spirocycle 84q and supress the formation of a C2-annulated product 85q 
(Table 4, entry 3). At room temperature, the rate of reaction was insufficient, whilst at 
marginally higher temperatures (40 °C) the formation of the C2-annulated by-product 85q 
was significantly increased. The structure of the annulated indole 85q was also proven by X-
ray crystallography (Figure 5) and is proposed to form either via a 1,2-migration process or 
from direct attack from the C2-position. 
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  Yield (%)
 
Entry Temperature (°C) 84q 85q 
1 RT 34 - 
2 40 52 48 
3 35 75 11 
Table 4. Reactivity of extended ynone 83q with AgOTf. 
 
Figure 5. X-ray structure of C2-annuated indole 85q with thermal ellipsoids shown at 50% (CCDC 
1531214). 
In similar fashion, the further extended homologue 83r could only be induced to form another 
C2-annulated indole 85r in poor yield by reaction with stoichiometric AgOTf (Scheme 24). 
The proposed structure of 84r was also confirmed by X-ray crystallography (Figure 6).  
 
Scheme 24. Reactivity of extended ynone 83r with stoichiometric AgOTf. 
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Figure 6. X-ray structure of C2-annulated indole 85r with thermal ellipsoids shown at 50% (CCDC 
1531215). 
 
2.1.4 Heterogeneous silver(I) catalysis 
Heterogeneous catalysis can greatly improve the efficiency of a reaction by simplifying both 
catalyst recovery and product isolation, which in turn can improve reaction yields.
56
 
Considering both this, and the high catalytic activity of Ag(I) catalysts in the spirocyclisation 
reaction, AgNO3 impregnated silica (AgNO3·SiO2), which is traditionally used in column 
chromatography as a method to separate E- and Z-alkene isomers, was investigated as a 
potential reusable heterogeneous catalyst.
57
  
Studies began by preparing a batch of AgNO3·SiO2 (10 wt % AgNO3 on silica) and adding the 
solid supported catalyst (10 mol%) to a stirred solution of ynone 83a, which promoted 
quantitative conversion to the spirocycle 84a in just 5 minutes (Scheme 25a); the catalyst was 
then easily recovered by filtration and reused a total of 5 times with no loss in catalyst 
activity. Next, the prepared AgNO3 impregnated silica was applied to a flash chromatography 
column to form a make-shift flow reactor (Scheme 25b). Following a typical column 
chromatography procedure, the ynone 83a was loaded onto the column and eluted under 
gravity to afford the spirocycle 84a in quantitative yield; this procedure was again repeated 5 
times with the same column with no loss of catalyst activity observed. This flow reactor 
represents an attractive alternative to a typical flow chemistry set up as it forgoes the need for 
expensive equipment and specialist personnel to maintain it. 
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Scheme 25. Heterogeneous catalysis of AgNO3·SiO2: a) As a filtered reagent; b) For use in flow 
chemistry. 
Further optimisation of this heterogeneous catalyst was later carried out by Aimee Clarke 
(PhD student), where it was found that decreasing the loading of the AgNO3 on the silica from 
10 wt % to 1 wt % dramatically increased catalyst performance (see Appendix IV). A higher 
proportion of silica might increase the rate of reaction by accelerating protodemetallation on 
the acidic silica surface, and the silica surface might also serve to stabilise potential silver 
nanoparticles.  
The work described in this section was the subject of a recent publication.
58
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2.1.5 Indole-Ynone gold(I) catalysis 
During the initial catalyst screening studies the formation of carbazole 85a was observed 
when ynone 83a was reacted with a combination of Au(I) and Ag(I) catalysts (Ph3PAuCl and 
AgOTf, see Table 1, entry 14). To investigate the role of Au(I)-catalysis in this transformation 
further, a commerically available cationic catalyst Ph3PAuNTf2 was chosen as a catalyst 
probe;
59
 this catalyst is preferable to other typical gold(I) chloride complexes as it does not 
require a Ag(I) co-catalyst, which could complicate studies with background spirocyclisation 
reactions and other known silver effects.
60
 As hoped, carbazole 85a was then prepared in good 
yield by reacting ynone 83a with Ph3PAuNTf2 (10 mol%) in CH2Cl2, confirming this 
transformation does not require a Ag(I) catalyst  (Scheme 26). The structure of 85a was also 
proven by X-ray crystallography (Figure 7). 
 
Scheme 26. Initial studies using Ph3PAuNTf2 to form carbazole 85a. 
 
Figure 7. X-ray structure of carbazole 85a with thermal ellipsoids shown at 50% (CCDC 1531216). 
Interestingly, no reaction was observed when spirocycle 84a was reacted with Ph3PAuNTf2 
under the same reaction conditions, ruling out the spirocycle 84a as a direct precursor to the 
carbazole 85a. This is further supported by the proven stability of spirocycle 84a under 
various acidic conditions (see Table 1). Considering this, it is proposed that carbazole 85a is 
formed either via direct attack from the indole C2-position or C3-attack followed by a 1,2-
migration of a vinyl metal intermediate, which is more consistent with typical indole 
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reactivity. This 1,2-migration process might proceed through a three-center two-electron 
pathway
61
 (105 → 106 → 107, Scheme 27a) or via a formal cyclopropanation and 
fragmentation pathway (105 → 109 → 107, Scheme 27b).  A vinyl gold species 105 might 
have a higher proclivity for 1,2-migration relative to a vinyl silver species as it can more 
readily stabilise positive charge through π-back bonding.62 
 
Scheme 27. Proposed Au(I)-catalysed 1,2-migration mechanisms: a) A three-center two-electron 
pathway; b) A cyclopropanation and fragmentation pathway. 
This work was later expanded in wider scoping studies carried out primarily by Dr John 
Liddon (PDRA) and are shown here only for reference (Scheme 28). The work described in 
this section was also the subject of a recent publication.
63
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Scheme 28. Wider scoping studies using Ph3PAuNTf2 (conducted primarily by John T. R. Liddon).  
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2.1.6 Asymmetric indole-ynone spirocyclisations 
2.1.6.1 Catalyst discovery & optimisation studies 
Having adequately developed the racemic spirocyclisation protocol, the feasibility of an 
asymmetric variant was next examined. A wide array of different asymmetric catalyst systems 
were screened, using ynone 83a as the model substrate (Scheme 29), of which only the chiral 
phosphoric acid (CPA) silver salt Ag-114a showed any signs of asymmetric induction by 
chiral HPLC analysis, forming spirocycle 84a in 86% yield and with 8% ee. This initial hit 
and literature precedent for using CPA silver salts in related alkyne activations,
64,65
 prompted 
an in depth look into other CPA catalysts.  
  
Scheme 29. Initial asymmetric catalyst screen. 
A number CPA catalyst were then acquired from commercial sources or prepared by known 
literature procedures, using 117 as a common intermediate from which a telescoped reaction 
sequence afforded the corresponding CPAs (Table 5). 
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Entry R Yield over 3 steps [%] 
1 1-Naphthyl (114b) 59 
2 2-Naphthyl (114c) 81 
3 4-Ph-C6H4 (114d) 50 
4 1-Pyrene (114e) 20 
5 3,5-Ph2-C6H4 (114f) 94 
Table 5. Telescoped synthesis of BINOL-based CPA. 
The electron deficient CPA 114g was synthesised via an analogous route (Scheme 30), 
utilising an SNAr reaction with hexafluorobenzene to install the C6F5 aromatics in the 3,3′-
positions instead of employing a Suzuki cross-coupling. 
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Scheme 30. Synthesis of C6F5 substituted catalyst 187. 
A smaller number of H8-BINOL based catalysts were also prepared (Scheme 31). This route 
did not require a directed ortho metalation strategy thanks to the ability to selectively 
brominate 120 in only the 3,3′-positions. 
 
Scheme 31. Overview of H8-BINOL CPA synthesis. 
Finally, the corresponding silver salts were prepared according to a literature procedure,
66
 by 
reacting the CPAs with Ag2CO3 in a biphasic mixture of CH2Cl2 and water, affording the 
silver salts in yields ranging from 35–100% (Scheme 32). These salts were used as prepared 
and were not fully characterised. 
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Scheme 32. Formation of Ag-CPA salts by deprotonation with Ag2CO3. 
Before reacting ynone 83a with the full catalyst library, commercially available CPA 114h 
was chosen as a model catalyst to optimise the reaction conditions. Optimisation began by 
reacting ynone 83a with catalyst Ag-114h in CH2Cl2 at reduced temperature (−10 °C) to 
afford the spirocycle 84a in excellent yield and with 20% ee (Table 6, entry 1). Next, the same 
reaction was repeated in different solvents (CHCl3, DCE, THF and toluene, entries 2–5), with 
the reaction in CHCl3 proving particularly promising, affording the spirocycle 84a in 
quantitative yield and with 50% ee. This increase in ee was tentatively attributed to the 
sensitive nature of the ion pair between the Ag(I) cation and CPA anion. Reaction of ynone 
83a with catalyst Ag-114h in CHCl3 at lower temperatures (−40 °C) resulted in only a small 
increase in ee, but with a significantly reduced rate of reaction (entry 6), and thus the 
optimised conditions going forward were chosen as 1 mol% Ag-CPA in CHCl3 at −10 °C. 
 
Entry Catalyst Loading Temp.  (°C) Solvent Time Yield (%) ee
*
 (%) 
1 5 mol% –10 CH2Cl2 0.5 h 98 20 
2 1 mol% –10 THF 4 h 100 0 
3 5 mol% –10 DCE 3 h 95 8 
4 1 mol% –10 Toluene 2 h 91 26 
5 1 mol% –10 CHCl3 1.5 h 100 50 
6 1 mol% –40 CHCl3 17 h 86 52 
*Determined by CSP-HPLC (Chiralpak IB column, eluting with 10% IPA in hexanes, 1 mL/min). 
Table 6. Optimisation of the asymmetric reaction conditions with Ag-114h. 
Model ynone 83a was then reacted with the full catalyst library under the optimal reaction 
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conditions (CHCl3 at −10 °C, Scheme 33), with the best catalyst, phenanthrene derivative Ag-
114l, providing the spirocycle 84a with a pleasing 78% ee. 
 
Scheme 33. Optimisation of the Ag-CPA catalyst. 
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From these results it was noted that generally catalysts with rigid and large bulky aromatics at 
the 3,3′- positions (e.g. anthracene, phenanthrene and pyrene) performed best. Next, the 
modification of the catalyst backbone was examined, which was prompted by the comparison 
of catalysts Ag-114l and Ag-123b, which showed a significant reduction in ee upon switching 
between a BINOL and a H8-BINOL backbone. From this observation it was hypothesised that 
the larger sterics of the H8-BINOL catalyst backbone forms a more open catalyst cavity 
compared to the BINOL catalyst analogue (Figure 8a, b).
67,68
 Following this logic it was 
hypothesised that a catalyst based on a SPINOL backbone would provide the narrowest, most 
well-defined cavity (Figure 8c). Thus, it was hoped that SPINOL based-catalyst Ag-126 
would significantly improve the enantioselectivity. Therefore to conclude the asymmetric 
optimisation studies, the synthesis of a SPINOL based catalyst was carried out following the 
literature procedure to synthesise the requisite diol 136 (Scheme 34).
69
 
 
Figure 8. Hypothetical comparison of the different chiral phosphoric acid cavities: a) BINOL; b) H8-
BINOL; c) SPINOL. 
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Scheme 34. Literature synthesis of (S)-SPINOL 136.
69
  
With the enantiopure (S)-SPINOL 136 in hand, attempts to perform the known selective 
bromination of 136 were carried out (Scheme 35).
70
 Unfortunately, repeated efforts afforded 
at best an inseparable mixture of the desired dibrominated product 137 and the tribrominated 
product 138. Submission of the brominated mixture to the Suzuki cross-coupling fortunately 
allowed isolation of the desired product 139, from which the routine synthesis of Ag-126 was 
carried out.  
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Scheme 35. Synthesis of the SPINOL-based catalyst Ag-126. 
Finally, the reaction of Ag-126 with ynone 83a afforded the spirocycle in a disappointing 60% 
ee (Scheme 36). From this result a comparison with the fable of „Goldilocks and the three 
bears‟ was noted, where perhaps the BINOL-based cavity is „just right‟. 
 
Scheme 36. Asymmetric spirocyclisation reaction with SPINOL-based catalyst Ag-126.  
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2.1.6.2 Substrate Scope and absolute stereochemistry 
With the catalyst development reaching its conclusion the best BINOL-based catalyst Ag-114l 
was used with a wider range of substrates (Scheme 37). Over the chosen substrates the 
asymmetric catalyst system showed good consistency, affording the spirocycles in excellent 
yield and typically with >70% ee. Only two main outliers were identified: (i) phenyl 
spirocycle 84b, which without a substituent on the 4-position suffered a surprising drop in ee; 
(ii) dimethylaniline spirocycle 84c, which was isolated in moderate yield and with poor ee, 
this reduced performance was attributed to the poor solubility of the substrate and potential 
inhibitory/competing ligation of the aniline moiety. 
 
Scheme 37. Overview of asymmetric substrate scope with Ag-114l. 
The absolute stereochemistry of the major enantiomer was determined by recrystallisation of 
spirocycle 84f, which initially only accrued as enantioenriched mother liquor, as the racemic 
crystals proved more prone to crystallisation. However, once the mother liquor was 
sufficiently enriched (>96% ee) further recrystallisations afforded enantiopure crystals, from 
which X-ray crystallography could definitively determine the stereochemistry as S (Figure 9). 
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To fully confirm that this stereochemistry belonged to the major enantiomer, the discrete 
sample used to collect the XRD data was identified by CSP-HPLC as the major enantiomer. 
 
Figure 9. X-ray structure of enantiopure-spirocycle 84f with thermal ellipsoids shown at 50% (CCDC 
1049165). 
A tentative rationale for the enantioselectivity observed is shown in Figure 10, in which 
favourable sterics and where possible, a potential π-stacking interaction could sufficiently 
lower the energy of binding mode 140 relative to 141. 
 
Figure 10. Proposed models for asymmetric induction. 
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2.2 Indole-propargyl alcohol cyclisations 
2.2.1 Introduction & initial studies 
All of the developed spirocyclisation reactions so far have been limited to alkynes as a part of 
a conjugated ynone system (83 → 84). Thus, to potentially extend the scope of these reactions 
further, the Ag(I)-catalysed spirocyclisation of unconjugated alkyne systems was planned 
(142 → 143, Scheme 38). 
 
Scheme 38. Proposed spirocyclisation of unconjugated alkynes. 
Propargyl alcohols provided an expedient route into unconjugated alkyne substrates, as they 
could be easily prepared by reduction of the in-hand ynone substrates. Thus, studies began 
with the preparation of a model propargyl alcohol substrate 144a by the NaBH4 reduction of 
ynone 83a (Scheme 39). The resultant propargyl alcohol 144a was then reacted with AgOTf 
at elevated catalyst loading (10 mol%) in CH2Cl2 to afford carbazole 146a in excellent yield, 
with only a trace of the desired spirocycle 145a detected by 
1
H NMR spectroscopy (Scheme 
40). 
 
Scheme 39. Synthesis of propargyl alcohol 144a by NaBH4 reduction. 
 
Scheme 40. Initial studies with propargyl alcohol 144a. 
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The formation of carbazole 146a represents a benzannulation reaction of indole, which was 
presumed to proceed via a spirocyclisation and 1,2-migration pathway (similar to that 
proposed in section 2.5) followed by the elimination of water.  
Benzannulation reactions, whilst not within the original aims of this project, offer an attractive 
route into the controlled formation of valuable fused-polycyclic structures. For example, the 
carbazole framework is found in a number of biologically active natural products with 
anticancer, anti-HIV and antimalarial properties.
71–74
 Aside from biological activity, 
carbazoles have also featured in electroluminescent materials thanks to their desirable thermal, 
electrical and optical properties.
75
 Thus, the potential to access both high-value carbazoles and 
spirocycles from to a single starting material became a challenge of significant interest. 
The benzannulation of indole by the electrophilic activation of a pendant alkyne was first 
demonstrated by Larock and co-workers with a single example, whereby propargyl alcohol 
147 was reacted with iodine monochloride to form carbazole 148 in modest yield (Scheme 
41a).
76
 Later, Liang and co-workers demonstrated a range of similar iodocyclisations, reacting 
indoles 149 again with iodine monochloride to promote the formation of a range of 
synthetically useful carbazoles 150 in typically excellent yield (Scheme 41b).
77
 Interestingly, 
Liang and co-workers propose that carbazoles 150 also form via the 1,2-migration of a 
spirocyclic intermediate (151 → 152). 
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Scheme 41. Iodocyclisation-mediated benzannulations of alkyne tethered indoles. 
Other notable indole benzannulation reactions include the work of Hashmi and co-workers, 
who were the first to develop a transition metal-catalysed reaction of this type using Au(I)-
catalysis (Scheme 42a).
78
 For example, indole 153 was transformed into carbazole 154 in near 
quantitative yield using (IPr)AuCl and AgNTf2 as an activating co-catalyst. In the same year, 
Ma and co-workers reported a similar transformation, using Au(III)-catalysis across a wider 
range of substrates to afford carbazoles 156 in typically excellent yield (Scheme 42b).
79
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Scheme 42. Gold-catalysed benzannulation reactions of alkyne-tethered indoles.  
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2.2.2 Reaction optimisation 
To better understand the reactivity of the propargyl alcohol substrates and to potentially 
control the selectivity between spirocycle formation and benzannulation, a wider variety of 
conditions were screened across two substrates (144b and 144c, prepared as in Scheme 39), 
which were chosen for their differing electronic properties, allowing for a more balanced 
assessment of the reaction conditions. These studies were aided by four supervised BSc 
students, who are credited where appropriate. 
Screening studies began using AgNO3 and AgOTf as the primary catalysts and CH2Cl2, THF 
and toluene as solvents (Table 7).  From these screens it was found that AgOTf in THF 
consistently promoted high levels of carbazole formation across both substrates (entries 2 & 
8). Pleasingly, spirocycle formation was also consistently observed when using AgNO3 in 
CH2Cl2 (entries 4 & 10, albeit with no/minimal diastereoselectivity). 
 
Entry R
a
 Catalyst Solvent Ratio 144:145:146
b 
1 Ph (144b) AgOTf CH2Cl2 0:10:90 
2 Ph AgOTf THF 0:0:100 
3 Ph AgOTf PhMe 0:0:100 
4 Ph AgNO3 CH2Cl2 5:95:0 
5 Ph AgNO3 THF 10:90:0 
6 Ph AgNO3 PhMe 90:10:0 
7 n-Bu (144c) AgOTf CH2Cl2 35:65:0 
8 n-Bu AgOTf THF 0:5:95 
9 n-Bu AgOTf PhMe 95:0:5 
10 n-Bu AgNO3 CH2Cl2 20:80:0 
11 n-Bu AgNO3 THF 95:3:2 
12 n-Bu AgNO3 PhMe 0:45:55 
a
All reactions performed with 0.10–0.20 mmol of propargyl alcohol in the stated solvent (0.1 M) at RT;                  
b
Calculated by  
1
H NMR spectroscopic analysis of the unpurified reaction mixture, rounded to the 
nearest 5%. 
Table 7. Propargyl alcohol catalyst screening (experiments performed by Rosa E. Clubley, and 
Anthony C. Wyton). 
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Initial rationale for the difference in reactivity between AgOTf and AgNO3 was tentatively 
attributed to acidic impurities present in the catalysts as well as subtle counterion effects. 
Brønsted acids are known to promote 1,2-migration reactions of indolenines and AgOTf is 
known to promote “hidden Brønsted acid catalysis” in related processes.80 Conversely, 
AgNO3 does not share this feature and therefore might contain significantly less (if any) 
residual Brønsted acid, preventing a competing 1,2-migration process. The choice of solvent 
also clearly influenced the selectivity of the reaction and it is proposed that the relatively polar 
nature of THF favours carbazole formation by stabilising potential cationic rearrangements.  
To further explore the role of Brønsted acid catalysis in these reactions a number of additives 
were investigated in an attempt to invoke different selectivity profiles (Table 8). As expected, 
the incorporation of a base (Et3N, entry 2) with the previously carbazole-selective conditions 
(AgOTf, THF) resulted in only spirocycle formation, albeit with low levels of conversion. 
Conversely, the incorporation of an acid (p-TSA, entry 7) with the spirocycle-selective 
conditions (AgNO3, CH2Cl2) afforded a 1:1 mixture of spirocycle to carbazole.  
 
Entry Catalyst Solvent Additive Ratio 144b:145b:146b
b
 
1 AgOTf THF - 0:0:100 
2 AgOTf THF Et3N (5 mol%) 55:45:0 
3 AgOTf  THF K2CO3 (5 mol%) 75:20:5 
4 AgOTf THF NaHCO3 (5 mol%) 0:0:100 
5 AgNO3 CH2Cl2 - 5:95:0 
6 AgNO3 CH2Cl2 TfOH (2 mol%) 80:0:20 
7 AgNO3 CH2Cl2 p-TSA (2 mol%) 20:40:40 
8 AgNO3 CH2Cl2 AcOH (2 mol%) 15:70:15 
a
All reactions performed with 0.10–0.20 mmol of propargyl alcohol in the stated solvent (0.1 M) at RT;                  
b
Calculated by 
1
H NMR spectroscopic analysis, rounded to the nearest 5%. 
Table 8. Propargyl alcohol additive study (experiments performed by Rosa E. Clubley, and Anthony C. 
Wyton). 
Interestingly, when spirocycle 145b was submitted to the carbazole formation conditions 
(AgOTf in THF), no reaction was observed (Table 9, entry 1). However, spirocycle 145b 
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rapidly decomposed when reacted with TfOH (10 mol%), with traces of carbazole 146b 
observed by TLC analysis (entry 2). 
 
Entry Conditions Result
 
1 AgOTf (10 mol%), THF, RT, 24 h No reaction 
2 TfOH (10 mol%), CH2Cl2, RT, 16 h Decomposition, trace 146b detected by TLC. 
Table 9. Attempted synthesis of carbazole 146b by 1,2-migration of spirocycle 145b. 
Considering the above, it was deemed unlikely that spirocycle 145b is a direct precursor to the 
carbazole 146b. Thus, it is proposed that carbazole 146b is formed either via direct attack 
from the indole C2-position or C3-position followed by a 1,2-migration of the vinyl silver 
intermediate (as with the Au(I)-catalysis in section 2.5) and the elimination of water (Scheme 
43). In this instance, a vinyl silver intermediate might be more prone to a three-center two-
electron pathway (158 → 159 → 160) as it can stabilise positive charge more readily without 
the electron withdrawing effects of a conjugated carbonyl (as in the indole-ynone system).
61
 
Ultimately, a 1,2-migration process requires the indolenine of vinyl silver intermediate 158 to 
stay protonated, and as such, selectivity is thought to be strongly affected by both Brønsted 
acids or bases, as demonstrated in Table 8. 
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Scheme 43. Proposed mechanisms for spirocycle and carbazole formation. 
Finally, to conclude optimisation studies, the developed conditions were trialled on a synthetic 
scale with model substrate 144c. Pleasingly, the carbazole formation proceeded as expected 
(Scheme 44), but the spirocyclisation protocol produced a low yielding mixture of the desired 
spirocycle 145c and carbazole 146c (Table 10, entry 1). Therefore, to improve the yield and 
selectivity of the spirocyclisation protocol further, the addition of a basic additive, which 
would not retard the rate of reaction (as in Table 8), was investigated. Happily, Ag(I)-based 
additives were found to improve both the yield and selectivity, and in particular the addition 
of Ag2O (5 mol%) completely restored the desired selectivity and significantly improved the 
reaction yield (entry 3). 
 
Scheme 44. Synthesis of carbazole 146c. 
 
Chapter 2. Indole-alkyne cyclisations 
 
 
 
52 
 
Entry Additive Yield (%)
 
1 - 31 
2 Ag2CO3 (5 mol%) 40 
3 Ag2O (5 mol%) 92 
Table 10. Ag(I)-based additive screen with propargyl alcohol 144c.  
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2.2.3 Substrate Synthesis 
To fully explore the scope of the two optimised reaction protocols a wider range of substrates 
was prepared by NaBH4 reduction of the corresponding ynone (Scheme 45). 
 
Scheme 45. Propargyl alcohols prepared by sodium borohydride reduction. 
Attempts to prepare TMS alkyne 144h in a one-pot process (to avoid decomposition) also 
provided an appreciable amount of terminal alkyne 144i, presumably afforded by an 
adventitious sodium methoxide-mediated desilylation of 144h. Full conversion of 144h to 
144i was easily achieved by reaction with K2CO3 in methanol. 
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Scheme 46. Synthesis of TMS alkyne 144h and 144i by desilylation. 
Tertiary alcohol substrates 144j and 144k were prepared by reacting ynone 83b with an 
excess of the corresponding commercial organo-lithium reagent (Scheme 47a). A TBS-
protected propargyl alcohol substrate 144l was also readily accessed from substrate 144b 
(Scheme 47b).  
 
Scheme 47. Miscelleanous propargyl alcohol synthesis. 
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2.2.3 Substrate Scope 
First, the propargyl alcohol library was reacted under the optimised spirocyclisation 
conditions (AgNO3, Ag2O in CH2Cl2), which in almost all cases, afforded the desired 
spirocycles in excellent or near quantitative yields regardless of steric or electronic effects, 
albeit with no diastereocontrol (Scheme 48).  
 
Scheme 48. Substrate scope for propargyl alcohol spirocyclisations. 
The only substrates which failed to spirocyclise were alkynes 144h and 144l, which instead 
underwent a low yielding hydration reaction to form the α-hydroxy ketone natural product, 
(±)-actinopolymorphol B 162 (Scheme 49).
81
 Typically π-acid catalysed alkyne hydrations are 
carried out at higher temperatures and so it was somewhat surprising to see hydration under 
these mild reaction conditions.
82–84
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Scheme 49. Unexpected hydration reaction for the synthesis of (±)-actinopolymorphol B 162. 
Next, reaction of the same substrates under the carbazole-formation conditions (AgOTf in 
THF) afforded the desired carbazoles predominantly in excellent yield (Scheme 50). The only 
exceptions were: (i) tertiary alcohol 144k failed to afford any of the desired carbazole 146k, 
which may be due to the premature formation of unproductive carbocation intermediates; (ii) 
thiophenyl alkyne 144f, which afforded only a small quantity of carbazole 146f, with the 
major side-product being spirocycle 145f, suggesting that this heterocyclic system may be less 
prone to 1,2-migration. Finally, the structure of carbazole 146d was also definitively proven 
by X-ray crystallography (Figure 11). 
 
Scheme 50. Substrate scope of propargyl alcohol benzannulation reactions. 
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Figure 11. X-ray structure of carbazole 146d with thermal ellipsoids shown at 50% (CCDC 1404713). 
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2.3 Towards Spirobacillene B 
To conclude studies of the indole-alkyne systems, model studies towards the synthesis of 
spirobacillene B analogue 164 were examined using PMP spirocycle 84a. First, a strategy 
based upon an acid-mediated rearrangement of an α,β-epoxyketone 163, as employed in the 
total synthesis of spirobacillene A, was planned (Scheme 51).
17
  
 
Scheme 51. Retrosynthetic analysis of spirobacillene B analogue 164: a) Epoxidation and acid-
mediated rearrangement; b) Envisaged rearrangement. 
Attempts to prepare the required α,β-epoxyketone 163 by the epoxidation of spirocycle 84a 
under both nucleophilic and electrophilic conditions failed (Table 11). Under most conditions 
only decomposition was observed, however, when using DMDO a mass consistent with N-
oxide 167 was detected by HRMS (Entry 5), suggesting that the indolenine functionality is a 
potential source of incompatibility with this strategy.   
 
Entry Conditions Result
 
1 H2O2, NaHCO3, THF, H2O, RT Complex mixture 
2 H2O2, NaHCO3, MeOH, RT Complex mixture 
3 t-BuOOH, THF, RT No reaction 
4 m-CPBA, NaHCO3, CH2Cl2, 0 °C Complex mixture 
5 DMDO, Me2CO, RT Complex mixture, 167 detected 
Table 11. Attempted synthesis of α,β-epoxyketone 163. 
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In an attempt to increase the reactivity of the alkene system relative to the indolenine 
functionality, the epoxidation of allylic alcohol spirocycle 145a was proposed. Here, it was 
hoped that the electron rich allylic alcohol system could be more easily epoxidized to afford 
168, which following oxidation to 163 could be used to form model spirocycle 164 (Scheme 
52).  
 
Scheme 52. Retrosynthetic analysis of spirobacillene B analogue 164 by allylic alcohol epoxidation. 
Unfortunately, attempts to prepare epoxide 168 by the epoxidation of spirocycle 145a with m-
CPBA resulted only in rapid decomposition of the starting material (Scheme 53). This 
decomposition was consistent with the sensitivity of the spirocycles to Brønsted acids and 
oxidants previously observed. Degradation of spirocycle 145a was also observed after ~1 
week of storage at ambient temperature, dissuading any further studies with the allylic alcohol 
spirocycles as practical starting materials. 
 
Scheme 53. Attempted synthesis of epoxide 168. 
Finally, an alternative approach based on the E1cB elimination of dihydroxylated spirocycle 
169 was examined (Scheme 54).  
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Scheme 54. Retrosynthetic analysis of spirobacillene B analogue 164 via dihydroxylation. 
The synthesis of the dihydroxylated spirocycle 169 was attempted using Os(VIII)-catalysis 
(Table 12). Both Upjohn and Sharpless asymmetric dihydroxylation conditions resulted 
primarily in the decomposition of the starting material. The only isolable product from these 
reactions was a small quantity of oxindole 170 under the Upjohn conditions (Entry 1), which 
was presumably formed by reaction with NMO.  The indolenine functionality was again 
presumed to be incompatible with this strategy, potentially due to unproductive ligation to the 
OsO4 catalyst. 
 
Entry Conditions Result
 
1 OsO4, NMO, Me2CO, H2O, RT Complex mixture, 170 (7%) 
2 AD-mix α, MsNH2, t-BuOH, H2O, 25 °C Complex mixture 
Table 12. Attempted synthesis of dihydroxylated spirocycle 169. 
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2.4 Summary 
The Ag(I)-catalysed spirocyclisation of indole-ynone and indole-propargyl alcohol systems 
has been developed. A wide range of spirocyclic indolenines and benzannulated indoles have 
been prepared in high yield through catalyst-selective synthesis. A heterogeneous catalyst in 
the form of AgNO3·SiO2 was also discovered, which could be easily reused up to five times to 
afford spirocyclic indolenines in quantitative yield. An asymmetric spirocyclisation protocol 
using the silver salt of a chiral phosphoric acid was also developed, which can be used to 
furnish spirocyclic indolenines in up to 89:11 er. 
The developed methodologies were applied in the accidental synthesis of (±)-
actinopolymorphol B and in studies towards the synthesis of spirobacillene B. 
Overall, the work described in this Chapter was the subject of four publications.
58,63,85,86
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Chapter 3. Indole α-diazocarbonyl cyclisations 
3.1 Introduction 
In Chapter 2 a number of spirocyclic indolenines were prepared by the dearomative 
spirocyclisation of indole tethered alkynes. This approach utilised a general strategy where a 
latent electrophile, such as an alkyne, is activated by a metal catalyst to promote a 
dearomative spirocyclisation reaction (Scheme 55). Here, the development of a new 
spirocyclisation methodology was planned by varying the latent electrophile from an alkyne to 
an α-diazocarbonyl. An indole tethered α-diazocarbonyl posed as an attractive target for 
catalysis as α-diazocarbonyl compounds can readily form electrophilic metal carbenoids upon 
reaction with a metal catalyst.
87,88
 
 
Scheme 55. Synthesis of spirocyclic indolenines by a dearomatisation strategy. 
The reactivity of a diazo compound and the carbenoid it forms can be easily modulated by the 
electronics of the adjacent functional groups; these systems generally fall into three main 
categories: i) donor/acceptor, ii) acceptor and iii) acceptor/acceptor (Figure 12).
89,90
 An 
acceptor group increases the stability of a diazo compound by decreasing its nucleophilicity 
through electron withdrawing effects, but these effects also destabilise the ensuing 
electrophilic carbenoid, promoting unselective reactivity. Conversely, a donor group increases 
the nucleophilicity through electron donating effects, which decreases the stability of the 
diazo compound. However, following decomposition, the resultant carbenoid is stabilised by 
the donor group, which attenuates its reactivity, allowing for greater selectivity to be 
observed. 
 
Figure 12. Diazo compound and carbenoid categories.  
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3.2 Project background and aims 
The reactivity of indole-tethered α-diazocarbonyls has been scarcely explored outside of a few 
known instances. Predominately Rh(II)-catalysis has been used, as first demonstrated by Jung 
and Slowinski, who reacted indole 173 with Rh2(OAc)4 to afford the C2-annulated indole 174 
in good yield with a small quantity of spirocycle 175 (Scheme 56a).
91
 Although low-yielding, 
the formation of 175 was a significant proof of principle for a potential spirocyclisation 
protocol. Next, Cuevas-Yañez and co-workers reported two similar reactions with indoles 176 
and 177, again using Rh2(OAc)4 to promote the modest yielding formation of C2-annulated 
products 178 and 179, with no other reported products (Scheme 56b).
92
 More recently, Doyle 
and co-workers reported a single example of a Rh2(oct)4-catalysed C2-annulation reaction, 
affording indole 181 in excellent yield (Scheme 56c).
93
 
 
Scheme 56. Previous reactivity of indole-tethered α-diazcarbonyls with Rh(II)-based catalysts. 
All of these prior examples relied solely on acceptor/acceptor carbenoid systems in 
combination with a Rh(II)-catalyst. Qin and co-workers were the first to differ from this 
approach, by using a Cu(I)-catalyst with the donor/acceptor carbenoid system of 182 to form 
spirocyclic cyclopropane 183 in excellent yield (Scheme 57a).
94,95
 Later, Qin and co-workers 
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reacted indole 184 with the same Cu(I)-catalyst to afford indoline 185, which is proposed to 
form via the fragmentation of a cyclopropane intermediate (186 → 187, Scheme 57b).96 
 
Scheme 57. Previous reactivity of indole-tethered α-diazcarbonyls with a Cu(I)-based catalyst. 
Thus, as briefly demonstrated by Qin and co-workers, it was envisaged that a donor/acceptor 
carbenoid system, as in 188, might allow for a spirocyclisation methodology to be developed, 
especially when exposed to a wider range of catalysts (Scheme 38a). If successful, this 
strategy might also be applied in the synthesis of spirobacillene B 13 (Scheme 38b). 
 
Scheme 58. a) Proposed spirocyclisation methodology; b) Potential synthesis of spirobacillene B 13.  
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3.3 Reaction discovery & optimisation studies 
Studies began with the synthesis of model substrate 188a, which was made in two steps from 
the previously prepared Weinreb amide 81b (Scheme 59). Amide 81b was first reacted with 
benzylmagnesium chloride to form benzyl ketone 192a, which was then reacted under Regitz 
diazo-transfer conditions with p-ABSA and DBU to afford the desired α-diazocarbonyl 
188a.
88
 However, the isolation of α-diazocarbonyl 188a proved difficult, as it was found to 
degrade and form another product during column chromatography. This degradation product 
was isolated and identified as C2-annulated indole 193a by X-ray crystallographic analysis 
(Figure 13). Fortunately, this reaction could be completely suppressed by the addition of 3% 
Et3N to the column eluent, suggesting that the formation of indole 193a was catalysed by the 
Brønsted acidic silica gel. Further studies found that, if desired, indole 193a could be 
selectively formed in good yield by reacting 188a with an equivalent weight of silica gel in 
dichloromethane (Scheme 60).  
 
Scheme 59. Synthesis of model α-diazocarbonyl substrate 188a. 
 
Figure 13. X-ray structure of C2-annulated indole 193a with thermal ellipsoids shown at 50% 
(opposite enantiomer omitted for clarity, CCDC 1481930). 
 
Scheme 60. Silica gel-catalysed synthesis of C2-annulated indole 193a. 
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Based on the apparent change in substitution pattern, it is proposed that indole 193a is formed 
by a Wolff-rearrangement process (188a → 194 → 195, Scheme 61),97 whereby an 
electrophilic ketene intermediate might cyclise by nucleophilic attack from either the indole 
C2- (195 → 197 → 193a) or C3-position followed by a 1,2-migration (195 → 196 → 193a). 
 
Scheme 61. Proposed mechanisms for the synthesis of indole 193a. 
Having successfully prepared α-diazocarbonyl 188a and controlled the formation of indole 
193a, studies towards the synthesis of spirocycle 190a were resumed.  The α-diazocarbonyl 
188a was reacted with a range of potential catalysts (10 mol%) in dichloromethane (0.1 M) 
under an atmosphere of argon in an attempt to induce the formation of spirocycle 188a (Table 
13). These experiments were carried out on a small scale (0.05 mmol of 188a) and the 
1
H 
NMR spectra of the unpurified reaction mixtures were examined. 
Considering the literature precedent, Rh(II)-based catalysts were first examined (entries 1–4), 
from which Rh2oct4 was found to form both spirocycle 190a (~1:1 dr) as the major product 
and a small quantity of α,β-dicarbonyl 198a (entry 4). Interestingly, two other products were 
also identified during these studies, namely, another C2-annulated indole isomer 199a and a 
related oxidation product, carbazole 200a (entries 1–3).  
Intrigued by the number of products arising from these reactions, the aims of this project were 
broadened to include the selective synthesis of these other products, which was pursued 
through further catalyst screening. The potential synthesis of five products from a single 
starting material became an unprecedented and exciting challenge in the field of catalyst-
selective synthesis.
98
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Entry 
 
Catalyst
a
 
Ratiob 
188a
 
193a 190a 198a 199a 200a 
1 
R
h
(I
I)
 
Rh2(OAc)4 0 15 0 50 20 15 
2 Rh2esp2 0 20 10 55 15 0 
3 Rh2TPA4 0 10 0 70 20 0 
4 Rh2oct4 0 0 95 5 0 0 
5 
C
u
(I
) 
CuBr 5 0 75 20 0 0 
6 CuI 0 0 80 20 0 0 
7 Cu(MeCN)4OTf 0 0 20 0 60 20 
8 Cu(MeCN)4PF6 15 0 65 20 0 0 
9 
C
u
(I
I)
 
Cu(OAc)2 0 0 85 15 0 0 
10 Cu(2-ethylhexanoate)2 10 0 90 0 0 0 
11 CuCl2 25 0 0 0 50 25 
12 Cu(OTf)2 0 0 0 0 70 30 
13 
P
d
(I
I)
 
Pd(MeCN)2Cl2 0 0 55 0 45 0 
14 Pd(MeCN)4(BF4)2 0 0 0 0 95 5 
15 Pd(OAc)2 40 0 50 0 10 0 
16 PdCl2 30 5 50 10 5 0 
17 
A
g
(I
) 
AgOTf 0 0 0 0 90 10 
18 AgNO3 30 0 35 35 0 0 
19 AgOAc 20 0 65 15 0 0 
20 
A
u
(I
) Ph3PAuCl + AgOTf 0 0 0 0 95 5 
21 Ph3PAuNTf2 0 0 35 0 65 0 
22 
F
e/
S
n
(I
I)
 Fe(ClO4)2·xH2O 0 5 0 0 80 15 
23 FeCl2·4H2O 95 5 0 0 0 0 
24 SnCl2·2H2O 0 0 0 0 0 0 
a
Reactions performed with 0.05 mmol of 188a and 10 mol % catalyst in CH2Cl2 (0.1 M) under argon 
at RT for 16 h; 
b
Calculated by 
1
H NMR spectroscopic analysis of the unpurified reaction mixture, 
rounded to the nearest 5%. 
Table 13. Catalyst screening with α-diazocarbonyl 188a.  
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Investigation of  Cu(I)- (entries 5–8), Cu(II)- (entries 9–12), Pd(II)- (entries 13–16), Ag(I)- 
(entries 17–19), Au(I)- (entries 20–21), Fe(II)- (entries 22–23) and Sn(II)-based catalysts 
(entry 24), revealed Pd(MeCN)4(BF4)2 as a highly effective catalyst for the selective synthesis 
of indole 199a. During these studies, the concomitant formation of carbazole 200a was also 
typically observed alongside indole 199a, especially so when using Cu(OTf)2, which is 
presumed to catalyse the oxidation of indole 199a to carbazole 200a. 
Having completed the initial catalyst screening studies, the three most selective catalysts, 
Rh2oct4, Pd(MeCN)4(BF4)2 and Cu(OTf)2, were selected for further optimisation. First, the 
Rh2oct4-catalysed formation of spirocycle 190a was examined, where it was found that 
formation of the α,β-dicarbonyl 198a side-product was dependent on the presence of air in the 
reaction.  Thus, performing the reaction under oxygen-free conditions (with other minor 
modifications, such as switching the solvent from dichloromethane to chloroform and 
reducing catalyst loading) allowed spirocycle 190a to be prepared in excellent yield (Table 14, 
entry 1). Furthermore, carrying out the same reaction in a flask open to air (at reduced catalyst 
loading and concentration) was sufficient to completely switch the selectivity, affording the 
α,β-dicarbonyl 198a in 78% yield (entry 2). The structure of 198a was also proven by X-ray 
crystallography (Figure 14). 
 
Entry Conditions  Result 
1 Rh2oct4 (5 mol%), CHCl3 (0.1 M), argon, 6 h 190a, 92%, 54:46 dr 
2 Rh2oct4 (2 mol%), CHCl3 (0.05 M), air, 1 h 198a, 78% 
Table 14. Rh2oct4-catalysed synthesis of spirocycle 190a and α,β-dicarbonyl 198a. 
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Figure 14. X-ray structure of α,β-dicarbonyl 198a with thermal ellipsoids shown at 50% (CCDC 
1481924). 
It is proposed that both of these reactions initiate by the formation of rhodium carbenoid 201, 
which may then form spirocycle 190a either by: (i) a cyclopropanation and fragmentation 
pathway (201 → 202 → 190a, Scheme 62a) or (ii) direct attack from the indole C3-position 
followed by protodemetallation (201 → 203 → 190a). In a flask open to air, oxygen is 
proposed to abstract the α-keto H-atom of 190a to form α-keto radical 204 and a hydroperoxyl 
radical, which can then immediately recombine in a radical rebound process to afford 
peroxide 205 (Scheme 62b).
99–101
 Peroxide 205 may then cyclise to form endoperoxide 206, 
which following fragmentation would afford α,β-dicarbonyl 198a. A purified sample of 
spirocycle 190a in CDCl3 was also observed to form α,β-dicarbonyl 198a over time by 
1
H 
NMR analysis, confirming that spirocycle 190a was indeed a direct precursor to α,β-
dicarbonyl 198a.  
Chapter 3. Indole α-diazocarbonyl cyclisations 
 
 
70 
  
Scheme 62. a) Proposed mechanism for the Rh2oct4 catalysed formation of spirocycle 190a; b) 
Proposed mechanism for the formation of α,β-dicarbonyl 198a. 
Indirect supporting evidence for the formation of an endoperoxide intermediate was later 
found when endoperoxide 208 was isolated from the reaction of vinyl-substituted α-
diazocarbonyl 207 under the same reaction conditions (Scheme 63a). This 7-membered ring 
endoperoxide is proposed to form via a similar pathway to before, except in this case, the 
radical rebound process may occur at the less sterically hindered alkene terminus (Scheme 
63b). The structure of 208 was definitively proven by X-ray crystallography (Figure 15). 
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Scheme 63. Allyl α-diazocarbonyl endoperoxide formation. 
 
Figure 15. X-ray structure of endoperoxide 208 with thermal ellipsoids shown at 50% (CCDC 
1481929). 
Interestingly, during purification of α,β-dicarbonyl 198a by column chromatography, the 
formation of small quantities of a new product was also detected. Isolation of this product and 
X-ray analysis revealed the structure to be spirocyclic oxindole 212a, with a syn-relationship 
between the oxindole carbonyl and the hydroxyl group (Figure 16). Oxindole 212a was 
presumed to form by an aldol reaction promoted by the acidic silica gel; this diastereoselective 
aldol reaction could proceed via a 6-membered transition state, such as 213, where the syn-
diastereoselectivity might be dictated by hydrogen bonding between the oxindole-enol and the 
reactive phenone carbonyl (Scheme 64). Pleasingly, it was found that this reactivity could be 
harnessed in a one-pot process, where α,β-dicarbonyl 198a was formed as previously and then 
immediately reacted with TFA following a solvent switch to THF to afford oxindole 212a in 
near-quantitative yield (Scheme 65). 
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Figure 16. X-ray structure of spirocyclic oxindole syn-diastereoisomer 212a with thermal ellipsoids 
shown at 50% (CCDC 1481927). 
 
Scheme 64. Proposed 6-membered transition state in the diastereoselective Brønsted acid catalysed 
formation of oxindole 212a. 
 
Scheme 65. One-pot Brønsted acid promoted synthesis of spirocyclic syn-oxindole 212a. 
Intrigued by the reactivity of α,β-dicarbonyl 198a with Brønsted acids, Brønsted bases were 
next examined in hopes of accessing the opposite anti-diastereoisomer. Indeed, the anti-
diastereoisomer 214a could be prepared in modest yield by another one-pot process, where the 
α,β-dicarbonyl 198a was formed in situ then reacted with t-BuOK in THF at −78 °C (Scheme 
66). The anti-diastereoisomer is believed to be formed via a transition state such as 215 
(Scheme 67), where unfavourable steric clashes are minimised and the carbonyl dipoles are 
opposed. The relative stereochemistry of the anti-diastereoisomer was also confirmed by X-
ray crystallography (Figure 17). 
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Scheme 66. One-pot Brønsted base promoted synthesis of spirocyclic anti-oxindole 214a. 
 
Scheme 67. Proposed transition state for the diastereoselective Brønsted base catalysed formation of 
oxindole 214a. 
 
Figure 17. X-ray structure of spirocyclic oxindole anti-diastereoisomer 214a with thermal ellipsoids 
shown at 50% (CCDC 1481928). 
Next, the Pd(MeCN)4(BF4)2-catalysed conditions for the synthesis of indole 199a were 
examined, which following a solvent switch to chloroform and a reduction of the catalyst 
loading, could be used to prepare indole 199a in excellent yield (Scheme 68). The structure of 
indole 199a was definitively proven by X-ray crystallography (Figure 18). 
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Scheme 68. The Pd(MeCN)4(BF4)2-catalysed synthesis of indole 199a. 
 
Figure 18. X-ray structure of indole 199a with thermal ellipsoids shown at 50% (CCDC 1481925). 
Finally, the Cu(OTf)2-catalysed conditions for the synthesis of carbazole 200a were 
optimised. To drive the oxidation of indole 199a to completion, an increased catalyst loading 
(20 mol%) was required, followed by the delayed introduction of an oxygen atmosphere at a 
higher temperature (50 °C). If the reaction was initiated under oxygen then the yield was 
diminished by the formation of the α,β-dicarbonyl 198a, which strongly suggests that the 
precursor, spirocycle 190a, is an intermediate in this reaction. The structure of carbazole 200a 
was definitively proven by X-ray crystallography (Figure 19). 
 
Scheme 69. The Cu(OTf)2-catalysed synthesis of carbazole 200a. 
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Figure 19. X-ray structure of carbazole 200a with thermal ellipsoids shown at 50% (CCDC 1481926). 
To further probe whether spirocycle 190a was indeed an intermediate in the formation of 
indole 199a, spirocycle 190a was reacted with both Pd(MeCN)4(BF4)2 and Cu(OTf)2 (Table 
15). Interestingly, Pd(MeCN)4(BF4)2 had no effect on spirocycle 190a (entry 1), whilst 
Cu(OTf)2 reacted rapidly with spirocycle 190a to form indole 199a as evident by analysis of 
the 
1
H NMR spectrum of the reaction mixture. These results suggest that although the Pd(II)- 
and Cu(II)-catalysed reactions share indole 199a as a common intermediate/product, they may 
promote different mechanistic pathways. 
 
Entry Additive Result
a 
1 Pd(MeCN)4(BF4)2 (5 mol%) No reaction 
2 Cu(OTf)2 (20 mol%) Rapid conversion into 199a 
a
Determined by analysis of the 
1
H NMR spectra of the unpurifed reaction mixture 
Table 15. Additive screening with spirocycle 190a. 
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Considering these results, it is proposed that Cu(OTf)2 might initially promote the formation 
spirocycle 190a as previously proposed with Rh2(oct)4 (Scheme 70). However, upon 
formation of spirocycle 190a, Cu(OTf)2 may induce a Lewis acid catalysed 1,2-migration to 
form indole 199a, which may then undergo a Cu(II)-catalysed oxidation (with oxygen as the 
terminal oxidant) to form carbazole 200a. 
 
Scheme 70. Proposed mechanism for the Cu(OTf)2-catalysed synthesis of carbazole 200a. 
For the Pd(MeCN)4(BF4)2-catalysed synthesis of indole 199a an alternative mechanism is 
proposed, in which the reaction is initiated by electrophilic palladation at the indole C2-
postion (188a → 219, Scheme 71a).102–104 Following palladation, the diazo group could 
coordinate to the metal centre (219 → 220), which after the extrusion of nitrogen would afford 
palladium carbenoid 221; subsequent migratory insertion would generate palladium-species 
222, which after protodemetallation would regenerate the Pd(II) catalyst and afford indole 
199a.
105–108
Supporting evidence for a mechanism initiated by palladation at the indole 2-
position was found when a control substrate 223, with a methyl group blocking the 2-position, 
was reacted under the standard conditions, from which no reaction was observed (Scheme 
71b). 
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Scheme 71. a) Proposed mechanism for the Pd(MeCN)4(BF4)2-catalysed synthesis of indole 199a; b) 
Supporting control reaction with 2-methyl substituted substrate 223. 
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3.4 Substrate Synthesis 
To fully explore the scope of the developed transformations, a wider range of α-diazocarbonyl 
substrates were prepared. First, Weinreb amides 81i,j were prepared in a three step sequence 
(Table 16). Commerically available indoles 224 were readily converted into 3-indolepropionic 
esters by a ZrCl4-catalysed conjugate addition into ethyl acrylate,
109
 which following 
saponification and a T3P-mediated amide coupling afforded Weinreb amides 81i,j. 
 
Entry R Yield over 3 steps (%)
 
1 6-Cl (81i) 55 
2 5-OMe (81j) 65 
Table 16. Synthesis of 3-indolepropionic acid derivatives. 
The 3-indolepropionic acid derived Weinreb amides 81 were than reacted with the appropriate 
benzyl Grignard reagents to form benzyl ketones 192a–e (Scheme 72). 
 
Scheme 72. Scope of benzyl ketones prepared by Grignard addition. 
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The benzyl ketones 192 were then used to prepare α-diazocarbonyls 188 by Regitz diazo 
transfer using p-ABSA and DBU (Scheme 73). 
 
Scheme 73. Scope of α-diazocarbonyls prepared by Regitz diazo transfer reactions. 
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3.5 Substrate Scope 
With a wider range of substrates in hand, the scope of the six optimised reaction protocols 
were examined. First, the silica gel-promoted formation of the C2-annulated indoles 193 was 
investigated (Scheme 74). Pleasingly, every substrate prepared underwent the desired 
transformation, affording indoles 193a–d in modest to good yield, whilst indole 193e was 
formed in a diminished 38% yield with no other isolable products detected. 
 
Scheme 74. The silica gel-catalysed cyclisation substrate scope. 
Next, the Rh2oct4-catalysed synthesis of spirocycles 190a–e was examined (Scheme 75). 
Again, every substrate successfully formed the corresponding spirocycle in modest to 
excellent yield. Modest diastereoselectivity was also observed, with the structure of the same 
major diastereoisomer assigned by nOe studies for each example (Figure 20). 
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Scheme 75. Scope of the Rh2(oct)4-catalysed spirocycle synthesis. 
 
Figure 20. Assignment of spirocycle diastereoisomers based on nOe correlations. 
All of the substrates were also successfully converted into the corresponding spirocyclic syn-
oxindoles 212a–e in good to excellent yield (Scheme 76). Aside, from the original X-ray 
analysis of oxindole 212a, diagnostic signals in 
1
H NMR spectra of oxindoles 212b–e were 
also used to confirm their stereochemistry (Figure 21). For example, in every case noticeable 
shielding of the H-2 proton was observed, likely due to the positioning and magnetic 
anisotropic effects of the α-keto aromatic ring, which is easily visualised in the structure 
provided by X-ray analysis of oxindole 212a. The opposite anti-diastereoisomers 214a–c,e 
were also prepared in consistently modest yield (40–58%) except for oxindole 214d, which 
was prepared in 73% yield (Scheme 77). 
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Scheme 76. Scope of the acid-promoted synthesis of syn-oxindoles. 
 
 
Figure 21. Diagnostic anisotropic shielding of the syn-oxindoles. 
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Scheme 77. Scope of the base-promoted synthesis of anti-oxindoles. 
Next, the optimised Pd(MeCN)4(BF4)2-catalysed conditions were successfully applied to 
every substrate, forming indoles 199a–e in modest to excellent yield (Scheme 78). Finally, the 
Cu(OTf)2-catalysed carbazole formation conditions were examined (Scheme 79), where every 
carbazole 200a–d except for 200e was isolated in good yield.  
 
Scheme 78. Scope of the Pd(MeCN)4(BF4)2-catalysed annulation reaction. 
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Scheme 79. Scope of the Cu(OTf)2-catalysed tandem annulation-oxidation reaction. 
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3.6 Preliminary studies towards spirobacillene B 
To conclude studies with the α-diazocarbonyl system, studies towards the synthesis of 
spirobacillene B were resumed. Here, it was envisaged that the developed Rh(II)-catalysed 
spirocyclisation could be readily applied to an α-diazocarbonyl 225 derived from Tang‟s 
intermediate 21 (Scheme 80).
16
 The resultant spirocycle 24 used by Tang and co-workers 
could then be deprotected and oxidised under their conditions to afford spirobacillene B (24 
→ 224 → 13). 
 
Scheme 80. Retrosynthetic analysis of spirobacillene B 13 using an α-diazocarbonyl. 
Attempts to prepare model substrate 227 with an oxygen substituent in the required para-
position were unsuccessful (Scheme 81). The benzyl ketone 226 was prepared in good yield, 
but the required α-diazocarbonyl 227 could not be isolated under the Regitz diazo transfer 
conditions, with only decomposition of the starting material observed by TLC analysis. This 
result was attributed to the destabilising effects of the electron donating oxygen substituent, 
which is in direct conjugation to the reactive diazo centre (as shown in 228). At this point, no 
further studies were attempted, but future work might look to attenuate the destabilising 
effects of the oxygen substituent with an electron withdrawing protecting group. 
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Scheme 81. Attempted synthesis of α-diazocarbonyl 227. 
 
3.7 Summary 
The selective synthesis of six different products from a single indole α-diazocarbonyl 
precursor has been developed (Figure 22). This feat, which is to the best of our knowledge a 
record number of products formed from a single precursor, was achieved by using Brønsted 
acid-, Rh(II)-, Pd(II)- and Cu(II)- catalysis to exploit a variety of different mechanistic 
pathways. Full elucidation of the proposed mechanistic pathways, as well as the application of 
this chemistry to other heteroarenes, such as pyrrole, remains the focus of future work. 
The work described in this Chapter was the subject of a recent publication.
110
 
 
Figure 22. Illustrative rainbow of products from a single “pot of gold”. 
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Chapter 4. Dearomatisation approach to quinolizidine and 
indolizidine alkaloids 
4.1 Introduction 
In the previous chapters, all of the work was focused on the synthesis of spirocyclic 
indolenines through the dearomatisation of indole. Here, it was planned to tether alkynes to 
other heteroaromatic systems, such as pyridine 228 and pyrrole 231, in hopes of promoting 
cyclisation through the nitrogen atom to afford quinolizinones 229 or indolizines 232, which 
following a dearomative hydrogenation would provide access to quinolizidine 230 and 
indolizidine 233 frameworks (Scheme 82). Ideally, the two catalytic steps would be performed 
in a one-pot process, which could potentially be rendered asymmetric if an enantioselective 
hydrogenation step could be realised. 
 
Scheme 82. The proposed two-step cyclisation and hydrogenation of pyridine- and pyrrole-ynones. 
The quinolizidine and indolizidine frameworks are found in a number of bioactive natural 
products, such as 234–237 (Scheme 83).111–115 These natural products have typically been 
isolated in small quantities, which hinders their study as potential therapeutics, and so, it is 
hoped that the proposed sequence will provide an expedient and scalable route for their 
synthesis. 
 
Scheme 83. Quinolizidine and indolizidine alkaloids.  
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4.2 Background 
Quinolizinones have previously been prepared by the cyclisation of pyridine-alkyne systems, 
as first demonstrated by Katritzky and co-workers (Scheme 84a), who found that 
quinolizinones 240 could be prepared by heating pyridines 238 and benzotriazoles 239 in 
acetonitrile at 120 °C in a sealed tube.
116
 Later, Natarajan and co-workers reported a modified 
protocol (Scheme 84b), whereby picoline derivatives 241 were first acylated with a methyl 
ester 242 and then cyclised at a reduced temperature (80 °C).
117,118
 Both of these protocols 
suffered from the requirement of relatively harsh thermal cyclisation conditions as well as 
modest yields across a limited range of substrates. It was hoped that all of these negative 
aspects could be alleviated by a catalytic method. 
 
Scheme 84. Pyridine alkyne cyclisation reactions to form quinolizinones. 
Indolizines have also been prepared by the cyclisation of pyridine-alkyne systems. Notable 
examples include the work of Gevorgyan and co-workers, who first reported the Au(III)-
catalysed cyclisation of TBS-protected propargyl alcohols 244 to afford indolizines 246 in 
modest to excellent yield (Scheme 85a).
119
 This reaction proceeded via the formation and 
cyclisation of an electrophilic vinylidene intermediate 245. Later, Gevorgyan and co-workers 
reported a simpler Ag(I)-catalysed protocol, where propargyl alcohols 247 were activated with 
AgBF4 and cyclised to afford indolizines 249 in typically excellent yields (Scheme 85b).
120
 
Finally, Sarpong and co-workers reported a Pt(II)-catalysed procedure to form indolizinones 
253 from tertiary propargyl alcohols 250 by a cyclisation and 1,2-migration sequence 
(Scheme 85b).
121
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Scheme 85. Pyridine alkyne cyclisation reactions to form  indolizidines. 
The current leading methods for the catalytic synthesis of quinolizidine and indolizidine 
alkaloids have arguably been developed by Rovis and co-workers, who used Rh(I)-catalysis to 
promote [2+2+2] cycloadditions with alkenyl isocyanates 254 and terminal alkynes 255 to 
generate quinolizidine or indolizidine alkaloid precursors 258 in good to excellent yield and 
with excellent enantioselectivity (Scheme 86).
122,123
 Rovis and co-workers first employed this 
methodology in the synthesis of (+)-lasubine II 235 (Scheme 86a), by hydrogenating the 
[2+2+2] product 259 to form quinolizidine 260. The hydroxyl group stereochemistry of 
quinolizidine 260 was then inverted by a Mitsunobu and hydrolysis sequence to afford 27.0 
mg of (+)-lasubine II 235.
122
 Later, the same group applied this methodology in the synthesis 
of (−)-indolizidine 209D 237 (Scheme 86b), using a new phosphoramidite ligand 247 to form 
the [2+2+2] product 261 in good yield.
123
 The [2+2+2] product 261 was then hydrogenated 
and deoxygenated under Barton-McCombie conditions to afford 18.2 mg of (−)-indolizidine 
209D 237. Overall, whilst this [2+2+2] methodology provided access to these natural products 
in a concise enantioselective fashion, only small quantities were ever prepared and required an 
expensive catalyst system to do so. Thus, it is hoped that the proposed method could improve 
upon this pioneering work. 
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Scheme 86. Leading methods for the catalytic synthesis of quinolizidine and indolizidine alkaloids. 
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4.3 Pyridine-ynone cyclisations 
4.3.1 Reaction discovery & optimisation studies 
Studies of the proposed pyridine-ynone system began with preparation of ynone 228a, which 
was made by the acylation of 2-picoline 264 with methyl phenylpropiolate under modified 
conditions reported by Natarajan and co-workers (Scheme 87).
117
 
 
Scheme 87. Synthesis of pyridine-ynone 228 by the acylation of 2-picoline 264. 
Ynone 228a was then reacted with a range of catalysts in dichloromethane in an attempt to 
promote cyclisation (Table 17). These experiments were performed on a small scale (0.2 
mmol of ynone 228a) and examined by analysis of the 
1
H NMR spectra of the unpurified 
reaction mixtures. These studies were also aided by a York MChem student (Niall Grant). 
First, a range of Cu(I/II)-, Au(I)- and Ag(I)-based catalysts were examined (entries 1–4), of 
which only AgOTf was found to promote the formation of quinolizinone 229a. Further 
examination of other Ag(I) catalysts (at reduced catalyst loading), showed that both AgNO3 
and AgNTf2 were the most effective catalysts (entries 9 & 10). However, only AgNO3 was 
selected for further study as it is significantly cheaper than AgNTf2. Finally, using AgNO3     
(1 mol%) as the optimal catalyst, the solvent system was varied (entries 11–16), which 
showed that the rate of reaction could be significantly improved by performing the reaction in 
either EtOH or to a lesser extent DCE. 
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Entry Catalyst
a
 mol % Solvent Time (h) Ratio
b
 228a:229a 
1 Cu(MeCN)4PF6 10 CH2Cl2 16 100:0 
2 Cu(OTf)2 10 CH2Cl2 16 100:0 
3 Ph3PAuNTf2 10 CH2Cl2 16 100:0 
4 AgOTf 10 CH2Cl2 16 5:95 
5 AgOTf 2 CH2Cl2 2 10:90 
6 AgSbF6 2 CH2Cl2 2 75:25 
7 Ag2O 2 CH2Cl2 2 68:32 
8 AgOAc 2 CH2Cl2 2 36:64 
9 AgNTf2 2 CH2Cl2 2 5:95 
10 AgNO3 2 CH2Cl2 2 5:95 
11 AgNO3 1 CH2Cl2 0.5 50:50 
12 AgNO3 1 Toluene 0.5 100:0 
13 AgNO3 1 THF 0.5 100:0 
14 AgNO3 1 CHCl3 0.5 10:90 
15 AgNO3 1 DCE 0.5 5:95 
16 AgNO3 1 EtOH 0.5 0:100 
a
All reactions performed with 0.2 mmol of ynone 228a in the stated solvent at RT; 
b
Calculated by  
1
H NMR spectroscopy of the unpurified reaction mixture. 
Table 17. Optimisation of the pyridine-ynone cyclisation conditions. 
The rate of reaction was believed to be highly susceptible to the degree of keto–enol 
tautomerisation of ynone 228a (which exists primarily as the enol tautomer in CDCl3, Figure 
23). The geometry of the enol tautomer was assigned as the cis-alkene, based upon the high 
chemical shift of the enol proton observed in the 
1
H NMR spectrum (15.02 ppm in CDCl3), 
which is likely to be due to intramolecular hydrogen bonding with the nitrogen lone pair of the 
pyridine ring. This cis-alkene geometry is believed to hinder reactivity by decreasing the 
proximity of the nitrogen lone pair and alkyne moiety; thus, the reaction is proposed to 
proceed via the electrophilic activation of the keto tautomer (which can freely rotate), 
followed by a 6-endo-dig cyclisation through the nitrogen lone pair (228a → 265 → 266, 
Scheme 88).
124
 Subsequent aromatisation and protodemetallation of 266 would then afford the 
observed quinolizinone 229a and regenerate the Ag(I) catalyst. 
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Figure 23. 
1
H NMR spectrum of pyridone-ynone 228a in CDCl3. 
 
 
Scheme 88. Proposed mechanism for Ag(I)-catalysed synthesis of quinolizinone 229a. 
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4.3.2 Substrate synthesis 
To explore the scope of the Ag(I)-catalysed cyclisation a wider range of pyridine-ynones 228 
were required. First, a number of methyl propiolate esters 269a–c, which were not 
commercially available, were prepared in modest, unoptimised yields from the corresponding 
commerically available terminal alkynes 268 by deprotonation and trapping with methyl 
chloroformate (Scheme 89). 
 
Scheme 89. Synthesis of methyl propiolate esters. 
Alternatively, where the requisite alkyne was not commercially available, the ester could be 
accessed from an aldehyde and a partial Corey-Fuchs reaction e.g. in the preparation of 
alkynyl ester 269d (Scheme 90).
125
 
 
Scheme 90. Synthesis of ester 269d from a partial Corey-Fuchs reacton. 
Next, the methyl propiolate esters were used to acylate a number picoline-type systems (as 
demonstrated in Scheme 87) to afford pyridine-, isoquinoline- and pyrazine-ynones 228a–l in 
generally good yields (Scheme 91). 
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Scheme 91. Library of pyridine-ynone substrates prepared. 
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4.3.3 Substrate scope 
With a number of ynones in hand, attention switched to examining the scope of the Ag(I)-
catalysed cyclisation reaction. It was then realised that a number of substrates demonstrated 
poor solubility in EtOH, the solvent used in the originally optimised conditions, and so DCE 
was used as a solubilising co-solvent to alleviate this problem. The catalyst loading was also 
raised to 2 mol% of AgNO3 in all examples for consistency. These new optimal conditions 
were then applied across the full substrate library (Scheme 92).  
First, aryl and aliphatic ynones 228a–d with varying electronics were all converted into 
quinolizinones 229a–d in quantitative/near-quantitative yield. Thiophene and methylated 
ynones 228e,f were then examined, but unfortunately these substrates were unstable at room 
temperature and so afforded the corresponding quinolizinones 229e,f in diminished yield. 
Next, ynones 228g–i with different substituents on the pyridine ring were converted into 
quinolizinones 229g–i in excellent yield. The structure of quinolizinone 229h was proven by 
X-ray crystallography (Figure 24). Finally, isoquinoline- and pyrazine- ynones 228j,k were 
also successfully cyclised to afford the corresponding quinolizinone-type products 229j,k in 
excellent yield. 
 
Chapter 4. Dearomatisation approach to quinolizidine and indolizidine alkaloids 
 
 
97 
 
Scheme 92. Substrate scope of the Ag(I)-catalysed cyclisation. 
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Figure 24. X-ray structure of quniolizinone 229h with thermal ellipsoids shown at 50% (CCDC 
1507022). 
The only substrate which failed to undergo the desired cyclisation under the standard 
conditions was TMS-ynone 228l. Interestingly, this substrate was also unreactive under the 
thermal conditions employed by Natarajan and co-workers.
117
 However, by changing the 
conditions, a one-pot desilylation-cyclisation reaction could be performed by reacting 228l 
with AgNO3 (20 mol%) in acetone to afford quinolizinone 229l in excellent yield (Scheme 
93).  
 
Scheme 93. One-pot desilylation-cyclisation of ynone 228l. 
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4.3.4 Synthesis of (±)-lasubine II 
Having established an operationally simple, mild and high yielding catalytic protocol for the 
synthesis of quinolizinones, the dearomative hydrogenation of these frameworks to access 
quinolizidine natural products was planned. In particular, the synthesis lasubine II 235 was 
envisaged, as the known intermediate 230b was expected to be readily prepared from the 
hydrogenation of quinolizinone 229b (Scheme 94). 
 
Scheme 94. Retrosynthetic analysis of lasubine II. 
Studies towards the synthesis of (±)-lasubine II began with the previously described synthesis 
of quinolizinone 229b, which was readily prepared on a multi-gram scale (2.09 g) in two steps 
from 2-picoline 264 (Scheme 95). The dearomative hydrogenation of quinolizinone 229b was 
then attempted by reaction with Pd/C in MeOH under an atmosphere of hydrogen, which 
selectively hydrogenated only one of the desired ring systems to afford pyridone 273. 
Fortunately, both ring systems could be fully hydrogenated to afford quinolizidine 230b by 
using PtO2 as the catalyst and AcOH (3 equivalents) as an additive to prevent catalyst 
poisoning.
126
 The unpurified quinolizidine 230b was then oxidized under Swern conditions to 
afford ketone 274 in good yield over two steps. Ketone 274 was then reduced under known 
conditions with L-Selectride
®
 to afford 0.53 g of (±)-lasubine II 235 in 36% overall yield and 
in just five steps from 2-picoline 264.
127–130
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Scheme 95. Synthesis of (±)-lasubine II 235. 
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4.4 Pyrrole- & pyrroline-alkyne cyclisations 
Having proven the efficiency of this approach in the synthesis of quinolizidine alkaloids, 
indolizidine systems were next examined. Studies began with the preparation of pyrrole-ynone 
231a, which was prepared in four steps from pyrrole 275 (Scheme 96). First, pyrrole 275 was 
deprotonated with MeMgCl and alkylated with ethyl bromoacetate to form ethyl ester 276 in 
49% yield.
131
 Ester 276 was then saponified to afford acid 277, which was converted into 
Weinreb amide 278 using T3P in good yield over two steps. Amide 278 was then used to 
prepare ynone 231a in modest yield by reaction with a PMP-derived lithium acetylide. A 
small quantity of propargyl alcohol 279a was also prepared by reduction of ynone 231a with 
NaBH4. 
 
Scheme 96. Synthesis of pyrrole-ynone 231a and propargyl alcohol 279a (synthesis aided by Dr 
William Unsworth and Aimee Clarke). 
Initial studies with the pyrrole-alkyne systems began by reacting pyrrole-ynone 231a with 
AgNO3 (10 mol%) in CH2Cl2, which afforded spirocycle 280a in near-quantitative yield 
(Scheme 97a). The analogous pyrrole-based propargyl alcohol 279a was also reacted under 
the same conditions to afford the benzannulated product 281a in excellent yield (Scheme 
97b). Whilst, none of the desired cyclisation through the nitrogen atom was observed, these 
reactions were considered an interesting extension of the work shown in Chapter 2 and further 
studies into these systems are being undertaken in the Taylor group by Aimee Clarke. 
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Scheme 97. Reactivity of pyrrole-alkyne systems: a) Pyrrole-ynones; b) Pyrrole-propargyl alcohols. 
In an attempt to circumvent spirocyclisation/benzannulation reactivity and favour cyclisation 
through the nitrogen atom, the cyclisation of an alternative non-aromatic pyrroline-ynone 
system 283a was planned. The model pyrroline-ynone system 238a was readily prepared in 
one step by the acylation of 2-methyl-1-pyrroline 282 with methyl phenyl propiolate (Scheme 
98). Pyrroline-ynone 283a was then reacted under the pyridine-ynone cyclisation conditions to 
afford the desired pyridone 284a in quantitative yield. The structure of pyridone 284a was 
also confirmed by X-ray crystallography (Figure 25). 
 
Scheme 98. Synthesis and cyclisation of pyrroline-ynone 283a. 
 
Figure 25. X-ray structure of pyridone 284a with thermal ellipsoids shown at 50% (CCDC 1532716).  
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4.4.1 Optimisation studies 
The pyrroline-ynone 283a was then reacted with a range of different catalysts in an attempt to 
find the optimal cyclisation conditions (Table 17). These experiments were performed on a 
small scale (0.05-0.2 mmol of ynone 283a) and the yields were determined by analysis of the 
1
H NMR spectra of the unpurified reaction mixtures against an internal standard (1,3-
bis(trifluoromethyl)-5-bromobenzene). 
First, common Cu(I/II)-, Au(I)- and Ag(I)-based catalysts (10 mol%) were examined in 
CH2Cl2 at 40 °C for 18 h (entries 1–13), and both AgNO3 and AgTFA were found to form 
pyridone 284a in quantitative yield. Further comparison between AgNO3 and AgTFA at 
reduced catalyst loading (5 mol%), showed that AgTFA was slightly more effective in 
promoting the formation of pyridone 284a (entries 14–15). Solvent screening studies with 
AgTFA as the catalyst (entries 16–23) revealed that the rate of reaction could be significantly 
increased by performing the reaction in toluene. Finally, the catalyst loading of AgTFA could 
be further reduced to 2 mol% by raising the temperature to 110 °C, which also reduced the 
reaction time to 1 h (entry 24). A control experiment showed that only traces of pyridone 284a 
was formed under these thermal conditions without a Ag(I) catalyst (entry 25). 
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Entry Catalyst
a 
mol % Solvent Temp (°C) Time / h Yield
b
 (%) 
1 Cu(MeCN)4PF6 10 CH2Cl2 40 18 no reaction 
2 Cu(OTf)2 10 CH2Cl2 40 18 no reaction 
3 Ph3PAuNTf2 10 CH2Cl2 40 18 no reaction 
4 AgSbF6 10 CH2Cl2 40 18 no reaction 
5 AgBF4 10 CH2Cl2 40 18 no reaction 
6 AgOAc 10 CH2Cl2 40 18 <5 trace 
7 AgMs 10 CH2Cl2 40 18 34 
8 AgTs 10 CH2Cl2 40 18 36 
9 AgOTf 10 CH2Cl2 40 18 36 
10 AgNTf2 10 CH2Cl2 40 18 64 
11 AgNO3·SiO2 10 CH2Cl2 40 18 no reaction  
12 AgNO3 10 CH2Cl2 40 18 100 
13 AgTFA 10 CH2Cl2 40 18 100 
14 AgNO3 5 CH2Cl2 40 21 >95 
15 AgTFA 5 CH2Cl2 40 21 100 
16 AgTFA 5 MeCN 40 11 no reaction 
17 AgTFA 5 MeOH 40 11 49 
18 AgTFA 5 EtOH 40 11 55 
19 AgTFA 5 CH2Cl2 40 11 57 
20 AgTFA 5 DCE 40 11 60 
21 AgTFA 5 THF 40 11 68 
22 AgTFA 5 CHCl3 40 11 75 
23 AgTFA 5 PhMe 40 11 100 
24 AgTFA 2 PhMe 110 1 100 
25 no catalyst - PhMe 110 1 <5 trace 
a) Reactions performed with 0.05–0.2 mmol of 283a and catalyst in the stated solvent (0.1 M) and 
temperature; b) Determined by 
1
H NMR spectroscopy against an in internal standard (1,3-
bis(trifluoromethyl)-5-bromobenzene).  
Table 18. Optimisation of the pyrroline-ynone cyclisation conditions.  
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4.5 Future work 
With initial optimisation of the pyrroline-ynone cyclisation conditions completed, future work 
exploring the scope of this transformation and its application in the synthesis of indolizidine 
alkaloids, such as 209D 237 is envisaged (Scheme 99).  
 
Scheme 99. Retrosynthetic analysis of indolizidine 209D 237. 
The application of this chemistry in the synthesis of tricyclic alkaloid frameworks is also 
possible (Scheme 100). Here, it is proposed that a spirocyclic pyridine- or pyrroline-ynone 
286 could be cyclised to form an iminium species 287, which following a ring-expanding 1,2-
migration reaction and protodemetallation would afford tricycle 289. Hydrogenation of 
tricycle 289 would afford saturated tricycle 290, which could be oxidised and epimerised in a 
retro-Michael and Michael addition process (291 → 292 → 293) to access the relative 
stereochemistry found in the cyclindricine alkaloids. This process could also potentially be 
rendered asymmetric be using a silver salt with a chiral counterion, such as a CPA; this 
counterion could form a chiral ion-pair with iminium species 287 and thus promote an 
enantioselective 1,2-migration reaction. 
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Scheme 100. Proposed asymmetric synthesis of tricyclic alkaloid frameworks. 
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4.6 Chapter summary 
The Ag(I)-catalysed cyclisation of pyridine-, isoquinoline-, pyrazine- and pyrroline-ynones 
has been developed. A range of quinolizinones and pyridones have been prepared in high 
yield under mild catalytic conditions, which is a significant improvement over previously 
reported thermal cyclisations. One of these products was also hydrogenated to prepare the 
quinolizidine alkaloid, (±)-lasubine II, in a novel dearomatisation strategy. Further studies 
towards indolizidine alkaloids are also planned. Finally, the development of an asymmetric 
hydrogenation protocol is also planned, in hopes of enabling the enantioselective synthesis of 
other alkaloids. 
The work described in this chapter was the subject of a recent publication.
132
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Chapter 5. Experimental 
5.1 General experimental details 
Except where stated, all reagents were purchased from commercial sources and used without 
further purification. Anhydrous CH2Cl2, toluene and DMF were obtained from an Innovative 
Technology Inc. PureSolv
®
 solvent purification system. Anhydrous THF was obtained by 
distillation over sodium benzophenone ketyl immediately before use. CHCl3 was used as 
supplied without additional drying and deoxygenated CHCl3 was obtained by freeze-pump-
thaw degassing.  
1
H NMR and 
13
C NMR spectra were recorded on a JEOL ECX400 or JEOL 
ECS400 spectrometer, operating at 400 MHz and 100 MHz. Chemical shifts (δ) are quoted in 
parts per million (ppm). The residual solvent peak, δH 7.27 and δC 77.0 for CDCl3, δH 2.50 and 
δC 39.5 for DMSO-d6, δH 5.32 and δC 54.0 for CD2Cl2, were used as a reference. Coupling 
constants (J) are reported in Hertz (Hz) to the nearest 0.5 Hz. Signal assignment was achieved 
by analysis of DEPT, COSY, HSQC and HMBC experiments. Infrared (IR) spectra were 
recorded on a PerkinElmer UATR 2 spectrometer as a thin film dispersed from either CH2Cl2 
or CDCl3. Mass-spectra were obtained by the University of York Mass Spectrometry Service, 
using electrospray ionisation (ESI) on a Bruker Daltonics, Micro-tof spectrometer. Melting 
points were determined using Gallenkamp apparatus. Thin layer chromatography was carried 
out on Mercksilica gel 60F254 pre-coated aluminium foil sheets, which were visualised using 
UV light (254 nm) and stained with basic aqueous potassium permanganate. Column 
chromatography and silica gel mediated reactions were carried out using Fluka silica gel 
(SiO2), 35–70 µm, 60 Å; column chromatography was carried out under a light positive 
pressure, eluting with the specified solvent system. Petrol refers to petroleum ether 40–60 °C. 
Numbering schemes for compounds refer to NMR assignments and not to compound naming. 
Chiral stationary phase HPLC was performed on an Agilent 1200 series instrument and a 
multiple wavelength, UV/Vis diode array detector. 
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5.2 General procedures 
5.2.1 Chapter 2 
General procedure 2A: Weinreb amide formation 
 
To a stirred solution of acid (1.00 mmol), MeNHOMe·HCl (107 mg, 1.10 mmol) and DIPEA 
(0.52 mL, 3.00 mmol) in CH2Cl2 (2.5 mL) was added T3P (955 mg, 1.5 mmol, 50% wt. in 
EtOAc). The solution was stirred for 1 h at RT. The reaction mixture was poured into water 
(20 mL) and acidified using 10% HCl(aq) (5 mL). The organics were collected and the aqueous 
was extracted with EtOAc (3 × 30 mL). The organics were combined, washed with 2 M 
NaOH(aq) (20 mL), brine (20  mL), dried (MgSO4) and concentrated in vacuo to afford the 
crude Weinreb amide product. 
 
General procedure 2B: Ynone formation 
 
To a solution of alkyne (6.87 mmol) in THF (7 mL) at −78 °C under argon was added n-BuLi 
(3.6 mL, 5.73 mmol, 1.6 M in hexanes) dropwise. The mixture was stirred for 30 min at −78 
°C and then transferred via cannula to a −78 °C solution of Weinreb amide (2.29 mmol) in 
THF (21 mL). Upon complete transfer the mixture was warmed to RT and stirred for 30 min 
after which the reaction was quenched by the careful addition of sat. NH4Cl(aq) (20 mL). The 
organics were separated and the aqueous extracted with EtOAc (3 × 20 mL). The organics 
were combined, washed with brine, dried (MgSO4), concentrated in vacuo and purified by 
column chromatography to afford the ynone product. 
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General procedure 2C: Indole-ynone cyclisations 
 
To a solution of ynone (0.2 mmol) in CH2Cl2 (2 mL) was added either AgOTf, Cu(OTf)2 or 
(Ph3P)AuNTf2·½PhMe (1–20 mol%). The mixture was stirred at RT until completion was 
observed by TLC. The reaction mixture was concentrated in vacuo then purified by column 
chromatography to afford the cyclised product. 
 
General procedure 2D: Asymmetric indole-ynone spirocyclisations 
 
To a solution of ynone (0.2 mmol) in CHCl3 (2 mL) at −10 °C was added Ag-114l (2 µmol). 
The mixture was stirred at −10 °C for 16 h. The reaction mixture was then directly applied to 
a column and purified by column chromatography to afford the spirocyclic product. 
Enantiomeric excess was determined by CSP-HPLC (Chiralpak IB column), eluting with 5–
20% IPA in hexanes at 1 mL/min and UV detection at 280 or 254 nm. 
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General procedure 2E: CPA synthesis 
 
(R)-3,3'-Diiodo-2,2'-bis(methoxymethoxy)-1,1'-binaphthalene (117) (100 mg, 0.160 mmol), 
Ba(OH)2 (152 mg, 0.800 mmol) and the respective aryl boronic acid (0.384 mmol) were 
combined in 1,4-dioxane  (1.2 mL) and H2O (0.4 mL). The mixture was purged by alternating 
vacuum and argon three times. To the mixture was added Pd(PPh3)4 (28 mg, 0.024 mmol), 
which was again purged by alternating vacuum and argon three times. The mixture was stirred 
for 16 h at 80 °C under argon, then poured into 10% HCl(aq) (10 mL) and extracted with 
EtOAc (3 × 30 mL). The organics were collected, dried (MgSO4), filtered through celite and 
concentrated in vacuo. The crude material was eluted through a silica plug with (1:1) 
MeOH:CH2Cl2. The material was then dissolved in 12 M HCl(aq) (0.05 mL), MeOH (1.2 mL), 
CH2Cl2 (1.2 mL) and stirred for 2 h at 50 °C. The mixture was poured into sat. NaHCO3 (aq) 
(10 mL) and extracted with CH2Cl2 (3 × 10 mL). The organics were dried (MgSO4) and 
concentrated in vacuo. The material was then dissolved in pyridine (1.5 mL), to which POCl3 
(0.03 mL, 0.32 mmol) was added dropwise. The mixture was stirred for 16 h under argon at 
100 °C, then poured into 10% HCl(aq) (10 mL) and extracted with CH2Cl2 (3 × 10 mL). The 
organics were then washed with 10% HCl(aq) (5 × 30 mL), dried (Na2SO4) and concentrated in 
vacuo. The crude material was purified by column chromatography (MeOH/CH2Cl2) then 
dissolved in CH2Cl2 (10 mL), washed with 10% HCl(aq (2 × 10 mL), dried (Na2SO4) and 
concentrated in vacuo to to afford the BINOL phosphoric acid product. 
 
General procedure 2F: H8-BINOL Suzuki cross-coupling 
 
(S)-3,3'-Dibromo-5,5',6,6',7,7',8,8'-octahydro-[1,1'-binaphthalene]-2,2'-diol (121) (100 mg, 
0.221 mmol), Pd(OAc)2 (2.0 mg, 0.009 mmol), di(1-adamantyl)-n-butylphosphine (3.9 mg, 
0.011 mmol) and the respective aryl boronic acid (0.553 mmol) were combined in DME (2.2 
mL) and 1 M K2CO3 (aq) (1.1 mL). The mixture was purged by alternating vacuum and argon 
three times. The mixture was stirred for 16 h under argon at 95 °C, then poured into sat. 
Chapter 5. Experimental 
 
 
112 
NH4Cl(aq) (10 mL) and extracted with CH2Cl2 (3 × 10 mL). The organics were combined, 
washed with H2O (10 mL), dried (MgSO4) and concentrated in vacuo. The crude material was 
then purified by column chromatography (silica gel, hexane to hexane/CH2Cl2) to afford the 
H8-BINOL product. 
 
General procedure 2G: H8-BINOL phosphorylation 
 
To a solution of the respective (H8)-BINOL product (0.2 mmol) in pyridine (1 mL) was added 
POCl3 (0.4 mmol) dropwise. The mixture was stirred for 16 h under argon at 70 °C, then 
poured into 10% HCl(aq) (10 mL) and extracted with CH2Cl2 (3 × 10 mL). The organics were 
combined and concentrated in vacuo. The crude material was combined with DMAP (0.02 
mmol) in 2 M NaOH(aq) (1 mL) and THF (1 mL). The mixture was stirred for 16 h under 
argon at RT, then poured into 10% HCl(aq) (10 mL) and extracted with CH2Cl2 (3 × 10 mL). 
The organics were then washed with 10% HCl(aq) (5 × 30 mL), dried (Na2SO4) and 
concentrated in vacuo. The crude material was purified by column chromatography 
(MeOH/CH2Cl2) then dissolved in CH2Cl2 (10 mL), washed with 10% HCl(aq (2 × 10 mL), 
dried (Na2SO4) and concentrated in vacuo to afford the H8-BINOL phosphoric acid product. 
 
General procedure 2H: Ag-CPA preparation 
 
To a solution the respective phosphoric acid (0.20 mmol) in CH2Cl2 (2 mL) in the dark was 
added Ag2CO3 (27.6 mg, 0.10 mmol), followed by H2O (2 mL). The mixture was stirred 
vigorously for 1 h, then poured into H2O (10 mL) and extracted with CH2Cl2 (3 × 10 mL). The 
combined organics were filtered through Celite® and concentrated in vacuo to afford the 
phosphoric acid silver salt. 
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General procedure 2I: Ynone reduction 
 
To a solution of ynone (1.0 mmol) in MeOH (20 mL) at 0 °C was added NaBH4 (4.0 mmol). 
The reaction mixture was stirred for a 30 min at 0 °C before being quenched with the addition 
of sat. NH4Cl(aq) (30 mL). The organics were extracted with DCM (4 × 50 mL), dried 
(MgSO4) and purified by flash column chromatography to afford the desired propargyl 
alcohol.  
 
General procedure 2J: Telescoped propargyl alcohol formation 
 
To a solution of terminal alkyne (3.0 mmol) in THF (3 mL) at −78 °C under argon was added 
n-BuLi (1.0 mL, 2.5 mmol, 2.5 M in hexane). The resulting solution was stirred at −78 °C for 
30 min, then transferred via cannula to a cooled (−78 °C) solution of Weinreb amide (1.0 
mmol) in THF (9 mL). The mixture was stirred at −78 °C for 5 min then warmed to RT and 
stirred for a further 30 min. The reaction was then quenched with sat. NH4Cl(aq) (30 mL), 
allowed to warm to RT, diluted with water (70 mL), extracted with ethyl acetate (3 × 100 
mL). The combined organics were washed with brine, dried over MgSO4 and concentrated in 
vacuo. The resulting material was then dissolved in MeOH (20 mL), cooled to 0 °C and 
NaBH4 (4.0 mmol) was added. The reaction mixture was stirred for a 30 min at 0 °C before 
being quenched with sat. NH4Cl(aq) (30 mL). The organics were extracted with CH2Cl2 (4 × 30 
mL), dried (MgSO4) and purified by flash column chromatography to afford the propargyl 
alcohol.  
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General procedure 2K: Propargyl alcohol spirocyclisation 
 
To a solution of propargyl alcohol (0.2 mmol) in CH2Cl2 (2 mL) was added sequentially Ag2O 
(10 µmol) and AgNO3 (20 µmol). The mixture was stirred at RT for 24 h then concentrated in 
vacuo and purified by column chromatography to afford the spirocyclic indolenine product. 
 
General procedure 2L: Propargyl alcohol benzannulation 
 
To a solution of propargyl alcohol (0.2 mmol) in THF (2 mL) was added AgOTF (20 µmol). 
The mixture was stirred at RT for 24 h then concentrated in vacuo and purified by column 
chromatography to afford the carbazole product. 
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5.2.2 Chapter 3 
General procedure 3A: Benzyl ketone formation 
 
Based on a modified literature procedure.
16
 To a solution of Weinreb amide (1 equiv.) in THF 
(10 mL/mmol) at 0 °C under argon was added the benzyl Grignard (4 equiv.) dropwise. The 
resulting solution was allowed to warm to room temperature and stirred for 4–5 h. The 
reaction was then quenched with sat. NH4Cl(aq), diluted with water and extracted with EtOAc 
(3 ×). The combined organics were washed with brine, dried (MgSO4), concentrated in vacuo 
and purified by column chromatography to afford the desired benzyl ketone.  
 
General procedure 3B: α-Diazocarbonyl formation 
 
Based on a modified literature procedure.
133
 To a solution of benzyl ketone (1 equiv.) and p-
ABSA (1.2 equiv.) in MeCN (3 mL/mmol) at RT was added DBU (1.4 equiv.) dropwise. The 
reaction mixture was stirred for a 30−60 min before being concentrated in vacuo. The crude 
product was dissolved in CH2Cl2 and purified by column chromatography (eluting with 3% 
Et3N as a basic additive) to afford the desired α-diazocarbonyl compound. (Note: the α-
diazcarbonyl compounds were generally stable when stored at room temperature for ~1 month 
before significant degradation was observed). 
 
General procedure 3C: Formation of spirocyclic indolenines 
 
To the α-diazocarbonyl compound (1 equiv.) and Rh2oct4 (5 mol%) under argon was added 
deoxygenated CHCl3 (10 mL/mmol). The mixture was stirred at RT under argon for 6 h then 
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concentrated in vacuo and purified by column chromatography (under a positive pressure of 
nitrogen) to afford the spirocyclic indolenine diastereoisomers (The major diasteroisomers 
were identified by nOe experiments). 
 
General procedure 3D: Formation of spirocyclic syn-oxindoles 
 
To the α-diazocarbonyl compound (1 equiv.) and Rh2oct4 (2 mol%) in a flask open to air was 
added CHCl3 (20 mL/mmol). The mixture was stirred at RT for 1–5 h then concentrated in 
vacuo. The crude α,β-dicarbonyl product was then dissolved in THF (10 mL/mmol) and TFA 
(3 equiv.) was added. The mixture was stirred at RT for 4 h then concentrated in vacuo and 
purified by column chromatography to afford the spirocyclic syn-oxindole. 
 
General procedure 3E: Formation of spirocyclic anti-oxindoles 
 
To the α-diazocarbonyl compound (1 equiv.) and Rh2oct4 (2 mol%) in a flask open to air was 
added CHCl3 (20 mL/mmol). The mixture was stirred at RT for 1–5 h then concentrated in 
vacuo. The crude α,β-dicarbonyl product was then  dissolved in THF (10 mL/mmol) and 
cooled to −78 °C,  t-BuOK (3 equiv.) was added in one portion and the mixture was stirred at 
−78 °C for 1 h then at RT for a further 1 h. The reaction was quenched with the addition of 
silica gel (10 g/g) and the suspension was filtered, washing with MeOH. The obtained 
methanolic solution was concentrated in vacuo and purified by column chromatography to 
afford the spirocyclic anti-oxindole. 
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General procedure 3F: Pd(II)-catalysed indole annulation 
 
To the α-diazocarbonyl compound (1 equiv.) and Pd(MeCN)4(BF4)2 (5 mol%) under argon 
was added CHCl3 (10 mL/mmol). The mixture was stirred at RT under argon for 16 h then 
concentrated in vacuo and purified by column chromatography to afford the C-2 annulated 
indole product. 
 
General procedure 3G: Cu(II)-catalysed carbazole formation 
 
To the α-diazocarbonyl compound (1 equiv.) and Cu(OTf)2 (20 mol%) under argon was added 
CHCl3 (20 mL/mmol). The mixture was stirred at RT under argon for 1 h then at 50 °C under 
oxygen for 23 h. The mixture was then concentrated in vacuo and purified by column 
chromatography to afford the carbazole product. 
 
General procedure 3H: Silica-promoted indole annulation 
 
To the α-diazocarbonyl compound (1 equiv.) and silica gel (1 g/g) was added CH2Cl2 (10 
mL/mmol). The mixture was stirred at RT for 24 h then concentrated in vacuo and purified by 
column chromatography to afford the indole product. 
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5.2.3 Chapter 4 
General procedure 4A: pyridine-ynone formation 
 
Based on a modified literature procedure.
117
 To a solution of DIPA (2.1 mmol) in THF (15 
mL) at 0 °C under argon was added n-BuLi (0.85  mL, 2.1 mmol, 2.5 M in hexanes) dropwise. 
The mixture was stirred at 0 °C for 15 min and then cooled to −78 °C before the 2-
alkylpyridine (1.0 mmol) was added dropwise. After stirring at −78 °C for 30 min the methyl 
propiolate ester (1.05 mmol, neat or in THF) was added and the mixture was stirred at −78 °C 
for a further 30 min. The reaction was then quenched at −78 °C with water (15 mL) and 
extracted with EtOAc (3 × 30 mL). The combined organics were dried (MgSO4), concentrated 
in vacuo and purified by column chromatography to afford the pyridine-ynone product. 
 
General procedure 4B: pyridine-ynone cyclisations 
 
To a solution of aryl-ynone (1 equiv.) in DCE (5 mL/mmol) and EtOH (5 mL/mmol) at RT 
was added AgNO3 (2 mol%). The reaction mixture was stirred at RT until completion was 
observed by TLC then concentrated in vacuo. The crude product was dissolved in CH2Cl2 and 
purified by column chromatography (typically 5 → 10% MeOH in EtOAc) to afford the 
cyclised compound. 
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5.3 Experimental for Chapter 2 
2-(1H-Indol-3-yl)-N-methoxy-N-methylacetamide (81a) 
 
Synthesised using general procedure 2A with indole-3-acetic acid (500 mg, 2.85 mmol), T3P 
50% in EtOAc (2.72 g, 4.28 mmol), DIPEA (1.49 mL, 8.55 mmol) and MeNHOMe·HCl (306 
mg, 3.14 mmol) in CH2Cl2 (7.5 mL). Afforded the title compound 81a (623 mg, 100%) 
without further purification as a pale brown solid, mp 122–124 °C (lit.134 122–124 °C); δH 
(400 MHz, CDCl3) 3.22 (3H, s, H-12), 3.67 (3H, s, H-13), 3.92 (2H, s, H-10), 7.09–7.21 (3H, 
m, H-3/4/8), 7.34 (1H, d, J = 8.0 Hz, H-5), 7.65 (1H, d, J = 8.0 Hz, H-2), 8.18 (1H, br s, H-7); 
δC (100 MHz, CDCl3) 29.1 (CH2, C-10), 32.5 (CH3, C-12), 61.4 (CH3, C-13), 109.1 (C, C-9), 
111.1 (CH, C-5), 118.8 (CH, C-2), 119.5 (CH, C-3), 122.0 (CH, C-4), 123.1 (CH, C-8), 127.6 
(C, C-1), 136.2 (C, C-6), 173.3 (C, C-11). 
Lab notebook reference: MJJ/1/12 
Spectroscopic data matched those reported in the literature.
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3-(1H-Indol-3-yl)-N-methoxy-N-methylpropanamide (81b) 
 
Synthesised using general procedure 2A with indole-3-propionic acid (500 mg, 2.64 mmol), 
T3P (2.52 g, 3.96 mmol, 50% wt. in EtOAc), DIPEA (1.38 mL, 7.92 mmol) and 
MeNHOMe·HCl (283 mg, 2.90 mmol) in CH2Cl2 (7 mL). Afforded the title compound 81b 
(594 mg, 97%) without further purification as a yellow oil; vmax (cm
-1
) 3410, 3300, 2936, 
1642, 1458, 743; δH (400 MHz, CDCl3) 2.85 (2H, t, J = 7.5 Hz, H-11), 3.14 (2H, t,
 
J = 7.5 Hz, 
H-10), 3.20 (3H, s, H-13), 3.60 (3H, s, H-14), 7.05 (1H, d, J = 2.5 Hz, H-8), 7.13 (1H, ddd, J 
= 7.5, 7.5, 1.0 Hz, H-3), 7.20 (1H, ddd, J = 7.5, 7.5, 1.5 Hz, H-4), 7.37 (1H, ddd, J = 7.5, 1.0, 
1.0 Hz, H-5), 7.64 (1H, dd, J = 7.5, 1.5, 1.0 Hz, H-2), 8.09 (1H, br s, H-7); δC (100 MHz, 
CDCl3) 20.2 (CH2, C-10/11), 32.0 (CH3, C-13), 32.6 (CH2, C-10/11), 61.0 (CH3, C-14), 111.1 
(CH, C-5), 114.9 (C, C-9), 118.5 (CH, C-2/3/4), 118.9 (CH, C-2/3/4), 121.6 (CH, C-2/3/4), 
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121.7 (CH, C-8), 127.1 (C, C-1), 136.2 (C, C-6), 174.2 (C, C-12); HRMS (ESI
+
): Found: 
255.1095; C13H16N2NaO2 (MNa
+
) Requires 255.1104 (3.6 ppm error), Found: 233.1278; 
C13H17N2O2 (MH
+
) Requires 233.1285 (2.7 ppm error). 
Lab notebook reference: MJJ1/70  
 
4-(1H-Indol-3-yl)-N-methoxy-N-methylbutanamide (81c) 
 
Synthesised using general procedure 2A with indole-3-butyric acid (500 mg, 2.46 mmol), 
T3P (2.52 g, 3.96 mmol, 50% wt. in EtOAc), DIPEA (1.38 mL, 7.92 mmol) and 
MeNHOMe·HCl (283 mg, 2.90 mmol) in CH2Cl2 (7 mL). Afforded the title compound 81c 
(559 mg, 92%) without further purification as a yellow oil; vmax (cm
-1
) 3301, 2936, 1643, 
1458, 995, 743; δH (400 MHz, CDCl3) 2.08 (2H, tt, J = 7.5, 7.0 Hz, H-11), 2.52 (2H, t, J = 7.0 
Hz, H-12), 2.84 (2H, td, J = 7.5, 1.0 Hz, H-10), 3.19 (3H, s, H-14), 3.62 (3H, s, H-15), 7.01–
7.03 (1H, m, H-8), 7.09–7.14 (1H, m, H-3), 7.16–7.22 (1H, m, H-4), 7.36 (1H, ddd, J = 8.0, 
1.0, 1.0 Hz, H-5), 7.64 (1H, d, J = 8.0 Hz, H-2), 8.00 (1H, br s, H-7). 
Lab notebook reference: MJJ1/60 
Spectroscopic data matched those reported in the literature.
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N-Methoxy-N-methyl-2-(2-methyl-1H-indol-3-yl)acetamide (81d) 
 
Synthesised using general procedure 2A with 2-methyl-3-indoleacetic acid (1.00 g, 5.29 
mmol), T3P (5.05 g, 7.94 mmol, 50% wt. in EtOAc), DIPEA (2.76 mL, 15.9 mmol) and 
MeNHOMe·HCl (567 mg, 5.82 mmol) in CH2Cl2 (13 mL). Afforded the title compound 81d 
(1.21 g, 98%) without further purification as a pale brown solid, mp 85–87 °C; vmax (cm
-1
) 
3398, 3300, 2935, 1639, 1462, 1178, 1008, 742; δH (400 MHz, CDCl3) 2.30 (3H, s, H-9), 3.21 
(3H, s, H-13), 3.62 (3H, s, H-14), 3.85 (2H, s, H-11), 7.05–7.13 (2H, m, H-3,4), 7.14–7.21 
(1H, m, H-5), 7.55–7.62 (1H, m, H-2), 8.17 (1H, br s, H-7); δC (100 MHz, CDCl3) 11.6 (CH3, 
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C-9), 28.6 (CH2, C-11), 32.2 (CH3, C-13), 61.1 (CH3, C-14), 104.5 (C, C-10), 110.2 (CH, C-
5), 118.1 (CH, C-2), 119.2 (CH, C-3/4), 120.8 (CH, C-3/4), 128.6 (C, C-1), 132.8 (C, C-8), 
135.1 (C, C-6), 172.9 (C, C-12); HRMS (ESI
+
): Found: 255.1104; C13H16N2NaO2 (MNa
+
) 
Requires 255.1104 (−0.1 ppm error), Found: 233.1288; C13H17N2O2 (MH
+
) Requires 233.1285 
(−1.6 ppm error). 
Lab notebook reference: MJJ3/43 
 
N-Methoxy-N-methyl-2-(1-methyl-1H-indol-3-yl)acetamide (81e) 
 
Synthesised using general procedure 2A with 1-methyl-3-indoleacetic acid (2.00 g, 10.6 
mmol), T3P (10.1 g, 15.9 mmol, 50% wt. in EtOAc), DIPEA (5.54 mL, 31.8 mmol) and 
MeNHOMe·HCl (1.14 g, 11.7 mmol) in CH2Cl2 (27 mL). Afforded the title compound 81e 
(2.32 g, 94%) without further purification as a brown oil; vmax (cm
-1
) 2936, 1659, 1473, 1374, 
1001, 741; δH (400 MHz, CDCl3) 3.22 (3H, s, H-12), 3.69 (3H, s, H-13 ), 3.77 (3H, s, H-7), 
3.91 (2H, br s, H-10), 7.08 (1H, s, H-8), 7.10–7.15 (1H, m, H-3), 7.20–7.25 (1H, m, H-4), 
7.28–7.32 (1H, m, H-5), 7.63–7.67 (1H, m, H-2); δC (100 MHz, CDCl3) 28.6 (CH2, C-10), 
32.1 (CH3, C-12), 32.5 (CH3, C-7), 61.2 (CH3, C-13), 107.2 (C, C-9), 109.0 (CH, C-5), 118.7 
(CH, C-3/2), 118.8 (CH, C-3/2), 121.4 (CH, C-4), 127.6 (CH, C-8), 127.7 (C, C-1), 136.6 (C, 
C-6), 172.7 (C, C-11); HRMS (ESI
+
): Found: 255.1107; C13H16N2NaO2 (MNa
+
) Requires 
255.1104 (−1.2 ppm error), Found: 233.1288; C13H17N2O2 (MH
+
) Requires 233.1285 (−1.6 
ppm error). 
Lab notebook reference: MJJ1/84 
 
2-(5-Bromo-1H-indol-3-yl)-N-methoxy-N-methylacetamide (81f) 
 
Synthesised using general procedure 2A with 5-bromoindole-3-acetic acid (1.00 g, 3.94 
mmol), T3P (3.76 g, 5.91 mmol, 50% wt. in EtOAc), DIPEA (2.06 mL, 11.82 mmol) and 
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MeNHOMe·HCl (422 mg, 4.33 mmol) in CH2Cl2 (10 mL). Afforded the title compound 81f 
(1.17 g, 100%) without further purification as a yellow solid, mp 98–100 °C; vmax (cm
-1
) 3279, 
1646, 1459, 1386, 1101, 1001, 883, 793; δH (400 MHz, CDCl3) 3.24 (3H, s, H-12), 3.71 (3H, 
s, H-13), 3.87 (2H, br s, H-10), 7.18 (1H, d, J = 2.5 Hz, H-8), 7.21 (1H, d, J = 8.5 Hz, H-5), 
7.26 (1H, dd, J = 8.5,
 
2.0 Hz, H-4), 7.75–7.78 (1H, m, H-2), 8.24 (1H, br s, H-7); δC (100 
MHz, CDCl3) 28.6 (CH2, C-10), 32.3 (CH3, C-12), 61.4 (CH3, C-13), 108.2 (C, C-9), 112.6 
(C, C-3), 112.7 (CH, C-5), 121.2 (CH, C-2), 124.6 (CH, C-4/8), 124.7 (CH, C-4/8), 129.1 (C, 
C-1), 134.7 (C, C-6), 172.6 (C, C-11); HRMS (ESI
+
): Found: 319.0048; C12H13
79
BrN2NaO2 
(MNa
+
) Requires 319.0053 (1.3 ppm error), Found: 297.0234; C12H14
79
BrN2O2 (MH
+
) 
Requires 297.0233 (−0.1 ppm error). 
Lab notebook reference: MJJ3/38 
 
2-(1H-Indol-3-yl)-N-methoxy-N-methyl-3-phenylpropanamide (81g) 
 
Synthesised according to a modified literature procedure.
136
 To solution of DIPA (3.20 mL, 
22.8 mmol) in THF (11.5 mL) at a 0 °C under argon was added n-BuLi (9.12 mL, 22.8 mmol, 
2.5M in hexanes) dropwise. The solution was stirred for 15 min before being cooled to –10 
°C. Indole-3-acetic acid (1.00 g, 5.71 mmol) in THF (5 mL) was added dropwise to the 
solution, which was stirred at –10 °C for 2 h. Benzyl chloride (1.45 mL, 12.6 mmol) was then 
added dropwise and the mixture was allowed to warm to RT and stirred for 18 h. The reaction 
mixture was cooled to −10 °C and quenched with water (50 mL). The mixture was then 
partially concentrated in vacuo to remove the majority of the THF. The mixture was 
partitioned between toluene (50 mL) and water (30 mL), the aqueous was separated and the 
organic phase was washed with water (30 mL). The aqueous phases were combined, acidified 
to pH 1 with 10% HCl(aq) and extracted with toluene (5 × 60 mL). The combined organics 
were washed with water until the aqueous phase was neutral and then concentrated in vacuo to 
afford a crude pale brown solid (1.33 g). The crude material was dissolved in CH2Cl2 (14 mL), 
to which MeNHOMe·HCl (612 mg, 6.28 mmol), DIPEA (2.98 mL, 17.1 mmol) and T3P (5.45 
g, 8.57 mmol, 50% wt. in EtOAc) were added successively. The mixture was stirred for 2.5 h 
at RT. The reaction mixture was poured into water (30 mL) and the organics were collected. 
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The aqueous was extracted with EtOAc (2 × 30 mL). The organics were combined, washed 
with 10% HCl(aq) (2 × 20 mL), 2 M NaOH(aq) (20 mL), brine (20  mL) then dried (MgSO4) and 
concentrated in vacuo. The crude material was purified by column chromatography (1:1 
hexane:EtOAc) to afford the title compound 81g  (1.32 g, 75%) as a pale brown solid, mp 
139–141 °C; vmax (cm
-1
) 3422, 3288, 2936, 1637, 1455, 985, 742, 700; δH (400 MHz, CDCl3) 
3.14 (3H, s, H-12), 3.15 (1H, dd, J = 13.5,
 
5.5 Hz, H-14a), 3.29 (3H, br s, H-13), 3.54 (1H, dd,
 
J = 13.5,
 
10.0 Hz, H-14b), 4.68–4.74 (1H, m, H-10), 7.12–7.32 (8H, m, H-3,4,8,16,17,18), 
7.36–7.40 (1H, m, H-5), 7.77 (1H, d, J = 8.0, H-2), 8.35 (1H, br s, H-7); δC (100 MHz, 
CDCl3) 32.1 (CH3, C-12), 39.8 (CH2, C-14), 40.6 (CH, C-10), 61.2 (CH3, C-13), 111.2 (CH, 
C-5), 114.6 (C, C-9), 118.9 (CH, C-2/3/4/18), 119.5 (CH, C-2/3/4/18), 122.0 (CH, C-
2/3/4/18), 122.6 (CH, C-2/3/4/18), 126.1 (CH, C-8), 126.5 (C, C-1), 128.2 (CH, C-16/17), 
129.1 (CH, C-16/17), 136.0 (C, C-6), 140.4 (C, C-15), 174.5 (C, C-11); HRMS (ESI
+
): Found: 
331.1418; C19H20N2NaO2 (MNa
+
) Requires 331.1417 (−0.2 ppm error), Found: 309.1594; 
C19H21N2O2 (MH
+
) Requires 309.1598 (1.2 ppm error). 
Lab notebook reference: MJJ4/70 
 
N-Methoxy-N-methyl-2-(2-phenyl-1H-indol-3-yl)acetamide (81h) 
 
To a dry three-neck flask was charged indole 93 (490 mg, 1.65 mmol), phenylboronic acid 
(262 mg, 2.15 mmol), LiCl (140 mg, 3.30 mmol), Na2CO3 (438 mg, 4.13 mmol), toluene (3.6 
mL), EtOH (3.6 mL) and water (2.5 mL). The mixture was degassed with vacuum/argon 3 
times. Pd(PPh3)4 (95 mg, 82.5 µmol) was added to the mixture, which was then stirred for 16 
h at 80 °C. The reaction mixture was cooled to RT then poured into water (20 mL), the 
aqueous was extracted with EtOAc (3 × 20 mL). The organics were combined, washed with 
water (2 × 10 mL), brine (2 × 10 mL), dried (MgSO4) and concentrated in vacuo. The crude 
material was purified by column chromatography (9:1 hexane:EtOAc then 3:2 hexane:EtOAc) 
to afford the title compound 81h (400 mg, 82%) as a pale yellow foam, mp 53–55 °C; vmax 
(cm
-1
) 3289, 2963, 1644, 1458, 1178, 1000, 769, 740, 700; δH (400 MHz, CDCl3) 3.21 (3H, s, 
H-16), 3.55 (3H, s, H-17), 4.03 (2H, s, H-14), 7.06–7.22 (2H, m, H-3,4), 7.28–7.33 (1H, m, 
H-5), 7.34–7.41 (1H, m, H-12) 7.42–7.49 (2H, m, H-11), 7.57–7.63 (2H, m, H-10), 7.66–7.71 
(1H, m, H-2), 8.36 (1H, br s, H-7); δC (100 MHz, CDCl3) 28.9 (CH2, C-14), 32.4 (CH3, C-16), 
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61.0 (CH3, C-17), 106.0 (C, C-13), 110.9 (CH, C-5), 119.2 (CH, C-2/3/4), 119.8 (CH, C-
2/3/4), 122.3 (CH, C-2/3/4), 127.7 (CH, C-12), 128.2 (CH, C-10/11), 128.7 (CH, C-10/11), 
129.1 (C, C-1/8/9), 132.8 (C, C-1/8/9), 135.8 (C, C-1/8/9), 136.1 (C, C-6), 172.9 (C, C-15); 
HRMS (ESI
+
): Found: 317.1249; C18H18N2NaO2 (MNa
+
) Requires 317.1260 (3.7 ppm error), 
Found: 295.1434; C18H19N2O2 (MH
+
) Requires 295.1441 (2.3 ppm error). 
Lab notebook reference: MJJ1/44 
 
1-(1H-Indol-3-yl)-4-(4-methoxyphenyl)but-3-yn-2-one (83a) 
 
Synthesised using general procedure 2B with 4-ethynylanisole (4.95 g, 37.4 mmol), THF (40 
+ 60 mL), Weinreb 81a (2.72 g, 12.5 mmol) and n-BuLi (12.5 mL, 31.3 mmol, 2.5 M in 
hexanes). Purification by column chromatography (9:1 hexane:EtOAc, then 7:3 
hexane:EtOAc) afforded the title compound 83a (2.93 g, 81%) as a pale brown solid, mp 70–
72 °C; vmax (cm
-1
) 3411, 2196, 1658, 1602, 1509, 1255, 1172, 1082, 834, 744; δH (400 MHz, 
CDCl3) 3.82 (3H, s, H-18), 4.08 (2H, d, J = 1.0 Hz, H-10), 6.80–6.85 (2H, m, H-16), 7.14–
7.20 (1H, m, H–3), 7.21–7.27 (2H, m, H-4,8), 7.28–7.33 (2H, m, H-15), 7.38–7.42 (1H, m, H-
5), 7.66–7.71 (1H, m, H-2), 8.18 (1H, br s, H-7); δC (100 MHz, CDCl3) 41.8 (CH2, C-10), 
55.3 (CH3, C-18), 87.9 (C, C-12), 93.3 (C, C-13), 107.8 (C, C-9), 111.3 (CH, C-5), 111.6 (C, 
C-14), 114.2 (2CH, C-16), 118.9 (CH, C-2/3/4), 119.7 (CH, C-2/3/4), 122.2 (CH, C-2/3/4), 
123.7 (CH, C-8), 127.5 (C, C-1), 135.1 (2CH, C-15), 136.1 (C, C-6), 161.5 (C, C-17), 185.7 
(C, C-11); HRMS (ESI
+
): Found: 312.0981; C19H15NNaO2 (MNa
+
) Requires 312.0995 (4.4 
ppm error), Found: 290.1168; C19H16NO2 (MH
+
) Requires 290.1176 (2.6 ppm error). 
Lab notebook reference: MJJ1/92 
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1-(1H-Indol-3-yl)-4-phenylbut-3-yn-2-one (83b) 
 
Synthesised using general procedure 2B with phenylacetylene (0.75 mL, 6.87 mmol), THF 
(7 + 21 mL), Weinreb 81a (500 mg, 2.29 mmol) and n-BuLi (3.00 mL, 5.73 mmol, 1.89M in 
hexanes). Purification by column chromatography (9:1 hexane:EtOAc, then 7:3 
hexane:EtOAc) afforded the title compound 83b (543 mg, 91%) as a brown solid, mp 90–92 
°C; vmax (cm
-1
) 3410, 2202, 1662, 1084, 743; δH (400 MHz, CDCl3) 4.08 (2H, s, H-10), 7.13–
7.19 (1H, m, H-3), 7.20–7.26 (2H, m, H-4,8), 7.27–7.44 (6H, m, H-5,15,16,17) 7.67 (1H, br d, 
J = 8.0 Hz, H-2), 8.16 (1H, br s, H-7); δC (100 MHz, CDCl3) 42.0 (CH2, C-10), 88.0 (C, C-
12), 92.1 (C, C-13), 107.8 (C, C-9), 111.3 (CH, C-5), 118.9 (CH, C-2/3/4), 119.8 (CH, C-
2/3/4), 119.9 (C, C-14), 122.3 (C, C-2/3/4), 123.7 (CH, C-8), 127.7 (C, C-1), 128.5 (2CH, C-
16), 130.6 (CH, C-17), 133.1 (2CH, C-15), 136.4 (C, C-6), 186.1 (C, C-11); HRMS (ESI
+
): 
Found: 282.0881; C18H13NNaO (MNa
+
) Requires 282.0889 (2.8 ppm error), Found: 260.1066; 
C18H14NO (MH
+
) Requires 260.1070 (1.6 ppm error).  
Lab notebook reference: MJJ/1/5 
 
4-[4-(Dimethylamino)phenyl]-1-(1H-indol-3-yl)but-3-yn-2-one (83c) 
 
Synthesised using general procedure 2B with 4-ethynyl-N,N-dimethylaniline (998 mg, 6.87 
mmol), THF (7 + 21 mL), Weinreb 81a (500 mg, 2.29 mmol) and n-BuLi (2.29 mL, 5.73 
mmol, 2.5 M in hexanes). Purification by column chromatography (9:1 hexane:EtOAc, then 
CH2Cl2) afforded the title compound 83c (624 mg, 90%) as a yellow solid, mp 157–159 °C; 
vmax (cm
-1
) 2192, 2149, 1642, 1597, 1526, 1377, 1093; δH (400 MHz, DMSO-d6) 2.95 (6H, s, 
H-18), 4.00 (2H, s, H-10), 6.61–6.68 (2H, m, H-16), 6.99–7.05 (1H, ddd, J = 7.5, 7.5, 1.0 Hz, 
H-3), 7.07–7.14 (1H, ddd J = 7.5, 7.5, 1.0 Hz, H-4), 7.19–7.25 (2H, m, H-15), 7.34 (1H, d, J = 
2.0 Hz, H-8), 7.39 (1H, d, J = 8.0 Hz, H-5), 7.56 (1H, d, J = 8.0 Hz, H-2) 11.05 (1H, br s, H-
7); δC (100 MHz, DMSO-d6) 41.6 (CH2, C-10), 75.3 (CH3, C-18), 88.7 (C, C-12), 95.4 (C, C-
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13), 103.9 (C, C-9), 106.7 (C, C-14), 111.5 (CH, C-5), 111.7 (2CH, C-16), 118.6 (CH, C-2/3), 
121.1 (CH, C-2/3), 124.7 (CH, C-4), 127.4 (C, C-1), 132.2 (CH, C-8), 134.7 (2CH, C-15), 
136.2 (C, C-6), 151.7 (C, C-17), 185.0 (C, C-11); HRMS (ESI
+
): Found: 325.1294; C20H18N-
2NaO (MNa
+
) Requires 325.1311 (5.5 ppm error), Found: 303.1481; C20H19N2O (MH
+
) 
Requires 303.1492 (3.5 ppm error). 
Lab notebook reference: MJJ1/7 
 
4-(4-Fluorophenyl)-1-(1H-indol-3-yl)but-3-yn-2-one (83d) 
 
Synthesised using general procedure 2A with Weinreb 81a (2.00 g, 9.16 mmol), 1-ethynyl-
4-fluorobenzene (3.15 mL, 27.5 mmol), n-BuLi (14.3 mL, 22.9 mmol, 1.6 M in hexanes) and 
THF (30 mL + 80 mL). Purification by column chromatography (9:1 hexane:EtOAc then 3:2 
hexane:EtOAc)  afforded the title compound 83d (2.06 g, 81%) as an orange solid, mp 131–
133 °C; vmax (cm
-1
) 3408, 2203, 1656, 1598, 1505, 1232, 1094, 837, 742; δH (400 MHz, 
CDCl3) 4.09 (2H, s, H-10), 6.96–7.05 (2H, dd, J = 8.5, 8.5 Hz, H-16), 7.15–7.20 (1H, dd, J = 
7.5, 7.5 Hz, H-3), 7.21–7.27 (2H, m, H-4,8), 7.29–7.35 (2H, m, H-15), 7.41 (1H, d, J  = 7.5 
Hz, H-5), 7.68 (1H, d, J = 7.5 Hz, H-2), 8.24 (1H, br s, H-7); δC (100 MHz, CDCl3) 41.9 
(CH2, C-10), 87.9 (C, C-12), 91.1 (C, C-13), 107.6 (C, C-9), 111.3 (CH, C-5), 115.98 (C, d, J 
= 4.0 Hz, C-14), 116.0 (2CH, d, J = 22 Hz, C-16), 118.9 (CH, C-2), 119.9 (CH, C-3/4/8), 
122.3 (CH, C-3/4/8), 123.7 (CH, C-3/4/8), 127.5 (C, C-1), 135.4 (2CH, d, J = 8.5 Hz, C-15), 
136.1 (C, C-6), 163.9 (C, d, J  = 254 Hz, C-17), 185.6 (C, C-11); δF (376 MHz, CDCl3) 
−106.0–−106.2 (1F, m); HRMS (ESI+): Found: 300.0795; C18H12FNNaO (MNa
+
) Requires 
300.0795 (0.2 ppm error), Found: 278.0971; C18H13FNO (MH
+
) Requires 278.0976 (1.8 ppm 
error). 
Lab notebook reference: BSC 
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1-Chloro-4-(2,2-dibromovinyl)benzene (95) 
 
To a suspension of CBr4 (4.72 g, 14.22 mmol) in CH2Cl2 (11 mL) at 0 °C was added PPh3 
(7.46 g, 28.4 mmol) in CH2Cl2 (11 mL). The mixture was stirred for 30 min at 0 °C. 4-
Chlorobenzaldehyde (1.00 g, 7.11 mmol) and Et3N (7.9 mL, 56.9 mmol) in CH2Cl2 (4 mL) 
was added to the reaction mixture, which was stirred for 3 h at RT. The reaction mixture was 
poured into water (30 mL) and extracted with CH2Cl2 (3 × 30 mL). The organics were 
combined, washed with sat. NaHCO3 (aq) (30 mL), dried (MgSO4) and concentrated in vacuo. 
The crude material was purified by column chromatography (4:1 Petrol:EtOAc) to afford the 
title compound 95 (1.79 g, 85%) as a pale yellow oil, vmax (cm
-1
) 1591, 1488, 1098, 1013, 872, 
709, 782, 506; δH (400 MHz, CDCl3) 7.35 (2H, d, J = 8.5 Hz), 7.44 (1H, s), 7.48 (2H, d, J = 
8.5 Hz); δC (100 MHz, CDCl3) 90.4, 128.6, 129.6, 133.6, 134.3, 135.6. 
Lab notebook reference: MJJ1/13 
Spectroscopic data matched those reported in the literature.
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4-(4-Chlorophenyl)-1-(1H-indol-3-yl)but-3-yn-2-one (83e) 
 
To a solution of 95 (1.68 g, 5.66 mmol) in THF (30 mL) at –78 °C under argon was added n-
BuLi (4.16 mL, 10.4 mmol, 2.5 M in hexanes) dropwise. The mixture was warmed to 0 °C 
and stirred for 30 min. The mixture was cooled to –78 °C and transferred via cannula to a –78 
°C solution of Weinreb 81a (413 mg, 1.89 mmol) in THF (5 mL). Upon complete transfer the 
reaction mixture was allowed to warm to RT and stirred for 30 min. The reaction mixture was 
poured into water (40 mL) and extracted with CH2Cl2 (3 × 40 mL). The organics were 
combined, washed with sat. NaHCO3 (aq) (40 mL), dried (MgSO4) and concentrated in vacuo. 
The crude material was purified by column chromatography (9:1 Petrol:EtOAc then 7:3 
Petrol:EtOAc) to afford the title compound 83e (363 mg, 66%) as a brown solid, mp 127–129 
°C; vmax (cm
-1
) 3408, 2202, 1661, 1489, 1088, 1014, 829, 742; δH (400 MHz, CDCl3) 4.09 
(2H, s, H-10), 7.15–7.20 (1H, m, H-3), 7.22–7.32 (6H, m, H-4,8,15,16), 7.42 (1H, ddd, J = 
8.0, 1.0, 1.0 Hz, H-5), 7.67 (1H, m, H-2), 8.20 (1H, br s, H-7); δC (100 MHz, CDCl3) 41.9 
Chapter 5. Experimental 
 
 
128 
(CH2, C-10), 88.6 (C, C-12), 90.7 (C, C-13), 107.5 (C, C-9), 111.3 (CH, C-5), 118.3 (C, C-
14), 118.9 (CH, C-2), 119.9 (CH, C-3), 122.3 (CH, C-4), 123.8 (CH, C-8), 127.4 (C, C-1), 
128.9 (2CH, C-16), 134.2 (2CH, C-15), 136.1 (C, C-6/17), 137.0 (C, C-6/17), 185.5 (C, C-
11); HRMS (ESI
+
): Found: 316.0489; C18H12
35
ClNNaO (MNa
+
) Requires 316.0500 (3.5 ppm 
error), Found: 294.0676; C18H13
35
ClNO (MH
+
) Requires 294.0680 (1.5 ppm error). 
Lab notebook reference: MJJ1/19 
 
4-(4-Bromophenyl)-1-(1H-indol-3-yl)but-3-yn-2-one (83f) 
 
Synthesised using general procedure 2B with 4-bromophenylacetylene (0.75 mL, 6.87 
mmol), THF (6 + 18 mL), Weinreb amide 81a (421 mg, 1.93 mmol) and n-BuLi (1.93 mL, 
4.83 mmol, 2.5M in hexanes). Purification by column chromatography (9:1 hexane:EtOAc, 
then 3:1 hexane:EtOAc) and recrystallisation from hexanes:EtOAc afforded the title 
compound 83f (445 mg, 68%) as a yellow solid, mp 135–136 °C; vmax (cm
-1
) 3409, 2202, 
1660, 1485, 1068, 1011, 824, 742; δH (400 MHz, CDCl3) 4.09 (2H, d, J = 1.0 Hz, H-10), 
7.13–7.29 (5H, m, H-3,4,8,15), 7.41 (1H, br d, J = 8.0 Hz, H-5) 7.43–7.49 (2H, m, H-16), 
7.67 (1H, br d, J = 8.0 Hz, H-2), 8.23 (1H, br s, H-7); δC (100 MHz, CDCl3) 41.9 (CH2, C-
10), 88.7 (C, C-12), 90.7 (C, C-13), 107.5 (C, C-9), 111.3 (CH, C-5), 118.8 (C, C-14), 118.9 
(CH, C-2), 119.9 (CH, C-3/4/8), 122.3 (CH, C-3/4/8), 123.7 (CH, C-3/4/8), 125.4 (C, C-17), 
127.4 (C, C-1), 131.9 (2CH, C-16), 134.3 (2CH, C-15), 136.1 (C, C-6), 185.4 (C, C-11); 
HRMS (ESI
+
): Found: 359.9993; C18H12
79
BrNNaO (MNa
+
) Requires 359.9994 (0.4 ppm 
error), Found: 338.0188; C18H13
79
BrNO (MH
+
) Requires 338.0175 (−3.9 ppm error).  
Lab notebook reference: MJJ4/6 
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1-(1H-Indol-3-yl)pent-3-yn-2-one (83g) 
 
To a –78 °C solution of DIPA (3.06 mL, 21.8 mmol) in THF (22 mL) was added dropwise n-
BuLi (8.72 mL, 21.8 mmol, 2.5 M in hexanes). Upon complete addition the mixture was 
warmed to 0 °C and stirred for 30 min. The mixture was cooled to –78 °C before the dropwise 
addition of 1,2-dibromopropane (0.72 mL, 6.87 mmol). The mixture was warmed to 0 °C and 
stirred for 30 min. The mixture was cooled to –78 °C and transferred via cannula to a –78 °C 
solution of Weinreb 81a (500 mg, 2.29 mmol) in THF (23 mL). Upon complete transfer the 
reaction mixture was warmed to RT and stirred for 30 min. The reaction mixture was 
quenched with sat. NH4Cl(aq) (20 mL). The organics were separated and the aqueous extracted 
with EtOAc (3 × 20 mL). The organics were combined, washed with brine, dried (MgSO4), 
concentrated in vacuo. The crude material was purified by column chromatography (9:1 
hexane:EtOAc then 3:2 hexane:EtOAc) to afford the title compound 83g (386 mg, 86%) as an 
orange oil; vmax (cm
-1
) 3409, 2217, 1665, 743; δH (400 MHz, CDCl3) 1.96 (3H, s, H-14), 3.98 
(2H, d, J = 1.0 Hz, H-10), 7.12–7.18 (2H, m, H-3,8), 7.19–7.25 (1H, m, H-4), 7.38 (1H, d, J = 
8.0 Hz, H-5), 7.60 (1H, dd, J = 8.0, 1.0 Hz, H-2), 8.17 (1H, br s, H-7); δC (100 MHz, CDCl3) 
4.1 (CH3, C-14), 42.0 (CH2, C-10), 80.2 (C, C-12), 91.3 (C, C-13), 107.4 (C, C-9), 111.2 (CH, 
C-5), 118.7 (CH, C-2), 119.6 (CH, C-3), 122.1 (CH, C-4), 123.6 (CH, C-8), 127.2 (C, C-1), 
136.1 (C, C-6), 185.7 (C, C-11); HRMS (ESI
+
): Found: 220.0726; C13H11NNaO (MNa
+
) 
Requires 220.0733 (2.9 ppm error), Found: 198.0905; C13H12NO (MH
+
) Requires 198.0913 
(4.4 ppm error). 
Lab notebook reference: MJJ1/14 
 
1-(1H-Indol-3-yl)oct-3-yn-2-one (83h) 
 
Synthesised using general procedure 2B with 1-hexyne (0.79 mL, 6.87 mmol), THF (7 + 21 
mL), Weinreb 81a (500 mg, 2.29 mmol) and n-BuLi (3.00 mL, 5.73 mmol, 1.89 in hexanes). 
Purification by column chromatography (9:1 hexane:EtOAc, then 3:1 hexane:EtOAc) afforded 
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the title compound 83h (450 mg, 82%) as a yellow solid, mp 59–61 °C; vmax (cm
-1
) 3411, 
2958, 2933, 2210, 1664, 1458, 741; δH (400 MHz, CDCl3) 0.86 (3H, t, J = 7.5 Hz, H-17), 
1.25–1.36 (2H, m, H-16), 1.40–1.49 (2H, m, H-15), 2.28 (2H, t, J = 7.0 Hz, H-14), 3.97 (2H, 
d, J = 1.0 Hz, H-10), 7.12–7.17 (1H, m, H-3), 7.18–7.25 (2H, m, H-4,8), 7.39 (1H, br d, J = 
8.0 Hz, H-5), 7.60 (1H, br d, J = 8.0 Hz, H-2), 8.12 (1H, br s, H-7); δC (100 MHz, CDCl3) 
13.4 (CH3, C-17), 18.6 (CH2, C-14), 21.8 (CH2, C-16), 29.5 (CH2, C-15), 42.0 (CH2, C-10), 
80.9 (C, C-12), 95.8 (C, C-13), 107.6 (C, C-9), 111.2 (CH, C-5), 118.8 (CH, C-2), 119.6 (CH, 
C-3), 122.1 (CH, C-4), 123.6 (CH, C-8), 127.3 (C, C-1), 136.1 (C, C-6), 185.9 (C, C-11); 
HRMS (ESI
+
): Found: 262.1209; C16H17NNaO (MNa
+
) Requires 262.1202 (−2.6 ppm error), 
Found: 240.1386; C16H18NO (MH
+
) Requires 240.1383 (−1.5 ppm error). 
Lab notebook reference: MJJ1/6 
 
1-(1H-Indol-3-yl)-4-(thiophen-2-yl)but-3-yn-2-one (83i) 
 
Synthesised using general procedure 2B with Weinreb 81a (306 mg, 1.40 mmol), 2-
ethynylthiophene (0.40 mL, 4.21 mmol), n-BuLi (1.4 mL, 3.50 mmol, 2.5 M in hexanes) and 
THF (4 mL + 13 mL). Purification by column chromatography (7:3 hexane:EtOAc) afforded 
the title compound 83i (252 mg, 68%) as a brown oil; vmax (cm
-1
) 3405, 2178, 1651, 1215, 
1091, 742, 714; δH (400 MHz, CDCl3) 4.07 (2H, s, H-10), 6.98 (1H, dd, J = 5.0, 3.5 Hz, H-
16), 7.13–7.28 (4H, m, H-3,4,8,15), 7.37 (1H, d, J = 8.0 Hz, H-5), 7.42 (1H, dd, J = 5.0, 1.0 
Hz, H-17), 7.66 (1H, d, J = 8.0 Hz, H-2), 8.23 (1H, br s, H-7); δC (100 MHz, CDCl3) 41.7 
(CH2, C-10), 86.2 (C, C-12), 92.6 (C, C-13), 107.4 (C, C-9), 111.3 (CH, C-5), 118.9 (CH, C-
2), 119.6 (C, C-14), 119.8 (CH, C-3/4/8), 122.3 (CH, C-3/4/8), 123.7 (CH, C-3/4/8), 127.4 (C, 
C-1), 127.6 (CH, C-16), 131.7 (CH, C-17), 136.1 (C, C-6), 136.7 (CH, C-15), 185.2 (C, C-
11); HRMS (ESI
+
): Found: 288.0452; C16H11NNaOS (MNa
+
) Requires 288.0454 (0.6 ppm 
error), Found: 266.0634; C16H12NOS (MH
+
) Requires 266.0634 (−0.1 ppm error). 
Lab notebook reference: MJJ4/84 
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4-(1H-Indol-3-yl)-1,5-diphenylpent-1-yn-3-one (83j) 
 
Synthesised using general procedure 2A with Weinreb amide 81g (300 mg, 0.973 mmol), 
phenylacetylene (0.32 mL, 2.92 mmol), n-BuLi (0.97 mL, 2.43 mmol, 2.5 M in hexanes) and 
THF (3 + 9 mL). Purification by column chromatography (8:2 hexane:EtOAc) afforded the 
title compound 83j (250 mg, 74%) as a yellow oil; vmax (cm
-1
) 3413, 2195, 1653, 1489, 1456, 
1099, 742, 688; δH (400 MHz, CDCl3) 3.29 (1H, dd, J = 14.0, 7.0 Hz, H-18a), 3.69 (1H, dd, J 
= 14.0, 8.0 Hz, H-18b), 4.49 (1H, dd, J = 8.0, 7.0 Hz, H-10), 7.12–7.33 (10H, m, ArH), 7.34–
7.42 (4H, m, ArH), 7.75 (1H, d, J = 8.0 Hz, H-2), 8.23 (1H, br s, H-7); δC (100 MHz, CDCl3) 
37.0 (CH2, C-18), 53.9 (CH, C-10), 87.8 (C, C-12), 92.1 (C, C-13), 111.4 (CH, C-5), 112.1 
(C, C-9), 119.2 (CH, C-2/3/4/22), 119.85 (CH, C-2/3/4/22),), 119.92 (C, C-14), 122.3 (CH, C-
2/3/4/22),), 123.0 (CH, C-2/3/4/22),), 126.3 (CH, C-8), 126.7 (C, C-1), 128.3 (2CH, C-
15/16/20/21), 128.4 (2CH, C-15/16/20/21), 129.0 (2CH, C-15/16/20/21), 130.5 (CH, C-17), 
132.9 (2CH, C-15/16/20/21), 136.2 (C, C-6), 139.4 (C, C-19), 187.1 (C, C-11); HRMS (ESI
+
): 
Found: 372.1346; C25H19NNaO (MNa
+
) Requires 372.1359 (3.6 ppm error), Found: 350.1538; 
C25H20NO (MH
+
) Requires 350.1539 (0.3 ppm error). 
Lab notebook reference: MJJ4/77 
 
4-(1H-Indol-3-yl)-1-(4-methoxyphenyl)-5-phenylpent-1-yn-3-one (83k) 
 
Synthesised using general procedure 2B with 4-ethynylanisole (0.83 mL, 6.42 mmol), THF 
(6.5 + 18 mL), Weinreb 81g (661 mg, 2.14 mmol) and n-BuLi (2.54 mL, 5.99 mmol, 2.36M 
in hexanes). Purification by column chromatography (9:1 hexane:EtOAc, then 8:2 
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hexane:EtOAc) afforded the title compound 83k (267 mg, 33%) as a yellow solid, mp 150–
152 °C; vmax (cm
-1
) 3414, 2186, 1654, 1601, 1509, 1254, 743; δH (400 MHz, CDCl3) 3.28 (1H, 
dd, J = 14.0, 7.0 Hz, H-19a), 3.68 (1H, dd, J = 14.0, 7.0 Hz, H-19b), 3.81 (3H, s, H-18), 4.47 
(1H, t, J =
 
7.0 Hz, H-10), 6.79–6.84 (2H, m, H-16), 7.14–7.27 (9H, m, H-3,4,21,22,23), 7.31–
7.35 (2H, m, H-15), 7.38 (1H, dt, J = 8.0, 1.0 Hz, H-5), 7.75 (1H, d, J = 8.0 Hz, H-2), 8.19 
(1H, br s, H-7); δC (100 MHz, CDCl3) 37.1 (CH2, C-19), 53.8 (CH, C-10), 55.4 (CH3, C-18), 
87.7 (C, C-12), 93.2 (C, C-13), 111.3 (CH, C-5), 111.8 (C, C-9), 112.6 (C, C-14), 114.2 (2CH, 
C-16), 119.3 (CH, C-2/3/4/23), 119.8 (CH, C-2/3/4/23), 122.3 (CH, C-2/3/4/23), 122.9 (CH, 
C-2/3/4/23), 126.2 (CH, C-8), 126.8 (C, C-1), 128.3 (2CH, C-21/22), 129.0 (2CH, C-21/22), 
135.0 (2CH, C-15), 136.2 (C, C-6), 139.5 (C, C-20), 161.5 (C, C-17), 187.1 (C, C-11); HRMS 
(ESI
+
): Found: 402.1451; C26H21NNaO2 (MNa
+
) Requires 402.1465 (3.3 ppm error), Found: 
380.1632; C26H22NO2 (MH
+
) Requires 380.1645 (3.5 ppm error). 
Lab notebook reference: MJJ1/63 
 
4-(4-Methoxyphenyl)-1-(2-methyl-1H-indol-3-yl)but-3-yn-2-one (83l) 
 
Synthesised using general procedure 2B with 4-ethynylanisole (0.84 mL, 6.45 mmol), THF 
(6.5 + 19.5 mL), Weinreb 81d (500 mg, 2.15 mmol) and n-BuLi (2.15 mL, 5.38 mmol, 2.5 M 
in hexanes). Purification by column chromatography (8:2 hexane:EtOAc, then 7:3 
hexane:EtOAc) afforded the title compound 83l (502 mg, 77%) as a thick yellow oil; vmax (cm
-
1
) 3396, 2194, 1653, 1600, 1508, 1252, 832, 728; δH (400 MHz, CDCl3) 2.38 (3H, s, H-9), 
3.77 (3H, s, H-19), 3.98 (2H, s, H-11), 6.75–6.82 (2H, m, H-17), 7.11–7.18 (2H, m, H-3,4), 
7.20–7.29 (3H, m, H-5,16), 7.58–7.64 (1H, m, H-2), 8.15 (1H, br s, H-7); δC (100 MHz, 
CDCl3) 11.6 (CH3, C-9), 41.0 (CH2, C-11), 55.2 (CH3, C-19), 87.9 (C, C-13), 93.0 (C, C-14), 
103.4 (C, C-10), 110.4 (CH, C-5), 111.5 (C, C-15), 114.1 (2CH, C-17), 118.0 (CH, C-2), 
119.5 (CH, C-3/4), 121.1 (CH, C-3/4), 128.6 (C, C-1), 133.5 (CH, C-8), 135.0 (2CH, C-16), 
135.2 (C, C-6), 161.4 (C, C-18), 185.5 (C, C-12); HRMS (ESI
+
): Found: 326.1152; 
C20H17NNaO2 (MNa
+
) Requires 326.1151 (−0.1 ppm error), Found: 304.1332; C20H18NO2 
(MH
+
) Requires 304.1332 (−0.1 ppm error). 
Lab notebook reference: MJJ3/44 
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4-(4-Methoxyphenyl)-1-(2-phenyl-1H-indol-3-yl)but-3-yn-2-one (83m) 
 
Synthesised using general procedure 2B with 4-ethynylanisole (516 mg, 3.90 mmol), THF (4 
+ 12 mL), Weinreb 81h (384 mg, 1.30 mmol) and n-BuLi (1.30 mL, 3.25 mmol, 2.5 M in 
hexanes). Purification by column chromatography (9:1 hexane:EtOAc, then 7:3 
hexane:EtOAc) afforded the title compound 83m (100 mg, 21%) as a yellow oil; vmax (cm
-1
) 
3362, 1255, 2196, 1655, 1601, 1509, 744; δH (400 MHz, CDCl3) 3.80 (3H, s, H-22), 4.16 (2H, 
s, H-14), 6.77–6.82 (2H, m, H-20), 7.17–7.28 (4H, m, H-3,4,19), 7.38–7.44 (2H, m, H-5,12) 
7.46–7.53 (2H, m, H-11), 7.59–7.67 (2H, m, H-10), 7.70–7.74 (1H, m, H-2), 8.38 (1H, br s, 
H-7); δC (100 MHz, CDCl3) 41.7 (CH2, C-14), 55.5 (CH3, C-22), 88.4 (C, C-16), 93.8 (C, C-
17), 105.1 (C, C-13), 111.1 (C, C-18), 111.7 (CH, C-5), 114.3 (2CH, C-20), 119.5 (CH, C-2), 
120.3 (CH, C-3/4), 122.7 (CH, C-3/4), 128.2 (3CH, C-12,10/11), 129.1 (2CH, C-10/11), 129.4 
(C, C-9), 132.5 (C, C-1/8), 135.3 (2CH, C-19), 136.0 (C, C-1/8), 136.8 (C, C-6), 161.7 (C, C-
21), 186.3 (C, C-15); HRMS (ESI
+
): Found: 388.1302; C25H19NNaO2 (MNa
+
) Requires 
388.1308 (1.6 ppm error), Found: 366.1491; C25H20NO2 (MH
+
) Requires 366.1489 (−0.5 ppm 
error). 
Lab notebook reference: MJJ1/48 
 
1-(5-Bromo-1H-indol-3-yl)-4-(4-methoxyphenyl)but-3-yn-2-one (83n) 
 
Synthesised using general procedure 2B with 4-ethynylanisole (0.65 mL, 5.04 mmol), THF 
(5 + 15 mL), Weinreb 81f (500 mg, 1.68 mmol) and n-BuLi (1.70 mL, 4.20 mmol, 2.5 M in 
hexanes). Purification by column chromatography (7:3 hexane:EtOAc) afforded the title 
compound 83n (460 mg, 74%) as a yellow solid, mp 131–133 °C; vmax (cm
-1
) 3414, 2195, 
Chapter 5. Experimental 
 
 
134 
1655, 1601, 1509, 1255, 1170, 1095, 833; δH (400 MHz, CDCl3) 3.82 (3H, s, H-18), 4.03 (2H, 
s, H-10), 6.83–6.88 (2H, m, H-16), 7.18 (1H, d, J = 2.5 Hz, H-8), 7.23 (1H, d, J = 8.5 Hz, H-
5), 7.29 (1H, dd, J = 8.5, 2.0 Hz, H-4), 7.35–7.40 (2H, m, H-15), 7.83 (1H, d, J = 2.0 Hz, H-
2), 8.35 (1H, br s, H-7); δC (100 MHz, CDCl3) 41.7 (CH2, C-10), 55.4 (CH3, C-18), 87.9 (C, 
C-12), 93.7 (C, C-13), 107.5 (C, C-9), 111.4 (C, C-14), 112.8 (CH, C-5), 113.1 (C, C-3), 
114.3 (2CH, C-16), 121.6 (CH, C-2), 124.9 (CH, C-4/8), 125.1 (CH, C-4/8), 129.2 (C, C-1), 
134.8 (C, C-6), 135.2 (2CH, C-15), 161.7 (C, C-17), 185.2 (C, C-11); HRMS (ESI
+
): Found: 
390.0089; C19H14
79
BrNNaO2 (MNa
+
) Requires 390.0100 (2.8 ppm error), Found: 368.0275; 
C19H15
79
BrNO2 (MH
+
) Requires 368.0281 (1.5 ppm error). 
Lab notebook reference: MJJ3/39 
 
1-(1H-Indol-3-yl)-4-(trimethylsilyl)but-3-yn-2-one (83o) 
 
Synthesised using general procedure 2B with ethynyltrimethylsilane (0.95 mL, 6.87 mmol), 
THF (6 + 11 mL), Weinreb 81a (500 mg, 2.29 mmol) and n-BuLi (2.29 mL, 5.73 mmol, 2.5 
M in hexanes). Purification by column chromatography (15% EtOAc in hexane) afforded the 
title compound 83o (455 mg, 78%) as a brown oil; vmax (cm
-1
) 3408, 1671, 1252, 1100, 847, 
741; δH (400 MHz, CDCl3) 0.18 (9H, s, H-14), 4.02 (2H, s, H-10), 7.12–7.18 (2H, m, H-3,8), 
7.19–7.25 (1H, m, H-4), 7.36 (1H, d, J = 8.0 Hz, H-5), 7.62 (1H, dd, J = 8.0, 0.5 Hz, H-2), 
8.25 (1H, br s, H-7); δC (100 MHz, CDCl3) −0.9 (CH3, C-14), 41.8 (CH2, C-10), 99.3 (C, C-
13), 102.0 (C, C-12), 107.1 (C, C-9), 111.2 (CH, C-5), 118.9 (CH, C-2/3), 119.7 (CH, C-2/3), 
122.2 (CH, C-4), 123.7 (CH, C-8), 127.3 (C, C-1), 136.1 (C, C-6), 185.3 (C, C-11); HRMS 
(ESI
+
): Found: 278.0974; C15H17NNaOSi (MNa
+
) Requires 278.0972 (−0.7 ppm error), 
Found: 256.1149; C15H18NOSi (MH
+
) Requires 256.1152 (1.3 ppm error). 
Lab notebook reference: MJJ2/6 
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4-(4-Methoxyphenyl)-1-(1-methyl-1H-indol-3-yl)but-3-yn-2-one (83p) 
 
Synthesised using general procedure 2B with 4-ethynylanisole (854 mg, 6.46 mmol), THF 
(6.5 + 19.5 mL), Weinreb 81e (499 mg, 2.15 mmol) and n-BuLi (2.28 mL, 5.38 mmol, 2.36 M 
in hexanes). Purification by column chromatography (9:1 hexane:EtOAc, then 8:2 
hexane:EtOAc) afforded the title compound 83p (279 mg, 43%) as a yellow oil; vmax (cm
-1
) 
2197, 1660, 1602, 1509, 1254, 742; δH (400 MHz, CDCl3) 3.80 (3H, s, H-7), 3.83 (3H, s, H-
18), 4.07 (2H, d, J = 1.0 Hz, H-10), 6.81–6.86 (2H, m, H-16), 7.09 (1H, s, H-8) 7.14–7.19 
(1H, m, H-3), 7.24–7.29 (1H, m, H-4), 7.30–7.36 (3H, m, H-5,15), 7.68 (1H, dt, J = 8.0, 1.0 
Hz, H-2); δC (100 MHz, CDCl3) 32.7 (CH3, C-7), 41.7 (CH2, C-10), 55.3 (CH3, C-18), 88.0 
(C, C-12), 93.0 (C, C-13), 106.1 (C, C-9), 109.3 (CH, C-5), 111.6 (C, C-14), 114.2 (2CH, C-
16), 119.0 (CH, C-2/3), 119.2 (CH, C-2/3), 121.7 (CH, C-4), 127.9 (C, C-1), 128.2 (CH, C-8), 
135.0 (2CH, C-15), 136.9 (C, C-6), 161.5 (C, C-17), 185.6 (C, C-11); HRMS (ESI
+
): Found: 
326.1153; C20H17NNaO2 (MNa
+
) Requires 326.1151 (−0.6 ppm error), Found: 304.1330; 
C20H18NO2 (MH
+
) Requires 304.1332 (0.7 ppm error). 
Lab notebook reference: MJJ1/86 
 
5-(1H-Indol-3-yl)-1-(4-methoxyphenyl)pent-1-yn-3-one (83q) 
 
Synthesised using general procedure 2B with 4-ethynylanisole (1.02 g, 7.68 mmol), THF (8 
+ 23 mL), Weinreb 81b (594 mg, 2.56 mmol) and n-BuLi (2.71 mL, 6.40 mmol, 2.36M in 
hexanes). Purification by column chromatography (9:1 hexane:EtOAc, then EtOAc) afforded 
the title compound 83q (748 mg, 96%) as a yellow solid, mp 126-128 °C; vmax (cm
-1
) 3406, 
2190, 1658, 1601, 1509, 1254, 1172, 1094, 834, 744; δH (400 MHz, CDCl3) 3.06–3.11 (2H, 
m, H-11), 3.20–3.26 (2H, m, H-10), 3.83 (3H, s, H-19), 6.87–6.92 (2H, m, H-17), 7.04–7.07 
(1H, m, H-8), 7.12–7.18 (1H, m, H-3), 7.19–7.24 (1H, m, H-4), 7.38 (1H, d, J = 8.0 Hz, H-5), 
7.47–7.52 (2H, m, H-16), 7.65 (1H, d, J = 8.0 Hz, H-2), 7.98 (1H, br s, H-7); δC (100 MHz, 
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CDCl3) 19.8 (CH2, C-10), 45.7 (CH2, C-11), 55.4 (CH3, C-19), 87.8 (C, C-13), 92.3 (C, C-14), 
111.2 (CH, C-5), 111.7 (C, C-9), 114.3 (2CH, C-17), 114.7 (C, C-15), 118.6 (CH, C-2), 119.3 
(CH, C-3), 121.6 (CH, C-8), 122.0 (CH, C-4), 127.1 (C, C-1), 135.1 (2CH, C-16), 136.3 (C, 
C-6), 161.6 (C, C-18), 187.7 (C, C-12); HRMS (ESI
+
): Found: 326.1149; C20H17NNaO2 
(MNa
+
) Requires 326.1151 (0.9 ppm error), Found: 304.1334; C20H18NO2 (MH
+
) Requires 
304.1332 (−0.6 ppm error). 
Lab notebook reference: MJJ1/71 
 
6-(1H-Indol-3-yl)-1-(4-methoxyphenyl)hex-1-yn-3-one (83r) 
 
Synthesised using general procedure 2B with 4-ethynylanisole (0.93 mL, 7.17 mmol), THF 
(7 + 20 mL), Weinreb 81c (556 mg, 2.26 mmol) and n-BuLi (2.83 mL, 6.69 mmol, 2.36M in 
hexanes). Purification by column chromatography (9:1 hexane:EtOAc, then 8:2 
hexane:EtOAc) afforded the title compound 83r (708 mg, 99%) as a pale brown solid, mp 
110–112 °C; vmax (cm
-1
) 3411, 2943, 2191, 1656, 1601, 1509, 1253, 1095, 834, 743; δH (400 
MHz, CDCl3) 2.20 (2H, quin, J = 7.5 Hz, H-11), 2.75 (2H, t, J = 7.5 Hz, H-12), 2.88 (2H, J = 
7.5 Hz, H-10), 3.85 (3H, s, H-20), 6.87–6.92 (2H, m, H-18), 7.01–7.03 (1H, m, H-8), 7.11–
7.16 (1H, m, H-3), 7.19–7.24 (1H, m, H-4), 7.38 (1H, dt, J = 8.0, 1.0 Hz, H-5), 7.48–7.53 
(2H, m, H-17), 7.65–7.68 (1H, m, H-2), 8.10 (1H, br s, H-7); δC (100 MHz, CDCl3) 24.3 
(CH2, C-10/11), 24.6 (CH2, C-10/11), 44.9 (CH2, C-12), 55.3 (CH3, C-20), 87.8 (C, C-14), 
92.0 (C, C-15), 111.1 (CH, C-5), 111.6 (C, C-9), 114.3 (2CH, C-18), 115.4 (C, C-16), 118.8 
(CH, C-2/3), 119.1 (CH, C2/3), 121.6 (CH, C4/8), 121.9 (CH, C4/8), 127.3 (C, C-1), 135.1 
(2CH, C-17), 136.3 (C, C-6), 161.5 (C, C-19), 188.3 (C, C-13); HRMS (ESI
+
): Found: 
340.1314; C21H19NNaO2 (MNa
+
) Requires 340.1308 (−1.9 ppm error), Found: 318.1493; 
C21H19NNaO2 (MH
+
) Requires 318.1489 (−1.4 ppm error). 
Lab notebook reference: MJJ1/62 
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2-(4-Methoxyphenyl)spiro[cyclopent[2]ene-1,3'-indol]-4-one (84a) 
 
Synthesised using general procedure 2C with ynone 83a (58 mg,  0.2 mmol) and AgOTf 
(0.5 mg, 2 µmol) in CH2Cl2 (2 mL) at RT for 30 min. Purification by column chromatography 
(1:1 hexane:EtOAc) afforded the title compound 84a (58 mg, 100%) as an off-white solid, mp 
48–50 °C; vmax (cm
-1
) 2923, 1693, 1604, 1510, 1255, 1181, 1030, 832; δH (400 MHz, CDCl3) 
2.64 (1H, d, J = 19.0 Hz, H-10a), 3.02 (1H, d, J = 19.0 Hz, H-10b), 3.73 (3H, s, H-18), 6.66–
7.71 (2H, m, H-16), 6.77 (1H, s, H-12), 6.91–6.97 (2H, m, H-15), 7.21–7.31 (2H, m, H-2,3), 
7.45 (1H, td, J = 7.5, 1.0 Hz, H-4), 7.77 (1H, d, J = 7.5 Hz, H-5), 8.21 (1H, s, H-8); δC (100 
MHz, CDCl3) 42.3 (CH2, C-10), 55.3 (CH3, C-18), 65.8 (C, C-9), 114.3 (2CH, C-16), 121.5 
(CH, C-2/5), 122.1 (CH, C-2/5), 124.8 (C, C-14), 127.7 (CH, C-3/4/12), 128.5 (CH, C-
3/4/12), 128.8 (2CH, C-15), 129.0 (CH, C-3/4/12), 141.3 (C, C-1), 154.7 (C, C-6), 162.1 (C, 
C-17), 171.1 (C, C-13), 174.6 (CH, C-8), 204.2 (C, C-11); HRMS (ESI
+
): Found: 290.1168; 
C19H16NO2 (MH
+
) Requires 290.1176 (2.7 ppm error). 
Spirocycle 84a was also synthesised using general procedure 2C from ynone 83a (82 mg, 
0.283 mmol) and Cu(OTf)2 (1.0 mg, 2.8 µmol) in CH2Cl2 (3 mL) for 8.5 h. Purification by 
column chromatography afforded the title compound 84a (78 mg, 95%). 
Spirocycle 84a was also synthesised using general procedure 2D from ynone 83a (58 mg, 
0.2 mmol) and Ag-114l (1.6 mg, 2 µmol) in CHCl3 (2 mL). Purification by column 
chromatography afforded the title compound 84a (58 mg, 100%) in 89:11 er (S:R). [α]D
20 
−122.4 (c = 1.0, CHCl3). CSP-HPLC conditions: 10% IPA in hexane, (R)-84a 28.1 min, (S)-
84a 30.7 min, UV detection at 280 nm. 
Lab notebook reference: MJJ1/32 + 2/22 + 2/66 
 
2-Phenylspiro[cyclopent[2]ene-1,3'-indol]-4-one (84b) 
 
Synthesised using general procedure 2C with ynone 83b (52 mg, 0.2 mmol) and AgOTf (0.5 
mg, 2 µmol) in CH2Cl2 (2 mL) at RT for 30 min. Purification by column chromatography (3:2 
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hexane:EtOAc) afforded the title compound 84b (52 mg, 100%) as a brown oil; vmax (cm
-1
) 
1697, 1592, 754; δH (400 MHz, CDCl3) 2.69 (1H, d, J = 18.5 Hz, H-10a), 3.06 (1H, d, J = 18.5 
Hz, H-10b), 6.85 (1H, s, H-12), 6.97–7.00 (2H, m, H-15), 7.17–7.23 (2H, m, H-16), 7.27–7.33 
(3H, m, H-2,3,17), 7.46 (1H, ddd, J = 7.5, 7.5, 1.5 Hz, H-4), 7.78 (1H, d, J = 8.0 Hz, H-5), 
8.22 (1H, s, H-8); δC (100 MHz, CDCl3) 42.3 (CH2, C-10), 65.9 (C, C-9), 121.5 (CH, C-2), 
122.1 (CH, C-5), 126.7 (2CH, C-15), 128.9 (2CH, C-16), 127.7 (CH, C-3), 128.9 (2CH, C-
16), 129.0 (CH, C-4), 130.7 (CH, C-12/17), 131.3 (CH, C-12/17), 132.4 (C, C-14), 140.8 (C, 
C-1), 154.8 (C, C-6), 171.9 (C, C-13), 174.0 (CH, C-8), 204.3 (C, C-11); HRMS (ESI
+
): 
Found: 282.0885; C18H13NNaO (MNa
+
) Requires 282.0889 (1.5 ppm error), Found: 260.1068; 
C18H14NO (MH
+
) Requires 260.1070 (0.9 ppm error). 
Spirocycle 84b was also synthesised using general procedure 2C from ynone 83b (133 mg, 
0.513 mmol) and Cu(OTf)2 (1.8 mg, 5 µmol) in CH2Cl2 (5 mL) for 16 h. Purification by 
column chromatography afforded the title compound 84b (114 mg, 86%). 
Spirocycle 84b was also synthesised using general procedure 2D from ynone 83b (52 mg, 
0.2 mmol) and Ag-114l (1.6 mg, 2 µmol) in  CHCl3 (2 mL). Purification by column 
chromatography afforded the title compound 84b (45 mg, 87%) in 70:30 er (S:R). [α]D
20 
 +5.0 
(c = 1.0, CHCl3). CSP-HPLC conditions: 10% IPA in hexane, (R)-84b 24.3 min, (S)-84b 26.8 
min, UV detection at 280 nm. 
Lab notebook reference: MJJ1/3 + 3/16 + 3/25  
 
2-(4-(Dimethylamino)phenyl)spiro[cyclopent[2]ene-1,3'-indol]-4-one (84c) 
 
Synthesised using general procedure 2C with ynone 83c (104 mg, 0.344 mmol), AgOTf (0.9 
mg, 3.44 µmol) in CH2Cl2 (3.4 mL) at RT for 20 min. Purification by column chromatography 
(2:1 hexane:EtOAc) afforded the title compound 84c (101 mg, 97%) as a yellow oil; vmax (cm
-
1
) 2923, 1685, 1605, 1570, 1522, 1202, 818; δH (400 MHz, CDCl3) 2.60 (1H, d, J = 19.0 Hz, 
H-10a), 2.93 (6H, s, H-18), 2.98 (1H, d, J = 19.0 Hz, H-10b), 6.39–6.45 (2H, m, H-16), 6.72 
(1H, s, H-12), 6.86–6.92 (2H, m, H-15), 7.21–7.30 (2H, m, H-2,3), 7.40–7.47 (1H, m, H-4), 
7.77 (1H, dt, J = 8.0, 1.0 Hz, H-5), 8.22 (1H, s, H-8); δC (100 MHz, CDCl3) 39.8 (CH3, C-18), 
42.3 (CH2, C-10), 65.7 (C, C-9), 111.3 (2CH, C-16), 119.3 (C, C-14), 121.5 (CH, C-2), 121.9 
(CH, C-5), 125.2 (CH, C-3), 127.6 (CH, C-12), 128.7 (CH, C-4), 128.9 (2CH, C-15), 142.1 
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(C, C-1), 152.2 (C, C-17), 154.6 (C, C-6), 171.2 (C, C-13), 175.3 (CH, C-8), 204.1 (C, C-11); 
HRMS (ESI
+
): Found: 325.1295; C20H18N2NaO (MNa
+
) Requires 325.1311 (5.2 ppm error), 
Found: 303.1487; C20H19N2O (MH
+
) Requires 303.1492 (1.7 ppm error). 
Spirocycle 84c was also synthesised using general procedure 2C from ynone 83c (100 mg, 
0.331 mmol) and Cu(OTf)2 (1.1 mg, 3 µmol) in CH2Cl2 (5 mL) for 3 h. Purification by 
column chromatography afforded the title compound 84c (90 mg, 90%). 
Spirocycle 84c was also synthesised using general procedure 2D from ynone 83c (60 mg, 
0.198 mmol) and Ag-114l (1.6 mg, 2 µmol) in CHCl3 (4 mL). Purification by column 
chromatography afforded the title compound 84c (30 mg, 50%) in 69:31 er (S:R). [α]D
20 −47.6 
(c = 1.0, CHCl3). CSP-HPLC conditions: 20% IPA in hexane, (R)-84c 17.5 min, (S)-84c 19.5 
min, UV detection at 280 nm. 
Lab notebook reference: MJJ1/11 + 1/16 + 3/14 
 
2-(4-Fluorophenyl)spiro[cyclopent[2]ene-1,3'-indol]-4-one (84d) 
 
Synthesised using general procedure 2C with ynone 83d (100 mg, 0.361 mmol) and AgOTf 
(0.9 mg, 3.6 µmol) in CH2Cl2 (3.6 mL) at RT for 1 h. Purification by column chromatography 
(1:1 hexane:EtOAc) afforded the title compound 84d (100 mg, 100%) as a red oil; vmax (cm
-1
) 
1696, 1602, 1508, 1239, 1164, 835; δH (400 MHz, CDCl3) 2.68 (1H, d, J = 19.0 Hz, H-10a), 
3.05 (1H, d, J = 19.0 Hz, H-10b), 6.79 (1H, s, H-12), 6.83–6.91 (2H, m, H-16), 6.93–7.00 
(2H, m, H-15), 7.24 (1H, br d, J = 8.0 Hz, H-2), 7.30 (1H, dd, J = 7.5, 7.5 Hz, H-3), 7.46 (1H, 
dd, J = 8.0, 7.5 Hz, H-4), 7.77 (1H, d, J = 8.0 Hz, H-5), 8.22 (1H, s, H-8); δC (100 MHz, 
CDCl3) 42.3 (CH2, C-10) , 65.9 (C, C-9), 116.1 (2CH, d, J = 22 Hz, H-16), 121.5 (CH, C-2), 
122.2 (CH, C-5), 127.9 (CH, C-3), 128.5 (C, d, J = 4.0 Hz, C-14), 129.0 (2CH, d, J = 8.5 Hz, 
C-15), 129.2 (CH, C-4), 130.6 (CH), 140.6 (C, C-1), 154.7 (C, C-6), 164.3 (C, d, J = 254 Hz, 
C-17), 170.5 (C, C-13), 174.1 (CH, C-8), 204.0 (C, C-11); δF (376 MHz, CDCl3) −107.1–
−107.3 (1F, m); HRMS (ESI+): Found: 300.0794; C18H12FNNaO (MNa
+
) Requires 300.0795 
(0.4 ppm error). 
Lab notebook reference: MJJ3/85 
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2-(4-Chlorophenyl)spiro[cyclopent[2]ene-1,3'-indol]-4-one (84e) 
 
Synthesised using general procedure 2C with ynone 83e (33 mg, 0.112 mmol) and AgOTf 
(0.3 mg, 1.1 µmol) in CH2Cl2 (1.1 mL) at RT for 1.5 h. Purification by column 
chromatography (1:1 hexane:EtOAc) afforded the title compound 84e (33 mg, 100%) as a pale 
brown oil; vmax (cm
-1
) 1696, 1593, 1489, 1095, 828, 730; δH (400 MHz, CDCl3) 2.69 (1H, d, J 
= 18.5 Hz, H-10a), 3.05 (1H, d, J = 18.5 Hz, H-10b), 6.82 (1H, s, H-12), 6.88–6.92 (2H, m, 
H-15), 7.13–7.18 (2H, m, H-16), 7.24 (1H, m, H-2), 7.29 (1H, dd, J = 7.5, 7.5 Hz, H-3), 7.46 
(1H, ddd, J = 7.5, 7.5, 1.0 Hz, H-4), 7.77 (1H, d, J = 7.5 Hz, H-5), 8.22 (1H, s, H-8); δC (100 
MHz, CDCl3) 42.3 (CH2, C-10), 65.8 (C, C-9), 121.5 (CH, C-2), 122.2 (CH, C-5), 127.8 (CH, 
C-3), 128.0 (2CH, C-15), 129.19 (2CH, C-16), 129.23 (CH, C-4), 130.7 (C, C-14), 131.0 (CH, 
C-12), 137.5 (C, C-17), 140.5 (C, C-1), 154.8 (C, C-6), 170.4 (C, C-13), 173.7 (CH, C-8), 
204.0 (C, C-11); HRMS (ESI
+
): Found: 316.0494; C18H12
35
ClNNaO (MNa
+
) Requires 
316.0500 (1.6 ppm error), Found: 294.0673; C18H13
35
ClNO (MH
+
) Requires 294.0680 (2.6 
ppm error). 
Spirocycle 84e was also synthesised using general procedure 2C from ynone 83e (87 mg, 
0.296 mmol) and Cu(OTf)2 (1.1 mg, 3 µmol) in CH2Cl2 (3 mL) for 16 h. Purification by 
column chromatography afforded the title compound 84e (75 mg, 86%). 
Spirocycle 84e was also synthesised using general procedure 2D from ynone 83e (21 mg, 
71.5 µmol) and Ag-114l (0.6 mg, 0.715 µmol) in CHCl3 (4 mL). Purification by column 
chromatography afforded the title compound 84e (15 mg, 71%) in 86:14 er (S:R). [α]D
20 −68.9 
(c = 1.0, CHCl3). CSP-HPLC conditions: 10% IPA in hexane, (R)-84e 22.5 min, (S)-84e 27.2 
min, UV detection at 280 nm. 
Lab notebook reference: MJJ3/21 + 1/24 + 3/23 
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2-(4-Bromophenyl)spiro[cyclopent[2]ene-1,3'-indol]-4-one (84f) 
 
Synthesised using general procedure 2C with ynone 83f (68 mg, 0.2 mmol) and AgOTf (0.5 
mg, 2 µmol) in CH2Cl2 (2 mL) at RT for 1.5 h. Purification by column chromatography (1:1 
hexane:EtOAc) afforded the title compound 84f (68 mg, 100%) as an off white solid, mp 201–
203 °C; vmax (cm
-1
) 1694, 1589, 1075, 1008, 824, 730; δH (400 MHz, CDCl3) 2.66 (1H, d, J = 
18.5Hz, H-10a), 3.02 (1H, d, J = 18.5 Hz, H-10b), 6.75–6.86 (3H, m, H-12,15/16), 7.17–7.35 
(4H, m, H-2,3,15/16), 7.43 (1H, ddd, J = 7.5, 7.5, 1.0 Hz, H-4), 7.74 (1H, d, J = 8.0 Hz, H-5), 
8.17 (1H, s, H-8); δC (100 MHz, CDCl3) 42.2 (CH2, C-10), 65.8 (C, C-9), 121.5 (CH, C-2), 
122.2 (CH, C-5), 125.9 (C, C-17), 127.8 (CH, C-3), 128.2 (CH, C-15/16), 129.2 (CH, C-5), 
131.1 (CH, C-12), 131.2 (C, C-14), 132.1 (2CH, C-15/16), 140.4 (C, C-1), 154.8 (C, C-6), 
170.5 (C, C-13), 173.7 (CH, C-8), 203.9 (C, C-11); HRMS (ESI
+
): Found: 360.0004; 
C18H12
79
BrNNaO (MNa
+
) Requires 359.9994 (−2.6 ppm error), Found: 338.0197; 
C18H13
79
BrNO (MH
+
) Requires 338.0175 (−6.5 ppm error). 
Spirocycle 84f was also synthesised using general procedure 2D from ynone 83f (68 mg, 0.2 
mmol) and Ag-114l (1.6 mg, 2 µmol) in CHCl3 (4 mL). Purification by column 
chromatography afforded the title compound 84f (42 mg, 62%) in 86:14 er (S:R). [α]D
20 
 
−148.2 (c = 1.0, CHCl3). CSP-HPLC conditions: 10% IPA in hexane, (R)-84f 26.6 min, (S)-
84f 32.9 min, UV detection at 280 nm. 
Lab notebook reference: MJJ4/9 + 4/10 
 
2-Methylspiro[cyclopent[2]ene-1,3'-indol]-4-one (84g) 
 
Synthesised using general procedure 2C with ynone 83g (60 mg, 0.304 mmol) and AgOTf 
(0.8 mg, 3 µmol) in CH2Cl2 (3 mL) at RT for 2 h. Purification by column chromatography 
(9:1 hexane:EtOAc, then 3:2 hexane:EtOAc) afforded the title compound 84g (57 mg, 95%) 
as an off white solid, mp 120–122 °C; vmax (cm
-1
)  1716, 1620, 1551, 773, 759; δH (400 MHz, 
CDCl3) 1.57 (3H, d, J = 1.0 Hz, H-14), 2.68 (1H, d, J =19.0 Hz, H-10a), 2.94 (1H, d, J = 19.0 
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Hz, H-10b), 6.27–6.31 (1H, m, H-12), 7.22 (1H, br d, J = 7.0 Hz, H-2) 7.30–7.36 (1H, m, H-
3), 7.41–7.47 (1H, m, H-5), 7.72 (1H, br d, J = 8.0 Hz, H-5), 7.96 (1H, s, H-8); δC (100 MHz, 
CDCl3) 14.6 (CH3, C-14), 40.4 (CH2, C-10), 67.8 (C, C-9), 121.5 (CH, C-2), 121.7 (CH, C-5), 
127.4 (CH, C-3), 129.0 (CH, C-4), 132.8 (CH, C-12), 139.1 (C, C-6), 155.6 (C, C-1), 173.1 
(CH, C-8), 175.7 (C, C-13), 205.6 (C, C-11); HRMS (ESI
+
): Found: 220.0726; C13H11NNaO 
(MNa
+
) Requires 220.0733 (2.9 ppm error), Found: 198.0905; C13H12NO (MH
+
) Requires 
198.0913 (4.5 ppm error). 
Spirocycle 84g was also synthesised using general procedure 2C from ynone 83g (87 mg, 
0.441 mmol) and Cu(OTf)2 (1.6 mg, 4 µmol) in CH2Cl2 (2 mL) for 5 h. Purification by 
column chromatography afforded the title compound 84g (79 mg, 91%). 
Spirocycle 84g was also synthesised using general procedure 2D from ynone 83g (51 mg, 
0.259 mmol) and insert Ag-114l (2.1 mg, 2.6 µmol) in CHCl3 (2.5 mL). Purification by 
column chromatography afforded the title compound 84g (48 mg, 94%) in 86:14 er (S:R, 
CSP-HPLC performed on the TFA salt). [α]D
20 
+208.1 (c = 1.0, CHCl3). CSP-HPLC 
conditions: 10% IPA in hexane, (R)-84g 34.4 min, (S)-84g 40.1 min, UV detection at 254 nm. 
Lab notebook reference: MJJ1/18 + 3/36 + 3/95 
 
2-Butylspiro[cyclopent[2]ene-1,3'-indol]-4-one (84h) 
 
Synthesised using general procedure 2C with ynone 83h (48 mg, 0.2 mmol), AgOTf (0.5 
mg, 2 µmol) in CH2Cl2 (2 mL) at RT for 3.5 h. Purification by column chromatography (9:1 
hexane:EtOAc, then 7:3 hexane:EtOAc) afforded the title compound 84h (approximately 1:1.4 
ratio of monomer:trimer, 48 mg, 100%) as a pale yellow oil; vmax (cm
-1
) 2957, 2929, 2871, 
1715, 1694, 1610, 1475, 1458, 1267, 1174, 730; δH (400 MHz, CDCl3) 0.65 (3H, t, J = 7.5 Hz, 
H-17, trimer), 0.74 (3H, t, J = 7.5 Hz, H-17, trimer), 0.77 (6H, t, J = 7.5 Hz, H-17, monomer 
+ trimer), 1.01–1.26 (8H, m, H-15,16, monomer + trimer), 1.26–1.49 (8H, m, H-15,16, 
monomer + trimer), 1.58–1.83 (3H, m, H-14, monomer + trimer), 1.83–2.07 (3H, m, H-14, 
monomer + trimer), 2.11–2.26 (1H, m, H-14, trimer), 2.28–2.44 (1H, m, H-14, trimer), 2.60 
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(1H, d, J = 19.5 Hz, H-10, monomer), 2.64 (2H, d, J = 19.0 Hz, H-10, trimer), 2.85 (1H, d, J = 
19.0 Hz, H-10, trimer), 2.91 (1H, d, J = 19.0 Hz, H-10, trimer), 2.93 (1H, d, J = 19.5 Hz, H-
10, monomer), 3.01 (1H, d, J = 19.0 Hz, H-10, trimer), 3.24 (1H, d, J = 19.0 Hz, H-10, 
trimer), 4.59 (1H, s, H-8, trimer), 4.81 (1H, s, H-8, trimer), 5.21 (1H, s, H-8, trimer), 5.78 
(1H, d,
 
J = 7.5 Hz, H-5, trimer), 5.83 (1H, d J = 7.5, H-5 Hz, trimer), 5.93 (1H, t, J =, 1.5 Hz, 
H-12, trimer), 5.99 (1H, t, J = 1.5 Hz, H-12, trimer), 6.00 (1H, t, J = 1.5 Hz, H-12, trimer), 
6.28 (1H, t, J = 1.5 Hz, H-12, monomer), 6.31 (1H, d, J = 8.0 Hz, H-5, trimer), 6.68 (1H, ddd, 
J = 7.5, 7.5, 1.5 Hz, H3/4, trimer), 6.75 (1H, ddd, J = 7.5, 7.5, 1.0 Hz, H-3/4, trimer), 6.84 
(1H, ddd, J = 7.5, 7.5, 1.0 Hz, H3/4, trimer), 6.92 (1H, dd, J = 7.5, 1.0 Hz, H-2, trimer), 6.94 
(2H, dd, J = 7.0 Hz, H-3/4, trimer), 7.04–7.12 (2H, m, H-2,3/4, trimer), 7.20 (1H, dd, J = 7.5, 
1.0 Hz, H-2, trimer), 7.22 (1H, dd, J = 7.5,  1.0 Hz, H-2, monomer), 7.30 (1H, dd,
 
J = 7.5, 7.5 
Hz, H-3/4, monomer), 7.42 (1H, ddd, J = 7.5, 7.5, 1.0 Hz, H-3/4, monomer), 7.70 (1H, d, J = 
7.5 Hz, H-5, monomer), 7.96 (1H, br s, H-8, monomer); δC (100 MHz, CDCl3) 13.5 (CH3), 
13.57 (CH3), 13.63 (CH3), 13.7 (CH3), 22.07 (CH2), 22.09 (CH2), 22.11 (CH2), 22.2 (CH2), 
27.9 (CH2), 28.17 (CH2), 28.21 (CH2), 28.3 (CH2), 28.8 (CH2), 29.2 (CH2), 29.3 (CH2), 29.4 
(CH2), 40.3 (CH2), 44.1 (CH2), 44.2 (CH2), 45.2 (CH2), 57.8 (CH2), 60.2 (C), 62.8 (C), 78.8 
(CH), 81.9 (CH), 85.0 (CH), 105.9  (CH), 107.1 (CH), 114.9 (CH), 120.2 (CH), 121.4 (CH), 
121.6 (CH), 121.66 (CH), 121.67 (CH), 122.1 (CH), 123.1 (CH), 123.4 (CH), 127.30 (CH), 
127.31 (CH), 127.7 (CH), 128.1 (CH), 128.4 (CH), 129.0 (CH), 129.6 (CH), 129.7 (CH), 
130.1  (C), 131.0 (CH), 131.7  (C), 134.0  (C), 145.3 (C), 148.3 (C), 150.3 (C), 173.2 (C), 
180.3 (C), 183.4 (C), 184.0 (C), 184.8 (C), 205.6 (C), 206.3 (C), 206.4 (C), 206.9 (C); HRMS 
(ESI
+
): Found: 240.1382; C16H18NO (MH
+
) Requires 240.1383 (0.2 ppm error). 
Spirocycle 84h was also synthesised using general procedure 2C from ynone 83h (118 mg, 
0.493 mmol) and Cu(OTf)2 (1.8 mg, 5 µmol) in CH2Cl2 (5 mL) for 16 h. Purification by 
column chromatography afforded the title compound 84h (112 mg, 95%). 
Lab notebook reference: MJJ1/9 + 3/30 
 
2-(Thiophen-2-yl)spiro[cyclopent[2]ene-1,3'-indol]-4-one (84i) 
 
Synthesised using general procedure 2C with ynone 83i (34 mg, 0.128 mmol) and AgOTf 
(0.33 mg, 1.3 µmol) in CH2Cl2 (1.3 mL) at RT for 1 h. Purification by column 
chromatography (1:1 hexane:EtOAc) afforded the title compound 84i (34 mg, 100%) as a 
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brown oil; vmax (cm
-1
) 1719, 1689, 1584, 1572, 1198, 727, 711; δH (400 MHz, CDCl3) 2.70 
(1H, d, J = 19.0 Hz, H-10a), 3.00 (1H, d, J = 19.0 Hz, H-10b), 6.53 (1H, d, J = 3.5 Hz, H-15), 
6.68 (1H, s, H-12), 6.81 (1H, dd, J = 5.0, 3.5 Hz, H-16), 7.23–7.32 (2H, m, H-2,3), 7.34 (1H, 
d, J = 5.0 Hz, H-17), 7.45 (1H, ddd, J = 8.0, 8.0, 2.0 Hz, H-4), 7.76 (1H, d, J = 8.0 Hz, H-5), 
8.13 (1H, s, H-8); δC (100 MHz, CDCl3) 41.7 (CH2, C-10) , 65.6 (C, C-9), 121.9 (CH, CAr), 
122.0 (CH, CAr), 127.7 (CH, CAr), 128.2 (CH, CAr), 128.6 (CH, CAr), 129.3 (CH, CAr), 
129.4 (CH, CAr), 130.9 (CH, CAr), 135.0 (C, C-14), 140.5 (C, C-1), 155.1 (C, C-6), 164.3 (C, 
C-13), 174.0 (CH, C-8), 203.7 (C, C-11); HRMS (ESI
+
): Found: 288.0452; C16H11NNaOS 
(MNa
+
) Requires 288.0454 (0.7 ppm error), Found: 266.0636; C16H12NOS (MH
+
) Requires 
266.0634 (−0.6 ppm error). 
Lab notebook reference: MJJ4/91 
 
5-Benzyl-2-phenylspiro[cyclopent[2]ene-1,3'-indol]-4-one (84j) 
 
Synthesised using general procedure 2C with ynone 83j (35 mg, 0.100 mmol), AgOTf (0.26 
mg, 1 µmol) in CH2Cl2 (1 mL) at RT for 1 h. Purification by column chromatography (1:1 
hexane:EtOAc) afforded the title compound 84j (35 mg, 100%, 52:48 dr) as an off-white 
solid, mp 126–129 °C; vmax (cm
-1
) 1699, 1591, 1445, 752, 730, 695; δH (400 MHz, CDCl3) 
2.11 (1H, dd, J = 14.0, 10.0 Hz, H-18a, minor), 2.54 (1H, dd, J = 15.0, 8.5 Hz, H-18a, major), 
3.17–3.31 (2H, m, H-18b, minor + major), 3.49 (1H, dd, J = 8.5, 6.0 Hz, H-10, major), 3.57 
(1H, dd, J = 10.0, 4.0 Hz, H-10, minor), 6.47 (1H, s, H-12, minor), 6.49 (1H, s, H-12, major), 
6.81–6.89 (4H, m, ArH), 6.89–6.96 (4H, m, ArH), 6.97–7.11 (6H, m, ArH), 7.11–7.21 (6H, 
m, ArH), 7.21–7.38 (6H, m, ArH), 7.48 (1H, dd, J = 8.0, 7.5 Hz, H-4, major), 7.56 (1H, d, J = 
8.0 Hz, H-5, major), 7.59 (1H, d, J = 8.0 Hz, H-5, minor), 7.98 (1H, s, H-8, minor), 8.14 (1H, 
s, H-8, major); δC (100 MHz, CDCl3) 32.0 (CH2), 32.5 (CH2), 52.4 (CH), 57.9 (CH), 70.2 (C), 
70.5 (C), 121.8 (CH), 122.0 (CH), 122.5 (CH), 123.2 (CH), 126.1 (CH), 126.3 (CH), 126.7 
(6CH), 127.4 (CH), 127.9 (3CH), 128.2 (2CH), 128.4 (2CH), 128.7 (2CH), 128.8 (CH), 128.9 
(2CH), 129.2 (CH), 129.3 (CH), 130.4 (CH), 131.1 (CH), 131.2 (CH), 132.5 (C), 132.7 (C), 
137.57 (C), 137.62 (C), 137.64 (C), 140.0 (C), 155.4 (C), 156.4 (C), 170.7 (C), 171.4 (C), 
173.0 (CH), 173.4 (CH), 205.1 (2C); HRMS (ESI
+
): Found: 372.1344; C25H19NNaO (MNa
+
) 
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Requires 372.1359 (4.0 ppm error), Found: 350.1535; C25H20NO2 (MH
+
) Requires 350.1539 
(1.2 ppm error). 
Lab notebook reference: MJJ4/88 
 
5-Benzyl-2-(4-methoxyphenyl)spiro[cyclopent[2]ene-1,3'-indol]-4-one (84k) 
 
Synthesised using general procedure 2C with ynone 83k (114 mg, 0.300 mmol), AgOTf (0.8 
mg, 3.00 µmol) in CH2Cl2 (3 mL) at RT for 30 min. Purification by column chromatography 
(7:3 hexane:EtOAc) afforded the title compound 84k (108 mg, 95%, 55:45 dr) as a pale 
brown oil; vmax (cm
-1
) 1698, 1603, 1510, 1262, 1181, 832; δH (400 MHz, CDCl3) 2.10 (1H, dd, 
J = 14.5, 10.5 Hz, H-19a, major), 2.53 (1H, dd, J = 14.5, 9.0 Hz, H-19a, minor), 3.17–3.29 
(2H, m, H-19b, minor + major), 3.46 (1H, dd, J = 9.0, 6.0 Hz, H-10, minor), 3.55 (1H, dd, J = 
10.5, 4.5 Hz, H-10, major), 3.71 (3H, s, H-18, minor), 3.72 (3H, s, H-18, major), 6.44–6.49 
(2H, m, H-2, minor + major), 6.62–6.70 (4H, m, H-16, minor + major), 6.78 (1H, s, H-12, 
major), 6.80 (1H, s, H-12, minor), 6.84–6.93 (6H, m, ArH, H-15, minor + major), 6.98–7.09 
(6H, m, ArH) 7.14–7.25 (3H, m, ArH), 7.29–7.36 (2H, m, ArH), 7.47 (1H, ddd, J = 7.5, 7.5, 
1.5 Hz, H-4, major), 7.56 (1H, d, J = 7.5 Hz, H-5, minor), 7.58 (1H, d, J = 7.5 Hz, H-5, 
major), 8.00 (1H, s, H-8, major), 8.13 (1H, s, H-8, minor); δC (100 MHz, CDCl3) 32.0 (CH2), 
32.5 (CH2), 52.1 (CH), 55.2 (CH3), 55.3 (CH3), 57.8 (CH), 70.1 (C), 70.3 (C), 114.1 (2CH), 
114.23 (2CH), 121.8 (CH), 121.9 (CH), 122.4 (CH), 123.2 (CH), 124.8 (C), 125.0 (C), 126.1 
(CH), 126.2 (CH), 126.7 (CH), 126.9 (CH), 127.4 (CH), 127.9 (3CH), 128.0 (CH), 128.2 
(2CH), 128.4 (2CH), 128.67 (5CH), 128.70 (CH), 129.2 (CH), 137.68 (C), 137.73 (C), 138.00 
(C), 140.5 (C), 155.2 (C), 156.2 (C), 161.92 (C), 161.94 (C), 169.8 (C), 170.5 (C), 173.5 
(CH), 174.0 (CH), 204.95 (C), 204.97 (C); HRMS (ESI
+
): Found: 402.1454; C26H21NNaO2 
(MNa
+
) Requires 402.1465 (2.7 ppm error), Found: 380.1634; C26H22NO2 (MH
+
) Requires 
380.1645 (3.0 ppm error). 
Lab notebook reference: MJJ1/74 
  
Chapter 5. Experimental 
 
 
146 
2-(4-Methoxyphenyl)-2'-methylspiro[cyclopent[2]ene-1,3'-indol]-4-one (84l) 
 
Synthesised using general procedure 2C with ynone 83l (107 mg, 0.353 mmol), AgOTf (0.9 
mg, 3.53 µmol) in CH2Cl2 (3.5 mL) at RT for 10 min. Purification by column chromatography 
(1:1 hexane:EtOAc) afforded the title compound 84l (107 mg, 100%) as a pale yellow oil; vmax 
(cm
-1
) 1693, 1604, 1510, 1258, 1181, 1028, 829; δH (400 MHz, CDCl3) 2.20 (3H, s, H-9), 2.69 
(1H, d, J = 18.5 Hz, H-11a), 2.80 (1H, d, J = 18.5 Hz, H-11b), 3.72 (3H, s, H-19), 6.66–6.73 
(2H, m, H-17), 6.80 (1H, s, H-13), 6.91–6.98 (2H, m, H-16), 7.14–7.24 (2H, m, H-2,3), 7.35–
7.44 (1H, m, H-4), 7.66 (1H, d, J = 7.5 Hz, H-5); δC (100 MHz, CDCl3) 15.7 (CH3, C-9), 45.1 
(CH2, C-11), 55.3 (CH3, C-19), 66.5 (C, C-10), 114.4 (2CH, C-17), 120.8 (CH, C-2), 121.6 
(CH, C-5), 124.4 (C, C-15), 126.6 (CH, C-3), 128.7 (CH, C-4), 128.9 (2CH, C-16), 142.2 (C, 
C-1), 154.3 (C, C-6), 162.1 (C, C-18), 172.0 (C, C-14), 183.5 (C, C-8), 204.5 (C, C-12); 
HRMS (ESI
+
): Found: 326.1155; C20H17NNaO2 (MNa
+
) Requires 326.1151 (−1.2 ppm error), 
Found: 304.1339; C20H18NO2 (MH
+
) Requires 304.1332 (−2.3 ppm error). 
Spirocycle 84l was also synthesised using general procedure 2D from ynone 83l (65 mg, 
0.214 mmol) and Ag-114l (1.7 mg, 2.1 µmol) in CHCl3 (2 mL). Purification by column 
chromatography afforded the title compound 84l (47 mg, 72%) in 82:64 er (S:R). [α]D
20 
−159.3 (c = 1.0, CHCl3). CSP-HPLC conditions: 10% IPA in hexane, (R)-84l 33.9 min, (S)-
84l 36.4 min, UV detection at 280 nm. 
Lab notebook reference: MJJ3/45 + 3/70 
 
2-(4-Methoxyphenyl)-2'-phenylspiro[cyclopent[2]ene-1,3'-indol]-4-one (84m) 
 
Synthesised using general procedure 2C with ynone 83m (100 mg, 0.274 mmol), AgOTf 
(0.7 mg, 2.74 µmol) in CH2Cl2 (3 mL) at RT for 6 min. Purification by column 
chromatography (7:3 hexane:EtOAc) afforded the title compound 84m (84 mg, 84%) as a pale 
brown oil; vmax (cm
-1
) 1693, 1603, 1510, 1256, 1180, 834, 758; δH (400 MHz, CDCl3) 2.66 
(1H, d, J = 18.5 Hz, H-14a), 3.09 (1H, d, J = 18.5 Hz, H-14b), 3.68 (3H, s, H-22), 6.63–6.69 
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(2H, m, H-20), 6.91 (1H, s, H-16), 7.05–7.10 (2H, m, H-19), 7.18–7.27 (2H, m, H-2,3), 7.36–
7.48 (4H, m, H-4,11,12), 7.82 (1H, d, J = 8.0 Hz, H-5), 7.96–8.01 (2H, m, H-10); δC (100 
MHz, CDCl3) 47.2 (CH2, C-14), 55.2 (CH3, C-22), 65.2 (C, C-13), 114.5 (2CH, C-20), 120.8 
(CH, C-2), 121.7 (CH, C-5), 124.7 (C, C-18), 127.1 (CH, C-3/16), 127.3 (CH, C-3/16), 127.7 
(2CH, C-10), 129.0 (2CH, C-11/19), 129.08 (2CH, C-11/19), 129.12 (CH, C-4), 131.2 (CH, 
C-12), 132.2 (C, C-9), 143.4 (C, C-1), 153.7 (C, C-6), 162.1 (C, C-21), 174.0 (C, C-17), 178.9 
(C, C-8), 204.8 (C, C-15); HRMS (ESI
+
): Found: 388.1302; C25H19NNaO2 (MNa
+
) Requires 
388.1308 (1.7 ppm error), Found: 366.1477; C25H20NO2 (MH
+
) Requires 366.1489 (3.2 ppm 
error). 
Lab notebook reference: MJJ1/56 
 
5'-Bromo-2-(4-methoxyphenyl)spiro[cyclopent[2]ene-1,3'-indol]-4-one (84n) 
 
Synthesised using general procedure 2C with ynone 83n (74  mg,  0.20 mmol), AgOTf (0.5 
mg, 2 µmol) in CH2Cl2 (2 mL) at RT for 1 h. Purification by column chromatography (1:1 
hexane:EtOAc) afforded the title compound 84n (74 mg, 100%) as an off-white solid, mp 65–
67 °C; vmax (cm
-1
) 1692, 1603, 1509, 1255, 1180, 1030, 831, 730; δH (400 MHz, CDCl3) 2.62 
(1H, d, J = 18.5 Hz, H-10a), 3.01 (1H, d, J = 18.5 Hz, H-10b), 3.75 (3H, s, H-18), 6.68–6.74 
(2H, m, H-16), 6.77 (1H, s, H-12), 6.92–6.97 (2H, m, H-15), 7.36 (1H, d, J = 2.0 Hz, H-2), 
7.57 (1H, dd, J = 8.0, 2.0 Hz, H-4), 7.64 (1H, d, J = 8.0 Hz, H-5), 8.20 (1H, s, H-8); δC (100 
MHz, CDCl3) 42.1 (CH2, C-10), 55.3 (CH3, C-18), 66.0 (C, C-9), 114.4 (2CH, C-16), 121.6 
(C, C-3), 123.4 (CH, C-5), 124.5 (C, C-14), 125.0 (CH, C-2), 128.6 (CH, C-12), 128.7 (2CH, 
C-15), 132.2 (CH, C-4), 143.5 (C, C-1), 153.6 (C, C-6), 162.2 (C, C-17), 170.1 (C, C-13), 
174.9 (CH, C-8), 203.4 (C, C-11); HRMS (ESI
+
): Found: 390.0075; C19H14
79
BrNNaO2 
(MNa
+
) Requires 390.0100 (6.5 ppm error), Found: 368.0269; C19H15
79
BrNO2 (MH
+
) 
Requires 368.0281 (3.1 ppm error). 
Spirocycle 84n was also synthesised using general procedure 2D from ynone 83n (352 mg, 
0.956 mmol) and Ag-114l (7.7 mg, 9.6 µmol) in CHCl3 (20 mL). Purification by column 
chromatography afforded the title compound 84n (352 mg, 100%) in 85:15 er (R:S). [α]D
20  
−145.6 (c = 1.0, CHCl3). CSP-HPLC conditions: 10% IPA in hexane, (R)-84n 32.4 min, (S)-
84n 38.6 min, UV detection at 280 nm. 
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Lab notebook reference: MJJ3/41 + 3/42 
 
Spiro[cyclopent[2]ene-1,3'-indol]-4-one (84o) 
 
To a stirred solution of ynone 83o (51mg, 0.200 mmol) in acetone (2 mL) was added AgNO3 
(6.8 mg, 0.040 mmol). The mixture was stirred for 16 h at RT. The reaction mixture was 
concentrated in vacuo then purified by column chromatography (6:4 hexane:EtOAc) to afford 
the title compound 84o (34 mg, 93%, ~2:1 mixture of trimer:monomer) as a pale brown oil; 
vmax (cm
-1
) 1714, 1600, 1475, 753, 735; NMR data of TFA salt, δH (400 MHz, CDCl3) 2.97 
(1H, d, J = 19.5 Hz, H-10a), 3.46 (1H, d, J = 19.5 Hz, H-10b), 6.93 (1H, d, J = 5.5 Hz, H-12), 
7.34 (1H, d, J = 5.5 Hz, H-13), 7.52–7.57 (1H, m, H-2), 7.70–7.76 (2H, m, H-3,4), 7.87–7.92 
(1H, m, H-5), 9.31 (1H, s, H-8); δC (100 MHz, CDCl3) 38.7 (CH2, C-10), 63.8 (C, C-9), 118.9 
(CH, C-5), 123.9 (CH, C-2), 131.5 (CH, C-3/4), 132.3 (CH, C-3/4), 136.4 (C, C-1), 138.4 
(CH, C-12), 140.6 (C, C-6), 158.8 (CH, C-13), 178.4 (CH, C-8), 208.4 (C, C-11); HRMS 
(ESI
+
): Found: 206.0583; C12H9NNaO (MNa
+
) Requires 206.0576 (−3.1 ppm error), Found: 
184.0753; C12H10NO (MH
+
) Requires 184.0757 (2.1 ppm error).  
Lab notebook reference: MJJ3/5 
 
1-(4-Methoxyphenyl)spiro[cyclohex[6]ene-2,3'-indol]-5-one (84q) 
 
Synthesised using general procedure 2C with ynone 83q (40 mg, 0.132 mmol), AgOTf (3.4 
mg, 13.2 µmol) in CH2Cl2 (1.3 mL) at 35 °C for 16 h. Purification by column chromatography 
(3:1 hexane:EtOAc) afforded the title compound 84q (30 mg, 75%) as a pale brown oil; vmax 
(cm
-1
) 1664, 1603, 1510, 1240, 1179, 1030, 831, 729; δH (400 MHz, CDCl3) 1.78 (1H, ddd, J 
= 13.5, 5.0, 5.0 Hz, H-10a), 2.55–2.64 (1H, m, H-10b), 2.70 (1H, ddd, J = 18.0, 5.0, 5.0 Hz, 
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H-11a), 2.81–2.92 (1H, m, H-11b), 3.71 (3H, s, H-19), 6.47 (1H, s, H-13), 6.63–6.68 (2H, m, 
H-17), 6.69–6.74 (2H, m, H-16), 7.29 (1H, ddd, J = 7.5, 7.5, 0.5 Hz, H-3), 7.36 (1H, br d, J = 
7.5 Hz, H-2), 7.47 (1H, ddd, J = 7.5, 7.5, 1.5 Hz, H-4), 7.78 (1H, br d, J = 7.5 Hz, H-5), 8.19 
(1H, br s, H-8); δC (100 MHz, CDCl3) 31.9 (CH2, C-10), 34.3 (CH2, C-11), 55.2 (CH3, C-19), 
61.5 (C, C-9), 114.0 (2CH, C-17), 122.5 (CH, C2/5), 122.7 (CH, C2/5), 126.9 (CH, C-3), 
127.3 (2CH, C-16), 128.3 (CH, C-13), 129.1 (CH, C-4), 129.6 (C, C-15), 140.7 (C, C-1), 
154.8 (C, C-6), 157.3 (C, C-14), 160.9 (C, C-18), 176.2 (CH, C-8) 197.9 (C, C-12); HRMS 
(ESI
+
): Found: 326.1152; C20H17NNaO2 (MNa
+
) Requires 326.1151 (-0.3 ppm error), Found: 
304.1330; C20H18NO2 (MH
+
) Requires 304.1332 (0.6 ppm error). 
Lab notebook reference: MJJ1/81 + WPU/2134 
 
2-Methoxyspiro[cyclopent[2]ene-1,3'-indol]-4-one (84s) 
 
To a 0 °C solution of Et2NH (2.48 mL, 24.0 mmol) in THF (48 mL) under argon was added n-
BuLi (8.80 mL, 22.0 mmol, 2.5 M in hexanes) dropwise. The mixture was stirred at 0 °C for 
10 min and then chloroacetaldehyde dimethylacetal (0.78 mL, 6.87 mmol) was slowly added. 
The mixture was stirred for 2 h at 0 °C, then cooled to −78 °C before being transferred via 
cannula to a −78 °C solution of Weinreb 81a (500 mg, 2.29 mmol) in THF (11.5 mL). Upon 
complete transfer the mixture was warmed to RT and stirred for 30 min after which the 
reaction was quenched by the careful addition of sat. NH4Cl(aq) (20  mL). The organics were 
separated and the aqueous extracted with EtOAc (3 × 20 mL). The organics were combined, 
washed with brine, dried (MgSO4), concentrated in vacuo and purified by column 
chromatography (6:4 hexane:EtOAc, then 8:2 EtOAc:hexane) to afford the title compound 84s 
(148 mg, 30% yield) as a pale brown oil; vmax (cm
-1
) 1691, 1595, 1251, 749; δH (400 MHz, 
CDCl3) 2.70 (1H, d, J = 18.0 Hz, H-10a), 3.00 (1H, d, J = 18.0 Hz, H-10b), 3.73 (3H, s, H-
14), 5.63 (1H, s, H-12), 7.27–7.35 (2H, m, H-2,3), 7.44 (1H, ddd, J = 7.5, 7.5, 2.0 Hz, H-4), 
7.70 (1H, d, J = 8.0 Hz, H-5), 8.03 (1H, s, H-8); δC (100 MHz, CDCl3) 40.3 (CH2, C-10), 59.4 
(CH3, C-14), 64.4 (C, C-9), 105.6 (CH, C-12), 121.2 (CH, C-2), 121.6 (CH, C-5), 127.2 (CH, 
C-3), 129.1 (CH, C-4), 138.4 (C, C-1), 155.4 (C, C-6), 171.5 (CH, C-8), 187.3 (C, C-13), 
201.7 (C, C-11); HRMS (ESI
+
): Found: 236.0682; C13H11NNaO2 (MNa
+
) Requires 236.0682 
(0.1 ppm error), Found: 214.0859; C13H12NO2 (MH
+
) Requires 214.0863 (1.8 ppm error). 
Lab notebook reference: MJJ2/36 
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1-(4-Methoxyphenyl)-9H-carbazol-3-ol (85a) 
 
Synthesised using general procedure 2C with ynone 83a (58 mg, 0.2 mmol) and 
(Ph3P)AuNTf2·½PhMe (15.7 mg, 0.02 mmol) in CH2Cl2 (2 mL) at RT for 30 min. Purification 
by column chromatography (3:2 hexane:EtOAc) afforded the title compound 85a (44 mg, 
76%) as an off-white semi-solid; vmax (cm
-1
) 3368, 1609, 1517, 1495, 1317, 1237, 1174, 1152, 
830, 728; δH (400 MHz, CDCl3) 3.86 (3H, s, H-19), 4.58 (1H, br s, H-12), 6.96–7.05 (3H, m, 
H-13,17), 7.17–7.23 (1H, m, H-3), 7.35–7.43 (2H, m, H-4,5), 7.49 (1H, d, J = 2.5 Hz, H-10), 
7.51–7.56 (2H, m, H-16), 7.98 (1H, d, J = 8.0 Hz, H-2), 8.15 (1H, br s, H-7); δC (100 MHz, 
CDCl3) 55.3 (CH3, C-19), 104.5 (CH, C-10), 110.8 (CH, C-5), 114.5 (CH, C-13), 114.6 (2CH, 
C-17), 119.0 (CH, C-3), 120.5 (CH, C-2), 123.3 (C, CAr), 124.3 (C, CAr), 125.4 (C, CAr), 
125.9 (CH, C-4), 129.3 (2CH, C-16), 130.9 (C, CAr), 132.3 (C, CAr), 140.3 (C, CAr), 149.6 
(C, C-11), 159.0 (C, C-18); HRMS (ESI
+
): Found: 312.0992; C19H15NNaO2 (MNa
+
) Requires 
312.0995 (0.8 ppm error), Found: 290.1173; C19H16NO2 (MH
+
) Requires 290.1176 (1.0 ppm 
error). 
Lab notebook reference: MJJ6/2 
 
6-(4-Methoxyphenyl)-9,10-dihydrocyclohepta[b]indol-8(5H)-one (85q) 
 
Synthesised using general procedure 2C with ynone 83q (61 mg, 0.2 mmol) and 
(Ph3P)AuNTf2·½PhMe (31 mg, 0.04 mmol) in CH2Cl2 (2 mL) at 40 °C for 24 h. Purification 
by column chromatography (1:1 hexane:EtOAc) afforded the title compound 85q (51 mg, 
84%) as a yellow solid, mp 209–211 °C; vmax (cm
-1
) 3318, 1625, 1604, 1509, 1331, 1248, 
1177, 735; δH (400 MHz, CDCl3) 2.88–2.96 (2H, m, H-11), 3.15–3.23 (2H, m, H-10), 3.89 
(3H, s, H-19), 6.23 (1H, s, H-13), 6.89–7.04 (2H, m, H-17), 7.15–7.21 (1H, m, H-3), 7.23–
7.32 (2H, m, H-4,5), 7.38–7.43 (2H, m, H-16), 7.66 (1H, br d, J = 8.0 Hz, H-2), 7.86 (1H, br 
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s, H-7); δC (100 MHz, CDCl3) 18.1 (CH2, C-10) , 42.8 (CH2, C-11), 55.4 (CH3, C-19), 111.3 
(CH, C-5), 114.3 (2CH, C-17), 119.5 (CH, C-2), 120.3 (CH, C-3), 121.1 (C, C-9), 124.4 (CH, 
C-4), 127.0 (C, C-1), 127.7 (CH, C-13), 130.2 (2CH, C-16), 131.5 (C, C-8/15), 131.7 (C, C-
8/15), 135.5 (C, C-6), 145.0 (C, C-14), 160.6 (C, C-18), 200.8 (C, C-12); HRMS (ESI
+
): 
Found: 326.1152; C20H17NNaO2 (MNa
+
) Requires 326.1151 (−0.3 ppm error), Found: 
304.1331; C20H18NO2 (MH
+
) Requires 304.1332 (0.4 ppm error). 
Lab notebook reference: MJJ6/3 
 
6-(4-Methoxyphenyl)-5H,8H,9H,10H,11H-cycloocta[b]indol-8-one (85r) 
 
Synthesised using general procedure 2C with ynone 83r (48 mg, 0.15 mmol) and 
(Ph3P)AuNTf2·½PhMe (24 mg, 0.03 mmol) in CH2Cl2 (1.5 mL) at 40 °C for 24 h. Purification 
by column chromatography (7:3 hexane:EtOAc) afforded the title compound 85r (41 mg, 
85%) as a yellow oil, which solidified on standing, mp 204–206 °C; vmax (cm
-1
) 3307, 2931, 
1621, 1603, 1508, 1334, 1248, 1177, 1135, 731; δH (400 MHz, CDCl3) 2.25–2.35 (2H, m, H-
11), 2.44–2.54 (2H, m, H-10), 2.99–3.10 (2H, m, H-12), 3.86 (3H, s, H-20), 6.90–6.95 (2H, 
m, H-18), 7.17–7.23 (1H, m, H-3), 7.25–7.37 (4H, m, H-4,5,17), 7.70 (1H, d, J = 8.0 Hz, H-
2), 8.02 (1H, br s, H-7); δC (100 MHz, CDCl3) 22.4 (CH2, C-12), 34.0 (CH2, C-11), 38.3 (CH2, 
C-10), 55.4 (CH3, C-20), 111.3 (CH, C-5), 114.1 (2CH, C-18), 119.4 (CH, C-2), 120.0 (CH, 
C-3), 121.9 (C, C-9), 124.4 (CH, C-4), 127.0 (C, C-1), 127.9 (CH, C-14), 131.0 (2CH, C-17), 
132.1 (C, C-8/16), 132.5 (C, C-8/16), 136.4 (C, C-6), 144.0 (C, C-15), 161.0 (C, C-19), 204.8 
(C, C-13); HRMS (ESI
+
): Found: 340.1298; C21H19NNaO2 (MNa
+
) Requires 340.1308 (3.1 
ppm error), Found: 318.1478; C21H20NO2 (MH
+
) Requires 318.1489 (3.2 ppm error). 
Lab notebook reference: MJJ6/16 
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(R)-2,2'-Bis(methoxymethoxy)-1,1'-binaphthalene (116) 
 
To a suspension of NaH (307 m, 7.68 mmol, 60% wt.) in THF (12 mL) under argon at 0 °C 
was added a solution of (R)-BINOL (1.00 g, 3.49 mmol) in THF (5 mL). The mixture was 
stirred for 1 h under argon at 0 °C, then MOMCl (0.66 mL, 8.73 mmol) was added dropwise. 
The mixture was stirred for a further 1 h under argon at RT, then quenched with the careful 
addition of sat. NH4Cl(aq) (10 mL) and extracted with EtOAc (3 × 20 mL). The combined 
organics were washed with brine, dried (MgSO4) and concentrated in vacuo. The crude 
material was purified by column chromatography (silica, 9:1 hexane:EtOAc) to afford the title 
compound 116 (1.06 g, 81%) as a white solid, mp 98.5–99.5 °C (lit.138 98–100 °C); [α]D
20
 = 
+91.7 (c 1.0, CHCl3) [lit.
138
 [α]D
25
 = +95.0 (c 1.0, THF)]; vmax (cm
-1
) 1592, 1506, 1238, 1147, 
1031, 1012, 810, 750; δH (400 MHz, CDCl3) 3.14 (6H, s), 4.98 (2H, d,
 
J = 7.0 Hz), 5.09 (2H, 
d,
 
J = 7.0 Hz), 7.17 (2H, d, J = 8.5 Hz), 7.20–7.26 (2H, m), 7.35 (2H, t, J = 8.0 Hz), 7.60 (2H, 
d, J = 9.0 Hz), 7.88 (2H, d, J = 8.5 Hz), 7.96 (2H, d, J = 9.0 Hz); δC (100 MHz, CDCl3) 55.8, 
95.1, 117.2, 121.2, 124.0, 125.5, 126.2, 127.8, 129.3, 129.8, 134.0, 152.6. 
Lab notebook reference: MJJ2/14 
Spectroscopic data matched those reported in the literature.
138
 
 
(R)-3,3'-Diiodo-2,2'-bis(methoxymethoxy)-1,1'-binaphthalene (117) 
 
To a solution of 2,2'-bis(methoxymethoxy)-1,1'-binaphthalene (116) (475 mg, 1.27 mmol) in 
THF (11.4 mL) under argon at 0 °C was added n-BuLi (1.52 mL, 3.81 mmol, 2.5 M in 
hexanes) dropwise. The mixture was stirred for 30 min at 0 °C. The mixture was cooled to 
−78 °C and iodine (967 mg, 3.81 mmol) was added in one portion. The mixture was allowed 
to warm to RT and stirred for 1.5 h, then poured into sat. NH4Cl(aq) (15 mL) and extracted with 
EtOAc (3 × 20 mL). The organics were combined, washed with Na2S2O3 (15 mL), brine (15 
mL), dried (MgSO4) and concentrated in vacuo to afford the title compound 117 (805 mg, 
100%) as a pale yellow solid, mp 81–82 °C (lit.139 127–128 °C); [α]D
20
 = −35.6 (c 1.0, CHCl3) 
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[lit.
139
 [α]D
20
 = −9.3 (c 0.98, THF)]; vmax (cm
-1
) 1382, 1345, 1232, 1202, 1158, 1085, 995, 955, 
905, 748; δH (400 MHz, CDCl3) 2.60 (6H, s), 4.70 (2H, d, J = 6.0 Hz), 4.82 (2H, d, J = 6.0 
Hz), 7.18 (2H, dd, J = 8.5, 0.5 Hz), 7.28–7.34 (2H, m), 7.41–7.46 (2H, m), 7.79 (2H, d, J = 
8.0 Hz), 8.55 (2H, s); δC (100 MHz, CDCl3) 56.4, 92.4, 99.3, 125.8, 126.2, 126.5, 126.7, 
127.1, 132.1, 133.7, 139.9, 152.1. 
Lab notebook reference: MJJ2/37 
Spectroscopic data matched those reported in the literature.
139
 
 
(R)-4-Hydroxy-2,6-di(naphthalen-1-yl)dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine 
4-oxide (114b) 
 
Synthesised using general procedure 2E with naphthalen-1-ylboronic acid (66 mg, 0.384 
mmol). Purification by column chromatography (CH2Cl2, then 9:1 CH2Cl2:MeOH) afforded 
the title compound 114b (57 mg, 59%) as an off white solid; [α]D
20
 = −120.7 (c 1.0, CH2Cl2); 
δH (400 MHz, CDCl3) 6.83–8.03 (24H, m); δp (162 MHz, CDCl3) 3.1 (br s). Ag-114b 
synthesised using general procedure 2H using CPA 114b (56 mg, 0.0932 mmol), Ag2CO3 
(12.9 mg, 0.0466 mmol), CH2Cl2 (0.9 mL) and H2O (0.9 mL) to afford the silver salt as an off 
white solid (50 mg, 76%). 
Lab notebook reference: MJJ2/43 + MJJ2/45 
Spectroscopic data matched those reported in the literature.
140
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 (R)-4-Hydroxy-2,6-di(naphthalen-2-yl)dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine 
4-oxideoxide (114c) 
 
Synthesised using general procedure 2E with naphthalen-2-ylboronic acid (66 mg, 0.384 
mmol). Purification by column chromatography (CH2Cl2, then 9:1 CH2Cl2:MeOH) afforded 
the title compound 114c (78 mg, 81%) as an off white solid; [α]D
20
 = −268.3 (c 1.0, CHCl3) 
[lit.
141
 [α]D
25
 = −265.0 (c 0.2, CHCl3)]; vmax (cm
-1
) 1252, 1102, 857, 747; δH (400 MHz, 
CDCl3) 7.00–7.19 (4H, m), 7.20–7.58 (14H, m), 7.63–7.76 (2H, m), 7.86–7.94 (2H, m), 7.97–
8.07 (2H, m); δp (162 MHz, CDCl3) 0.3 (br s). Ag-114c synthesised using general procedure 
2H using CPA 114c (78 mg, 0.130 mmol), Ag2CO3 (18 mg, 0.065 mmol), CH2Cl2 (1.3 mL) 
and H2O (1.3 mL) to afford the silver salt as an off white solid (50 mg, 54%). 
Lab notebook reference: MJJ2/48 + MJJ2/49 
Spectroscopic data matched those reported in the literature.
141
 
 
(R)-2,6-Di([1,1'-biphenyl]-4-yl)-4-hydroxydinaphtho[2,1-d:1',2'-
f][1,3,2]dioxaphosphepine 4-oxide (114d) 
 
Synthesised using general procedure 2E with [1,1'-biphenyl]-4-ylboronic acid (76 mg, 0.384 
mmol). Purification by column chromatography (CH2Cl2, then 39:1 CH2Cl2:MeOH) afforded 
the title compound 114d (54 mg, 50%) as a white solid; [α]D
20
 = −204.1 (c 1.0, CHCl3) [lit.
140
 
[α]D
21
 = −335.6 (c 1.2, CHCl3)]; δH (400 MHz, CDCl3) 6.89–7.64 (24H, m) 7.74–7.89 (2H, 
m), 7.91–8.08 (2H, m); δp (162 MHz, CDCl3) 1.5 (br s). Ag-114d synthesised using general 
Chapter 5. Experimental 
 
 
155 
procedure 2H using CPA 114d (44 mg, 0.0674 mmol), Ag2CO3 (8.3 mg, 0.0337 mmol), 
CH2Cl2 (1.0 mL) and H2O (1.0 mL) to afford the silver salt as an off white solid (33 mg, 
64%). 
Lab notebook reference: MJJ2/54 + MJJ2/58 
Spectroscopic data matched those reported in the literature.
140
 
 
(R)-4-Hydroxy-2,6-di(pyren-1-yl)dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine 4-oxide 
(114e) 
 
Synthesised using general procedure 2E with pyren-1-ylboronic acid (95 mg, 0.384 mmol). 
Purification by column chromatography (CH2Cl2, then 20:1 CH2Cl2:MeOH) afforded the title 
compound 114e (24 mg, 20%) as a yellow solid; [α]D
20
 = −90.0 (c 1.0, CHCl3); vmax (cm
-1
) 
1437, 1182, 1119, 1096, 906, 842, 719, 693, 538; δH (400 MHz, CDCl3) 7.20–8.20 (28H, m); 
δp (162 MHz, CDCl3) 29.9 (s). Ag-114e synthesised using general procedure 2H using CPA 
114e (23 mg, 0.0307 mmol), Ag2CO3 (4.2 mg, 15.4 µmol), CH2Cl2 (0.5 mL) and H2O (0.5 
mL) to afford the silver salt as a yellow solid (23 mg, 88%) 
Lab notebook reference: MJJ2/62 + MJJ2/70 
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 (R)-2,6-Di([1,1':3',1''-terphenyl]-5'-yl)-4-hydroxydinaphtho[2,1-d:1',2'-
f][1,3,2]dioxaphosphepine 4-oxide (114f) 
 
Synthesised using general procedure 2E with [1,1':3',1''-terphenyl]-5'-ylboronic acid (105 
mg, 0.384 mmol). Purification by column chromatography (CH2Cl2, then 20:1 CH2Cl2:MeOH) 
afforded the title compound 114f (121 mg, 94%) as a white solid; [α]D
20
 = −202.3 (c 1.0, 
CHCl3) [lit.
142
 (S enantiomer) [α]D
32
 = 247.1 (c 1.0, CHCl3)]; vmax (cm
-1
) 1594, 1437, 1261, 
1182, 1104, 758, 723, 696, 542; δH (400 MHz, CDCl3) 7.03–7.14 (3H, m), 7.15–7.51 (27H, 
m), 7.89–8.04 (6H, m); δC (100 MHz, CDCl3) 123.2, 124.6, 125.3, 126.2, 127.0, 127.3, 127.9, 
128.1, 128.2, 128.7, 130.8, 131.0, 131.7, 131.8, 131.9, 132.5, 134.0, 138.9, 140.7, 141.3; δP 
(162 MHz, CDCl3) 4.5 (br s). Ag-114f synthesised using general procedure 2H using CPA 
114f (121 mg, 0.150 mmol), Ag2CO3 (21 mg, 0.075 mmol), CH2Cl2 (2 mL) and H2O (2 mL) 
to afford the silver salt as a pale yellow solid (113 mg, 83%). 
Lab notebook reference: MJJ2/73 + MJJ2/74 
Spectroscopic data matched those reported in the literature.
142
 
 
(R)-2,2'-Bis(methoxymethoxy)-3,3'-bis(perfluorophenyl)-1,1'-binaphthalene (118g) 
 
To a solution of (R)-2,2'-bis(methoxymethoxy)-1,1'-binaphthalene (117) (475 mg, 1.27 mmol) 
in THF (11.4 mL) under argon at 0 °C was added n-BuLi (1.52 mL, 3.81 mmol, 2.5 M in 
hexanes) dropwise. The mixture was stirred for 30 min at 0 °C. The mixture was cooled to 
−78 °C and hexafluorobenzene (967 mg, 3.81 mmol) was added in one portion. The mixture 
was allowed to warm to RT and stirred for 16 h, then poured into sat. NH4Cl(aq) (15 mL) and 
extracted with EtOAc (3 × 20 mL). The organics were combined, washed with brine (15 mL), 
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dried (MgSO4) and concentrated in vacuo. The crude material was purified by column 
chromatography (silica, 9:1 hexane:EtOAc) to afford the title compound 118g (745 mg, 78%) 
as a white solid, mp 72–74 °C; [α]D
20
 = −19.1 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 2.63 (6H, 
s), 4.43 (2H, d, J = 6.0 Hz), 4.48 (2H, d, J = 6.0 Hz), 7.34 (2H, d, J = 8.5 Hz), 7.39–7.45 (2H, 
m), 7.48–7.54 (2H, m), 7.94 (2H, d, J = 8.0 Hz), 7.98 (2H, s); δF (376 MHz, CDCl3) −162.4–
−162.1 (4F, m), −154.7 (2F, t, J = 20.5 Hz), −139.7 (2F, dd, J = 23.0, 8.0 Hz), −139.1 (2F, dd, 
J = 23.0, 8.0 Hz). 
Lab notebook reference: MJJ2/16 
Spectroscopic data matched those reported in the literature.
143
 
 
 (R)-3,3'-Bis(perfluorophenyl)-[1,1'-binaphthalene]-2,2'-diol (119g) 
 
To a stirred solution of (R)-2,2'-bis(methoxymethoxy)-3,3'-bis(perfluorophenyl)-1,1'-
binaphthalene (118g) (710 mg, 1.00 mmol) in MeOH (7 mL) and CH2Cl2 (1.5 mL) was added 
12 M HCl(aq) (0.22 mL, 2.60 mmol). The mixture was stirred for 16 h at 50 °C, then poured 
into sat. NaHCO3 (aq) (10 mL) and extracted with CH2Cl2 (3 × 10 mL). The organics were 
dried (MgSO4) and concentrated in vacuo to afford the title compound 119g (613 mg, 99%) 
without further purification as a white solid, mp 122–124 °C; [α]D
20
 = +87.5 (c 1.0, CHCl3); 
δH (400 MHz, CDCl3) 5.25 (2H, s), 7.24–7.28 (2H, m), 7.43–7.51 (4H, m), 7.95–7.98 (2H, m), 
8.04 (2H, s); δF (376 MHz, CDCl3) −162.3 (4F, quind, J = 23.0, 8.0 Hz), −154.5 (2F, t, J = 
20.5 Hz), −139.9 (2F, dd, J = 23.0, 8.0 Hz), −139.5 (2F, dd, J = 23.0, 8.0 Hz). 
Lab notebook reference: MJJ2/17 
Spectroscopic data matched those reported in the literature.
144
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(R)-4-Hydroxy-2,6-bis(perfluorophenyl)dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine 
4-oxide (114g) 
 
To a stirred solution of (R)-3,3'-bis(perfluorophenyl)-[1,1'-binaphthalene]-2,2'-diol (119g) 
(592 mg, 0.98 mmol) in pyridine (2.1 mL) was added POCl3 (0.18 mL, 1.91 mmol) was added 
dropwise. The mixture was stirred for 16 h under argon at RT then cooled to 0 °C and 12 M 
HCl(aq) (2 mL) was added. The mixture was stirred for a further 5 h at RT then poured into 
10% HCl(aq) (10 mL) and extracted with CH2Cl2 (3 × 10 mL). The organics were then washed 
with 10% HCl(aq) (5 × 30 mL), dried (MgSO4) and concentrated in vacuo. The crude material 
was purified by column chromatography (9:1 CH2Cl2:MeOH) then dissolved in CH2Cl2 (10 
mL), washed with 10% HCl(aq) (2 × 10 mL), dried (Na2SO4) and concentrated in vacuo to 
afford the title compound 114g (612 mg, 93%) as a white powder; [α]D
20
 = −236.0 (c 1.0, 
CHCl3) [lit.
143
 [α]D
24
 = −164.5 (c 1.0, CHCl3)]; δH (400 MHz, DMSO-d6) 7.34 (2H, d, J = 8.5 
Hz), 7.43–7.49 (2H, m), 7.53–7.58 (2H, m), 8.12 (2H, d, J = 8.0 Hz), 8.24 (2H, s); δF (376 
MHz, DMSO-d6) −164.4 (2F, td, J = 24.0, 7.0 Hz), −163.1–−162.9 (2F, m), −155.9 (2F, t, J  = 
22.0 Hz), −139.6 (2F, dd, J = 24.0, 7.0 Hz), −138.7 (2F, dd, J = 24.0, 7.0 Hz); δP (162 MHz, 
DMSO-d6) 4.24. Ag-114g synthesised using general procedure 2H using CPA 114g (50 mg, 
0.0735 mmol), Ag2CO3 (10 mg, 0.037 mmol), CH2Cl2 (0.7 mL) and H2O (0.7 mL) to afford 
the silver salt as a pale yellow solid (20 mg, 34%). 
Lab notebook reference: MJJ/2/21 + MJJ2/23 
Spectroscopic data matched those reported in the literature.
143
 
 
 (S)-3,3'-Dibromo-5,5',6,6',7,7',8,8'-octahydro-[1,1'-binaphthalene]-2,2'-diol (121) 
 
To a solution of (S)-(H8)-BINOL (500 mg, 1.70 mmol) in CH2Cl2 (9.5 mL) under argon at −30 
°C was added bromine (0.19 mL, 3.74 mmol) dropwise. The mixture was stirred for 40 min at 
−30 °C, then quenched with sat. Na2S2O3 (aq) (10 mL) and allowed to warm to room 
temperature. The organics were separated, washed with sat. NaHCO3 (aq) (10 mL), brine (10 
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mL), dried (MgSO4) and concentrated in vacuo. The crude material was recrystallised from 
warm hexane to afford the title compound 121 (718 mg, 94%) as an off white solid, mp 138–
140 °C; [α]D
20
 = −25.7 (c 1.0, CHCl3) [lit.
145
 (R enantiomer) [α]D
25
 = 21.2 (c 0.1, CHCl3)]; vmax 
(cm
-1
) 3511, 1930, 1450, 1265, 1211, 1179, 1159, 909, 731; δH (400 MHz, CDCl3) 1.60–1.79 
(8H, m), 2.06–2.16 (2H, m), 2.25–2.36 (2H, m), 2.69–2.83 (2H, m), 5.11 (2H, s), 7.30 (2H, s); 
δC (100 MHz, CDCl3) 22.7, 22.8, 26.9, 29.0, 107.2, 122.2, 131.5, 132.5, 136.7, 147.2. 
Lab notebook reference: MJJ2/68 
Spectroscopic data matched those reported in the literature.
146
 
 
 (S)-5',5'',6',6'',7',7'',8',8''-octahydro-[1,2':4',1'':3'',1'''-quaternaphthalene]-2'',3'-diol 
(122a) 
 
Synthesised using general procedure 2F with (S)-3,3'-dibromo-5,5',6,6',7,7',8,8'-octahydro-
[1,1'-binaphthalene]-2,2'-diol 121 (100 mg, 0.221 mmol), Pd(OAc)2 (2.0 mg, 0.009 mmol), 
di(1-adamantyl)-n-butylphosphine (3.9 mg, 0.011 mmol), naphthalen-1-ylboronic acid (95 
mg, 0.553 mmol), DME (2.2 mL) and 1 M K2CO3 (aq) (1.1 mL). Purification by column 
chromatography (silica gel, hexane to 9:1 hexane:EtOAc) afforded the title compound 122a 
(129 mg, 100%) as a pale yellow oil, [α]D
20
 = +25.0 (c 1.0, CHCl3) [lit.
147
 (R enantiomer) 
[α]D
18
 = −35.2 (c 1.0, CHCl3)]; vmax (cm
-1
) 3527, 2928, 1449, 1234, 802, 778, 753; δH (400 
MHz, CDCl3) 1.79–1.99 (8H, m), 2.40–2.74 (4H, m), 2.81–2.94 (4H, m), 4.77 (0.5H, s, 
rotamer), 4.79 (0.5H, s, rotamer), 4.83 (0.5H, s, rotamer), 4.86 (0.5H, s, rotamer), 7.14–7.19 
(2H, m), 7.38–7.65 (8H, m), 7.73 (0.5H, d, J = 8.5 Hz, rotamer), 7.79–7.87 (1.5H, m, 
rotamers), 7.89–8.00 (4H, m). 
Lab notebook reference: MJJ2/89 
Spectroscopic data matched those reported in the literature.
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(S)-3,3'-Di(phenanthren-9-yl)-5,5',6,6',7,7',8,8'-octahydro-[1,1'-binaphthalene]-2,2'-diol 
(122b) 
 
Synthesised using general procedure 2F with (S)-3,3'-dibromo-5,5',6,6',7,7',8,8'-octahydro-
[1,1'-binaphthalene]-2,2'-diol 121 (100 mg, 0.221 mmol), Pd(OAc)2 (2.0 mg, 0.009 mmol), 
di(1-adamantyl)-n-butylphosphine (3.9 mg, 0.011 mmol), phenanthren-9-ylboronic acid (123 
mg, 0.553 mmol), DME (2.2 mL) and 1 M K2CO3 (aq) (1.1 mL). Purification by column 
chromatography (silica gel, hexane to 7:3 hexane:CH2Cl2) afforded the title compound 122b 
(140 mg, 98%) as a white solid, mp 206–209 °C (lit.148 193–195 °C); [α]D
20
 = 50.4 (c 1.0, 
CHCl3) [lit.
148
 R enantiomer [α]D
23
 = −45.3 (c 0.5, CHCl3)]; vmax (cm
-1
) 3528, 2928, 1450, 
1227, 771, 747, 726; δH (400 MHz, CDCl3) 1.83–2.04 (8H, m), 2.47–2.81 (4H, m), 2.86–2.98 
(4H, m), 4.87 (0.5H, s, rotamer), 4.88 (0.5H, s, rotamer), 4.92 (0.5H, s, rotamer), 4.97 (0.5H, 
s, rotamer), 7.21–7.28 (2H, m), 7.47–7.60 (1H, m), 7.61–7.85 (8H, m), 7.87–8.02 (5H, m), 
8.73–8.87 (4H, m). 
Lab notebook reference: MJJ2/79 
Spectroscopic data matched those reported in the literature.
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(S)-4-Hydroxy-2,6-di(naphthalen-1-yl)-8,9,10,11,12,13,14,15-octahydrodinaphtho[2,1-
d:1',2'-f][1,3,2]dioxaphosphepine 4-oxide (123a) 
 
Synthesised using general procedure 2G with diol 122a (129 mg, 0.236 mmol), pyridine (1 
mL) and POCl3 (0.04 mL, 0.429 mmol). Then DMAP (3 mg, 0.022 mmol), 2 M NaOH(aq) (1 
mL) and THF (1 mL). Purification by column chromatography (19:1 CH2Cl2:MeOH then 9:1 
CH2Cl2:MeOH) afforded the title compound 123a (125 mg, 87%) as an off white solid, [α]D
20
 
= 65.0 (c 0.5, CHCl3) [lit.
147
 (R enantiomer) [α]D
18
 = −146.5 (c 1.0, CH2Cl2)]); vmax (cm
-1
) 
2929, 1261, 1089, 1017, 801, 778; δH (400 MHz, DMSO-d6) 1.61–1.94 (8H, m), 2.31–2.47 
(2H, m), 2.73–2.95 (6H, m), 7.33–7.56 (8H, m), 7.59–7.71 (2H, m), 7.81–7.98 (4H, m); δp 
(162 MHz, DMSO-d6) 3.2 (s); Ag-123a synthesised using general procedure 2H using CPA 
123 (122 mg, 0.200 mmol) Ag2CO3 (27.6 mg, 0.100 mmol), CH2Cl2 (2 mL) and H2O (2 mL) 
to afford the silver salt as an off white solid (117 mg, 82%). 
Lab notebook reference: MJJ2/92 + MJJ2/95 
Spectroscopic data matched those reported in the literature.
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(S)-4-hydroxy-2,6-di(phenanthren-9-yl)-8,9,10,11,12,13,14,15-octahydrodinaphtho[2,1-
d:1',2'-f][1,3,2]dioxaphosphepine 4-oxide (123b) 
 
Synthesised using general procedure 2G with diol 122b (140 mg, 0.216 mmol), pyridine (0.5 
mL) and POCl3 (0.04 mL, 0.429 mmol). Then DMAP (3 mg, 0.022 mmol), 2 M NaOH(aq) (1 
mL) and THF (1 mL). Purification by column chromatography (19:1 CH2Cl2:MeOH) afforded 
the title compound 123b (142 mg, 93%) as a white solid, [α]D
20
 = +26.5 (c 1.0, CHCl3); vmax 
(cm
-1
) 2931, 1423, 1243, 1101, 1087, 749, 727; δH (400 MHz, DMSO-d6) 1.58–1.94 (8H, m), 
2.35–2.51 (2H, m), 2.71–2.94 (6H, m), 7.00–7.09 (2H, m), 7.44–7.68 (10H, m), 7.85–8.01 
(4H, m), 8.76–8.88 (4H, m); δp (162 MHz, DMSO-d6) 0.39 (br s). Ag-123b synthesised using 
general procedure 2H using CPA 123b (132 mg, 0.186 mmol) Ag2CO3 (26 mg, 0.0931 
mmol), CH2Cl2 (2 mL) and H2O (2 mL) to afford the silver salt as an off white solid (112 mg, 
74%). 
Lab notebook reference: MJJ2/84 + MJJ2/87 
Spectroscopic data matched those reported in the literature.
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(S)-2,6-Bis(3,5-dimethylphenyl)-4-hydroxy-8,9,10,11,12,13,14,15-
octahydrodinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine 4-oxide (123c) 
 
Synthesised using general procedure 2G with (S)-3,3'-bis(3,5-dimethylphenyl)-
5,5',6,6',7,7',8,8'-octahydro-[1,1'-binaphthalene]-2,2'-diol (102 mg, 0.203 mmol), pyridine (0.5 
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mL) and POCl3 (0.04 mL, 0.429 mmol). Then DMAP (2.5 mg, 0.0203 mmol), 2 M NaOH(aq) 
(1 mL) and THF (1 mL). Purification by column chromatography (9:1 CH2Cl2:MeOH) 
afforded the title compound 123c (38 mg, 33%) as a pale yellow solid; [α]D
20
 = +260.8 (c 1.0, 
CH2Cl2); vmax (cm
-1
) 2925, 1260, 1234, 1098, 1082, 1019, 845, 801, 713; δH (400 
MHz,CD2Cl2) 1.56–1.68 (2H, m), 1.76–1.87 (6H, m), 2.13 (12H, br s), 2.25–2.36 (2H, m), 
2.62–2.93 (6H, m), 6.79 (2H, br s, ArH), 7.04 (2H, br s, ArH), 7.09 (2H, br s, ArH); δC (100 
MHz, CD2Cl2)  21.4 (CH3), 23.3 (CH2), 23.4 (CH2), 28.3 (CH2), 29.7 (CH2), 30.3 (CH2), 128.0 
(CH), 128.6 (C), 128.9 (CH), 131.2 (CH), 132.0 (C), 132.1 (C), 134.4 (C), 137.2 (C), 138.0 
(C), 138.6 (C), 144.8 (C), 144.9 (C); δp (162 MHz, CDCl3) −0.24 (br s); HRMS (APCI
+
): 
Found: 565.2481; C36H38O4P (MH
+
) Requires 565.2502 (3.8 ppm error). Ag-123c synthesised 
using general procedure 2H using CPA 123c (31 mg, 0.0549 mmol), Ag2CO3 (7.6 mg, 
0.0275 mmol), CH2Cl2 (0.6 mL) and H2O (0.6 mL) to afford the silver salt as an off white 
solid (17 mg, 46%). 
Lab notebook reference: MJJ2/15 + MJJ2/18 
 
(1E,4E)-1,5-Bis(3-methoxyphenyl)penta-1,4-dien-3-one (128) 
 
To a solution of NaOH (15 g, 375 mmol) in EtOH/H2O (264 mL, 1:1 v/v) was added drop-
wise a solution of m-anisaldehyde (20 g, 147 mmol) in acetone (5.4 mL, 73.4 mmol) and 
EtOH (20 mL). The mixture was stirred for 2 h at RT. The mixture was poured into water 
(300 mL) and extracted with CH2Cl2 (3 × 300 mL). The organics were combined, dried 
(MgSO4) and concentrated in vacuo. The crude material was purified by column 
chromatography (15–30% EtOAc in hexane) to afford the title compound 128 (10.95 g, 51%) 
as a yellow oil; vmax (cm
-1
) 1652, 1619, 1577, 1594, 1253, 1184, 1157, 1041, 982, 783; δH (400 
MHz, CDCl3) 3.87 (6H, s), 6.97 (2H, ddd, J = 8.0, 3.0, 1.0 Hz), 7.07 (2H, d, J = 16.0 Hz), 
7.13–7.16 (2H, m), 7.23 (2H, br d, J = 7.5 Hz), 7.34 (2H, dd, J = 8.0,  7.5 Hz), 7.71 (2H, d, J = 
16.0 Hz); δC (100 MHz, CDCl3) 55.2, 113.2, 116.2, 121.0, 125.5, 129.8, 136.0, 143.1, 159.8, 
188.7. 
Lab notebook reference: MJJ2/69 
Spectroscopic data matched those reported in the literature.
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1,5-Bis(3-methoxyphenyl)pentan-3-one (129) 
 
To a suspension of Raney Ni (34 mL, volume of solid in undisturbed suspension) in acetone 
(40 mL) was added a solution of dienone 128 (5.32 g, 18.1 mmol) in acetone (85 mL). The 
mixture was stirred for 16 h at RT under H2. The reaction mixture was carefully decanted 
through celite, ensuring the Raney Ni remained wet. To the retained Raney Ni was added a 
second solution of dienone 129 (5.63 g, 19.1 mmol) in acetone (85 mL). The mixture was 
stirred for 16 h at RT under H2. The mixture was carefully decanted through celite and the two 
filtrates were combined. The combined filtrates were poured into water (100 mL) and 
extracted with CH2Cl2 (3 × 100 mL). The organics were dried (MgSO4) and concentrated in 
vacuo to afford the title compound 129 (crude, 9.35 g, 84%) as a pale yellow oil; vmax (cm
-1
) 
2938, 1713, 1601, 1584, 1490, 1258, 1153, 1043, 781, 696; δH (400 MHz, CDCl3) 2.72 (4H, 
dd, J = 8.0, 7.5 Hz), 2.88 (4H, dd, J = 8.0, 7.5 Hz), 3.80 (6H, s), 6.71–6.78 (6H, m), 7.20 (2H, 
t, J = 8.0 Hz); δC (100 MHz, CDCl3) 29.7, 44.3, 55.1, 111.4, 114.0, 120.6, 129.4, 142.6, 159.7, 
209.0. 
Lab notebook reference: MJJ2/75 
Spectroscopic data matched those reported in the literature.
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1,5-Bis(2-bromo-5-methoxyphenyl)pentan-3-one (130) 
 
To a solution of ketone 129 (9.35 g, 31.3 mmol) in CH2Cl2 (172 mL) and pyridine (9.39 mL, 
116 mmol) at −10 °C was added Br2 (4.01 mL, 78.3 mmol) dropwise. Upon complete addition 
the reaction mixture was allowed to warm to RT and stirred for 4 h. The mixture was poured 
into Na2S2O3 (aq) (200 mL), the organics were collected, washed with 10% HCl(aq) (100 mL) 
and water (100 mL). The organics were dried (MgSO4) and concentrated in vacuo to afford 
the title compound 130 (crude, 13.05 g, 91%) as a yellow oil; vmax (cm
-1
) 2936, 1714, 1572, 
1471, 1241, 1163, 1056, 1016, 802, 601; δH (400 MHz, CDCl3) ) 2.74 (4H, dd, J = 8.0, 7.5 
Hz), 2.97 (4H, dd, J = 8.0, 7.5 Hz), 3.78 (6H, s), 6.64 (2H, dd, J = 9.0, 3.0 Hz), 6.78 (2H, d, J 
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= 3.0 Hz), 7.40 (2H, d, J = 9.0 Hz); δC (100 MHz, CDCl3) 30.6, 42.5, 55.4, 113.6, 114.6, 
116.2, 133.3, 141.2, 159.0, 208.4. 
Lab notebook reference: MJJ2/81 
Spectroscopic data matched those reported in the literature.
69
 
 
4,4'-Dibromo-7,7'-dimethoxy-2,2',3,3'-tetrahydro-1,1'-spirobi[indene] (131) 
 
Ketone 130 (13.05 g, 28.6 mmol) was dissolved in PPA (115 g) and stirred for 6 h at 105 °C. 
The mixture was carefully poured into water (500 mL) and extracted with CH2Cl2 (5 × 500 
mL). The organics were dried onto silica gel and eluted through a pad of silica gel with 
hexane:EtOAc (9:1). The filtrate was concentrated in vacuo to afford the title compound 131 
(crude, 9.53 g, 76%) as a yellow solid; vmax (cm
-1
) 2934, 1471, 1262, 1081, 798; δH (400 MHz, 
CDCl3) 2.13–2.21 (2H, m), 2.27–2.37 (2H, m), 2.90–3.01 (2H, m), 3.02–3.12 (2H, m), 3.53 
(6H, s), 6.53 (2H, d, J = 8.5 Hz), 7.27 (2H, d, J = 8.5 Hz); δC (100 MHz, CDCl3) 33.1, 37.9, 
55.3, 61.8, 110.5, 110.8, 130.3, 138.0, 144.8, 155.6. 
Lab notebook reference: MJJ2/82 
Spectroscopic data matched those reported in the literature.
69
 
 
7,7'-Dimethoxy-2,2',3,3'-tetrahydro-1,1'-spirobi[indene] (132) 
 
To a solution of 131 (9.53 g, 21.7 mmol) in THF (190 mL) at −78 °C was added n-BuLi (34.7 
mL, 86.8 mmol, 2.5 M in hexanes) drop-wise. The mixture was stirred for 1 h at −78 °C then 
quenched with the slow addition of EtOH (8 mL). The mixture was diluted with water (150 
mL) and extracted with CH2Cl2 (3 × 150 mL). The organics were dried (MgSO4) and 
concentrated in vacuo to afford the title compound 132 (crude, 6.10 g, 100%) as a yellow 
solid; vmax (cm
-1
) 2931, 1586, 1475, 1232, 1097, 1085, 1061, 773; δH (400 MHz, CDCl3) 2.14–
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2.23 (2H, m), 2.31–2.41 (2H, m), 2.95–3.13 (4H, m), 3.55 (6H, s), 6.64 (2H, d, J = 8.0 Hz), 
6.87 (2H, d, J = 7.5 Hz), 7.15 (2H, dd, J = 8.0, 7.5 Hz); δC (100 MHz, CDCl3) 31.6, 38.8, 
55.2, 59.2, 108.6, 116.8, 127.5, 136.9, 145.3, 156.5. 
Lab notebook reference: MJJ2/85 
Spectroscopic data matched those reported in the literature.
69
 
 
2,2',3,3'-Tetrahydro-1,1'-spirobi[indene]-7,7'-diol (133) 
 
To a solution of 132 (6.10 g, 22.8 mmol) in CH2Cl2 (100 mL) at −78 °C was added drop-wise 
BBr3 (52.4 mL, 52.5 mmol, 1M in CH2Cl2). Upon complete addition the mixture was allowed 
to warm to RT and stirred overnight. The reaction mixture was carefully poured into water 
(100 mL) and extracted with CH2Cl2 (2 × 100 mL). The organics were combined, dried 
(MgSO4) and concentrated in vacuo. The crude material was purified by column 
chromatography (5–10% EtOAc in hexane) to afford the title compound 133 (3.14 g, 57%) as 
a white solid, mp 112–113 °C (lit.69 115–116 °C); vmax (cm
-1
) 3516, 2936, 1586, 1463, 1278, 
1231, 1181, 995, 777, 734; δH (400 MHz, CDCl3) 2.15–2.26 (2H, m), 2.29–2.36 (2H, m), 
2.97–3.13 (4H, m), 4.60 (2H, s), 6.69 (2H, d, J = 8.0 Hz), 6.91 (2H, dd, J = 7.5, 1.0 Hz), 7.19 
(2H, dd, J = 8.0, 7.5 Hz); δC (100 MHz, CDCl3) 31.2, 37.4, 57.4, 114.2, 117.6, 129.8, 130.5, 
145.8, 152.8. 
Lab notebook reference: MJJ2/90 
Spectroscopic data matched those reported in the literature.
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7,7’-Bis-(L-menthyloxy-carbonyloxy)-1,1’-spiorbiindane (134 and 135) 
 
To a solution of 133 (3.14 g, 12.4 mmol), Et3N (6.47 mL, 46.4 mmol) and DMAP (152 mg, 
1.24 mmol) in CH2Cl2 (124 mL) was added L-menthyl chloroformate (6.45 mL, 30.1 mmol). 
The mixture was stirred for 16 h at RT. The mixture was washed with water (100 mL), 10% 
HCl(aq) (100 mL) and brine (100 mL). The organics were dried (MgSO4) and concentrated in 
vacuo. The crude material was purified by column chromatography (3% Et2O in hexane) to 
afford the title compound 135 (1.81 g, 24%) as a white solid (134 not isolated), mp 187–188 
°C (lit.
69
 185.5–186 °C); vmax (cm
-1
) 2951, 1753, 1267, 1258, 1236; δH (400 MHz, CDCl3) 0.68 
(6H, d, J = 7.0), 0.74–1.03 (18H, m), 1.17–1.28 (2H, m), 1.33–1.46 (2H, m), 1.47–1.57 (2H, 
m), 1.57–1.67 (4H, m), 1.86–1.94 (2H, m), 2.12–2.22 (2H, m), 2.23–2.32 (2H, m), 2.91–3.11 
(4H, m), 4.36 (2H, ddd, J = 11.0, 10.5, 4.5 Hz), 6.93 (2H, d, J = 8.0 Hz), 7.11 (2H, d, J = 7.5 
Hz), 7.21 (2H, dd, J = 8.0, 7.5 Hz); δC (100 MHz, CDCl3) 14.1, 16.0, 20.7, 21.9, 22.6, 23.0, 
25.5, 31.1, 31.3, 31.6, 34.0, 38.4, 40.4, 46.7, 58.9, 78.6, 120.4, 122.2, 128.0, 139.2, 145.6, 
147.5, 153.3. 
Lab notebook reference: MJJ2/91 
Spectroscopic data matched those reported in the literature.
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(S)-SPINOL (136) 
 
To a solution of 135 (731 mg, 1.19 mmol) in THF (8 mL) was added NH2NH2·H2O (0.41 
mL). The mixture was stirred for 2 h at 70 °C under argon. The mixture was diluted with 
CH2Cl2 (50 mL) and washed with 10% HCl(aq) (20 mL) and water (20 mL). The organics were 
dried (MgSO4) and concentrated in vacuo. The crude material was purified by column 
chromatography (15% EtOAc in hexane) to afford the title compound (S)-SPINOL (291 mg, 
97%) as a white solid, mp 153–155 °C (lit.69 155–156 °C); [α]D
20
 = −24.9 (c 1.0, CHCl3) [lit.
69
 
[α]D
25
 = −32.7 (c 1.0, CHCl3)]; vmax (cm
-1
) 3516, 2936, 1586, 1463, 1278, 1231, 1181, 995, 
777, 734; δH (400 MHz, CDCl3) 2.15–2.26 (2H, m), 2.29–2.36 (2H, m), 2.97–3.13 (4H, m), 
4.60 (2H, s), 6.69 (2H, d, J = 8.0 Hz), 6.91 (2H, dd, J = 7.5, 1.0 Hz), 7.19 (2H, dd, J = 8.0, 7.5 
Hz); δC (100 MHz, CDCl3) 31.2, 37.4, 57.4, 114.2, 117.6, 129.8, 130.5, 145.8, 152.8. 
Lab notebook reference: MJJ3/2 
Spectroscopic data matched those reported in the literature.
69
 
 
(S)-6,6'-Di(phenanthren-9-yl)-2,2',3,3'-tetrahydro-1,1'-spirobi[indene]-7,7'-diol (139) 
 
To a solution of 136 (25 mg, 0.10 mmol), KHCO3 (20 mg, 0.20 mmol) in CH2Cl2 (0.5 mL) at 
−30 °C was added a solution of NBS (36.5 mg, 0.205 mmol) in CH2Cl2 (2 mL) over 30 min. 
The mixture was stirred for 4 h at −30 °C. The mixture was poured into 10% HCl(aq) (5 mL) 
and extracted with CH2Cl2 (3 × 5 mL). The organics were concentrated in vacuo and then 
eluted through a silica plug (9:1 hexane:EtOAc) to afford a crude inseparable mixture of 
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dibrominated (137) and tribrominated (138) material. The crude material was combined with 
Pd(OAc)2 (0.45 mg, 2 µmol), (Ad)2n-BuP (0.9 mg, 2.5 µmol), phenanthren-9-ylboronic acid 
(39 mg, 0.175 mmol) in 1 M K2CO3 (aq) (0.25 mL) and DME (0.5 mL). The mixture was 
purged by alternating vaccum and argon three times. The mixture was stirred for 16 h under 
argon at 95 °C, then poured into sat. NH4Cl(aq) (5 mL) and extracted with CH2Cl2 (3 × 5 mL). 
The organics were combined, dried (MgSO4) and concentrated in vacuo. The crude material 
was purified by column chromatography (5% EtOAc in hexane) to afford the title compound 
139 (12 mg, 20%) as a colourless oil; [α]D
20
 = −37.9 (c 1.0, CHCl3); vmax (cm
-1
) 3524, 2929, 
1440, 1226, 748, 726; δH (400 MHz, CDCl3) 2.42–2.62 (4H, m), 3.06–3.28 (4H, m), 4.79 
(0.5H, s, rotamer), 4.86 (0.5H, s, rotamer), 4.88 (0.5H, s, rotamer), 4.97 (0.5H, s, rotamer), 
6.68–6.74 (0.5 H, m), 6.95–7.02 (2H, m), 7.07–7.13 (0.5H, m), 7.15–7.23 (2H, m), 7.41–7.92 
(13H, m), 8.68–8.83 (4H, m). 
Lab notebook reference: MJJ3/27 + MJJ3/32 
Spectroscopic data matched those reported in the literature.
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(S)-6,6’-Bis(9-phenanthryl)-1,1’-spirobiindanyl-7,7’-diylhydrogenphosphate (126) 
 
Synthesised using general procedure 2G with diol 126 (12 mg, 0.020 mmol), pyridine (0.2 
mL) and POCl3 (0.01 mL, 0.040 mmol). Then DMAP (0.24 mg, 2 µmol), 2 M NaOH(aq) (0.2 
mL) and THF (0.2 mL) for 2 days. Purification by column chromatography (CH2Cl2 then 9:1 
CH2Cl2:MeOH) afforded the title compound 126 (12 mg, 90%) as a colourless oil; [α]D
20
 = 
−297.6 (c 1.0, CHCl3); vmax (cm
-1
) 2926, 1618, 1440, 1258, 1218, 1093, 1025, 815, 748, 726; 
δH (400 MHz, CDCl3) 2.41–2.64 (4H, m), 2.77–3.12 (2H, m), 3.15–3.35 (2H, m), 7.14–7.23 
(6H, m), 7.30–7.77 (11H, m), 7.79–7.87 (1H, m), 8.36–8.63 (4H, m); δp (162 MHz, CDCl3) 
−7.5 (br s), −9.2 (br s). Ag-126 synthesised using general procedure 2H using CPA 126 (12 
mg, 0.186 mmol) Ag2CO3 (2.5 mg, 9 µmol), CH2Cl2 (0.2 mL) and H2O (0.2 mL) to afford the 
silver salt as a pale yellow solid (14 mg, 100%). 
Lab notebook reference: MJJ3/35 + MJJ3/37 
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Spectroscopic data matched those reported in the literature.
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1-(1H-Indol-3-yl)-4-(4-methoxyphenyl)but-3-yn-2-ol (144a) 
 
Synthesised using general procedure 2I with ynone 83a (100mg, 0.346 mmol), MeOH (13 
mL) and NaBH4 (52 mg, 1.38 mmol). Purified by column chromatography (3:2 
hexane:EtOAc) to afford title compound 144a (97 mg, 96%) as a brown oil; vmax (cm
-1
) 3412, 
1605, 1509, 1248, 1029, 832, 744; δH (400 MHz, CDCl3) 2.49 (1H, br s, H-18), 3.27 (1H, ddd, 
J = 14.5,
 
6.5, 0.5 Hz, H-10a), 3.34 (1H, ddd, J = 14.5,
 
6.0, 0.5 Hz, H-10b), 3.80 (3H, s, H-19), 
4.90 (1H, dd,
 
J = 6.5, 6.0 Hz, H-11),  6.81–6.86 (2H, m, H-16), 7.12–7.20 (2H, m, H-3,8), 
7.21–7.26 (1H, m, H-4), 7.31–7.38 (3H, m, H-5,15), 7.75 (1H, d, J  = 8.0 Hz, H-2), 8.24 (1H, 
br s, H-7); δC (100 MHz, CDCl3) 34.0 (CH2, C-10), 55.2 (CH3, C-19), 62.9 (CH, C-11), 84.9 
(C, C-12), 88.8 (C, C-13), 110.4 (C, C-9), 111.2 (CH, C-5), 113.8 (2CH, C-16), 114.6 (C, C-
14), 119.0 (CH, C-2), 119.4 (CH, C-3), 122.0 (CH, C-4), 123.5 (CH, C-8), 127.6 (C, C-1), 
133.1 (2CH, C-15), 136.1 (C, C-6), 159.5 (C, C-17); HRMS (ESI
+
): Found: 314.1136; 
C19H17NNaO2 (MNa
+
) Requires 314.1151 (4.9 ppm error), Found: 292.1330; C19H18NO2 
(MH
+
) Requires 292.1332 (0.7 ppm error). 
Lab notebook reference: MJJ4/43 
 
1-(1H-Indol-3-yl)-4-phenylbut-3-yn-2-ol (114b) 
 
Synthesised using general procedure 2I with ynone 83b (250 mg, 0.96 mmol), NaBH4 (140 
mg, 3.70 mmol) and MeOH (19 mL). Purified by column chromatography (7:3 petrol:EtOAc) 
afford the title compound 144b (230 mg, 92%) as a yellow oil; vmax (cm
-1
) 3413, 1489, 1457, 
1070, 1029, 743, 691; δH (400 MHz, CDCl3) 2.24 (1H, br s, H-18), 3.29 (1H, ddd, J = 14.5, 
6.5, 0.5 Hz, H-10a), 3.35 (1H, ddd, J = 14.5, 5.5, 0.5 Hz, H-10b), 4.91 (1H, dd,
 
J = 6.5, 5.5 
Hz, H-11), 7.14–7.20 (2H, m, H-8,17), 7.21–7.27 (1H, m, H-3), 7.28–7.36 (3H, m, H-4,16), 
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7.37–7.43 (3H, m, H-5,15), 7.73–7.77 (1H, m, H-2), 8.15 (1H, br s, H-7); δC (100 MHz, 
CDCl3) 34.0 (CH2, C-10), 62.9 (CH, C-11), 85.0 (C, C-12), 90.1 (C, C-13), 110.5 (C, C-9), 
111.2 (CH, C-5), 119.1 (CH, C-2), 119.6 (CH, C-3), 122.1 (CH, C-4), 122.6 (C, C-14), 123.5 
(CH, C8), 127.7 (C, C-1), 128.2 (2CH, C-16), 128.3 (CH, C-17), 131.7 (2CH, C-15), 136.2 
(C, C-6); HRMS (ESI
+
): Found: 284.1057; C18H15NNaO (MNa
+
) Requires 284.1046 (−4.0 
ppm error), Found: 262.1233; C18H16NO (MH
+
) Requires 262.1226 (−2.6 ppm error). 
Lab notebook reference: MJJ3/10 
 
1-(1H-Indol-3-yl)oct-3-yn-2-ol (144c) 
 
Synthesised using general procedure 2I with ynone 83h (500 mg, 2.09 mmol), MeOH (42 
mL) and NaBH4 (316 mg, 8.36 mmol). Purification by column chromatography (7:3 
hexane:EtOAc) afforded the title compound 144c (340 mg, 67 %) as a brown oil; vmax (cm
-1
) 
3410, 2930, 1457, 1027, 1010, 738; δH (400 MHz, CDCl3) 0.91 (3H, t, J = 7.5 Hz, H-17), 
1.33–1.54 (4H, m, H-15,16), 2.21 (2H, td, J = 7.5, 2.0 Hz, H-14), 2.49 (1H, br s, H-18), 3.14 
(1H, dd, J = 14.5, 7.5 Hz, H-10a), 3.23 (1H, dd, J = 14.5, 6.0 Hz, H-10b), 4.62–4.72 (1H, m, 
H-11), 7.12–7.18 (2H, m, H-3,8), 7.19–7.25 (1H, m, H-4), 7.38 (1H, d, J = 8.0 Hz, H-5), 7.69 
(1H, d, J = 8.0 Hz, H-2), 8.14 (1H, br s, H-7); δC (100 MHz, CDCl3) 13.6 (CH3, C-17), 18.4 
(CH2, C-14), 21.9 (CH2, C-15/16), 30.6 (CH2, C-15/16), 34.4 (CH2, C-10), 62.6 (CH, C-11), 
81.0 (C, C-12/13), 85.7 (C, C-12/13), 110.9 (C), 111.1 (CH, C-5), 119.1 (CH, C-2), 119.5 
(CH, C-3), 122.1 (CH, C-4), 123.3 (CH, C-8), 127.7 (C, C-1), 136.2 (C, C-6); HRMS (ESI
+
): 
Found: 264.1352; C16H19NNaO (MNa
+
) Requires 264.1359 (2.4 ppm error), Found: 242.1534; 
C16H20NO (MH
+
) Requires 242.1539 (2.2 ppm error). 
Lab notebook reference: BSC 
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4-(4-Fluorophenyl)-1-(1H-indol-3-yl)but-3-yn-2-ol (144d) 
 
Synthesised using general procedure 2I with ynone 83d (2.06 g, 7.43 mmol), MeOH (150 
mL) and NaBH4 (1.12 g, 29.7 mmol). Purification by column chromatography (1:1 
petrol:EtOAc) afforded the title compound 144d (2.02 g, 97%) as a brown oil; vmax (cm
-1
) 
3411, 1601, 1506, 1229, 1011, 836, 743; δH (400 MHz, CDCl3) 2.18 (1H, br s, H-18), 3.27 
(1H, dd, J = 14.0, 6.5 Hz, H-10a), 3.34 (1H, ddd, J = 14.0, 5.5 Hz, H-10b), 4.88 (1H, dd, J = 
6.0, 6.0 Hz, H-11), 6.96–7.03 (2H, m, H-16), 7.13–7.18 (1H, m, H-3), 7.20 (1H, br d, J = 2.5 
Hz, H-8), 7.21–7.26 (1H, m, H-4), 7.32–7.38 (2H, m, H-15), 7.40 (1H, br d, J = 8.0 Hz, H-5), 
7.74 (1H, br d, J = 7.5 Hz, H-2), 8.15 (1H, br s, H-7); δC (100 MHz, CDCl3) 34.0 (CH2, C-10), 
62.9 (CH, C-11), 84.0 (C, C-12), 89.7 (C, C-13), 110.5 (C, C-9), 111.2 (CH, C-5), 115.5 
(2CH, d, J = 22 Hz, C-16), 118.7 (C, d, J = 3.0 Hz, C-14), 119.1 (CH, C-2), 119.6 (CH, C-3), 
122.2 (CH, C-4), 123.4 (CH, C-8), 127.7 (C, C-1), 133.6 (2CH, d, J = 8.5 Hz, C-15), 136.2 
(C, C-6), 162.5 (C, d, J = 250 Hz, C-17); δF (376 MHz, CDCl3) −110.6–−110.8 (1F, m); 
HRMS (ESI
+
): Found: 302.0937; C18H14FNNaO (MNa
+
) Requires 302.0952 (4.7 ppm error), 
Found: 280.1121; C18H15FNO (MH
+
) Requires 280.1132 (4.0 ppm error). 
Lab notebook reference: BSC 
 
4-Cyclopropyl-1-(1H-indol-3-yl)but-3-yn-2-ol (144e) 
 
Synthesised using general procedure 2J with Weinreb 81a (500 mg, 2.29 mmol), 
ethynylcyclopropane (0.58 mL, 6.87 mmol), n-BuLi (2.29 mL, 5.73 mmol, 2.5 M in hexanes) 
and THF (7 mL + 21 mL). Then NaBH4 (346 mg, 9.16 mmol) and MeOH (46 mL). 
Purification by column chromatography (7:3 hexane:EtOAc) afforded the title compound 144e 
(384 mg, 74%) as a yellow oil; vmax (cm
-1
) 3408, 2236, 1456, 1027, 1010, 740; δH (400 MHz, 
CDCl3) 0.61–0.83 (4H, m, H-15), 1.21–1.32 (1H, m, H-14), 2.13 (1H, br s, C-16), 3.13 (1H, 
dd, J = 14.5, 7.0 Hz, H-10a), 3.22 (1H, dd, J = 14.5, 5.5 Hz, H-10b), 4.59–4.69 (1H, m, H-11), 
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7.09 (1H, d, J = 2.5 Hz, H-8), 7.16 (1H, dd, J = 8.0, 7.5 Hz, H-3), 7.23 (1H, dd, J = 8.0, 7.5 
Hz, H-4), 7.36 (1H, d, J = 8.0 Hz, H-5), 7.69 (1H, d, J = 8.0 Hz, H-2), 8.18 (1H, br s, H-7); δC 
(100 MHz, CDCl3) −0.6 (CH, C-14), 8.0 (2CH2, C-15), 34.3 (CH2, C-10), 62.6 (CH, C-11), 
76.3 (C, C-12/13), 88.7 (C, C-12/13), 110.7 (C, C-9), 111.1 (CH, C-5), 119.0 (CH, C-2), 
119.4 (CH, C-3), 122.0 (CH, C-4), 123.4 (CH, C-8), 127.6 (C, C-1), 136.1 (C, C-6); HRMS 
(ESI
+
): Found: 248.1047; C15H15NNaO (MNa
+
) Requires 248.1046 (−0.3 ppm error). 
Lab notebook reference: MJJ5/14 
 
1-(1H-Indol-3-yl)-4-(thiophen-2-yl)but-3-yn-2-ol (144f) 
 
Synthesised using general procedure 2I with ynone 83i (186 mg, 0.701 mmol), NaBH4 (106 
mg, 2.80 mmol) and MeOH (14 mL). Purification by column chromatography (7:3 
hexane:EtOAc) afforded the title compound 144f (139 mg, 74%) as a brown oil; vmax (cm
-1
) 
3411, 2221, 1456, 1033, 1010, 743, 704; δH (400 MHz, CDCl3) 2.20 (1H, d, J = 5.0 Hz, H-
18), 3.25 (1H, dd, J = 14.0, 6.5 Hz, H-10a), 3.32 (1H, dd, J = 14.0, 5.5 Hz, H-10b), 4.84–4.92 
(1H, m, H-11), 6.95 (1H, dd, J = 4.5, 4.0 Hz, H-16), 7.12–7.27 (5H, m, ArH), 7.37 (1H, d, J = 
8.0 Hz, H-5), 7.72 (1H, d, J = 8.0 Hz, H-2), 8.12 (1H, br s, H-7); δC (100 MHz, CDCl3) 33.8 
(CH2, C-10), 63.0 (CH, C-11), 78.4 (C, C-12), 93.9 (C, C-13), 110.3 (C, C-9), 111.2 (CH, C-
5), 119.1 (CH, C-2), 119.6 (CH, CAr), 122.2 (CH, CAr), 122.5 (C, C-14), 123.5 (CH, CAr), 
126.9 (CH, CAr), 127.2 (CH, Ar), 127.6 (C, C-1), 132.2 (CH, C-17), 136.2 (C, C-6); HRMS 
(ESI
+
): Found: 290.0611; C16H13NNaOS (MNa
+
) Requires 290.0610 (−0.3 ppm error), Found: 
268.0782; C16H14NOS (MH
+
) Requires 268.0791 (3.3 ppm error). 
Lab notebook reference: MJJ4/94 
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1-(2-Methyl-1H-indol-3-yl)-4-phenylbut-3-yn-2-ol (144g) 
 
Synthesised using general procedure 2J with Weinreb 81a (313 mg, 1.35 mmol), 
phenylacetylene (0.44 mL, 4.05 mmol), n-BuLi (1.35 mL, 3.38 mmol, 2.5 M in hexanes) and 
THF (4 mL + 12 mL). Then NaBH4 (204 mg, 5.40 mmol) and MeOH (27 mL). Purification by 
column chromatography (7:3 hexane:EtOAc) afforded the title compound 144g (282 mg, 
76%) as a yellow oil; vmax (cm
-1
) 3400, 1489, 1462, 1041, 1011, 908, 739, 691; δH (400 MHz, 
CDCl3) 2.45 (3H, s, H-9), 3.25 (1H, dd, J = 14.0, 6.5 Hz, H-11a), 3.30 (1H, dd, J = 14.0, 6.0 
Hz, H-11b), 4.86–4.94 (1H, m, H-12), 7.11–7.21 (2H, m, ArH), 7.28–7.36 (4H, m, ArH), 
7.38–7.43 (2H, m, ArH), 7.67 (1H, d, J = 8.0 Hz, H-2), 7.92 (1H, br s, H-7); δC (100 MHz, 
CDCl3) 11.9 (CH3, C-9), 32.9 (CH2, C-11), 63.3 (CH,  C-12), 84.8 (C, C-13), 90.3 (C, C-14), 
106.0 (C, C-10), 110.2 (CH, C-5), 118.2 (CH, C-2), 119.4 (CH, CAr), 121.1 (CH, CAr), 122.6 
(C, C-15), 128.17 (2CH, C-17), 128.23 (CH, CAr), 128.9 (C, C-1), 131.6 (2CH, C-16), 133.4 
(C, C-6/8), 135.2 (C, C-6/8); HRMS (ESI
+
): Found: 298.1212; C19H17NNaO (MNa
+
) Requires 
298.1202 (−3.4 ppm error), Found: 276.1390; C19H18NO (MH
+
) Requires 276.1383 (−2.4 ppm 
error). 
Lab notebook reference: MJJ4/51 
 
1-(1H-Indol-3-yl)-4-(trimethylsilyl)but-3-yn-2-ol (144h) & 1-(1H-Indol-3-yl)but-3-yn-2-ol 
(114i) 
 
Synthesised using general procedure 2J with 79 (1.00 g, 4.58 mmol), trimethylsilylacetylene 
(1.94 mL, 13.7 mmol), n-BuLi (4.60 mL, 11.5 mmol, 2.5 M in hexanes) and THF (14 mL + 
41 mL). Then NaBH4 (692 mg, 18.3 mmol) and MeOH (90 mL). Purification by column 
chromatography (7:3 then 3:2 hexane:EtOAc) afforded the title compounds 144h (676 mg, 
57%) as a brown oil and 144i (205 mg, 24%) as a brown oil. 
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Data for 144h: vmax (cm
-1
) 3412, 1457, 1249, 838, 737; δH (400 MHz, CDCl3) 0.19 (9H, s, H-
14), 2.27 (1H, d, J = 5.5 Hz, H-15), 3.17 (1H, dd, J = 14.5, 7.0 Hz, H-10a), 3.25 (1H, dd, J = 
14.5, 5.5 Hz, H-10b), 4.62–4.71 (1H, m, H-11), 7.06 (1H, d, J = 2.0 Hz, H-8), 7.16 (1H, dd, J 
= 7.5, 7.5 Hz, H-3), 7.23 (1H, dd, J = 8.0, 7.5 Hz, H-4), 7.34 (1H, d, J = 8.0 Hz, H-5), 7.71 
(1H, d, J = 7.5 Hz, H-2), 8.17 (1H, br s, H-7); δC (100 MHz, CDCl3) −0.26 (CH3, C-14), 33.8 
(CH2, C-10), 62.7 (CH, C-11), 89.6 (C, C-13), 106.6 (C, C-12), 110.2 (C, C-9), 111.2 (CH, C-
5), 119.1 (CH, C-2), 119.4 (CH, C-3), 122.0 (CH, C-4), 123.5 (CH, C-8), 127.5 (C, C-1), 
136.1 (C, C-6); HRMS (ESI
+
): Found: 280.1121; C15H19NNaOSi (MNa
+
) Requires 280.1128 
(2.7 ppm error), Found: 258.1303; C15H20NOSi (MH
+
) Requires 258.1309 (2.2 ppm error). 
Data for 144i: vmax (cm
-1
) 3408, 3281, 1457, 1025, 1010, 742, 647; δH (400 MHz, CDCl3) 2.28 
(1H, br d, J = 3.0 Hz, H-14), 2.49 (1H, d, J = 2.0 Hz, H-13), 3.19 (1H, dd, J = 14.5, 7.0 Hz, H-
10a), 3.27 (1H, dd, J = 14.5, 5.5 Hz, H-10b), 4.64–4.73 (1H, m, H-11), 7.12 (1H, d, J = 2.0 
Hz, H-8), 7.17 (1H, dd, J = 7.5, 7.0 Hz, H-3), 7.25 (1H, dd, J = 7.5, 7.0 Hz, H-4), 7.37 (1H, d, 
J = 7.5 Hz, H-5), 7.69 (1H, d, J = 7.5 Hz, H-2), 8.15 (1H, br s, H-7); δC (100 MHz, CDCl3) 
33.7 (CH2, C-10), 62.2 (CH, C-11), 73.2 (CH, C-13), 84.7 (C, C-12), 110.1 (C, C-9), 111.2 
(CH, C-5), 118.9 (CH, C-2), 119.5 (CH, C-3), 122.1 (CH, C-4), 123.5 (CH, C-8), 127.5 (C, C-
1), 136.1 (C, C-6); HRMS (ESI
+
): Found: 208.0735; C12H11NNaO (MNa
+
) Requires 208.0733 
(−0.8 ppm error).  
Propargyl alcohol 144i was also synthesised by adding K2CO3 (475 mg, 3.44 mmol) to a 
solution of alcohol 144h (589 mg, 2.29 mmol) in MeOH (11.5 mL). After stirring for 5 h the 
reaction mixture was diluted with H2O (20 mL) and extracted with DCM (4 × 30 mL). The 
organics were combined, washed with brine, dried (MgSO4) and concentrated in vacuo. The 
crude material was purified by column chromatography (3:2 hexane:EtOAc) to afford the title 
compound 144i (420 mg, 99%) as a brown oil. 
Lab notebook reference: MJJ4/27 + 4/54 
 
1-(1H-Indol-3-yl)-2-methyl-4-phenylbut-3-yn-2-ol (144j) 
 
To a solution of ynone 83b (200 mg, 0.771 mmol) in THF (7.7 mL) at −78 °C under argon 
was added drop-wise MeLi (1.93 mL, 3.08 mmol, 1.6 M in Et2O) and the mixture was stirred 
for 4 h at −78 °C. The mixture was quenched by the careful addition of sat. NH4Cl(aq) (10 mL) 
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and diluted with EtOAc (5 mL). The organics were separated and the aqueous extracted with 
EtOAc (2 × 10 mL). The organics were combined, washed with brine (10 mL), dried (MgSO4) 
and concentrated in vacuo. The crude material was purified by column chromatography (7:3 
hexanes:EtOAc) to afford the title compound 114j (175 mg, 82%) as a yellow oil; vmax (cm
-1
) 
3411, 1489, 1456, 1104, 742, 691; δH (400 MHz, CDCl3) 1.71 (3H, s, H-19), 2.42 (1H, br s, 
H-18), 3.20 (1H, d, J = 14.0 Hz, H-10a), 3.33 (1H, d, J = 14.0 Hz, H-10b), 7.11–7.16 (1H, m, 
H-3), 7.18–7.23 (2H, m, H-4,8), 7.24–7.34 (5H, m, H-15,16,17), 7.37 (1H, d, J = 8.0 Hz, H-
5), 7.79 (1H, dd, J = 8.0, 1.0 Hz, H-2), 8.17 (1H, br s, H-7); δC (100 MHz, CDCl3) 29.4 (CH3, 
C-19), 39.6 (CH2, C-10), 68.7 (C, C-11), 83.4 (C, C-12), 93.4 (C, C-13), 110.5 (C, C-9), 111.1 
(CH, C-5), 119.6 (CH, C-2/3), 119.7 (CH, C-2/3), 122.0 (CH, C-4), 122.8 (C, C-14), 124.0 
(CH, C-8), 128.1 (3CH, C-16,17), 128.3 (C, C-1), 131.6 (2CH, C-15), 136.0 (C, C-6); HRMS 
(ESI
+
): Found: 298.1201; C19H17NNaO (MNa
+
) Requires 298.1202 (0.6 ppm error). 
Lab notebook reference: MJJ4/11 
 
1-(1H-Indol-3-yl)-2,4-diphenylbut-3-yn-2-ol (144k) 
 
To a solution of ynone 83b (159 mg, 0.613 mmol) in THF (6.1 mL) at −78 °C under argon 
was added drop-wise PhLi (1.29 mL, 2.45 mmol, 1.9 M in Bu2O) and the mixture was stirred 
for 5 h at −78 °C. The mixture was quenched by the careful addition of sat. NH4Cl(aq) (10 mL) 
and diluted with EtOAc (5 mL). The organics were separated and the aqueous extracted with 
EtOAc (2 × 10 mL). The organics were combined, washed with brine (10 mL), dried (MgSO4) 
and concentrated in vacuo. The crude material was purified by column chromatography (8:2 
hexanes:EtOAc) to afford the title compound 144k (173 mg, 84%) as a yellow oil; vmax (cm
-1
) 
3416, 1490, 1456, 1070, 1010, 756, 742, 692; δH (400 MHz, CDCl3) 2.84 (1H, br s, H-18), 
3.45 (1H, d, J = 14.0 Hz, H-10a), 3.53 (1H, d, J = 14.0 Hz, H-10b), 7.08–7.16 (2H, m, ArH), 
7.22 (1H, dd, J = 7.5, 7.0 Hz, ArH), 7.26–7.40 (7H, m, ArH), 7.43 (2H, dd, J = 8.0, 7.5 Hz, 
ArH), 7.72 (1H, d, J = 8.0 Hz, ArH), 7.81 (2H, d, J = 7.5 Hz, ArH), 8.11 (1H, br s, H-7); δC 
(100 MHz, CDCl3) 42.2 (CH2, C-10), 73.6 (C, C-11), 85.9 (C, C-12), 92.0 (C, C-13), 110.2 
(C, C-9), 111.0 (CH, CAr), 119.6 (CH, CAr), 119.7 (CH, CAr), 122.0 (CH, CAr), 122.6 (C, 
C-14), 124.2 (CH, CAr), 125.6 (2CH, CAr), 127.7 (CH, CAr), 128.15 (2CH, CAr), 128.16 
(2CH, CAr), 128.3 (CH, CAr), 128.4 (C, C-1), 131.7 (2CH, CAr), 135.9 (C, C-6), 144.4 (C, 
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C-19); HRMS (ESI
+
): Found: 360.1355; C24H19NNaO (MNa
+
) Requires 360.1359 (1.1 ppm 
error).  
Lab notebook reference: MJJ4/93 
 
3-(2-((tert-Butyldimethylsilyl)oxy)-4-phenylbut-3-yn-1-yl)-1H-indole (144l) 
 
To a stirred solution of propargyl alcohol 144b (100 mg, 0.383 mmol), imidazole (37, 0.536 
mmol) and DMAP (5 mg, 0.038 mmol) in CH2Cl2 (4 mL) was added TBSCl (115 mg, 0.766 
mmol). The mixture was stirred for 16 h, then filtered through Celite, washing with CH2Cl2 
(20 mL). The collected filtrate was washed with 10% HCl(aq) (10 mL) and water (10 mL) 
successively. The organics were collected, dried (MgSO4) and concentrated in vacuo. The 
crude material was purified by column chromatography (hexane then 9:1 hexane:EtOAc) to 
afford the title compound 144l (95 mg, 66%) as a pale red oil; vmax (cm
-1
) 3420, 2958, 2927, 
2856, 1490, 1457, 1253, 1081, 837, 778, 756, 740; δH (400 MHz, CDCl3) 0.05 (3H, s, H-19a), 
0.07 (3H, s, H-19b), 0.92 (9H, s, H-21), 3.25 (1H, dd, J = 14.0,
 
7.0 Hz, H-10a), 3.29 (1H, dd, 
J = 14.0, 6.5 Hz, H-10b), 4.83 (1H, dd, J = 7.0,
 
6.5 Hz, H-11), 7.12–7.18 (2H, m, H-8,17), 
7.19–7.24 (1H, m, H-3), 7.28-7.33 (3H, m, H-4,16), 7.35–7.41 (3H, m, H-5,15), 7.71 (1H, d, J 
= 8.0 Hz, H-2), 8.03 (1H, br s, H-7); δC (100 MHz, CDCl3) −5.0 (CH3, C-19a), −4.8 (CH3, C-
19b), 18.3 (C, C-20), 25.8 (3CH3, C-21), 34.9 (CH2, C-10), 64.3 (CH, C-11), 84.4 (C, C-12), 
91.3 (C, C-13), 111.0 (CH, C-5), 111.9 (C, C-9), 119.0 (CH, C-2), 119.3 (CH, C-3), 121.8 
(CH, C-4), 123.1 (C, C-14), 123.2 (CH, C-8), 127.9 (C, C-1), 128.0 (CH, C-17), 128.2 (2CH, 
C-16), 131.5 (2CH, C-15), 136.0 (C, C-6); HRMS (ESI
+
): Found: 398.1892; C24H29NNaOSi 
(MNa
+
) Requires 398.1911 (4.8 ppm error). 
Lab notebook reference: MJJ4/53 
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2-(4-Methoxyphenyl)spiro[cyclopent[2]ene-1,3'-indol]-4-ol (145a) 
 
Synthesised using general procedure 2K with alcohol 144a (81 mg, 0.278 mmol), Ag2O (3.2 
mg, 0.0139 mmol), AgNO3 (4.7 mg, 0.0278 mmol) and CH2Cl2 (2.8 mL). Purification by 
column chromatography (2%→10% MeOH in DCM) afforded the title compound 145a (77 
mg, 98%, 54:46 dr) as a yellow oil; vmax (cm
-1
) 3295, 2930, 1606, 1510, 1251, 1180, 1032, 
908, 828, 756, 730; δH (400 MHz, CDCl3) 2.06 (1H, dd, J = 14.0, 4.0 Hz, H-10a, major), 2.33 
(1H, dd, J = 13.5, 4.0 Hz, H-10b minor), 2.46 (2H, br s, H-19, major + minor), 2.47 (1H, dd, J 
= 13.5, 6.5 Hz, H-10b, minor), 2.80 (1H, dd, J = 14.0, 7.0 Hz, H-10b, major), 3.68 (6H, s, H-
18, major + minor), 5.20–5.27 (1H, m, H-11, major), 5.28–5.35 (1H, m, H-11, minor), 6.49 (2 
H, br s, H-12, major + minor), 6.57–6.63 (4H, m, ArH, major + minor), 6.71–6.78 (4H, m, 
ArH, major + minor), 7.17–7.29 (3H, m, ArH, major + minor), 7.38 (2H, dd, J = 8.0, 7.5 Hz, 
ArH, major + minor), 7.44 (1H, d, J = 7.5 Hz, H-2, major), 7.70 (1H, d, J = 8.0 Hz, H-5, 
major), 7.72 (1H, d, J = 8.0 Hz, H-5, minor), 8.11 (1H, s, H-8, major), 8.25 (1H, s, H-8, 
minor); δC (100 MHz, CDCl3) 42.5 (CH2), 43.6 (CH2), 55.0 (2CH3), 69.6 (C), 69.9 (C), 74.7 
(CH), 74.8 (CH), 113.65 (2CH), 113.69 (2CH), 121.2 (CH), 121.5 (CH), 121.8 (CH), 123.0 
(CH), 126.4 (2C), 126.87 (CH), 126.93 (2CH), 127.0 (3CH), 128.2 (2CH), 132.2 (CH), 132.4 
(CH), 142.0 (C), 142.5 (C), 144.0 (C), 144.8 (C), 154.58 (C), 154.61 (C), 159.48 (C), 159.54 
(C), 177.3 (CH), 177.4 (CH); HRMS (ESI
+
): Found: 292.1321; C19H18NO2 (MH
+
) Requires 
292.1332 (3.8 ppm error). 
Lab notebook reference: MJJ4/46 
 
2-Phenylspiro[cyclopent[2]ene-1,3'-indol]-4-ol (145b) 
 
Synthesised using general procedure 2K with alcohol 144b (100 mg, 0.383 mmol), Ag2O 
(4.4 mg, 0.0192 mmol), AgNO3 (6.5 mg, 0.0383 mmol) and CH2Cl2 (3.8 mL). Purification by 
column chromatography (2%→10% MeOH in DCM) afforded the title compound 145b (96 
mg, 96%, 54:46 dr) as a brown oil; vmax (cm
-1
) 3294, 1549, 1455, 1445, 1075, 1014, 907, 776, 
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752, 731, 692; δH (400 MHz, CDCl3) 2.08 (1H, dd, J = 13.5, 4.0 Hz, H-10a, major), 2.35 (1H, 
dd, J = 13.5, 4.0 Hz, H-10a, minor), 2.47 (1H, dd, J = 13.5, 6.5 Hz, H-10b, minor), 2.61 (2H, 
br s, H-18, major + minor), 2.80 (1H, dd, J = 13.5, 7.0 Hz, H-10b, major), 5.22–5.29 (1H, m, 
H-11, major), 5.31–5.37 (1H, m, H-11, minor), 6.58 (1H, d, J = 2.5 Hz, H-12, major), 6.59 
(1H, d, J = 2.5 Hz, H-12, minor), 6.76–6.84 (4H, m, ArH, major + minor), 7.03–7.17 (6H, m, 
ArH, major + minor), 7.18–7.26 (3H, m, ArH, major + minor), 7.34–7.41 (2H, m, ArH, major 
+ minor), 7.45 (1H, d, J = 7.5 Hz, H-2, major), 7.70 (1H, d, J = 8.0 Hz, H-5, major), 7.72 (1H, 
d, J = 8.0 Hz, H-5, minor), 8.11 (1H, s, H-8, major), 8.25 (1H, s, H-8, minor); δC (100 MHz, 
CDCl3) 42.5 (CH2), 43.6 (CH2), 69.6 (C), 69.9 (C), 74.68 (CH), 74.71 (CH), 121.2 (CH), 
121.5 (CH), 121.7 (CH), 123.0 (CH), 125.6 (2CH), 125.7 (2CH), 126.9 (CH), 127.1 (CH), 
128.25 (3CH), 128.28 (2CH), 128.32 (3CH), 133.9 (2C), 134.2 (CH), 134.4 (CH), 141.8 (C), 
142.3 (C), 144.6 (C), 145.3 (C), 154.6 (2C), 177.0 (CH), 177.1 (CH); HRMS (ESI
+
): Found: 
262.1214; C18H16NO (MH
+) Requires 262.1226 (−4.7 ppm error). 
Lab notebook reference: MJJ4/44 
 
2-n-Butylspiro[cyclopent[2]ene-1,3'-indol]-4-ol (145c) 
 
Synthesised using general procedure 2K with alcohol 144c (154 mg, 0.638 mmol), Ag2O 
(7.4 mg, 0.0319 mmol), AgNO3 (10.8 mg, 0.0638 mmol) and CH2Cl2 (6.4 mL). Purification 
by column chromatography (2%→10% MeOH in DCM) afforded the title compound 145c 
(141 mg, 92%, 53:47 dr) as a brown oil; vmax (cm
-1
) 3315, 2956, 2828, 2871, 1551, 1455, 
1048, 1022, 751; δH (400 MHz, CDCl3) 0.74 (6H, dd, J = 7.5, 7.0 Hz, H-17, major + minor), 
1.05–1.30 (8H, m, H-15,16, major + minor), 1.34–1.51 (4H, m, H-14, major + minor), 2.01 
(1H, dd, J = 14.0, 4.0 Hz, H-10a, major), 2.22 (1H, dd, J = 14.0, 3.0 Hz, H-10a, minor), 2.46 
(1H, dd, J = 14.0, 6.5 Hz, H-10b, minor), 2.71 (2H, br s, H-18, major + minor), 2.72 (1H, dd, 
J = 14.0, 7.0 Hz, H-10b, major), 5.12–5.18 (1H, m, H-11, major), 5.18–5.22 (1H, m, H-11, 
minor), 5.94–5.96 (1H, m, H-12, major), 5.96–5.99 (1H, m, H-12, minor), 7.17 (1H, dd, J = 
7.5, 1.5 Hz, H-2, major/minor), 7.22–7.30 (2H, m, ArH, major + minor), 7.32–7.38 (2H, m, 
ArH, major + minor), 7.39–7.42 (1H, m, ArH, major/minor), 7.63 (1H, br d, J = 7.5 Hz, H-5, 
major), 7.64 (1H, br d, J = 8.0 Hz, H-5, minor), 7.88 (1H, s, H-8, major), 8.07 (1H, s, H-8, 
minor); δC (100 MHz, CDCl3) 13.7 (2CH3), 22.2 (2CH2), 26.7 (CH2), 26.9 (CH2), 29.6 (CH2), 
29.8 (CH2), 40.7 (CH2), 41.6 (CH2), 71.1 (C), 71.5 (C), 75.60 (CH), 75.63 (CH), 120.8 (CH), 
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121.0 (CH), 121.8 (CH), 122.8 (CH), 126.5 (CH), 126.6 (CH), 128.06 (CH), 128.09 (CH), 
131.3 (CH), 131.6 (CH), 141.2 (C), 141.6 (C), 147.6 (C), 149.0 (C), 155.2 (C), 155.4 (C), 
176.7 (CH), 177.0 (CH); HRMS (ESI
+
): Found: 264.1364; C16H19NNaO (MNa
+
) Requires 
264.1359 (−1.8 ppm error), Found: 242.1546; C16H20NO (MH
+) Requires 242.1539 (−2.8 ppm 
error). 
Lab notebook reference: MJJ4/55 
 
2-(4-Fluorophenyl)spiro[cyclopent[2]ene-1,3'-indol]-4-ol (145d) 
 
Synthesised using general procedure 2K with alcohol 144d (95 mg, 0.340 mmol), Ag2O (3.9 
mg, 0.0170 mmol), AgNO3 (5.8 mg, 0.0340 mmol) and CH2Cl2 (3.4 mL). Purification by 
column chromatography (2%→10% MeOH in DCM) afforded the title compound 145d (93 
mg, 98%, 52:48 dr) as a brown oil; vmax (cm
-1
) 3330, 2928, 1673, 1600, 1507, 1259, 1233, 
1160, 1023, 832, 732; δH (400 MHz, CDCl3) 2.09 (1H, dd, J = 14.0, 4.0 Hz, H-10a, major), 
2.35 (1H, dd, J = 13.5, 3.5 Hz, H-10a, minor), 2.41 (2H, br s, H-18, major + minor), 2.50 (1H, 
dd, J = 13.5, 6.5 Hz, H-10b, minor), 2.81 (1H, dd, J = 14.0, 7.0 Hz, H-10b, major), 5.21–5.29 
(1H, m, H-11, major), 5.29–5.36 (1H, m, H-11, minor), 6.51 (1H, d, J = 2.5 Hz, H-12, major), 
6.52 (1H, d, J = 2.0 Hz, H-12, minor), 6.72–6.81 (8H, m, ArH, major + minor), 7.17–7.30 
(3H, m, ArH, major + minor), 7.39 (2H, dd, J = 8.0, 7.5 Hz, ArH, major + minor), 7.44 (1H, 
d, J = 7.5 Hz, H-2, major), 7.69 (1H, d, J = 8.0 Hz, H-5, major), 7.71 (1H, d, J = 7.5 Hz, H-5, 
minor), 8.10 (1H, s, H-8, major), 8.26 (1H, s, H-8, minor); δC (100 MHz, CDCl3) 42.4 (CH2), 
43.6 (CH2), 69.7 (C), 70.0 (C), 74.75 (CH), 74.82 (CH), 115.29 (2CH, d, J = 22 Hz), 115.32 
(2CH, d, J = 22 Hz), 121.3 (CH), 121.6 (CH), 121.8 (CH), 123.0 (CH), 127.0 (CH), 127.1 
(CH), 127.5 (2CH, d, J = 7.5 Hz), 127.6 (2CH, d, J = 8.5 Hz), 128.4 (2CH), 130.0 (C), 130.1 
(C), 133.9 (CH), 134.1 (CH), 141.6 (C), 142.0 (C), 143.8 (C), 144.6 (C), 154.69 (C), 154.74 
(C), 162.5 (C, d, J = 248 Hz), 162.6 (C, d, J = 249 Hz), 176.8 (CH), 176.9 (CH); δF (376 
MHz, CDCl3) −112.6–−112.7 (1F, m, minor), −112.7–−112.8 (1F, m, major); HRMS (ESI
+
): 
Found: 302.0948; C18H14FNNaO (MNa
+
) Requires 302.0952 (1.2 ppm error), Found: 
280.1125; C18H15FNO (MH
+
) Requires 280.1132 (2.6 ppm error). 
Lab notebook reference: MJJ4/31 
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2-Cyclopropylspiro[cyclopent[2]ene-1,3'-indol]-4-ol (145e) 
 
Synthesised using general procedure 2K with alcohol 144e (152 mg, 0.675 mmol), Ag2O 
(7.8 mg, 0.0338 mmol), AgNO3 (11.5 mg, 0.0675 mmol) and CH2Cl2 (6.8 mL). Purification 
by column chromatography (30%→100% EtOAc in hexane) afforded the title compound 145e 
(132 mg, 87%, 53:47 dr) as a brown oil; vmax (cm
-1
) 3305, 1456, 1020, 752, 733; δH (400 
MHz, CDCl3) 0.24–0.58 (10H, m, H-14,15, major + minor), 2.03 (1H, dd, J = 14.0, 4.0 Hz, 
H-10a, minor), 2.24 (1H, dd, J = 14.0, 3.0 Hz, H-10a, major), 2.38 (2H, br s, H-18, major + 
minor), 2.50 (1H, dd, J = 14.0, 6.5 Hz, H-10b, major), 2.75 (1H, dd, J = 14.0, 7.0 Hz, H-10b, 
minor), 5.08–5.14 (1H, m, H-11, minor), 5.14–5.20 (1H, m, H-11, major), 5.68 (1H, d, J = 2.0 
Hz, H-12, minor), 5.70 (1H, d, J = 2.0 Hz, H-12, major), 7.20–7.32 (4H, m, ArH, major + 
minor), 7.33–7.40 (2H, m, ArH, major + minor), 7.45 (1H, d, J = 7.5 Hz, H-2, major), 7.64 
(1H, d, J = 8.0 Hz, H-5, minor), 7.65 (1H, d, J = 7.5 Hz, H-5, major), 7.93 (1H, s, H-8, 
minor), 8.11 (1H, s, H-8, major); δC (100 MHz, CDCl3) 7.5 (CH2), 7.7 (CH2), 8.1 (CH), 8.2 
(CH), 8.35 (CH2), 8.37 (CH2), 40.7 (CH2), 41.7 (CH2), 71.3 (C), 71.6 (C), 75.4 (2CH), 120.8 
(CH), 121.0 (CH), 122.0 (CH), 123.0 (CH), 126.5 (CH), 126.6 (CH), 127.2 (CH), 127.4 (CH), 
128.07 (CH), 128.10 (CH), 141.4 (C), 141.7 (C), 150.3 (C), 151.5 (C), 155.2 (C), 155.4 (C), 
176.7 (CH), 177.0 (CH); HRMS (ESI
+
): Found: 248.1042; C15H15NNaO (MNa
+
) Requires 
248.1046 (1.4 ppm error), Found: 226.1224; C15H16NO (MH
+
) Requires 226.1226 (1.1 ppm 
error). 
Lab notebook reference: MJJ5/21 
 
2-(Thiophen-2-yl)spiro[cyclopent[2]ene-1,3'-indol]-4-ol (145f) 
 
Synthesised using general procedure 2K with alcohol 144f (68 mg, 0.254 mmol), Ag2O (2.9 
mg, 0.0127 mmol), AgNO3 (4.3 mg, 0.0254 mmol) and CH2Cl2 (2.5 mL). Purification by 
column chromatography (2→10% MeOH in DCM) afforded the title compound 145f (65 mg, 
96%, 59:41 dr) as a pale brown oil; vmax (cm
-1
) 3307, 1455, 1046, 754, 731, 701; δH (400 
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MHz, CDCl3) 2.11 (1H, dd, J = 14.0, 4.0 Hz, H-10a, major), 2.34 (1H, dd, J = 13.5, 3.0 Hz, 
H-10a, minor), 2.54 (1H, dd, J = 13.5, 6.5 Hz, H-10b, minor), 2.81 (1H, dd, J = 14.0, 7.0 Hz, 
H-10b, major), 3.02 (2H, br s, H-18, major + minor), 5.22–5.28 (1H, m, H-11, major), 5.28–
5.33 (1H, m, H-11, minor), 6.12 (1H, s, H-12, major/minor), 6.13 (1H, s, H-12, major/minor), 
6.50 (1H, d, J = 2.5 Hz, H-15, major), 6.52 (1H, d, J = 2.5 Hz, H-15, minor), 6.63–6.68 (2H, 
m, ArH, major + minor), 7.01–7.06 (2H, m, ArH, major + minor), 7.22–7.30 (3H, m, ArH, 
major + minor), 7.37–7.44 (2H, m, ArH, major + minor), 7.48 (1H, d, J = 7.5 Hz, H-2, 
major), 7.68–7.75 (2H, m, H-5, major + minor), 8.05 (1H, s, H-8, major), 8.22 (1H, s, H-8, 
minor); δC (100 MHz, CDCl3) 41.8 (CH2), 43.0 (CH2), 69.7 (C), 69.9 (C), 75.0 (CH), 75.1 
(CH), 121.2 (CH), 121.4 (CH), 122.1 (CH), 123.1 (CH), 124.66 (CH), 124.73 (CH), 125.5 
(CH), 125.6 (CH), 126.9 (CH), 127.1 (CH), 127.45 (CH), 127.47 (CH), 128.55 (CH), 128.56 
(CH), 132.4 (CH), 132.9 (CH), 136.2 (C), 136.3 (C), 138.0 (C), 139.1 (C), 141.4 (C), 141.7 
(C), 154.8 (C), 155.0 (C), 176.6 (CH), 176.8 (CH); HRMS (ESI
+
): Found: 290.0612; 
C16H13NNaOS (MNa
+) Requires 290.0610 (−0.8 ppm error), Found: 268.0791; C16H14NOS 
(MH
+) Requires 268.0791 (−0.1 ppm error). 
Lab notebook reference: MJJ5/4 
 
2'-Methyl-2-phenylspiro[cyclopent[2]ene-1,3'-indol]-4-ol (145g) 
 
Synthesised using general procedure 2K with alcohol 144g (106 mg, 0.385 mmol), Ag2O 
(4.5 mg, 0.0193 mmol), AgNO3 (6.5 mg, 0.0385 mmol) and CH2Cl2 (3.9 mL). Purification by 
column chromatography (1→10% MeOH in DCM) afforded the title compound 145g (102 
mg, 96%, 50:50 dr) as a yellow oil; vmax (cm
-1
) 3234, 1575, 1457, 1445, 1051, 909, 757, 730, 
692; δH (400 MHz, CDCl3) 2.14 (1H, dd, J = 14.0, 4.0 Hz, H-11a), 2.18 (3H, s, H-9), 2.25 
(3H, s, H-9),  2.30 (1H, dd, J = 13.5, 5.0 Hz, H-11a), 2.46 (1H, dd, J = 13.5, 7.0 Hz, H-11b), 
2.66 (1H, dd, J = 14.0, 7.0 Hz, H-11b), 3.45 (2H, br s, H-18), 5.26–5.33 (1H, m, H-12), 5.40–
5.47 (1H, m, H-12), 6.60 (2H, br s, H-13), 6.76–6.83 (4H, m, ArH), 7.02–7.20 (9H, m, ArH), 
7.30–7.37 (2H, m, ArH), 7.39 (1H, d, J = 7.5 Hz, H-2), 7.59 (1H, d, J = 8.0 Hz, H-5), 7.62 
(1H, d, J = 8.0 Hz, H-5); δC (100 MHz, CDCl3) 15.9 (CH3), 16.3 (CH3), 44.7 (CH2), 45.5 
(CH2), 70.5 (C), 70.8 (C), 74.6 (CH), 74.7 (CH), 119.8 (CH), 120.2 (CH), 121.5 (CH), 123.0 
(CH), 125.6 (2CH), 125.7 (2CH), 125.8 (CH), 126.1 (CH), 128.15 (CH), 128.17 (CH), 128.27 
(CH), 128.30 (CH), 128.4 (2CH), 128.5 (2CH), 133.66 (C), 133.74 (C), 134.4 (CH), 134.5 
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(CH), 143.1 (C), 143.8 (C), 145.1 (C), 145.7 (C), 153.8 (C), 154.0 (C), 185.5 (C), 186.0 (C); 
HRMS (ESI
+
): Found: 276.1377; C19H18NO (MH
+
) Requires 276.1383 (2.3 ppm error). 
Lab notebook reference: MJ4/60 
 
4-Methyl-2-phenylspiro[cyclopent[2]ene-1,3'-indol]-4-ol (145j) 
 
Synthesised using general procedure 2K with alcohol 144j (40 mg, 0.134 mmol), Ag2O (1.7 
mg, 7.26 µmol), AgNO3 (2.5 mg, 0.0145 mmol) and CH2Cl2 (1.7 mL). Purification by column 
chromatography (2→10% MeOH in DCM) afforded the title compound 145j (38 mg, 95%, 
50:50 dr) as a brown oil; vmax (cm
-1
) 3324, 2965, 1456, 1098, 908, 755, 731, 693; δH (400 
MHz, CDCl3) 1.69 (3H, s, H-19), 1.72 (3H, s, H-19), 2.27 (1H, d, J = 14.0 Hz, H-10a), 2.38 
(1H, d, J = 14.0 Hz, H-10a), 2.45 (1H, d, J = 14.0 Hz, H-10b), 2.59 (1H, d, J = 14.0 Hz, H-
10b), 6.48 (1H, s, H-12), 6.49 (1H, s, H-12), 6.77–6.84 (4H, m, ArH), 7.00–7.16 (6H, m, 
ArH), 7.19–7.26 (3H, m, ArH), 7.33–7.40 (2H, m, ArH), 7.47 (1H, d,  J = 7.5 Hz, H-2), 7.69 
(1H, J = 8.0 Hz, H-5), 7.71 (1H, d, J = 7.5 Hz, H-5), 8.15 (1H, s, H-8), 8.36 (1H, s, H-8); δC 
(100 MHz, CDCl3) 28.6 (CH3), 28.8 (CH3), 47.8 (CH2), 48.8 (CH2), 70.1 (C) 70.2 (C), 80.9 
(C), 81.1 (C), 121.2 (CH), 121.4 (CH), 122.1 (CH), 122.9 (CH), 125.6 (2CH), 125.7 (2CH), 
126.8 (CH), 127.0 (CH), 128.15 (CH), 128.18 (3CH), 128.25 (2CH), 128.29 (2CH), 133.88 
(C), 133.89 (C), 138.0 (CH), 138.2 (CH), 142.08 (C), 142.12 (C), 142.5 (C), 143.7 (C), 154.5 
(C), 154.9 (C), 176.9 (CH), 177.5 (CH); HRMS (ESI
+
): Found: 298.1197; C19H17NNa (MNa
+
) 
Requires 298.1202 (1.9 ppm error), Found: 276.1384; C19H18N (MH
+
) Requires 276.1383 
(−0.4 ppm error). 
Traces of the imine trimer were also observed, characteristic data: δH (400 MHz, CDCl3) 4.86 
(s, H-8a), 5.39 (s, H-8b), 5.94 (s, H-8c) 
Lab notebook reference: MJJ4/64 
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2,4-Diphenylspiro[cyclopent[2]ene-1,3'-indol]-4-ol (145k) 
 
Synthesised using general procedure 2K with alcohol 144k (69 mg, 0.205 mmol), Ag2O (2.4 
mg, 0.0103 mmol), AgNO3 (3.5 mg, 0.0205 mmol) and CH2Cl2 (2.1 mL). Purification by 
column chromatography (2→10% MeOH in DCM) afforded the title compound 145k (67 mg, 
97%, 64:36 dr) as a brown oil; vmax (cm
-1
) 3255, 3058, 1491, 1446, 906, 754, 727, 695; δH 
(400 MHz, CDCl3) 2.45 (1H, d, J = 14.0 Hz, H-10a, minor), 2.61 (1H, d, J = 14.0 Hz, H-10a, 
major), 2.73 (1H, d, J = 14.0 Hz, H-10b, major), 2.85 (1H, d, J = 14.0 Hz, H-10b, minor), 
2.89 (2H, br s, H-18, major + minor), 6.66 (1H, s, H-12, minor), 6.68 (1H, s, H-12, major), 
6.83–6.91 (4H, m, ArH, major + minor), 7.03–7.20 (9H, m, ArH, major + minor), 7.28–7.38 
(4H, m, ArH, major + minor), 7.38–7.47 (4H, m, ArH, major + minor), 7.57–7.71 (7H, m, 
ArH, major + minor), 8.00 (1H, s, H-8, minor), 8.48 (1H, s, H-8, major); δC (100 MHz, 
CDCl3) 49.0 (CH2), 51.1 (CH2), 70.2 (C), 70.3 (C), 84.3 (C), 84.9 (C), 121.3 (CH), 121.4 
(CH), 122.4 (CH), 123.2 (CH), 125.28 (2CH), 125.32 (2CH), 125.8 (2CH), 125.9 (2CH), 
126.9 (CH), 127.1 (CH), 127.7 (CH), 127.8 (CH), 128.3 (CH), 128.4 (3CH), 128.45 (3CH), 
128.51 (CH), 128.6 (2CH), 128.7 (2CH), 133.88 (C), 133.91 (C), 136.3 (CH), 136.5 (CH), 
141.5 (C), 141.9 (C), 145.4 (C), 146.0 (C), 146.19 (C), 146.21 (C), 154.6 (C), 155.2 (C), 
176.5 (CH), 177.6 (CH); HRMS (ESI
+
): Found: 338.1528; C24H20NO (MH
+
) Requires 
338.1539 (3.5 ppm error).  
Lab notebook reference: MJJ5/8 
 
4-((Tert-butyldimethylsilyl)oxy)-2-phenylspiro[cyclopent[2]ene-1,3'-indole] (145l) 
 
Synthesised using general procedure 2K with alcohol 144l (44 mg, 0.117 mmol), Ag2O (1.4 
mg, 5.85 µmol), AgNO3 (2.0 mg, 0.0117 mmol) and CH2Cl2 (1.1 mL). Purification by column 
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chromatography (8:2 hexane:EtOAc) afforded the title compound 145l (41 mg, 93%, 52:48 
dr) as a colourless oil; vmax (cm
-1
) 2954, 2928, 2856, 1252, 1087, 1089, 836, 776, 751, 692; δH 
(400 MHz, CDCl3) 0.12 (3H, s, H-18a, major/minor), 0.13 (3H, s, H-18a, major/minor), 0.15 
(3H, s, H-18b, major/minor), 0.16 (3H, s, H-18b, major/minor), 0.94 (18H, br s, H-20, major 
+ minor), 2.01 (1H, dd, J = 13.5, 4.0 Hz, H-10a, major), 2.29 (1H, dd, J = 13.0, 4.0 Hz, H-
10a, minor), 2.38 (1H, dd, J = 13.0, 6.0 Hz, H-10b, minor), 2.72 (1H, dd, J = 13.5, 6.5 Hz, H-
10b, major), 5.14–5.19 (1H, m, H-11, major), 5.22–5.28 (1H, m, H-11, minor), 6.47 (1H, d, J 
= 2.5 Hz, H-12, major), 6.49 (1H, d, J = 2.5 Hz, H-12, minor), 6.76–6.83 (4H, m, ArH, major 
+ minor), 7.02–7.14 (6H, m, ArH, major + minor), 7.16–7.27 (3H, m, ArH, major + minor), 
7.33–7.40 (2H, m, ArH, major + minor), 7.52 (1H, d, J = 7.5 Hz, H-2, major), 7.68 (1H, d, J = 
7.5 Hz, H-5, major), 7.70 (1H, d, J = 7.5 Hz, H-5, minor), 8.09 (1H, s, H-8m major), 8.26 
(1H, s, H-8, minor); δC (100 MHz, CDCl3) −4.7 (CH3), −4.6 (CH3), −4.5 (2CH3), 18.2 (2C), 
25.9 (6CH3), 42.7 (CH2), 44.3 (CH2), 69.6 (C), 69.8 (C), 75.1 (CH), 75.3 (CH), 121.1 (CH), 
121.6 (CH), 121.8 (CH), 123.5 (CH), 125.6 (2CH), 125.7 (2CH), 126.7 (CH), 126.8 (CH), 
128.09 (2CH), 128.11 (CH), 128.13 (CH), 128.3 (4CH), 134.2 (C), 134.3 (C), 134.69 (CH), 
134.72 (CH), 142.1 (C), 142.3 (C), 143.9 (C), 144.4 (C), 154.8 (C), 155.1 (C), 177.1 (CH), 
177.5 (CH); HRMS (ESI
+
): Found: 398.1909; C24H29NNaOSi (MNa
+
) Requires 398.1911 (0.3 
ppm error), Found: 376.2084; C24H30NOSi (MH
+
) Requires 376.2091 (2.0 ppm error). 
Lab notebook reference: MJJ4/67 
 
1-(4-Methoxyphenyl)-9H-carbazole (146a) 
 
Synthesised using general procedure 2L with alcohol 144a (70 mg, 0.240 mmol), AgOTf 
(6.2 mg, 0.024 mmol) and THF (2.4 mL). Purification by column chromatography (9:1 
hexane:EtOAc) afforded the title compound 146a (64 mg, 98%) as a white solid, mp 134–136 
°C; vmax (cm
-1
) 3418, 1924, 1611, 1515, 1456, 1246, 750; δH (400 MHz, CDCl3) 3.92 (3H, s, 
H-18), 7.09–7.14 (2H, m, H-16), 7.25–7.31 (1H, m, H-3), 7.34 (1H, dd, J = 7.5, 7.5 Hz, H-
11), 7.41–7.46 (3H, m, H-4,5,12), 7.62–7.67 (2H, m, H-15), 8.08 (1H, d, J = 7.5 Hz, H-10), 
8.14 (1H, d, J = 7.5 Hz, H-2), 8.31 (1H, br s, H-7); δC (100 MHz, CDCl3) 55.4 (CH3, C-18), 
110.6 (CH, C-5), 114.7 (2CH, C-16), 119.0 (CH, C-10), 119.5 (CH, C-3/11), 119.9 (CH, C-
3/11), 120.5 (CH, C-2), 123.6 (2C, C-1/9,13), 124.8 (C, C-1/9), 125.6 (CH, C-4/12), 125.9 
Chapter 5. Experimental 
 
 
186 
(CH, C-4/12), 129.5 (2CH, C-15), 131.4 (C, C-14), 137.3 (C, C-6), 139.4 (C, C-6), 159.1 (C, 
C-17); HRMS (APCI
+
): Found: 274.1234; C19H16NO (MH
+
) Requires 274.1226 (−2.7 ppm 
error). 
Lab notebook reference: MJJ4/47 
Spectroscopic data matched those reported in the literature.
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1-Phenyl-9H-carbazole (146b) 
 
Synthesised using general procedure 2L with alcohol 144b (92 mg, 0.352 mmol), AgOTf 
(9.0 mg, 0.0352 mmol) and THF (3.5 mL). Purification by column chromatography (9:1 
hexane:EtOAc) afforded the title compound 146b (72 mg, 84%) as a white solid, mp 124–126 
°C;  vmax (cm
-1
) 3435, 3057, 2923, 1456, 1413, 1232, 749, 734, 701; δH (400 MHz, CDCl3) 
7.30 (1H, ddd, J = 7.5, 7.5, 1.0 Hz, H-3), 7.38 (1H, dd, J = 7.5, 7.5 Hz, H-11), 7.40–7.52  (4H, 
m, H-4,5,12,17), 7.60 (2H, dd, J = 8.0, 7.5 Hz, H-16), 7.73 (2H, d, J = 7.5 Hz, H-15), 8.13 
(1H, d, J = 7.5 Hz, H-10), 8.16 (1H, d, J = 7.5 Hz, H-2), 8.33 (1H, br s, H-7); δC (100 MHz, 
CDCl3) 110.7 (CH, C-5), 119.46 (CH, C-2/3/10/11), 119.52 (CH, C-2/3/10/11), 119.9 (CH, C-
2/3/10/11), 120.5 (CH, C-2/3/10/11), 123.5 (C, C-1/9/13), 123.7 (C, C-1/9/13), 125.0 (C, C-
1/9/13), 125.7 (CH, C-4/12/17), 125.9 (CH, C-4/12/17), 127.5 (CH, C-4/12/17), 128.3 (2CH, 
C-15), 129.2 (2CH, C-16), 137.2 (C, C-8), 139.0 (C, C-6/14), 139.4 (C, C-6.14); HRMS 
(APCI
+
): Found: 244.1127; C18H14N (MH
+
) Requires 244.1121 (−2.7 ppm error). 
Carbazole 146b also synthesised using general procedure 2A with alcohol 144l (45 mg, 
0.120 mmol), AgOTf (3.1 mg, 0.012 mmol) and THF (1.2 mL). Purification by column 
chromatography afforded the title compound 146b (27 mg, 93%) as a white solid. 
Lab notebook reference: MJJ4/45 + 4/68 
Spectroscopic data matched those reported in the literature.
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1-n-Butyl-9H-carbazole (146c) 
 
Synthesised using general procedure 2L with alcohol 144c (133 mg, 0.551 mmol), AgOTf 
(14.2 mg, 0.0551 mmol) and THF (5.5 mL). Purification by column chromatography (8:2 
hexane:EtOAc) afforded the title compound 146c (106 mg, 86%) as an off-white solid, mp 
53–54 °C; vmax (cm
-1
) 3429, 2955, 2927, 1501, 1455, 1425, 1325, 1232, 748; δH (400 MHz, 
CDCl3) 1.02 (3H, t, J = 7.0 Hz, H-17), 1.50 (2H, tq, J = 7.5, 7.0 Hz, H-16), 1.81 (2H, tt, J = 
7.5 Hz, H-15), 2.93 (2H, t, J = 7.5 Hz, H-14), 7.19–7.31 (3H, m, ArH), 7.41–7.52 (2H, m, 
ArH), 7.97 (1H, d, J = 7.5 Hz, H-2/10), 8.01 (1H, br s, H-7), 8.11 (1H, d, J = 7.5 Hz, H-2/10); 
δC (100 MHz, CDCl3) 14.0 (CH3, C-17), 22.7 (CH2, C-16), 31.1 (CH2, C-14), 31.7 (CH2, C-
15), 110.6 (CH, C-5), 117.9 (CH, CAr), 119.4 (CH, CAr), 119.5 (CH, CAr), 120.4 (CH, CAr), 
123.0 (C, C-1/9/13), 123.8 (C, C-1/9/13), 124.6 (C, C-1/9/13), 125.4 (CH, CAr), 125.6 (CH, 
CAr), 138.3 (C, C6/8), 139.3 (C, C-6/8); HRMS (ESI
+
): Found: 246.1250; C16H17NNa (MNa
+
) 
Requires 246.1253 (1.4 ppm error), Found: 224.1432; C16H17N (MH
+
) Requires 224.1434 (0.8 
ppm error). 
Lab notebook reference: MJJ4/56 
 
1-(4-Fluorophenyl)-9H-carbazole (146d) 
 
Synthesised using general procedure 2L with alcohol 144d (96 mg, 0.344 mmol), AgOTf 
(8.8 mg, 0.0344 mmol) and THF (3.4 mL). Purification by column chromatography (9:1 
hexane:EtOAc) afforded the title compound 146d (86 mg, 96%) as a white solid, mp 155–157 
°C; vmax (cm
-1
) 3468, 1603, 1509, 1455, 1314, 1222, 1156, 840, 749, 738; δH (400 MHz, 
CDCl3) 7.19–7.36 (4H, m, ArH), 7.37–7.49 (3H, m, ArH), 7.60–7.70 (2H, m, ArH), 8.09 (1H, 
d, J = 7.5 Hz, H-2/10), 8.12 (1H, d, J = 8.5 Hz, H-2/10), 8.21 (1H, br s, H-7); δC (100 MHz, 
CDCl3) 110.7 (CH, CAr), 116.2 (2CH, d, J = 22.0 Hz, C-16), 119.5 (CH, CAr), 119.6 (CH, 
CAr), 119.9 (CH, CAr), 120.5 (CH, CAr), 123.5 (C, C-2/9/13), 123.7 (C, C-2/9/13), 124.0 (C, 
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C-2/9/13), 125.7 (CH, CAr), 126.0 (CH, CAr), 129.9 (2CH, d, J = 8.5 Hz, C-15), 135.0 (C, d, 
J = 4.0 Hz. C-14), 137.2 (C, C-6/9), 139.4 (C, C-6/8), 162.3 (C, d, J = 246 Hz, C-17); δF (376 
MHz, CDCl3) −114.3–−114.5 (1F, m); HRMS (ESI
+
): Found: 262.1015; C18H13FN (MH
+
) 
Requires 262.1027 (4.3 ppm error). 
Lab notebook reference: MJJ4/32 
 
1-Cyclopropyl-9H-carbazole (146e) 
 
Synthesised using general procedure 2L with alcohol 144e (160 mg, 0.710 mmol), AgOTf 
(18.2 mg, 0.0710 mmol) and THF (7.1 mL). Purification by column chromatography (8:2 
hexane:EtOAc) afforded the title compound 146e (133 mg, 90%) as an off-white solid, mp 
88–90 °C; vmax (cm
-1
) 3433, 1455, 1422, 1234, 749; δH (400 MHz, CDCl3) 0.77–0.86 (2H, m, 
H-15a), 1.01–1.09 (2H, m, H-15b), 2.07–2.18 (1H, m, H-14), 7.14–7.21 (2H, m, H-11,12), 
7.25 (1H, dd, J = 8.0, 7.5 Hz, H-3), 7.43 (1H, dd, J = 8.0, 7.5 Hz, H-4), 7.50 (1H, d, J = 8.0 
Hz, H-5), 7.91–7.98 (1H, m, H-10), 8.08 (1H, d, J = 8.0 Hz, H-2), 8.28 (1H, br s, H-7); δC 
(100 MHz, CDCl3) 5.6 (2CH2, C-15), 11.1 (CH, C-14), 110.7 (CH, C-5), 118.1 (CH, C-10), 
119.36 (CH, C-2/3/11), 119.39 (CH, C-2/3/11), 120.4 (CH, C-2/3/11), 122.6 (C, C-1/9/13), 
123.7 (CH, C-12), 123.8 (C, C-1/9/13), 125.0 (C, C-1/9/13), 125.7 (CH, C-4), 139.3 (C, C-
6/8), 139.8 (C, C-6/8); HRMS (ESI
+
): Found: 208.1124; C15H14NO (MH
+
) Requires 208.1121 
(−1.5 ppm error). 
Lab notebook reference: MJJ5/20 
 
1-(Thiophen-2-yl)-9H-carbazole (146f) 
 
Synthesised using general procedure 2L with alcohol 144f (77 mg, 0.288 mmol), AgOTf 
(7.4 mg, 0.0288 mmol) and THF (2.9 mL). Purification by column chromatography (7:3 
hexane:EtOAc) afforded the title compound 146f (20 mg, 28%) as an off white semi-solid; 
vmax (cm
-1
) 3430, 1493, 1455, 1420, 1317, 1231, 746, 698; δH (400 MHz, CDCl3) 7.20–7.32 
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(3H, m, ArH), 7.40–7.49 (4H, m, ArH), 7.57 (1H, d, J = 8.0 Hz, H-12), 8.06 (1H, d, J = 8.0 
Hz, H-2/10), 8.10 (1H, d, J = 8.0 Hz, H-2/10), 8.54 (1H, br s, H-7); δC (100 MHz, CDCl3) 
110.8 (CH, C-5), 117.9 (C, C-13), 119.8 (2CH, CAr), 119.9 (CH, CAr), 120.5 (CH, CAr), 
123.5 (C, C-1/9), 124.0 (C, C1/9), 124.8 (CH, CAr), 125.1 (CH, CAr), 125.6 (CH, CAr), 
126.1 (CH, CAr), 128.0 (CH, CAr), 136.8 (C, C-6/8), 139.4 (C, C-6/8), 141.0 (C, C-14); 
HRMS (ESI
+
): Found: 250.0685; C16H12NS (MH
+
) Requires 250.0685 (0.1 ppm error). 
Lab notebook reference: MJJ5/3 
 
9H-Carbazole (146i) 
 
Synthesised using general procedure 2L with alcohol 144i (70 mg, 0.378 mmol), AgOTf 
(9.7 mg, 0.0378 mmol) and THF (3.8 mL). Purification by column chromatography (8:2 
hexane:EtOAc) afforded the title compound 146i (62 mg, 98%) as an off-white solid, mp 242–
243 °C; vmax (cm
-1
) 3416, 1450, 746, 722, 573; δH (400 MHz, DMSO-d6) 7.15 (2H, dd, J = 7.5, 
7.5 Hz), 7.38 (2H, dd, J = 8.0, 7.5 Hz), 7.49 (2H, d, J = 8.0 Hz), 8.11 (2H, d, J = 7.5 Hz), 
11.26 (1H, br s); δC (100 MHz, DMSO-d6) 111.0 (2CH), 118.5 (2CH), 120.2 (2CH), 122.4 
(2C), 125.5 (2CH), 139.7 (2C); HRMS (ESI
+
): Found: 168.0812; C12H10N (MH
+
) Requires 
168.0813 (0.6 ppm error). 
Carbazole 146i also synthesised using general procedure 2L with alcohol 144h (46 mg, 
0.179 mmol), AgOTf (4.6 mg, 0.0179 mmol) and THF (1.8 mL). Purification by column 
chromatography (8:2 hexane:EtOAc) afforded the title compound 146i (30 mg, 100%) as an 
off-white solid. 
Lab notebook reference: MJJ4/36 + 4/38 
Spectroscopic data matched those reported in the literature.
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3-Methyl-1-phenyl-9H-carbazole (146j): 
 
Synthesised using general procedure 2L with alcohol 144j (36 mg, 0.131 mmol), AgOTf 
(3.4 mg, 0.0131 mmol) and THF (1.3 mL). Purification by column chromatography (9:1 
hexane:EtOAc) afforded the title compound 146j (29 mg, 86%) as a colourless oil; vmax (cm
-1
) 
3435, 3031, 2919, 1608, 1499, 1488, 1452, 1317, 1235, 776, 734, 703, 578; δH (400 MHz, 
CDCl3) 2.63 (3H, s, H-18), 7.27 (1H, br dd, J = 7.0, 7.0 Hz, H-3), 7.32 (1H, s, H-12), 7.38–
7.45 (2H, m, H-5,17), 7.47 (1H, dd, J = 7.5, 7.0 Hz, H-4), 7.59 (2H, dd, J = 7.5, 7.5 Hz, H-
16), 7.73 (2H, d, J = 7.5 Hz, H-15), 7.92 (1H, br s, H-10), 8.12 (1H, d, J = 8.0 Hz, H-2), 8.23 
(1H, br s, H-7); δC (100 MHz, CDCl3) 21.4 (CH3, C-18), 110.6 (CH, C-5), 119.3 (CH, C-
3/10), 119.4 (CH, C-3/10), 120.3 (CH, C-2), 123.4 (C, C-1/9/13), 123.9 (C, C-1/9/13), 124.6 
(C, C-1/9/13), 125.7 (CH, C-17), 127.1 (CH, C-4/12), 127.4 (CH, C-4/12), 128.3 (2CH, C-
15), 129.2 (C + 2CH, C-11,16), 135.5 (C, C-6/8/14), 139.1 (C, C-6/8/14), 139.7 (C, C-6/8/14); 
HRMS (ESI
+
): Found: 280.1099; C19H15NNa (MNa
+
) Requires 280.1097 (−0.8 ppm error), 
Found: 258.1278; C19H16N (MH
+
) Requires 258.1277 (−0.3 ppm error). 
Lab notebook reference: MJJ4/65 
 
Actinopolymorphol B (162) 
 
To a solution of alcohol 144i (112 mg, 0.605 mmol) in CH2Cl2 (6.1 mL) was added 
sequentially Ag2O (7.0 mg, 0.0303 mmol) and AgNO3 (10.3 mg, 0.0605 mmol). The reaction 
mixture was stirred for 24 h then concentrated in vacuo. The crude material was purified by 
column chromatography (3:2 hexane:EtOAc) to afford the title compound 162 (33 mg, 27%) 
as a pale brown oil; vmax (cm
-1
) 3408, 1710, 1457, 1355, 1093, 744; δH (400 MHz, CDCl3) 2.21 
(3H, s), 3.15 (1H, dd, J = 15.0, 7.0 Hz), 3.33 (1H, dd, J = 15.0, 4.5 Hz), 3.47 (1H, d, J = 5.0 
Hz), 4.50–4.57 (1H, m), 7.11–7.18 (2H, m), 7.22 (1H, dd, J = 8.0, 7.5 Hz), 7.37 (1H, d, J = 
8.0 Hz), 7.65 (1H, d, J = 8.0 Hz), 8.09 (1H, br s); δC (100 MHz, CDCl3) 25.8 (CH3), 29.5 
(CH2), 77.1 (CH), 110.4 (C), 111.2 (CH), 118.7 (CH), 119.6 (CH), 122.2 (CH), 122.9 (CH), 
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127.4 (C), 136.0 (C), 209.8 (C); HRMS (ESI
+
): Found: 226.0833; C12H13NNaO2 (MNa
+
) 
Requires 226.0838 (2.3 ppm error). 
Compound 162 also synthesised using alcohol 144h (45 mg, 0.175 mmol), CH2Cl2 (1.8 mL), 
Ag2O (2.0 mg, 8.75 µmol) and AgNO3 (3.0 mg, 0.0175 mmol). After stirring for 24 h the 
reaction mixture was stirred was purified by column chromatography (3:2 hexane:EtOAc then 
EtOAc) to afford the title compound 162 (7 mg, 20%) as a pale brown oil. 
Lab notebook reference: MJJ4/35 + 4/37 
Spectroscopic data matched those reported in the literature.
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5.4 Experimental for Chapter 3 
3-(6-Chloro-1H-indol-3-yl)propanoic acid (80i) 
 
Synthesised according to a modified literature procedure.
109
 To a solution of 6-chloroindole 
(2.00 g, 13.2 mmol), ethyl acrylate (1.71 mL, 15.8 mmol) in anhydrous CH2Cl2 (66 mL) under 
argon was added ZrCl4 (308 mg, 1.32 mmol) in one portion. The mixture was stirred at RT 
under argon for 48 h then concentrated in vacuo. The crude ester was then dissolved in 
MeOH:THF (1:1 v/v, 264 mL) and 2 M NaOH(aq) (66 mL) was added. The mixture was stirred 
at RT for 18 h then concentrated in vacuo, the crude material was dissolved in H2O (50 mL) 
and washed with CH2Cl2 (2 × 50 mL). The organics were discarded and the aqueous was 
acidified to pH 1 with 10% HCl(aq) and extracted with CH2Cl2 (3 × 50 mL). The organics were 
dried (MgSO4) and concentrated in vacuo to afford the title compound 80i (1.86 g, 63%) as an 
off-white solid, mp 94–96 °C; vmax (cm
-1
) 3438, 1705, 1410, 1279, 1205, 804, 463; δH (400 
MHz, DMSO-d6) 2.57 (2H, t, J = 7.5 Hz, H-11), 2.91 (2H, t, J = 7.5 Hz, H-10), 6.98 (1H, dd, 
J = 8.5, 2.0 Hz, H-3), 7.16 (1H, d, J = 2.5 Hz, H-8), 7.37 (1H, d, J = 2.0 Hz, H-5), 7.52 (1H, d, 
J = 8.5 Hz, H-2), 10.95 (1H, br s, H-7), 12.10 (1H, br s, H-13); δC (100 MHz, DMSO-d6) 20.1 
(CH2, C-10), 34.5 (CH2, C-11), 111.0 (CH, C-5), 113.8 (C, C-9), 118.6 (CH, C-3), 119.7 (CH, 
C-2), 123.5 (CH, C-8), 125.7 (C, C-1/4), 125.8 (C, C-1/4), 136.6 (C, C-6), 174.2 (C, C-12); 
HRMS (ESI
+
): Found: 246.0300; C11H10
35
ClNNaO2 (MNa
+) Requires 246.0292 (−3.1 ppm 
error). 
Lab notebook reference: MJJ7/48 
 
3-(5-Methoxy-1H-indol-3-yl)propanoic acid (80j) 
 
Synthesised according to a modified literature procedure.
109
 To a solution of 5-methoxyindole 
(2.00 g, 13.6 mmol), ethyl acrylate (1.77 mL, 16.3 mmol) in anhydrous CH2Cl2 (68 mL) under 
argon was added ZrCl4 (317 mg, 1.36 mmol) in one portion. The mixture was stirred at RT 
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under argon for 24 h then concentrated in vacuo. The crude ester was then dissolved in 
MeOH:THF (1:1 v/v, 272 mL) and 2 M NaOH(aq) (68 mL) was added. The mixture was stirred 
at RT for 18 h then concentrated in vacuo, the crude material was dissolved in H2O (50 mL) 
and washed with CH2Cl2 (2 × 50 mL). The organics were discarded and the aqueous was 
acidified to pH 1 with 10% HCl(aq) and extracted with CH2Cl2 (3 × 50 mL). The organics were 
dried (MgSO4) and concentrated in vacuo to afford the title compound 80j (2.36 g, 79%) as a 
white solid, mp 132–134 °C; vmax (cm
-1
) 3343, 1714, 1488, 1211, 1177, 1018, 797, 640, 621, 
541; δH (400 MHz, DMSO-d6) 2.58 (2H, t, J = 7.5 Hz, H-12), 2.89 (2H, t, J = 7.5 Hz, H-11), 
3.76 (3H, s, H-4), 6.71 (1H, dd, J = 8.5, 2.5 Hz, H-5), 6.99 (1H, d, J = 2.5 Hz, H-2), 7.07 (1H, 
d, J = 2.0 Hz, H-9), 7.22 (1H, d, J = 8.5 Hz, H-6), 10.62 (1H, br s, H-8), 12.08 (1H, br s, H-
14); δC (100 MHz, DMSO-d6)  20.4 (CH2, C-11), 34.5 (CH2, C-12), 55.3 (CH3, C-4), 100.0 
(CH, C-2), 111.1 (CH, C-5), 112.0 (CH, C-6), 113.2 (C, C-10), 122.9 (CH, C-9), 127.2 (C, C-
1), 131.4 (C, C-7), 153.0 (C, C-3), 174.4 (C, C-13); HRMS (ESI
+
): Found: 242.0789; 
C12H13NNaO3 (MNa
+
) Requires 242.0788 (−0.7 ppm error), Found: 220.0970; C12H14NO3 
(MH
+
) Requires 220.0968 (−0.8 ppm error). 
Lab notebook reference: MJJ7/46 
 
3-(2-Methyl-1H-indol-3-yl)propanoic acid (S1) 
 
Synthesised according to a modified literature procedure.
109
 To a solution of 2-methylindole 
(2.67 g, 20.4 mmol), ethyl acrylate (2.65 mL, 24.5 mmol) in anhydrous CH2Cl2 (102 mL) 
under argon was added ZrCl4 (475 mg, 2.04 mmol) in one portion. The mixture was stirred at 
RT under argon for 24 h then concentrated in vacuo. The crude ester was then dissolved in 
MeOH:THF (1:1 v/v, 408 mL) and 2 M NaOH(aq) (102 mL) was added. The mixture was 
stirred at RT for 18 h then concentrated in vacuo, the crude material was dissolved in H2O (50 
mL) and washed with CH2Cl2 (2 × 50 mL). The organics were discarded and the aqueous was 
acidified to pH 1 with 10% HCl(aq) and extracted with CH2Cl2 (3 × 50 mL). The organics were 
dried (MgSO4) and concentrated in vacuo to afford the title compound S1 (2.95 g, 71%) as a 
grey solid, mp 128–130 °C (lit. 121–123 °C); vmax (cm
-1) 1464, 1405, 1306, 1295, 1211; δH 
(400 MHz, DMSO-d6) 2.31 (3H, s); 2.45 (2H, t, J = 7.5 Hz), 2.87 (2H, t, J = 7.5 Hz), 6.91 
(1H, ddd, J = 7.5, 7.5, 1.0 Hz), 6.97 (1H, ddd, J = 7.5, 7.5, 1.0 Hz), 7.21 (1H, br d, J = 7.5 
Hz), 7.39 (1H, br d, J = 7.5 Hz), 10.68 (1H, s), 12.01 (1H, br s); δC (100 MHz, DMSO-d6) 
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11.2 (CH3), 19.4 (CH2), 35.1 (CH2), 108.9 (C), 110.4 (CH), 117.3 (CH), 118.1 (CH), 119.9 
(CH), 127.9 (C), 131.7 (C), 135.2 (C), 174.2 (C). 
Lab notebook reference: MJJ7/92 
Spectroscopic data matched those reported in the literature.
155
 
 
3-(6-Chloro-1H-indol-3-yl)-N-methoxy-N-methylpropanamide (81i) 
 
Synthesised using general procedure 2A with 80i (1.86 g, 8.31 mmol), T3P 50% in EtOAc 
(7.96 g, 12.5 mmol), DIPEA (4.34 mL, 24.9 mmol) and MeNHOMe·HCl (891 mg, 9.14 
mmol) in CH2Cl2 (21 mL) afforded the title compound 81i (1.92 g, 87%) as a pale brown 
solid, mp 104–106 °C; vmax (cm
-1
) 3281, 1641, 1457, 803; δH (400 MHz, CDCl3) 2.81 (2H, t, J 
= 7.5 Hz, H-11), 3.09 (2H, t, J = 7.5 Hz, H-10), 3.19 (3H, s, H-13), 3.59 (3H, s, H-14), 7.04 
(1H, br d, J = 2.0 Hz, H-8), 7.09 (1H, dd, J = 8.5, 1.5 Hz, H-3), 7.35 (1H, d, J = 1.5 Hz, H-5), 
7.53 (1H, d, J = 8.5 Hz, H-2), 8.00 (1H, br s, H-7); δC (100 MHz, CDCl3) 20.1 (CH2, C-10), 
32.2 (CH3, C-13), 32.5 (CH2, C-11), 61.2 (CH3, C-14), 111.0 (CH, C-5), 115.5 (C, C-9), 119.6 
(CH, C-2), 119.9 (CH, C-3), 122.3 (CH, C-8), 125.9 (C, C-1/4), 127.8 (C, C-1/4), 136.6 (C, 
C-6), 174.0 (C, C-12); HRMS (ESI
+
): Found: 289.0713; C13H15
35
ClN2NaO2 (MNa
+
) Requires 
289.0714 (0.5 ppm error), Found: 267.0896; C13H16
35
ClN2O2 (MH
+
) Requires 267.0895 (−0.5 
ppm error). 
Lab notebook reference: MJJ7/55 
 
N-Methoxy-3-(5-methoxy-1H-indol-3-yl)-N-methylpropanamide (81j) 
 
Synthesised using general procedure 2A with 80j (2.36 g, 8.31 mmol), T3P 50% in EtOAc 
(8.59 g, 13.5 mmol), DIPEA (4.70 mL, 27.0 mmol) and MeNHOMe·HCl (965 mg, 9.90 
mmol) in CH2Cl2 (23 mL) afforded the title compound 81j (2.31 g, 82%) as a brown oil; vmax 
(cm
-1
) 3301, 2967, 1639, 1485, 1440, 1214, 1062, 797; δH (400 MHz, CDCl3) 2.84 (2H, t, J = 
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7.5 Hz, H-12), 3.10 (2H, t, J = 7.5 Hz, H-11), 3.21 (3H,s, H-14), 3.60 (3H, s, H-15), 3.87 (3H, 
s, H-4), 6.86 (1H, dd, J = 8.5, 2.5 Hz, H-5), 7.01 (1H, d, J = 2.0 Hz, H-9), 7.08 (1H, d, J = 2.5 
Hz, H-2), 7.24 (1H, d, J = 8.5 Hz, H-6), 8.15 (1H, br s, H-8); δC (100 MHz, CDCl3) 20.2 
(CH2, C-11), 32.1 (CH3, C-14), 32.5 (CH2, C-12) , 55.9 (CH3, C-4), 61.1 (CH3, C-15), 100.4 
(CH, C-2), 111.8 (CH, C-5/6), 112.0 (CH, C-5/6), 115.0 (C, C-10), 122.4 (CH, C-9), 127.5 (C, 
C-1), 131.4 (C, C-7), 153.8 (C, C-3), 174.2 (C, C-13); HRMS (ESI
+
): Found: 285.1212; 
C14H18N2NaO3 (MNa
+
) Requires 285.1210 (−0.7 ppm error), Found: 263.1387; C14H19N2O3 
(MH
+
) Requires 263.1390 (1.3 ppm error). 
Lab notebook reference: MJJ7/53 
 
N-Methoxy-N-methyl-3-(2-methyl-1H-indol-3-yl)propanamide (S2) 
 
Synthesised using general procedure 2A with S1 (2.95 g, 14.5 mmol), T3P 50% in EtOAc 
(13.9 g, 21.8 mmol), DIPEA (7.57 mL, 43.5 mmol) and MeNHOMe·HCl (1.56 g, 16.0 mmol) 
in CH2Cl2 (36 mL) afforded the title compound S2 (3.28 g, 92%) as a brown oil; vmax (cm
-1
) 
3300, 1640, 1463, 1439, 742; δH (400 MHz, CDCl3) 2.39 (3H, s, H-9), 2.76 (2H, t, J = 7.5 Hz, 
H-12), 3.07 (2H, t, J = 7.5 Hz, H-11), 3.19 (3H, s, H-14), 3.55 (3H, s, H-15), 7.06–7.15 (2H, 
m, H-3,4), 7.24–7.28 (1H, m, H-5), 7.51–7.55 (1H, m, H-2), 7.97 (1H, br s, H-7); δC (100 
MHz, CDCl3) 11.5 (CH3, C-9), 19.3 (CH2, C-11), 32.1 (CH2, C-12), 32.8 (CH3, H-14), 61.1 
(CH3, H-15), 110.2 (CH, C-5), 110.6 (C, C-10), 117.8 (CH, C-2), 119.0 (CH, C-3), 120.8 
(CH, C-4), 128.3 (C, C-1), 131.3 (C, C-6/8), 135.2 (C, C-6/8), 174.3 (C, C-13); HRMS (ESI
+
): 
Found: 269.1253; C14H18N2NaO2 (MNa
+
) Requires 269.1260 (2.7 ppm error), Found: 
247.1450; C14H19N2O2 (MH
+) Requires 247.1441 (−3.5 ppm error). 
Lab notebook reference: MJJ7/94 
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4-(1H-Indol-3-yl)-1-phenylbutan-2-one (192a) 
 
Synthesised using general procedure 3A with Weinreb amide 81b (3.97 g, 17.1 mmol), 
BnMgCl (42.8 mL, 85.5 mmol, 2.0 M in THF) and THF (171 mL). Purification by column 
chromatography (7:3 hexane:EtOAc) afforded the title compound 192a (2.58 g, 57%) as a 
white solid, mp 105–107 °C; vmax (cm
-1
) 3310, 1708, 745; δH (400 MHz, CDCl3) 2.88 (2H, t, J 
= 7.5 Hz, H-11), 3.05 (2H, t, J = 7.5 Hz, H-10), 3.68 (2H, s, H-13), 6.92 (1H, d, J = 2.0 Hz, H-
8), 7.09–7.41 (8H, m, ArH), 7.54 (1H, d, J = 8.0 Hz, H-2), 7.94 (1H, br s, H-7); δC (100 MHz, 
CDCl3) 19.4 (CH2, C-10), 42.4 (CH2, C-11), 50.3 (CH2, C-13), 111.1 (CH, C-5), 115.1 (C, C-
9), 118.6 (CH, C-2), 119.3 (CH, C-3/4/17), 121.5 (CH, C-8), 122.0 (CH, C-3/4/17), 127.0 
(CH, C-3/4/17), 127.1 (C, C-1), 128.7 (2CH, C-15/16), 129.4 (2CH, C-15/16), 134.2 (C, C-
14), 136.2 (C, C-6), 208.2 (C, C-12); HRMS (ESI
+
): Found: 286.1193; C18H17NNaO (MNa
+
) 
Requires 286.1202 (3.2 ppm error), Found: 264.1377; C18H18NO (MH
+
) Requires 264.1383 
(2.3 ppm error). 
Lab notebook reference: MJJ5/97 
 
1-(1H-Indol-3-yl)hex-5-en-3-one (S3) 
 
Synthesised using general procedure 3A with Weinreb amide 81b (978 mg, 4.21 mmol), 
AllylMgBr (16.8 mL, 16.8 mmol, 1.0 M in Et2O) and THF (30 mL). Purification by column 
chromatography (7:3 hexane:EtOAc) afforded the title compound S3 (840 mg, 94%) as a 
white solid, mp 60–62 °C; vmax (cm
-1
) 3410, 1708, 1457, 743; δH (400 MHz, CDCl3) 2.87 (2H, 
t, J = 7.5 Hz, H-11), 3.07 (2H, t, J = 7.5 Hz, H-10), 3.17 (2H, d, J = 7.0 Hz, H-13), 5.11 (1H, 
dd,  J = 17.0, 1.5 Hz, H-15trans), 5.17 (1H, dd, J = 10.5, 1.5 Hz, H-15cis), 5.92 (1H, ddt, J = 
17.0, 10.5, 7.0 Hz, H-14), 7.00 (1H, d, J = 2.0 Hz, H-8), 7.13 (1H, dd, J = 7.5, 7.5 Hz, H-3), 
7.21 (1H, dd, J = 7.5, 7.5 Hz, H-4), 7.37 (1H, d, J = 7.5 Hz, H-5), 7.60 (1H, d, J = 7.5 Hz, H-
2), 7.95 (1H, br s, H-7); δC (100 MHz, CDCl3) 19.2 (CH2, C-10), 42.7 (CH2, C-11), 47.9 (CH2, 
C-13), 111.1 (CH, C-5), 115.1 (C, C-9), 118.6 (CH, C-2), 118.8 (CH, C-14/15), 119.3 (CH, C-
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14/15), 121.5 (CH, C-3), 122.0 (CH, C-8), 127.1 (C, C-1), 130.5 (CH, C-4), 136.2 (C, C-6), 
208.6 (C, C-12); HRMS (ESI
+
): Found: 236.1051; C14H15NNaO (MNa
+
) Requires 236.1046 
(−2.0 ppm error), Found: 214.1226; C14H16NO (MH
+
) Requires 214.1226 (0.3 ppm error). 
Lab notebook reference: MJJ7/23 
 
4-(2-Methyl-1H-indol-3-yl)-1-phenylbutan-2-one (S4) 
 
Synthesised using general procedure 3A with Weinreb amide 81b (1.00 g, 4.06 mmol), 
BnMgCl (8.1 mL, 16.2 mmol, 2.0 M in THF) and THF (41 mL). Purification by column 
chromatography (7:3 hexane:EtOAc) afforded the title compound S4 (697 mg, 62%) as a pale 
yellow oil; vmax (cm
-1
) 3398, 1708, 1462, 741, 700; δH (400 MHz, CDCl3) 2.33 (3H, s, H-9), 
2.80 (2H, t, J = 7.5 Hz, H-12), 2.97 (2H, t, J = 7.5 Hz, H-11), 3.63 (2H, s, H-14), 7.05–7.16 
(4H, m, ArH), 7.22–7.34 (4H, m, ArH), 7.41 (1H, d, J = 8.0 Hz, H-2), 7.74 (1H, br s, H-7); δC 
(100 MHz, CDCl3) 11.5 (CH3, C-9) , 18.6 (CH2, C-11), 42.3 (CH2, C-12) 50.6 (CH2, C-14), 
110.2 (CH, C-5), 110.3 (C, C-10) 117.7 (CH, C-2), 119.1 (CH, C-3), 120.9 (CH, C-4), 126.9 
(CH, C-18), 128.2 (C, C-1), 128.6 (2CH, C-16/17), 129.4 (2CH, C-16/17), 131.1 (C, C-
6/8/15), 134.1 (C, C-6/8/15), 135.2 (C, C-6/8/15), 208.5 (C, C-13); HRMS (ESI
+
): Found: 
300.1355; C19H19NNaO (MNa
+
) Requires 300.1359 (1.1 ppm error), Found: 278.1531; 
C19H20NO (MH
+) Requires 278.1539 (−3.9 ppm error). 
Lab notebook reference: MJJ9/16 
 
4-(1H-Indol-3-yl)-1-(3-methoxyphenyl)butan-2-one (192b) 
 
Iodine (2 crystals) was sublimed over freshly crushed magnesium turnings (836 mg, 34.4 
mmol) under argon by heating the solids with a heat gun (30 seconds). THF (4 mL) was then 
added, followed by 3-methoxybenzyl chloride (0.10 mL, 0.69 mmol), once a dark grey colour 
change was observed the mixture was diluted with THF (36 mL) and further 3-methoxybenzyl 
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chloride (2.40 mL, 16.5 mmol) was added. The mixture was stirred at RT under argon for 1 h 
then transferred via cannula into a cooled 0 °C solution of Weinreb amide 81b (1.18 g, 5.08 
mmol) in THF (22 mL). The resulting solution was allowed to warm to room temperature and 
stirred for 2 h then quenched with sat. NH4Cl(aq) (30 mL), diluted with water (20 mL) and 
extracted with EtOAc (3 × 50 mL). The combined organics were washed with brine, dried 
(MgSO4), concentrated in vacuo and purified by column chromatography (35% EtOAc in 
hexane) to afford the title compound 192b (620 mg, 42%) as a white solid, mp 72–74 °C; vmax 
(cm
-1
) 3409, 2920, 1711, 1598, 1490, 1457, 1260, 744; δH (400 MHz, CDCl3) 2.88 (2H, t, J = 
7.5 Hz, H-11), 3.05 (2H, t, J = 7.5 Hz, H-10), 3.65 (2H, s, H-17), 3.78 (3H, s, H-13), 6.70–
6.73 (1H, m, H-15), 6.76 (1H, d, J = 7.5 Hz, H-20), 6.81 (1H, dd, J = 8.0, 2.5 Hz, H-18), 6.92 
(1H, d, J = 2.0 Hz, H-8), 7.12 (1H, dd, J = 7.5, 7.5 Hz, H-3), 7.18–7.26 (2H, m, H-4,19), 7.35 
(1H, d, J = 8.0 Hz, H-5), 7.55 (1H, d, J = 7.5 Hz, H-2), 7.97 (1H, br s, H-7); δC (100 MHz, 
CDCl3) 19.4 (CH2, C-10), 42.3 (CH2, C-11), 50.4 (CH2, C-13), 55.1 (CH3, C-17), 111.1 (CH, 
C-5), 112.5 (CH, C-18), 114.95 (CH, C-15), 115.0 (C, C-9), 118.6 (CH, C-2), 119.2 (CH, C-
3), 121.5 (CH, C-8), 121.8 (CH, C-20), 122.0 (CH, C-4), 127.1 (C, C-1), 129.6 (CH, C-19), 
135.6 (C, C-14), 136.2 (C, C-6), 159.7 (C, C-16), 208.1 (C, C-12); HRMS (ESI
+
): Found: 
316.1305; C19H19NNaO (MNa
+
) Requires 316.1308 (0.8 ppm error). 
Lab notebook reference: MJJ7/26 
 
1-(4-Fluorophenyl)-4-(1H-indol-3-yl)butan-2-one (192c) 
 
Iodine (2 crystals) was sublimed over freshly crushed magnesium turnings (1.67 g, 68.8 
mmol) under argon by heating the solids with a heat gun (30 seconds). THF (5 mL) was then 
added, followed by 4-fluorobenzyl chloride (0.10 mL, 0.83 mmol), once a dark grey colour 
change was observed the mixture was diluted with THF (74 mL) and further 4-fluorobenzyl 
chloride (4.02 mL, 33.6 mmol) was added. The mixture was stirred at RT under argon for 1 h 
then transferred via cannula into a cooled 0 °C solution of Weinreb amide 81b (2.00 g, 8.60 
mmol) in THF (43 mL). The resulting solution was allowed to warm to room temperature and 
stirred for 4 h then quenched with sat. NH4Cl(aq) (30 mL), diluted with water (20 mL) and 
extracted with EtOAc (3 × 50 mL). The combined organics were washed with brine, dried 
(MgSO4), concentrated in vacuo and purified by column chromatography (35% EtOAc in 
Chapter 5. Experimental 
 
 
199 
hexane) to afford the title compound 192c (1.39 g, 57%) as a white solid, mp 111–113 °C; vmax 
(cm
-1
) 3379, 1714, 1509, 1221, 743; δH (400 MHz, CDCl3) 2.88 (2H, t, J = 7.5 Hz, H-11), 
3.06 (2H, t, J = 7.5 Hz, H-10), 3.64 (2H, s, H-13), 6.93 (1H, d, J = 1.5 Hz, H-8), 6.98 (2H, dd, 
J = 8.5, 8.5 Hz, H-16), 7.06–7.17 (3H, m, H-3,15), 7.21 (1H, dd, J = 7.5, 7.5 Hz, H-4), 7.36 
(1H, d, J = 7.5 Hz, H-5), 7.55 (1H, d, J = 8.0 Hz, H-2), 7.96 (1H, br s, H-7); δC (100 MHz, 
CDCl3) 19.4 (CH2, C-10), 42.5 (CH2, C-11), 49.3 (CH2, C-13), 111.1 (CH, C-5), 114.9 (C, C-
9), 115.4 (2CH, d, J = 21.0 Hz, C-16), 118.6 (CH, C-2), 119.3 (CH, C-3), 121.5 (CH, C-8), 
122.0 (CH, C-4), 127.0 (C, C-1), 129.7 (C, d, J = 4.0 Hz, C-14), 130.9 (2CH, d, J = 7.5 Hz, C-
15), 136.2 (C, C-6), 161.9 (C, d, J = 245 Hz, C-17), 207.9 (C, C-12); δF (376 MHz, CDCl3) 
−115.7–−115.8 (1F, m); HRMS (ESI+): Found: 304.1105; C18H16FNNaO (MNa
+
) Requires 
304.1108 (0.9 ppm error), Found: 282.1278; C18H17FNO (MH
+
) Requires 282.1289 (3.8 ppm 
error). 
Lab notebook reference: MJJ7/38 
 
4-(6-Chloro-1H-indol-3-yl)-1-phenylbutan-2-one (192d) 
 
Synthesised using general procedure 3A with Weinreb amide 81i (1.92 g, 7.20 mmol), 
BnMgCl (14.4 mL, 28.8 mmol, 2.0 M in THF) and THF (72 mL). Purification by column 
chromatography (3:2 hexane:EtOAc) afforded the title compound 192d (794 mg, 37%) as a 
white solid, mp 113–115 °C; vmax (cm
-1
) 3367, 1710, 1454, 1060, 804, 700; δH (400 MHz, 
CDCl3) 2.85 (2H, t, J = 7.5 Hz, H-11), 3.00 (2H, t, J = 7.5 Hz, H-10), 3.67 (2H, s, H-13), 6.89 
(1H, d, J = 1.5 Hz, H-8), 7.07 (1H, d, J = 8.5, 1.5 Hz, H-3), 7.16 (2H, d, J = 7.0 Hz. H-15), 
7.23–7.35 (4H, m, H-5,16,17), 7.41 (1H, d, J = 8.5 Hz, H-2), 7.96 (1H, br s, H-7); δC (100 
MHz, CDCl3) 19.2 (CH2, C-10), 42.2 (CH2, C-11), 50.4 (CH2, C-13), 111.0 (CH, C-5), 115.2 
(C, C-9), 119.5 (CH, C-2), 120.0 (CH, C-3), 122.1 (CH, C-8), 125.7 (C, C-1/4), 127.0 (CH, C-
17), 127.9 (C, C-1/4), 128.7 (2CH, C-16), 129.4 (2CH, C-15), 134.0 (C, C-14), 136.5 (C, C-
6), 208.0 (C, C-12); HRMS (ESI
+
): Found: 320.0824; C18H16
35
ClNNaO (MNa
+
) Requires 
320.0813 (−3.5 ppm error). 
Lab notebook reference: MJJ7/56 
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4-(5-Methoxy-1H-indol-3-yl)-1-phenylbutan-2-one (192e) 
 
Synthesised using general procedure 3A with Weinreb amide 81j (2.20 g, 8.39 mmol), 
BnMgCl (16.8 mL, 33.6 mmol, 2.0 M in THF) and THF (84 mL). Purification by column 
chromatography (3:2 hexane:EtOAc) afforded the title compound 192e (1.20 g, 49%) as a 
brown oil which solidified to a pale brown solid on standing, mp 48–50 °C; vmax (cm
-1
) 3407, 
1709, 1485, 1454, 1214, 1058, 700; δH (400 MHz, CDCl3) 2.87 (2H, t, J = 7.5 Hz, H-12), 3.01 
(2H, t, J = 7.5 Hz, H-11), 3.68 (2H, s, H-14), 3.86 (3H, s, H-4), 6.86 (1H, dd, J = 8.5, 2.5 Hz, 
H-5), 6.90 (1H, d, J = 2.0 Hz, H-9), 6.97 (1H, d, J = 2.5 Hz, H-2), 7.17 (2H, d, J = 7.0 Hz, H-
16), 7.21–7.35 (4H, m, H-6,17,18), 7.85 (1H, br s, H-8); δC (100 MHz, CDCl3) 19.4 (CH2, C-
11), 42.2 (CH2, C-12), 50.4 (CH2, C-14), 55.9 (CH3, C-4), 100.5 (CH, C-2), 111.8 (CH, C-6), 
112.2 (CH, C-5), 114.8 (C, C-10), 122.3 (CH, C-9), 127.0 (CH, C-18), 127.5 (C, C-1), 128.7 
(2CH, C-17), 129.4 (2CH, C-16), 131.4 (C, C-7), 134.2 (C, C-15), 153.9 (C, C-3), 208.3 (C, 
C-13); HRMS (ESI
+
): Found: 316.1301; C19H19NNaO2 (MNa
+
) Requires 316.1308 (2.1 ppm 
error). 
Lab notebook reference: MJJ7/59 
 
1-Diazo-4-(1H-indol-3-yl)-1-phenylbutan-2-one (188a) 
 
Synthesised using general procedure 3B with benzyl ketone 192a (527 mg, 2.00 mmol), p-
ABSA (576 mg, 2.40 mmol), DBU (0.42 mL, 2.80 mmol) and MeCN (6 mL). Purification by 
column chromatography (70:27:3 hexane:EtOAc:Et3N) afforded the title compound 188a (426 
mg, 74%) as a yellow solid, mp 105–106 °C (decomposition); vmax (cm
-1
) 3406, 2925, 2074, 
1640, 744; δH (400 MHz, CD2Cl2) 2.98 (2H, t, J = 7.5 Hz, H-11), 3.16 (2H, t, J = 7.5 Hz, H-
10), 7.05 (1H, d, J = 2.0 Hz, H-8), 7.08 (1H, dd, J = 8.0, 7.0 Hz, H-3), 7.17 (1H, dd, J = 8.0, 
7.0 Hz, H-4), 7.24 (1H, dd, J = 7.5, 7.5 Hz, H-17), 7.34–7.42 (3H, m, H-5,16), 7.44–7.50 (2H, 
m, H-15), 7.57 (1H, d, J = 8.0 Hz, H-2), 8.10 (1H, br s, H-7); δC (100 MHz, CD2Cl2) 20.7 
(CH2, C-10), 40.3 (CH2, C-11), 72.7 (C, C-13), 111.7 (CH, C-5), 115.3 (C, C-9), 119.1 (CH, 
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C-2), 119.8 (CH, C-3), 122.35 (CH, C-4/8), 122.45 (CH, C-4/8), 126.40 (C, C-1/14), 126.44 
(2CH, C-15), 127.4 (CH, C-17), 127.7 (C, C-1/14), 129.4 (2CH, C-16), 136.9 (C, C-6), 192.9 
(C, C-12); HRMS (ESI
+
): Found: 312.1111; C18H15N3NaO (MNa
+) Requires 312.1107 (−1.2 
ppm error). 
Lab notebook reference: MJJ6/8 
 
4-Diazo-1-(1H-indol-3-yl)hex-5-en-3-one (207) 
 
Synthesised using general procedure 3B with allyl ketone S3 (727 mg, 3.41 mmol), p-ABSA 
(982 mg, 4.09 mmol), DBU (0.71 mL, 4.77 mmol) and MeCN (10 mL). Purification by 
column chromatography (70:27:3 hexane:EtOAc:Et3N) afforded the title compound 207 (466 
mg, 57%) as a pale orange solid, mp 102–104 °C (decomposition); vmax (cm
-1
) 3410, 2078, 
1635, 1609, 1292, 742; δH (400 MHz, CD2Cl2) 2.90 (2H, t, J = 7.5 Hz, H-11), 3.12 (2H, t, J = 
7.5 Hz, H-10), 4.87 (1H, d, J = 17.5 Hz, H-15trans), 5.17 (1H, d, J = 11.0 Hz, H-15cis), 6.28 
(1H, dd, J = 17.5, 11.0 Hz, H-14), 7.03 (1H, d, J = 2.0 Hz, H-8),  7.09 (1H, dd, J = 7.5, 7.0 
Hz, H-3), 7.17 (1H, dd, J = 8.0, 7.0 Hz, H-4), 7.37 (1H, d, J = 8.0 Hz, H-5), 7.57 (1H, d, J = 
7.5 Hz, H-2), 8.12 (1H, br s, H-7); δC (100 MHz, CD2Cl2) 20.5 (CH2, C-10), 39.8 (CH2, C-11), 
108.6 (CH, C-15), 111.7 (CH, C-5), 115.2 (C, C-9), 119.0 (CH, C-2), 119.7 (CH, C-3), 120.6 
(CH, C-14), 122.3 (CH, C-4/8), 122.4 (CH, C-4/8), 127.7 (C, C-1), 136.9 (C, C-6), 191.9 (C, 
C-12), CN2 not observed.; HRMS (ESI
+
): Found: 262.0958; C14H13N3NaO (MNa
+
) Requires 
262.0951 (−2.9 ppm error). 
Lab notebook reference: MJJ7/25 
 
1-Diazo-4-(2-methyl-1H-indol-3-yl)-1-phenylbutan-2-one (223) 
 
Synthesised using general procedure 3B with benzyl ketone S4 (359 mg, 1.29 mmol), p-
ABSA (372 mg, 1.55 mmol), DBU (0.27 mL, 1.81 mmol) and MeCN (4 mL). Purification by 
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column chromatography (70:27:3 hexane:EtOAc:Et3N) afforded the title compound 223 (136 
mg, 35%) as a yellow solid, mp 77–79 °C (decomposition); vmax (cm
-1
) 3400, 2071, 1630, 
1462, 742, 693; δH (400 MHz, CD2Cl2) 2.36 (3H, s, H-9), 2.89 (2H, t, J = 7.5 Hz, H-12), 3.11 
(2H, t, J = 7.5 Hz, H-11), 7.04 (1H, ddd, J = 7.5, 7.5, 1.5 Hz, H-3), 7.09 (1H, ddd, J = 7.5, 7.5, 
1.5 Hz, H-4), 7.22–7.29  (2H, m, H-5,18), 7.35–7.41 (2H, m, H-17), 7.41–7.47 (3H, m, H-
2,16), 7.94 (1H, br s, H-7); δC (100 MHz, CD2Cl2) 11.8 (CH3, C-9), 20.0 (CH2, C-11), 40.4 
(CH2, C-12), 72.7 (C, C-14), 110.5 (C, C-10), 110.7 (CH, C-5), 118.1 (CH, C-2), 119.6 (CH, 
C-3), 121.4 (CH, C-4), 126.4 (C + 2CH, C-1/15,16), 127.3 (CH, C-18), 128.9 (C, C-1/15), 
129.4 (2CH, C-17), 132.1 (C, C-8), 135.9 (C, C-6), 193.2 (C, C-13); HRMS (ESI
+
): Found: 
326.1261; C19H17N3NaO (MNa
+) Requires 326.1264 (−0.8 ppm error). 
Lab notebook reference: MJJ9/18 
 
1-Diazo-4-(1H-indol-3-yl)-1-(3-methoxyphenyl)butan-2-one (188b) 
 
Synthesised using general procedure 3B with benzyl ketone 192b (568 mg, 1.94 mmol), p-
ABSA (560 mg, 2.33 mmol), DBU (0.41 mL, 2.72 mmol) and MeCN (6 mL). Purification by 
column chromatography (70:27:3 hexane:EtOAc:Et3N) afforded the title compound 188b (455 
mg, 73%) as a yellow solid, mp 87–89 °C (decomposition); vmax (cm
-1
) 3408, 2075, 1632, 
1601, 1231, 743; δH (400 MHz, CD2Cl2) 2.98 (2H, t, J = 7.5 Hz, H-11), 3.17 (2H, t, J = 7.5 
Hz, H-10), 3.80 (3H, s, H-17), 6.79 (1H, dd, J = 8.0, 2.5 Hz, H-18), 6.99 (1H, d, J = 8.0 Hz, 
H-20), 7.04 (1H, br s, H-8), 7.09 (1H, dd, J = 8.0, 7.5 Hz, H-3), 7.12–7.21 (2H, m, H-4/15), 
7.30 (1H, dd, J = 8.0, 8.0 Hz, H-19), 7.36 (1H, d,  J = 8.0 Hz, H-5), 7.57 (1H, d, J = 8.0 Hz, 
H-2), 8.15 (1H, br s, H-7); δC (100 MHz, CD2Cl2) 20.7 (CH2, C-10), 40.4 (CH2, C-11), 55.8 
(CH3, C-17), 72.8 (C, C-13), 111.7 (CH, C-5), 112.1 (CH, C-15), 112.8 (CH, C-18), 115.3 (C, 
C-9), 118.3 (CH, C-20), 119.1 (CH, C-2), 119.8 (CH, C-3), 122.4 (CH, C-4/8), 122.5 (CH, C-
4/8), 127.7 (CH, C-19), 127.8 (C, C-1), 130.4 (C, C-14), 136.9 (C, C-6), 160.6 (C, C-16), 
192.8 (C, C-12); HRMS (ESI
+
): Found: 342.1209; C19H17N3NaO2 (MNa
+
) Requires 342.1213 
(1.1 ppm error). 
Lab notebook reference: MJJ7/30 
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1-Diazo-1-(4-fluorophenyl)-4-(1H-indol-3-yl)butan-2-one (188c) 
 
Synthesised using general procedure 3B with benzyl ketone 192c (1.34 g, 4.76 mmol), p-
ABSA (1.37 g, 5.71 mmol), DBU (0.99 mL, 6.66 mmol) and MeCN (14 mL). Purification by 
column chromatography (65:32:3 hexane:EtOAc:Et3N) afforded the title compound 188c 
(1.09 g, 75%) as a yellow solid, mp 95–97 °C (decomposition); vmax (cm
-1
) 3316, 2075, 1636, 
1508, 1226, 1200, 832, 739; δH (400 MHz, CD2Cl2) 2.96 (2H, t, J = 7.5 Hz, H-11), 3.16 (2H, t, 
J = 7.5 Hz, H-10), 7.04 (1H, d, J = 1.5 Hz, H-8), 7.06–7.13 (3H, m, H-3,16), 7.17 (1H, dd, J = 
8.0, 7.5 Hz, H-4), 7.37 (1H, d, J = 8.0 Hz, H-5), 7.40–7.49 (2H, m, H-15), 7.56 (1H, d, J = 8.0 
Hz, H-2), 8.13 (1H, br s, H-7); δC (100 MHz, CD2Cl2) 20.7 (CH2, C-10), 40.2 (CH2, C-11), 
72.0 (C, C-13), 111.7 (CH, C-5), 115.2 (C, C-9), 116.4 (2CH, d, J = 22.0 Hz, C-16), 119.1 
(CH, C-2), 119.8 (CH, C-3), 122.2 (C, d, J = 3 Hz, C-14), 122.4 (CH, C-4/8), 122.5 (CH, C-
4/8), 127.7 (C, C-1), 128.5 (2CH, C-15), 136.9 (C, C-6), 162.1 (C, d, J = 246 Hz, C-17), 192.9 
(C, C-12); δF (376 MHz, CDCl3) −114.5–−116.5 (1F, m); HRMS (ESI
+
): Found: 330.1009; 
C18H14FN3NaO (MNa
+
) Requires 330.1013 (1.2 ppm error). 
Lab notebook reference:  MJJ7/52 
 
4-(6-Chloro-1H-indol-3-yl)-1-diazo-1-phenylbutan-2-one (188d) 
 
Synthesised using general procedure 3B with benzyl ketone 192d (774 mg, 2.60 mmol), p-
ABSA (749 mg, 3.12 mmol), DBU (0.54 mL, 3.64 mmol) and MeCN (8 mL). Purification by 
column chromatography (57:40:3 hexane:EtOAc:Et3N) afforded the title compound 188d (496 
mg, 59%) as a yellow solid, mp 110–112 °C (decomposition); vmax (cm
-1
) 3343, 2074, 1621, 
1203, 803, 698; δH (400 MHz, CD2Cl2) 2.95 (2H, t, J = 7.5 Hz, H-11), 3.14 (2H, t, J = 7.5 Hz, 
H, H-10), 7.03–7.08 (2H, m, H-5,8), 7.25 (1H, dd, J = 7.5, 7.5 Hz, H-17), 7.35–7.43 (3H, m, 
H-3,16), 7.43–7.52 (3H, m, H-2,15), 8.13 (1H, br s, H-7); δC (100 MHz, CD2Cl2) 20.5 (CH2, 
C-10), 40.1 (CH2, C-11), 66.9 (C, C-13), 111.6 (CH, C-5), 115.7 (C, C-9), 120.1 (CH, C-2), 
120.4 (CH, C-3), 123.2 (CH, C-8), 126.5 (CH, C-17), 127.4 (2CH, C-15), 128.2 (C, C-1/4), 
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128.6 (C, C-1/4), 129.5 (2CH, C-16), 131.3 (C, C-14), 137.1 (C, C-6), 192.6 (C, C-12); 
HRMS (ESI
+
): Found: 346.0721; C18H14
35
ClN3NaO (MNa
+) Requires 346.0718 (−1.0 ppm 
error). 
Lab notebook reference: MJJ7/63 
 
1-Diazo-4-(5-methoxy-1H-indol-3-yl)-1-phenylbutan-2-one (188e) 
 
Synthesised using general procedure 3B with benzyl ketone 192e (1.16 g, 3.95 mmol), p-
ABSA (1.14 g, 4.74 mmol), DBU (0.83 mL, 5.53 mmol) and MeCN (12 mL). Purification by 
column chromatography (70:27:3 hexane:EtOAc:Et3N) afforded the title compound 188e (780 
mg, 62%) as a dark yellow solid, mp 85–87 °C (decomposition); vmax (cm
-1
) 3311, 2082, 1634, 
1204, 759; δH (400 MHz, CD2Cl2) 2.97 (2H, dd, J = 7.5, 7.5 Hz, H-12), 3.14 (2H, dd, J = 7.5, 
7.5 Hz, H-11), 3.81 (3H, s, H-4), 6.81 (1H, dd, J = 9.0, 2.5 Hz, H-5), 6.99–7.02 (2H, m, H-
2,9), 7.22–7.28 (2H, m, H-16), 7.39 (2H, dd, J = 8.0, 8.0 Hz, H-17), 7.45–7.51 (2H, m, H-
6,18), 8.06 (1H, br s, H-8); δC (100 MHz, CD2Cl2) 20.8 (CH2, C-11), 40.3 (CH2, C-12), 56.2 
(CH3, C-4), 72.7 (C, C-14), 100.8 (CH, C-2), 112.4 (CH, C-5/6), 112.6 (CH, C-5/6), 115.1 (C, 
C-10), 123.1 (CH. C-9), 126.4 (C + CH, C-14,18), 127.4 (2CH, C-16), 128.1 (C, C-1), 129.4 
(2CH, C-17), 131.9 (C, C-7), 154.5 (C, C-3), 192.9 (C, C-13); HRMS (ESI
+
): Found: 
342.1203; C19H17N3NaO2 (MNa
+
) Requires 342.1218 (4.4 ppm error). 
Lab notebook reference: MJJ7/65 
 
2-Phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-one (193a) 
 
Synthesised using general procedure 3H with α-diazocarbonyl 188a (43 mg, 0.149 mmol), 
silica gel (34 mg) and CH2Cl2 (1.5 mL). Purification by column chromatography (40% Et2O 
in hexane) afforded the title compound 193a (28 mg, 72%) as a white solid, mp 169–171 °C; 
vmax (cm
-1
) 3275, 1642, 739; δH (400 MHz, CDCl3) 2.49–2.62 (2H, m, H-11), 3.03–3.20 (2H, 
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m, H-10), 3.91 (1H, dd, J = 9.0, 8.5 Hz, H-12), 7.16–7.22 (1H, m, H-3), 7.22–7.32 (3H, m, 
ArH), 7.33–7.45 (4H, m, ArH), 7.70 (1H, d, J = 8.0 Hz, H-2), 8.84 (1H, br s, H-7); δC (100 
MHz, CDCl3) 20.5 (CH2, C-10), 33.4 (CH2, C-11), 53.7 (CH, C-12), 112.7 (CH, C-5), 120.4 
(CH, C-3), 121.3 (CH, C-2), 125.8 (C, C-1/9), 127.0 (CH, C-4), 127.1 (CH, C-17), 128.5 
(2CH, C-15/16), 128.6 (2CH, C-15/16), 129.2 (C, C-1/9), 131.5 (C, C-6/8/14), 138.3 (C, C-
6/8/14), 139.6 (C, C-6/8/14), 191.5 (C, C-13); HRMS (ESI
+
): Found: 284.1036; C18H15NNaO 
(MNa
+
) Requires 284.1046 (3.4 ppm error), Found: 262.1216; C18H16NO (MH
+
) Requires 
262.1226 (3.9 ppm error). 
Lab notebook reference: 6/92 
 
2-Phenylspiro[cyclopentane-1,3'-indol]-3-one (190a) 
 
Synthesised using general procedure 3C with α-diazocarbonyl 188a (29 mg, 0.1 mmol), 
Rh2oct4 (3.9 mg, 5.0 µmol) and deoxygenated CHCl3 (1 mL). Purification by column 
chromatography (40→60% EtOAc in hexane, positive pressure of N2) afforded the title 
compound 190a (24 mg, 92%, 54:45 dr) as a colourless oil; vmax (cm
-1
) 1745, 1453, 734, 699; 
δH (400 MHz, CDCl3) 2.07–2.16 (1H, m, H-10a, minor), 2.17–2.27 (1H, m, H-10a, major), 
2.43–2.55 (1H, m, H-10b, major), 2.61–2.73 (1H, m, H-10b, minor), 2.76–3.03 (4H, m, H-11, 
major + minor), 4.02 (1H, s, H-13, major), 4.18 (1H, s, H-13, minor), 6.74–6.86 (4H, m, H-
15, major + minor), 7.05–7.19 (8H, m, ArH, major + minor), 7.24–7.30 (1H, m, ArH, 
major/minor), 7.35–7.41 (2H, m, ArH, major + minor), 7.48 (1H, d, J = 7.5 Hz, ArH, minor), 
7.51–7.57 (2H, m, ArH, major + minor), 8.12 (1H, s, H-8, major), 8.23 (1H, s, H-8, minor); 
δC (100 MHz, CDCl3) 26.7 (CH2), 28.2 (CH2), 36.5 (CH2), 38.1 (CH2), 59.8 (CH), 62.5 (CH), 
66.0 (C), 66.2 (C), 121.1 (CH), 121.58 (CH), 121.63 (CH), 122.6 (CH), 126.0 (CH), 126.8 
(CH), 127.5 (CH), 127.7 (CH), 128.0 (2CH), 128.4 (2CH), 128.5 (3CH), 128.7 (CH), 129.2 
(2CH), 132.3 (C), 133.0 (C), 138.7 (C), 139.7 (C), 155.1 (C), 155.4 (C), 173.1 (CH), 175.1 
(CH), 213.6 (C), 214.4 (C); HRMS (ESI
+
): Found: 262.1231; C18H16NO (MH
+
) Requires 
262.1226 (−1.7 ppm error). 
Lab notebook reference: MJJ6/99  
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4-(2-Oxoindolin-3-yl)-1-phenylbutane-1,2-dione (198a) 
 
To α-diazocarbonyl 188a (57 mg, 0.197 mmol) and Rh2oct4 (3.1 mg, 3.94 µmol) in a flask 
open to air was added CHCl3 (20 mL/mmol). The mixture was stirred at RT for 1 h then 
purified by rapid (compound reacts with silica) column chromatography (1:1 hexane:EtOAc) 
to afford the title compound 198a (45 mg, 78%) as a yellow solid, mp 122–123 °C; vmax (cm
-1
) 
1695, 1667, 1470, 749, 691; δH (400 MHz, CDCl3) 2.27–2.52 (2H, m, H-10), 2.95–3.15 (2H, 
m, H-11), 3.62 (1H, dd, J = 6.5, 6.5 Hz, H-9), 6.88 (1H, d, J = 8.0 Hz, H-5), 7.06 (1H, dd, J = 
8.0, 7.5 Hz, H-3), 7.20–7.30 (2H, m, H-2,4), 7.48 (2H, dd, J = 7.5, 7.5 Hz, H-16), 7.63 (1H, 
dd, J = 7.5, 7.5 Hz, H-17), 7.91–7.99 (3H, m, H-7,15); δC (100 MHz, CDCl3) 23.3 (CH2, C-
10), 34.5 (CH2, C-11), 44.4 (CH, C-9), 109.7 (CH, C-5), 122.6 (CH, C-3), 124.3 (CH, C-2), 
128.3 (CH, C-4), 128.6 (C, C-1), 128.8 (2CH, C-16), 130.3 (2CH, C-15), 131.8 (C, C-14), 
134.6 (CH, C-17), 141.2 (C, C-6), 179.0 (C, C-8), 191.7 (C, C-13), 201.9 (C, C-12); HRMS 
(ESI
+
): Found: 316.0955; C18H15NNaO3 (MNa
+
) Requires 316.0950 (−1.6 ppm error). 
Lab notebook reference: MJJ6/21 
 
4-(2-Oxoindolin-3-yl)-1-phenylbutane-1,2-dione (208) 
 
To α-diazocarbonyl 207 (53 mg, 0.221 mmol) and Rh2oct4 (8.6 mg, 11.1 µmol) in a flask open 
to air was added CHCl3 (4.4 mL). The mixture was stirred at RT for 24 h then purified by 
column chromatography (35% EtOAc in hexane) to afford the title compound 208 (10 mg, 
19%) as a white solid, mp 151–153 °C; vmax (cm
-1
) 3401, 2918, 1721, 1652, 1483, 1206, 1049, 
745; δH (400 MHz, CDCl3) 2.10–2.25 (2H, m, H-10), 2.58 (1H, ddd, J = 18.5, 7.5, 2.5 Hz, H-
11a), 2.69–2.82 (1H, m, H-11b), 4.58 (1H, ddd, J = 20.0, 2.5, 2.0 Hz, H-15a), 4.78–4.86 (1H, 
m, H-7), 5.02 (1H, dd, J = 20.0, 2.0 Hz, H-15b), 5.51 (1H, d, J = 2.5 Hz, H-8), 6.68–6.76 (3H, 
m, H-3,5,14), 6.83 (1H, d, J = 7.0 Hz, H-2), 7.11 (1H, dd, J = 7.5, 7.5 Hz, H-4); δC (100 MHz, 
CDCl3) 35.3 (CH2, C-10), 36.0 (CH2, C-11), 55.5 (C, C-9), 75.2 (CH2, C-15), 106.2 (CH, C-
8), 107.9 (CH, C-5), 118.7 (CH, C-3), 120.8 (CH, C-2), 128.0 (CH, C-4), 133.0 (CH, C-14), 
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136.3 (C, C-1/6), 138.1 (C, C-1/6), 146.5 (C, C-13), 205.2 (C, C-12); HRMS (ESI
+
): Found: 
266.0781; C14H13NNaO3 (MNa
+
) Requires 266.0788 (2.5 ppm error). 
Lab notebook reference: MJJ8/6 
 
syn-2-Hydroxy-2-phenylspiro[cyclopentane-1,3'-indoline]-2',3-dione (212a) 
 
Synthesised using general procedure 3D with α-diazocarbonyl 188a (29 mg, 0.1 mmol), 
Rh2oct4 (1.6 mg, 2.0 µmol) and CHCl3 (2 mL) for 1 h then TFA (23 µL, 0.3 mmol) and THF 
(1 mL) for 4 h. Purification by column chromatography (40→60% EtOAc in hexane) afforded 
the title compound 212a (29 mg, 99%) as a white solid, mp 175–177 °C;  vmax (cm
-1
) 3257, 
1746, 1703, 729, 699; δH (400 MHz, CDCl3) 2.29 (1H, ddd, J = 13.5, 10.0, 10.0 Hz, H-10a), 
2.41–2.51 (1H, m, H-10b), 2.85 (1H, ddd, J =  20.0, 10.0, 2.5 Hz, H-11a), 3.33 (1H, ddd, J = 
20.0, 10.0, 10.0 Hz, H-11b), 3.83 (1H, s, H-14), 5.82 (1H, d, J = 8.0 Hz, H-2), 6.74 (1H, dd, J 
= 8.0, 7.5 Hz, H-3), 6.85 (1H, d, J = 8.0 Hz, H-5), 7.11–7.21 (3H, m, H-4,16), 7.29–7.39 (3H, 
m, H-17,18), 7.89 (1H, br s, H-7); δC (100 MHz, CDCl3) 27.4 (CH2, C-10), 34.4 (CH2, C-11), 
59.6 (C, C-9), 84.6 (C, C-13), 109.7 (CH, C-5), 121.9 (CH, C-3), 125.4 (CH, C-2), 126.7 
(2CH, C-16), 127.9 (C, C-1), 128.1 (2CH, C-17), 128.5 (CH, C-4/18), 128.6 (CH, C-4/18), 
137.4 (C, C-15), 141.1 (C, C-6), 180.0 (C, C-8), 215.9 (C, C-12); HRMS (ESI
+
): Found: 
316.0956; C18H15NNaO3 (MNa
+
) Requires 316.0944 (−3.8 ppm error). 
Lab notebook reference: MJJ6/94 
 
anti-2-Hydroxy-2-phenylspiro[cyclopentane-1,3'-indoline]-2',3-dione (214a) 
 
Synthesised using general procedure 3E with α-diazocarbonyl 188a (29 mg, 0.1 mmol), 
Rh2oct4 (1.6 mg, 2.0 µmol) and CHCl3 (2 mL)  for 1 h then t-BuOK (34 mg, 0.3 mmol) and 
THF (1 mL) for 2 h. Purification by column chromatography (30→40% EtOAc in hexane) 
afforded the title compound 214a (17 mg, 58%) as a white solid, mp 184–186 °C; vmax (cm
-1
) 
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3276, 1742, 1697, 1471, 740; δH (400 MHz, CDCl3) 2.29 (1H, dd, J = 12.5, 9.5 Hz, H-10a), 
2.71 (1H, ddd, J = 12.5, 10.0, 9.5 Hz, H-10b), 2.86 (1H, dd, J = 19.5, 9.5 Hz, H-11a), 3.00 
(1H, s, H-14), 3.20 (1H, ddd, J = 19.5, 10.0, 9.5 Hz, H-11b), 6.64 (1H, d, J = 7.5 Hz, H-5), 
7.02–7.21 (7H, m, ArH), 7.24 (1H, dd, J = 8.0, 8.0 Hz, H-4), 7.73 (1H, d, J = 8.0 Hz, H-2); δC 
(100 MHz, CDCl3) 28.3 (CH2, C-10), 34.3 (CH2, C-11), 61.0 (C, C-9), 81.4 (C, C-13), 109.1 
(CH, C-5), 122.5 (CH, C-3), 126.8 (CH, C-2), 127.45 (2CH, C-16), 127.50 (2CH, C-17), 
127.7 (C, C-1), 128.4 (CH, C-4/18), 128.7 (CH, C-4/18), 135.2 (C, C-15), 140.8 (C, C-6), 
178.8 (C, C-8), 212.6 (C, C-12); HRMS (ESI
+
): Found: 316.0941; C18H15NNaO3 (MH
+
) 
Requires 316.0944 (1.0 ppm error). 
Lab notebook reference: MJJ7/7 
 
1-Phenyl-3,4-dihydro-1H-carbazol-2(9H)-one (199a) 
 
Synthesised using general procedure 3F with α-diazocarbonyl 188a (57 mg, 0.197 mmol), 
Pd(MeCN)4(BF4)2 (4.4 mg, 9.85 µmol) and CHCl3 (2 mL). Purification by column 
chromatography (20% EtOAc in hexane) afforded the title compound 199a (43 mg, 84%) as a 
white solid, mp 153–155 °C; vmax (cm
-1
) 3395, 1713, 1455, 1236, 741; δH (400 MHz, CDCl3) 
2.66–2.75 (1H, m, H-11a), 2.86–2.97 (1H, m, H-11b), 3.09–3.20 (1H, m, H-10a), 3.26–3.36 
(1H, m, H-10b), 4.83 (1H, s, H-13), 7.15–7.38 (9H, m, ArH), 7.60 (1H, d, J = 8.0 Hz, H-2), 
7.67 (1H, br s, H-7); δC (100 MHz, CDCl3) 20.2 (CH2, C-10), 36.8 (CH2, C-11), 55.1 (CH, H-
13), 111.0 (CH, C-5), 111.4 (C, C-9), 118.4 (CH, C-2), 119.8 (CH, C-3), 122.4 (CH, C-4/17), 
126.4 (C, C-1), 127.8 (CH, C-4/17), 128.5 (2CH, C-15/16), 128.9 (2CH, C-15/16), 132.3 (C, 
C-8), 136.9 (C, C-6/14), 137.3 (C, C-6/14), 207.7 (C, C-12); HRMS (ESI
+
): Found: 262.1238; 
C18H16NO (MH
+) Requires 262.1226 (−4.6 ppm error). 
Lab notebook reference: MJJ6/35 
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1-Phenyl-9H-carbazol-2-ol (200a) 
 
Synthesised using general procedure 3G with α-diazocarbonyl 188a (43 mg, 0.149 mmol), 
Cu(OTf)2 (10.9 mg, 30 µmol) and CHCl3 (3 mL). Purification by column chromatography 
(20→30% EtOAc in hexane) afforded the title compound 200a (27 mg, 70%) as a white solid, 
mp 211–213 °C; vmax (cm
-1
) 3389, 1460, 1175, 739; δH (400 MHz, CDCl3) 5.20 (1H, s, H-13), 
6.95 (1H, d, J = 8.5 Hz, H-11), 7.19–7.26 (1H, m, H-3), 7.29–7.37 (2H, m, H-4,5), 7.49–7.57 
(1H, m, H-18), 7.58–7.68 (4H, m, H-16,17), 7.88 (1H, br s, H-7), 7.95 (1H, d, J = 8.5 Hz, H-
10), 8.01 (1H, d, J = 8.0 Hz, H-2); δC (100 MHz, CDCl3) 108.8 (CH, C-11), 110.3 (CH, C-5), 
110.4 (C, C-1/9), 117.1 (C, C-1/9), 119.5 (CH, C-2/3), 119.6 (CH, C-2/3), 120.6 (CH, C-10), 
123.8 (C, C-14), 124.6 (CH, C-4), 128.6 (CH, C-18), 130.05 (2CH, C-16/17), 130.09 (2CH, 
C-16/17), 133.0 (C, C-6/8/15), 139.0 (C, C-6/8/15), 139.4 (C, C-6/8/15), 151.0 (C, C-12); 
HRMS (ESI
+
): Found: 260.1070; C18H14NO (MH
+
) Requires 260.1070 (0.0 ppm error). 
Lab notebook reference: 6/93 
 
2-(3-Methoxyphenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-one (193b) 
 
Synthesised using general procedure 3H with α-diazocarbonyl 188b (32 mg, 0.10 mmol), 
silica gel (32 mg) and CH2Cl2 (1 mL). Purification by column chromatography (50% Et2O in 
hexane) afforded the title compound 193b (19 mg, 65%) as a white solid, mp 146–148 °C; 
vmax (cm
-1
) 3279, 1646, 1251, 739; δH (400 MHz, CDCl3) 2.49–2.60 (2H, m, H-11), 3.02–3.19 
(2H, m, H-10), 3.80 (3H, s, H-17), 3.85–3.92 (1H, m, H-12), 6.78–6.87 (3H, m, H-5,18,20), 
7.16–7.22 (1H, m, H-3), 7.24–7.30 (1H, m, H-19), 7.36–7.46 (2H, m, H-4,15), 7.69 (1H, d, J 
= 8.0 Hz, H-2), 8.79 (1H, br s, H-7); δC (100 MHz, CDCl3) 20.5 (CH2, C-10), 33.4 (CH2, C-
11), 53.7 (CH, C-12), 55.2 (CH3, C-17), 112.2 (CH, C-5), 112.7 (CH, C-15), 114.5 (CH, C-
18), 120.4 (CH, C-3), 120.9 (CH, C-20), 121.3 (CH, C-2), 125.8 (C, C-1/9), 127.1 (CH, C-4), 
129.2 (C, C-1/9), 129.5 (CH, C-19), 131.4 (C, C-6/8/14), 138.3 (C, C-6/8/14), 141.2 (C, C-
6/8/14), 159.7 (C, C-16), 191.3 (C, C-13); HRMS (ESI
+
): Found: 314.1138; C19H17NNaO2 
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(MNa
+
) Requires 314.1151 (4.4 ppm error), Found: 292.1321; C19H18NO2 (MH
+
) Requires 
292.1332 (3.8 ppm error). 
Lab notebook reference: MJJ7/37 
 
2-(4-Fluorophenyl)-2,3,4,9-tetrahydro-1H-carbazol-1-one (193c) 
 
Synthesised using general procedure 3H with α-diazocarbonyl 188c (61 mg, 0.2 mmol), 
silica gel (61 mg) and CH2Cl2 (2 mL). Purification by column chromatography (40% Et2O in 
hexane) afforded the title compound 193c (28 mg, 50%) as an off-white solid, mp 185–187 
°C; vmax (cm
-1
) 3277, 1640, 1510, 1228, 742; δH (400 MHz, CDCl3) 2.44–2.60 (2H, m, H-11), 
3.03–3.21 (2H, m, H-10), 3.90 (1H, dd, J = 10.0, 5.0 Hz, H-12), 7.01–7.09 (2H, m, H-16), 
7.16–7.25 (3H, m, H-3,15), 7.38–7.44 (2H, m, H-4,5) 7.69 (1H, d, J = 8.0 Hz, H-2), 8.90 (1H, 
br s, H-7); δC (100 MHz, CDCl3) 20.6 (CH2, C-10), 33.5 (CH2, C-11), 53.0 (CH, C-12), 112.7 
(CH, C-5), 115.4 (2CH, d, J = 21.0 Hz, C-16), 120.5 (CH, C-3), 121.4 (CH, C-2), 125.7 (C, 
C-1/9), 127.2 (CH, C-4), 129.3 (C, C-1/9), 130.0 (2CH, d, J = 7.5 Hz, C-15), 131.3 (C, C-6/8), 
135.3 (C, d, J = 3.0 Hz, C-14), 138.4 (C, C-6/8), 161.9 (C, d, J = 245 Hz, C-17), 191.3 (C, C-
13); δF (376 MHz, CDCl3) −115.7–−115.9 (1F, m); HRMS (ESI
+
): Found: 302.0954; 
C18H14FNNaO (MNa
+) Requires 302.0952 (−0.9 ppm error), Found: 280.1133; C18H15FNO 
(MH
+
) Requires 280.1132 (−0.2 ppm error). 
Lab notebook reference: MJJ7/57 
 
7-Chloro-2-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-one (193d) 
 
Synthesised using general procedure 3H with α-diazocarbonyl 188d (65 mg, 0.2 mmol), 
silica gel (65 mg) and CH2Cl2 (2 mL). Purification by column chromatography (0→1% 
MeOH in CH2Cl2) afforded the title compound 193d (44 mg, 75%) as a white solid, mp 230–
232 °C; vmax (cm
-1
) 3241, 1649, 1636, 936, 737, 698; δH (400 MHz, DMSO-d6) 2.31–2.50 (2H, 
m, H-11), 2.96–3.10 (2H, m, H-10), 3.97 (1H, dd, J = 11.0, 4.5 Hz, H-12), 7.12 (1H, dd, J = 
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8.5, 2.0 Hz, H-3), 7.20–7.29 (3H, m, H-15/16,17), 7.30–7.36 (2H, m, H-15/16), 7.42 (1H, d, J 
= 2.0 Hz, H-5), 7.73 (1H, d, J = 8.5 Hz, H-2), 11.83 (1H, br s, H-7); δC (100 MHz, DMSO-d6) 
20.2 (CH2, C-10), 33.0 (CH2, C-11), 53.2 (CH, C-12), 112.2 (CH, C-5), 120.4 (CH, C-3), 
123.0 (CH, C-2), 124.0 (C, C-1/9), 126.6 (CH, C-17), 127.8 (C, C-1/9), 128.3 (2CH, C-
15/16), 128.7 (2CH, C-15/16), 130.7 (C, C-4/6/8/14), 132.2 (C, C-4/6/8/14), 138.5 (C, C-
4/6/8/14), 140.3 (C, C-4/6/8/14), 190.8 (C, C-13); HRMS (ESI
+
): Found: 318.0658; 
C18H14
35
ClNNaO (MNa
+) Requires 318.0656 (−0.6 ppm error), Found: 296.0837; 
C18H15
35
ClNO (MH
+
) Requires 296.0837 (0.0 ppm error). 
Lab notebook reference: MJJ7/67 
 
7-Chloro-2-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-one (193e) 
 
Synthesised using general procedure 3H with α-diazocarbonyl 188e (64 mg, 0.2 mmol), 
silica gel (64 mg) and CH2Cl2 (2 mL). The crude reaction mixture was then filtered (washing 
with MeOH) and concentrated in vacuo. The crude material was then suspended in a 0 °C 
solution of CH2Cl2:Et2O (1:1 v/v, 0.5 mL), after filtration the obtained solution was discarded 
and the remaining insoluble solids (product) were collected to afford the title compound 193e 
(22 mg, 38%) as an off-white solid, mp 197–199 °C; vmax (cm
-1
) 3268, 1638, 1483, 1215; δH 
(400 MHz, CDCl3) 2.47–2.63 (2H, m, H-12), 2.98–3.16 (2H, m, H-11), 3.88 (3H, s, H-4), 
3.88–3.95 (1H, m, H-13), 7.00–7.09 (2H, m, H-2,5), 7.22–7.41 (6H, m, H-6,16,17,18), 9.45 
(1H, br s, H-8); δC (100 MHz, CDCl3) 20.5 (CH2, C-11), 33.4 (CH2, C-12), 53.7 (CH, C-13), 
55.7 (CH3, C-4), 101.0 (CH, C-2), 113.7 (CH, C-6), 118.9 (CH, C-5), 125.8 (C, C-1/9), 126.9 
(CH. C-18), 128.5 (2CH, C-16/17), 128.56 (2CH, C-16/17), 128.58 (C, C-1/9), 132.0 (C, C-
7/9/15), 133.8 (C, C-7/9/15), 139.7 (C, C-7/9/15), 154.5 (C, C-3), 191.4 (C, C-14); HRMS 
(ESI
+
): Found: 314.1155; C19H17NNaO2 (MNa
+) Requires 314.1151 (−1.1 ppm error). 
Lab notebook reference: MJJ7/80 
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2-(3-Methoxyphenyl)spiro[cyclopentane-1,3'-indol]-3-one (190b) 
 
Synthesised using general procedure 3C with α-diazocarbonyl 188b (48 mg, 0.15 mmol), 
Rh2oct4 (5.8 mg, 7.5 µmol) and deoxygenated CHCl3 (1.5 mL). Purification by column 
chromatography (40→70% EtOAc in hexane, positive pressure of N2) afforded the title 
compound 190b (31 mg, 71%, 78:22 dr) as a colourless oil; vmax (cm
-1
) 1740, 1600, 1455, 
1248, 733; δH (400 MHz, CDCl3) 2.06–2.14 (1H, m, H-10a, minor), 2.16–2.26 (1H, m, H-10a, 
major), 2.40–2.52 (1H, m, H-10b, major), 2.59–2.70 (1H, m, H-10b, minor), 2.75–3.02 (4H, 
m, H-11, major + minor), 3.57 (3H, s, H-17, minor), 3.59 (3H, s, H-17, major), 3.98 (1H, s, 
H-13, major), 4.15 (1H, s, H-13, minor), 6.27 (1H, br s, H-15, major), 6.31 (1H, br s, H-15, 
minor), 6.39 (1H, d, J = 8.0 Hz, H-20, major), 6.43 (1H, d, J = 7.5 Hz, H-20, minor), 6.62 
(1H, dd, J = 8.0, 2.0 Hz, H-18, minor), 6.67 (1H, dd, J = 8.0, 2.0 Hz, H-18, major), 6.99 (1H, 
dd, J = 8.0, 8.0 Hz, H-19, minor), 7.04 (1H, dd, J = 8.0, 8.0 Hz, H-19, major), 7.14–7.20 (2H, 
m, ArH, minor), 7.24–7.32 (1H, m, ArH, minor), 7.35–7.41 (2H, m, ArH, major), 7.48–7.58 
(3H, m, ArH, major + minor), 8.09 (1H, s, H-8, major), 8.20 (1H, s, H-8, minor); δC (100 
MHz, CDCl3)  26.8 (CH2), 28.2 (CH2), 36.4 (CH2), 38.2 (CH2), 55.0 (2CH3), 59.7 (CH), 62.1 
(CH), 65.8 (C), 66.0 (C), 113.0 (CH), 113.3 (CH), 114.3 (CH), 114.6 (CH), 120.6 (CH), 121.1 
(CH), 121.6 (CH), 121.66 (CH), 121.69 (CH), 122.6  (CH), 125.9 (CH), 126.7 (CH), 128.5 
(CH), 128.6 (CH), 128.9 (CH), 129.4 (CH), 133.8 (C), 134.5 (C), 138.8 (C), 139.9 (C), 155.1 
(C), 155.4 (C), 159.0 (C), 159.2 (C), 173.1 (CH), 175.1 (CH), 213.3 (C), 214.1 (C); HRMS 
(ESI
+
): Found: 314.1152; C19H17NNaO2 (MNa
+) Requires 314.1151 (−0.0 ppm error). 
Lab notebook reference: MJJ7/64 
 
2-(4-Fluorophenyl)spiro[cyclopentane-1,3'-indol]-3-one (190c) 
 
Synthesised using general procedure 3C with α-diazocarbonyl 188c (61 mg, 0.199 mmol), 
Rh2oct4 (7.7 mg, 9.95 µmol) and deoxygenated CHCl3 (2 mL). Purification by column 
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chromatography (40→70% EtOAc in hexane, positive pressure of N2) afforded the title 
compound 190c (37 mg, 66%, 61:39 dr) as a pale brown oil; vmax (cm
-1
) 1742, 1511, 1225, 
733; δH (400 MHz, CDCl3) 2.06–2.13 (1H, m, H-10a, minor), 2.18 (1H, ddd, J = 13.5, 8.5, 1.5 
Hz, H-10a, major), 2.45–2.57 (1H, m, H-10b, major), 2.64–2.75 (1H, m, H-10b, minor), 2.75–
3.02 (4H, m, H-11, major + minor), 4.01 (1H, s, H-13, major), 4.19 (1H, s, H-14, minor), 
6.70–6.84 (8H, m, H-15,16, major + minor), 7.15–7.21 (2H, m, H-2,3, minor), 7.25–7.32 (1H, 
m, H-4, minor), 7.35–7.43 (2H, m, H-2,3 major), 7.49 (1H, d, J = 8.0 Hz, H-5, minor), 7.51–
7.58 (2H, m, H-4,5, major), 8.10 (1H, s, H-8, major), 8.21 (1H, s, H-8, minor); δC (100 MHz, 
CDCl3)  26.4 (CH2), 27.9 (CH2), 36.2 (CH2), 37.9 (CH2), 59.1 (CH), 61.8 (CH), 65.9 (C), 66.1 
(C), 114.9 (2CH, d, J = 22 Hz), 115.4 (2CH, d, J = 21 Hz), 121.1 (CH), 121.6 (CH), 121.8 
(CH), 122.4 (CH), 126.1 (CH), 126.9 (CH), 127.9 (C, d, J = 3.0 Hz), 128.6 (C, d, J = 3.0 Hz), 
128.7 (CH), 128.8 (CH), 130.2 (2CH, d, J = 7.5 Hz), 130.8 (2CH, d, J = 8.5 Hz), 138.5 (C), 
139.3 (C), 155.1 (C), 155.4 (C), 161.9 (C, d, J = 247 Hz), 162.1 (C, d, J = 247 Hz), 172.7 
(CH), 174.9 (CH), 213.2 (C), 213.9 (C); δF (376 MHz, CDCl3) −114.03–−114.14 (1F, m, 
major), −114.3–−114.4 (1F, m, minor); HRMS (ESI+): Found: 280.1125; C18H15FNO (MH
+
) 
Requires 280.1132 (2.4 ppm error). 
Lab notebook reference: MJJ7/66 
 
6'-Chloro-2-phenylspiro[cyclopentane-1,3'-indol]-3-one (190d) 
 
Synthesised using general procedure 3C with α-diazocarbonyl 188d (49 mg, 0.15 mmol), 
Rh2oct4 (5.8 mg, 7.5 µmol) and deoxygenated CHCl3 (4.5 mL). Purification by column 
chromatography (40→70% EtOAc in hexane, positive pressure of N2) afforded the title 
compound 190d (24 mg, 54%, 58:42 dr) as a pale brown oil; vmax (cm
-1
) 1745, 1453, 735, 699; 
δH (400 MHz, CDCl3) 2.05–2.14 (1H, m, H-10a, minor), 2.15–2.24 (1H, m, H-10a, major), 
2.40–2.52 (1H, m, H-10b, major), 2.58–2.70 (1H, m, H-10b, minor), 2.75–3.02 (4H, m, H-11, 
major + minor), 3.98 (1H, s, H-13 major), 4.15 (1H, s, H-13, minor), 6.73–6.86 (4H, m, H-15, 
minor + major), 7.01 (1H, d, J = 8.0 Hz, H-2, minor), 7.07–7.19 (7H, m, H-3,16,17 major + 
minor), 7.36 (1H, dd, J = 8.0, 1.5 Hz, H-3, major), 7.44 (1H, d, J = 8.0 Hz, H-2, major), 7.47 
(1H, br s, H-5, minor), 7.52 (1H, br s, H-5, major), 8.15 (1H, s, H-8, major), 8.26 (1H, s, H-8, 
minor); δC (100 MHz, CDCl3)  26.7 (CH2), 28.1 (CH2), 36.5 (CH2), 38.0 (CH2), 59.5 (CH), 
62.4 (CH), 65.9 (C), 66.1 (C), 121.8  (CH), 122.1  (CH), 122.2  (CH), 123.2  (CH), 125.9  
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(CH), 126.8  (CH), 127.6  (CH), 127.8  (CH), 128.1  (2CH), 128.47  (2CH), 128.51  (2CH), 
129.1  (2CH), 132.2 (C), 132.7 (C), 134.1 (C), 134.2 (C), 137.2 (C), 138.2 (C), 156.2 (C), 
156.6 (C), 174.7 (CH), 176.7 (CH), 213.1 (C), 213.7 (C); HRMS (ESI
+
): Found: 318.0665; 
C18H14
35
ClNNaO (MNa
+) Requires 318.0656 (−2.9 ppm error), Found: 296.0831; 
C18H15
35
ClNO (MH
+
) Requires 296.0837 (1.8 ppm error). 
Lab notebook reference: MJJ7/88 
 
5'-Methoxy-2-phenylspiro[cyclopentane-1,3'-indol]-3-one (190e) 
 
Synthesised using general procedure 3C with α-diazocarbonyl 188e (64 mg, 0.20 mmol), 
Rh2oct4 (7.8 mg, 10.0 µmol) and deoxygenated CHCl3 (2 mL). Purification by column 
chromatography (40→80% EtOAc in hexane, positive pressure of N2) afforded the title 
compound 190e (34 mg, 59%, 63:37 dr) as a colourless oil; vmax (cm
-1
) 1744, 1470, 1284, 
1027, 734, 699; δH (400 MHz, CDCl3) 2.12 (1H, ddd, J = 13.0, 8.0, 4.0 Hz, H-11a, minor), 
2.19 (1H, ddd J = 13.5, 9.0, 2.0 Hz, H-11a, major), 2.38–2.49 (1H, m, H-11b, major), 2.60 
(1H, ddd, J = 13.0, 9.5, 9.5 Hz, H-11b, minor), 2.73–3.01 (4H, m, H-12, major + minor), 3.74 
(3H, s, H-4, minor), 3.89 (3H, s, H-4, major), 3.96 (1H, s, H-14, major), 4.12 (1H, s, H-14, 
minor), 6.60 (1H, d, J = 2.0 Hz, H-2, minor),  6.72–6.91 (6H, m, H-5,16, major + minor), 7.06 
(1H, d, J = 2.0 Hz, H-2, major), 7.08–7.17 (6H, m, H-17,18 major + minor), 7.37 (1H, d, J = 
8.5 Hz, H-6, minor), 7.43 (1H, d, J = 8.0 Hz, H-6, major), 7.99 (1H, s, H-9, major), 8.08 (1H, 
s, H-9, minor); δC (100 MHz, CDCl3)  26.9 (CH2), 28.6 (CH2), 36.5 (CH2), 38.1 (CH2), 55.7 
(CH3), 55.8 (CH3), 59.6 (CH), 62.6 (CH), 65.9 (C), 66.1 (C), 107.9 (CH), 109.8 (CH), 112.7 
(CH), 112.8 (CH), 121.8 (CH), 121.9 (CH), 127.4 (CH), 127.6 (CH), 128.0 (CH), 128.4 (CH), 
128.6 (CH), 129.2 (CH), 132.6 (C), 133.0 (C), 140.3 (C), 141.5 (C), 148.8 (C), 149.0 (C), 
158.2 (C), 159.0 (C), 170.9 (CH), 173.0 (CH), 213.8 (C), 214.3 (C); HRMS (ESI
+
): Found: 
292.1339; C19H18NO2 (MH
+
) Requires 292.1332 (−2.5 ppm error). 
Lab notebook reference: MJJ7/89 
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syn-2-Hydroxy-2-(3-methoxyphenyl)spiro[cyclopentane-1,3'-indoline]-2',3-dione (212b) 
 
Synthesised using general procedure 3D with α-diazocarbonyl 188b (48 mg, 0.15 mmol), 
Rh2oct4 (2.3 mg, 3.0 µmol) and CHCl3 (3 mL) for 1 h then TFA (35 µL, 0.45 mmol) and THF 
(1.5 mL) for 4 h. Purification by column chromatography (50% EtOAc in hexane) afforded 
the title compound 212b (44 mg, 91%) as an off-white solid, mp 151–153 °C; vmax (cm
-1
) 
3286, 1753, 1702, 1471, 731; δH (400 MHz, CDCl3) 2.26–2.37 (1H, m, H-10a), 2.38–2.48 
(1H, m, H-10b), 2.83 (1H, ddd, J = 19.5, 10.0, 2.5 Hz, H-11a), 3.31 (1H, ddd, J = 19.5, 10.0, 
10.5 Hz, H-11b), 3.68 (3H, s, H-20), 5.88 (1H, d, J = 8.0 Hz, H-2), 6.68–6.73 (2H, m, H-
16,21), 6.76 (1H, dd, J =8.0, 7.5 Hz, H-3), 6.83–6.92 (2H, m, H-5,18), 7.16 (1H, dd, J = 7.5, 
7.5 Hz, H-4), 7.24 (1H, dd, J = 7.5, 7.5 Hz, H-17), 8.42 (1H, br s, H-7); δC (100 MHz, CDCl3) 
27.3 (CH2, C-10), 34.4 (CH2, C-11), 55.2 (CH3, C-20), 59.7 (C, C-9), 84.6 (C, C-13), 109.9 
(CH, C-5), 112.8 (CH, C-21), 114.4 (CH, C-18), 118.5 (CH, C-16), 121.9 (CH, C-3), 125.4 
(CH, C-2), 127.8 (C, C-1), 128.7 (CH, C-4), 129.0 (CH, C-17), 138.9 (C, C-15), 141.3 (C, C-
6), 159.2 (C, C-19), 180.4 (C, C-8), 215.9 (C, C-12); HRMS (ESI
+
): Found: 346.1048; 
C19H17NNaO4 (MNa
+
) Requires 346.1050 (0.5 ppm error). 
Lab notebook reference: MJJ7/43 
 
syn-2-(4-Fluorophenyl)-2-hydroxyspiro[cyclopentane-1,3'-indoline]-2',3-dione (212c) 
 
Synthesised using general procedure 3D with α-diazocarbonyl 188c (61 mg, 0.20 mmol), 
Rh2oct4 (3.1 mg, 4.0 µmol) and CHCl3 (4 mL) for 1 h then TFA (46 µL, 0.60 mmol) and THF 
(2 mL) for 4 h. Purification by column chromatography (50% EtOAc in hexane) afforded the 
title compound 212c (38 mg, 61%) as an off-white solid, mp 142–144 °C; vmax (cm
-1
) 3299, 
1755, 1704, 1508, 1471, 1231, 1205, 734; δH (400 MHz, CDCl3) 2.25 (1H, ddd, J = 13.5, 
10.0, 9.5 Hz, H-10a), 2.51 (1H, ddd, J = 13.5, 10.0, 3.0 Hz, H-10b), 2.83 (1H, ddd, J = 20.0, 
10.0, 3.0 Hz, H-11a), 3.32 (1H, ddd, J = 20.0, 10.0, 9.5 Hz, H-11b), 4.04 (1H, br s, H-14), 
5.98 (1H, d, J = 8.0 Hz, H-2), 6.80 (1H, dd, J = 8.0, 8.0 Hz, H-3), 6.85 (1H, d, J = 8.0 Hz, H-
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5), 6.96–7.03 (2H, m, H-17), 7.08–7.14 (2H, m, H-16), 7.18 (1H, dd, J = 8.0, 8.0 Hz, H-4), 
7.72 (1H, br s); δC (100 MHz, CDCl3) 27.3 (CH2, C-10), 34.2 (CH2, C-11), 59.7 (C, C-9), 84.1 
(C, C-13), 110.1 (CH, C-5), 115.0 (2CH, d, J = 22.0 Hz, C-17), 122.1 (CH, C-3), 125.1 (CH, 
C-2), 127.8 (C, C-1), 128.7 (2CH, d, J = 8.5 Hz, C-16), 128.8 (CH, C-4), 133.1 (C, d, J = 4.0 
Hz, C-15), 141.1 (C, C-6), 162.5 (C, d, J = 248 Hz, C-18), 180.3 (C, C-8), 215.2 (C, C-12); δF 
(376 MHz, CDCl3) –112.8–−112.9 (1F, m); HRMS (ESI
+
): Found: 334.0857; C18H14FNNaO3 
(MNa
+) Requires 334.0850 (−2.2 ppm error). 
Lab notebook reference: MJJ7/61 
 
syn-6'-Chloro-2-hydroxy-2-phenylspiro[cyclopentane-1,3'-indoline]-2',3-dione (212d) 
 
Synthesised using general procedure 3D with α-diazocarbonyl 188d (65 mg, 0.20 mmol), 
Rh2oct4 (3.1 mg, 4.0 µmol) and CHCl3 (6 mL) for 5 h then TFA (46 µL, 0.60 mmol) and THF 
(2 mL) for 4 h. Purification by column chromatography (40% EtOAc in hexane) afforded the 
title compound 212d (40 mg, 61%) as an off-white solid, mp 153–155 °C; vmax (cm
-1
) 3258, 
1743, 1702, 1207, 744, 696; δH (400 MHz, DMSO-d6) 2.06–2.27 (2H, m, H-10), 2.89 (1H, 
ddd, J = 19.5, 9.5, 1.5 Hz, H-11a), 3.02 (1H, ddd, J = 19.5, 10.0, 9.5 Hz, H-11b), 5.40 (1H, d, 
J = 8.0 Hz, H-2), 6.34 (1H, br s, H-14), 6.63 (1H, dd, J = 8.0, 1.5 Hz, H-3), 6.78 (1H, d, J = 
1.5 Hz, H-5), 7.09–7.16 (2H, m, H-16), 7.31–7.40 (3H, m, H-17,18), 10.51 (1H, br s, H-7); δC 
(100 MHz, DMSO-d6) 26.5 (CH2, C-10), 34.5 (CH2, C-11), 59.0 (C, C-9), 84.8 (C, C-13), 
109.0 (CH, C-5), 120.0 (CH, C-3), 126.0 (CH, C-2), 126.7 (2CH, C-16/17), 127.2 (C, C-1), 
127.8 (2CH, C-16/17), 128.1 (CH, C-18), 132.6 (C, C-4/15), 139.0 (C, C-4/15), 144.6 (C, C-
6), 179.3 (C, C-8), 217.3 (C, C-12); HRMS (ESI
+
): Found: 350.0568; C18H14
35
ClNNaO3 
(MNa
+) Requires 350.0554 (−3.8 ppm error). 
Lab notebook reference: MJJ7/71 
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syn-2-Hydroxy-5'-methoxy-2-phenylspiro[cyclopentane-1,3'-indoline]-2',3-dione (212e) 
 
Synthesised using general procedure 3D with α-diazocarbonyl 188e (64 mg, 0.20 mmol), 
Rh2oct4 (3.1 mg, 4.0 µmol) and CHCl3 (4 mL) for 1 h then TFA (46 µL, 0.60 mmol) and THF 
(2 mL) for 4 h. Purification by column chromatography (40% EtOAc in hexane) afforded the 
title compound 212e (45 mg, 70%) as an off-white solid, mp 161–163 °C; vmax (cm
-1
) 3262, 
1739, 1690, 1489, 1205, 700, 615; δH (400 MHz, DMSO-d6) 2.05–2.24 (2H, m, H-11), 2.87 
(1H, ddd, J = 19.5, 9.5, 1.5 Hz, H-12a), 3.03 (1H, ddd, J = 19.5, 10.0, 9.5 Hz, H-12b), 3.34 
(3H, s, H-4), 5.04 (1H, d, J = 2.0 Hz, H-2), 6.22 (1H, br s, H-15), 6.61–6.70 (2H, m, H-5,6), 
7.11–7.18 (2H, m, H-17/18), 7.33–7.41 (3H, m, H-17/18,19), 10.17 (1H, br s, H-8); δC (100 
MHz, DMSO-d6) 27.0 (CH2, C-11), 34.5 (CH2, C-12), 54.9 (CH3, C-4), 59.4 (C, C-10), 84.8 
(C, C-14), 109.2 (CH, C-6), 111.4 (CH, C-2), 113.3 (CH, C-5), 126.8 (2CH, C-17/18), 127.8 
(2CH, C-17/18), 127.9 (CH, C-19), 129.5 (C, C-1), 136.3 (C, C-7/16), 139.3 (C, C-7/16), 
153.6 (C, C-3), 179.3 (C, C-9), 217.6 (C, C-13); HRMS (ESI
+
): Found: 346.1044; 
C19H17NNaO4 (MNa
+
) Requires 346.1050 (1.6 ppm error). 
Lab notebook reference: MJJ7/83 
 
anti-2-Hydroxy-2-(3-methoxyphenyl)spiro[cyclopentane-1,3'-indoline]-2',3-dione (214b) 
 
Synthesised using general procedure 3E with α-diazocarbonyl 188b (48 mg, 0.15 mmol), 
Rh2oct4 (2.3 mg, 3.0 µmol) and CHCl3 (3 mL) for 1 h then t-BuOK (51 mg, 0.45 mmol) and 
THF (1.5 mL) for 2 h. Purification by column chromatography (40% EtOAc in hexane) 
afforded the title compound 214b (21 mg, 54%) as a white solid, mp 208–210 °C; vmax (cm
-1
) 
3348, 3240, 1745, 1685, 1211, 760, 691; δH (400 MHz, DMSO-d6) 2.08–2.18 (1H, m, H-10a), 
2.52–2.63 (1H, m, H-10b), 2.70–2.91 (2H, m, H-11), 3.35 (3H, s, H-20), 6.51 (1H, br s, H-
21), 6.58–6.65 (2H, m, H-5,16), 6.72 (1H, dd, J = 8.0, 2.5 Hz, H-18), 6.85 (1H, s), 6.99–7.06 
(2H, m, H-3,17), 7.17 (1H, dd, J = 7.5, 7.5 Hz, H-4), 7.62 (1H, d, J = 7.5 Hz, H-2), 10.07 (1H, 
br s, H-7); δC (100 MHz, DMSO-d6) 27.7 (CH2, C-10), 33.5 (CH2, C-11), 54.6 (CH3, C-20), 
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60.7 (C, C-9), 80.5 (C, C-13), 108.9 (CH, C-5), 112.9 (CH, C-18), 113.5 (CH, C-21), 120.1 
(CH, C-16), 121.3 (CH, C-3), 126.1 (CH, C-2), 127.7 (CH, C-17), 128.3 (CH, C-4), 128.5 (C, 
C-1), 137.9 (C, C-15), 142.3 (C, C-6), 157.7 (C, C-19), 178.9 (C, C-8), 210.9 (C, C-12); 
HRMS (ESI
+
): Found: 346.1047; C19H17NNaO4 (MNa
+
) Requires 346.1050 (0.9 ppm error), 
Found: 324.1230; C19H18NO4 (MH
+
) Requires 324.1230 (0.2 ppm error). 
Lab notebook reference: MJJ7/44 
 
anti-2-(4-Fluorophenyl)-2-hydroxyspiro[cyclopentane-1,3'-indoline]-2',3-dione (214c) 
 
Synthesised using general procedure 3E with α-diazocarbonyl 188c (61 mg, 0.20 mmol), 
Rh2oct4 (3.1 mg, 4.0 µmol) and CHCl3 (4 mL) for 1 h then t-BuOK (67 mg, 0.60 mmol) and 
THF (2 mL) for 2 h. Purification by column chromatography (35% EtOAc in hexane) 
afforded the title compound 214c (28 mg, 45%) as a white solid, mp 200–202 °C; vmax (cm
-1
) 
3416, 1748, 1698, 1470, 1219, 824, 759, 750, 538, 526; δH (400 MHz, DMSO-d6) 2.09–2.20 
(1H, m, H-10a), 2.53–2.64 (1H, m, H-10b), 2.72–2.91 (2H, m, H-11), 6.61 (1H, d, J = 7.5 Hz, 
H-5), 6.92 (1H, br s, H-14), 6.93–7.06 (5H, m, H-3,16,17), 7.17 (1H, ddd, J = 8.0, 8.0, 1.0 Hz, 
H-4), 7.61 (1H, d, J = 7.5 Hz, H-2), 10.09 (1H, br s, H-7); δC (100 MHz, DMSO-d6) 28.1 
(CH2, C-10), 33.9 (CH2, C-11), 61.2 (C, C-9), 80.8 (C, C-13), 109.4 (CH, C-5), 114.1 (2CH, 
d, J = 21.0 Hz, C-17), 121.9 (CH, C-3), 126.6 (CH, C-2), 128.7 (C, C-1), 129.0 (CH, C-4), 
130.3 (2CH, d, J = 7.5 Hz, C-16), 133.1 (C, d, J = 3.0 Hz, C-15), 142.8 (C, C-6), 162.1 (C, d, 
J = 243 Hz, C-18), 179.4 (C, C-8), 211.6 (C, C-12); δF (376 MHz, DMSO-d6) –114.8–−114.9 
(1F, m); HRMS (ESI
+
): Found: 334.0838; C18H14FNNaO3 (MNa
+
) Requires 334.0850 (3.7 
ppm error). 
Lab notebook reference: MJJ7/62 
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anti-6'-Chloro-2-hydroxy-2-phenylspiro[cyclopentane-1,3'-indoline]-2',3-dione (214d) 
 
Synthesised using general procedure 3E with α-diazocarbonyl 188d (49 mg, 0.15 mmol), 
Rh2oct4 (2.3 mg, 3.0 µmol) and CHCl3 (4.5 mL) for 5 h then t-BuOK (51 mg, 0.45 mmol) and 
THF (1.5 mL) for 2 h. Purification by column chromatography (35% EtOAc in hexane) 
afforded the title compound 214d (36 mg, 73%) as a white solid, mp 168–170 °C; vmax (cm
-1
) 
3237, 1737, 1698, 1617, 749, 694; δH (400 MHz, CDCl3) 2.29 (1H, ddd, J = 13.0, 9.5, 1.5 Hz, 
H-10a), 2.69 (1H, ddd, J = 13.0, 10.5, 9.5 Hz, H-10b), 2.79 (1H, s, H-14), 2.87 (1H, ddd, J = 
19.5, 9.5, 1.5 Hz, H-11a), 3.20 (1H, ddd, J = 19.5, 10.5, 9.5 Hz, H-11b), 6.66 (1H, d, J = 2.0 
Hz, H-5), 6.97 (1H, br s, H-7), 7.03–7.08 (2H, m, H-16) 7.12 (1H, dd, J = 8.0, 2.0 Hz, H-3), 
7.13–7.19 (2H, m, H-17), 7.19–7.23 (1H, m, H-18), 7.65 (1H, d, J = 8.0 Hz, C-2); δC (100 
MHz, CDCl3) 28.3 (CH2, C-10), 34.2 (CH2, C-11), 60.8 (C, C-9), 81.3 (C, C-13), 109.9 (CH, 
C-5), 122.6  (CH, C-3), 126.1 (C, C-1), 127.4 (2CH, C-16), 127.6 (2CH, C-17), 127.7  (CH, 
C-2), 128.5  (CH, C-18), 134.4 (C, C-4/15), 134.9 (C, C-4/15), 141.8 (C, C-6), 179.0 (C, C-8), 
212.4 (C, C-12); HRMS (ESI
+
): Found: 350.0561; C18H14
35
ClNNaO3 (MNa
+
) Requires 
350.0554 (−1.9 ppm error). 
Lab notebook reference: MJJ7/79 
 
anti-2-Hydroxy-5'-methoxy-2-phenylspiro[cyclopentane-1,3'-indoline]-2',3-dione (214e) 
 
Synthesised using general procedure 3E with α-diazocarbonyl 188e (64 mg, 0.20 mmol), 
Rh2oct4 (3.1 mg, 4.0 µmol) and CHCl3 (4 mL) for 1 h then t-BuOK (67 mg, 0.60 mmol) and 
THF (2 mL) for 2 h. Purification by column chromatography (50% EtOAc in hexane) 
afforded the title compound 214e (26 mg, 40%) as an off-white solid, mp 194–196 °C; vmax 
(cm
-1
) 3221, 1742, 1684, 1491, 1201, 1032, 751, 696; δH (400 MHz, DMSO-d6) 2.07–2.17 
(1H, m, H-11a), 2.51–2.62 (1H, m, H-11b), 2.69–2.90 (2H, m, H-12), 3.74 (3H, s, H-4), 6.50 
(1H, d, J = 8.0 Hz, H-6), 6.73 (1H, dd, J = 8.0, 3.0 Hz, H-5), 6.82 (1H, s, H-15), 7.00–7.06 
(2H, m, H-17), 7.09–7.18 (3H, m, H-18,19), 7.23 (1H, d, J = 3.0 Hz, H-2), 9.89 (1H, br s, H-
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8); δC (100 MHz, DMSO-d6) 28.0 (CH2, C-11), 33.5 (CH2, C-12), 55.4 (CH3, C-4), 61.1 (C, 
C-10), 80.6 (C, C-14), 109.0 (CH, C-6), 112.7 (CH, C-5), 113.2 (CH, C-2), 126.7 (2CH, C-
18), 127.4 (CH, C-19), 127.8 (2CH, C-17), 129.8 (C, C-1), 135.6 (C, C-7/16), 136.4 (C, C-
7/16), 154.5 (C, C-3), 178.7 (C, C-9), 211.0 (C, C-13); HRMS (ESI
+
): Found: 346.1046; 
C19H17NNaO4 (MNa
+
) Requires 346.1050 (1.0 ppm error). 
Lab notebook reference: MJJ7/84 
 
1-(3-Methoxyphenyl)-3,4-dihydro-1H-carbazol-2(9H)-one (199b) 
 
Synthesised using general procedure 3F with α-diazocarbonyl 188b (48 mg, 0.15 mmol), 
Pd(MeCN)4(BF4)2 (3.3 mg, 7.5 µmol) and CHCl3 (1.5 mL). Purification by column 
chromatography (30% EtOAc in hexane) afforded the title compound 199b (33 mg, 76%) as a 
white solid, mp 143–145 °C; vmax (cm
-1
) 3389, 1709, 1462, 1454, 1260, 1236, 737; δH (400 
MHz, CDCl3) 2.63–2.76 (1H, m, H-11a), 2.87–3.00 (1H, m, H-11b), 3.08–3.20 (1H, m, H-
10a), 3.24–3.37 (1H, m, H-10b), 3.76 (3H, s, H-17), 4.79 (1H, s, H-13), 6.74–6.88 (3H, m, H-
5,15,18), 7.13–7.34 (4H, m, H-3,4,19,20), 7.59 (1H, d, J = 7.5 Hz, H-2), 7.72 (1H, br s, H-7); 
δC (100 MHz, CDCl3) 20.2 (CH2, C-10), 36.7 (CH2, C-11), 55.0 (CH, C-13), 55.2 (CH3, C-
17), 111.0 (CH, C-20), 111.3 (C, C-9), 113.0 (CH, C-5), 114.4 (CH, C-15), 118.3 (CH, C-2), 
119.7 (CH, C-3), 120.8 (CH, C-18), 122.3 (CH, C-4/19), 126.3 (C, C-1), 129.9 (CH, C-4/19), 
132.2 (C, C-8), 136.9 (C, C-6/14), 138.8 (C, C-6/14), 160.0 (C, C-16), 207.6 (C, C-12); 
HRMS (ESI
+
): Found: 314.1144; C19H17NNaO2 (MNa
+
) Requires 314.1151 (2.4 ppm error), 
Found: 292.1325; C19H18NO2 (MH
+
) Requires 292.1332 (2.5 ppm error). 
Lab notebook reference: MJJ7/39 
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1-(4-Fluorophenyl)-3,4-dihydro-1H-carbazol-2(9H)-one (199c) 
 
Synthesised using general procedure 3F with α-diazocarbonyl 188c (61 mg, 0.20 mmol), 
Pd(MeCN)4(BF4)2 (4.4 mg, 10 µmol) and CHCl3 (2 mL). Purification by column 
chromatography (35% EtOAc in hexane) afforded the title compound 199c (39 mg, 70%) as a 
white solid, mp 172–174 °C; vmax (cm
-1
) 3394, 1714, 1505, 1224, 741; δH (400 MHz, CDCl3) 
2.73 (1H, ddd, J = 13.5, 6.0, 6.0 Hz, H-11a), 2.89 (1H, ddd, J = 13.5, 8.0, 8.0 Hz, H-11b), 
3.11–3.22 (1H, m, H-10a), 3.24–3.35 (1H, m, H-10b), 4.83 (1H, s, H-13), 6.99–7.07 (2H, m, 
H-16), 7.14–7.26 (4H, m, H-3,4,15), 7.31 (1H, d, J = 8.0 Hz, H-5), 7.59 (1H, d, J = 8.0 Hz, H-
2), 7.62 (1H, br s, H-7); δC (100 MHz, CDCl3) 20.2 (CH2, C-10), 36.7 (CH2, C-11), 54.1 (CH, 
C-13), 111.1 (C, C-9), 111.5 (CH, C-5), 115.8 (2CH, d, J = 22.0 Hz, C-16), 118.4 (CH, C-3), 
119.9 (CH, C-2), 122.5 (CH, C-4), 126.3 (C, C-1), 130.1 (2CH, d, J = 7.5 Hz, C-15), 132.0 
(C, C-8), 133.0 (C, d, J = 3.0 Hz, C-14), 136.9 (C, C-6), 162.4 (C, d, J = 246 Hz, C-17), 207.5 
(C, C-12); δF (376 MHz, CDCl3) −114.2–−114.3 (1F, m); HRMS (ESI
+
): Found: 280.1142; 
C18H15FNO (MH
+
) Requires 280.1132 (−3.4 ppm error). 
Lab notebook reference: MJJ7/58 
 
7-Chloro-1-phenyl-3,4-dihydro-1H-carbazol-2(9H)-one (199d) 
 
Synthesised using general procedure 3F with α-diazocarbonyl 188d (65 mg, 0.20 mmol), 
Pd(MeCN)4(BF4)2 (4.4 mg, 10 µmol) and CHCl3 (2 mL). Purification by column 
chromatography (20% EtOAc in hexane) afforded the title compound 199d (38 mg, 64%) as a 
white solid, mp 222–224 °C; vmax (cm
-1
) 3353, 1712, 1465, 1453, 909, 735, 705; δH (400 MHz, 
CDCl3) 2.65–2.74 (1H, m, H-11a), 2.85–2.95 (1H, m, H-11b), 3.07–3.17 (1H, m, H-10a), 
3.22–3.32 (1H, m, H-10b), 4.81 (1H, s, H-13), 7.14 (1H, d, J = 8.5, 1.5 Hz, H-3), 7.17–7.22 
(2H, m, H-15), 7.23–7.28 (1H, m, H-5), 7.29–7.38 (3H, m, H-16,17), 7.48 (1H, d, J = 8.5 Hz, 
H-2), 7.66 (1H, br s, H-7); δC (100 MHz, CDCl3) 20.1 (CH2, C-10), 36.6 (CH2, C-11), 54.9 
(CH, C-13), 111.0 (CH, C-5), 111.5 (C, C-9), 119.2 (CH, C-2), 120.5 (CH, C-3), 125.0 (C, C-
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1), 128.0 (CH, C-17), 128.3 (C, C-8), 128.5 (2CH, C-15), 129.0 (2CH, C-16), 133.1 (C, C-
4/6/14), 137.0 (C, C-4/6/14), 137.2 (C, C-4/6/14), 207.2 (C, C-12); HRMS (ESI
+
): Found: 
318.0653; C18H14
35
ClNNaO (MNa
+
) Requires 318.0656 (0.9 ppm error), Found: 296.0843; 
C18H15
35
ClNO (MH
+
) Requires 296.0837 (−2.2 ppm error). 
Lab notebook reference: MJJ7/68 
 
6-Methoxy-1-phenyl-3,4-dihydro-1H-carbazol-2(9H)-one (199e) 
 
Synthesised using general procedure 3F with α-diazocarbonyl 188e (64 mg, 0.20 mmol), 
Pd(MeCN)4(BF4)2 (4.4 mg, 10 µmol) and CHCl3 (2 mL). Purification by column 
chromatography (30% EtOAc in hexane) afforded the title compound 199e (30 mg, 59%) as a 
white solid, mp 153–155 °C; vmax (cm
-1
) 3395, 1714, 1485, 1456, 1217; δH (400 MHz, CDCl3) 
2.65–2.75 (1H, m, H-12a), 2.85–2.97 (1H, m, H-12b), 3.06–3.17 (1H, m, H-11a), 3.21–3.32 
(1H, m, H-11b), 3.90 (3H, s, H-4), 4.82 (1H, s, H-14), 6.87 (1H, dd, J = 8.5, 2.5 Hz, H-5), 
7.04 (1H, d, J = 2.5 Hz, H-2), 7.15–7.23 (3H, m, H-6,16), 7.29–7.36 (3H, m, H-17,18), 7.57 
(1H, br s, H-8); δC (100 MHz, CDCl3) 20.3 (CH2, C-11), 36.8 (CH2, C-12), 55.2 (CH, C-14), 
56.0 (CH3, C-4), 100.5 (CH, C-2), 111.2 (C, C-10), 111.8 (CH, C-6), 112.2 (CH, C-5), 126.8 
(C, C-1), 127.8 (CH, C-18), 128.5 (2CH, C-16), 128.9 (2CH, C-17), 131.9 (C, C-7/9/15), 
133.2 (C, C-7/9/15), 137.3 (C, C-7/9/15), 154.3 (C, C-3), 207.7 (C, C-13); HRMS (ESI
+
): 
Found: 314.1147; C19H17NNaO2 (MNa
+
) Requires 314.1151 (1.3 ppm error). 
Lab notebook reference: MJJ7/81 
 
1-(3-Methoxyphenyl)-9H-carbazol-2-ol (200b) 
 
Synthesised using general procedure 3G with α-diazocarbonyl 188b (48 mg, 0.15 mmol), 
Cu(OTf)2 (10.9 mg, 30 µmol) and CHCl3 (3 mL). Purification by column chromatography 
(20→30% EtOAc in hexane) afforded the title compound 200b (31 mg, 71%) as an off-white 
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solid, mp 146–148 °C; vmax (cm
-1
) 3409, 1604, 1460, 1413, 1219, 1178, 1166, 737; δH (400 
MHz, CDCl3) 3.88 (3H, s, H-18), 5.29 (1H, br s, H-13), 6.95 (1H, d, J = 8.5 Hz, H-11), 7.06 
(1H, dd, J = 8.5, 2.5 Hz, H-19), 7.12–7.16 (1H, m, H-16), 7.18 (1H, d, J = 7.5 Hz, H-21), 7.23 
(1H, ddd, J = 7.5, 6.0, 2.5 Hz, H-3), 7.29–7.37 (2H, m, H-4,5), 7.55 (1H, dd, J = 8.0, 7.5 Hz, 
H-20), 7.91–7.98 (2H, m, H-7,10), 8.02 (1H, d, J = 8.0 Hz, H-2); δC (100 MHz, CDCl3) 55.4 
(CH3, C-18), 108.7 (CH, C-11), 110.2 (C, C-1/9), 110.4 (CH, C-5), 114.2 (CH, C-19), 115.3 
(CH, C-16), 117.1 (C, C-1/9), 119.5 (CH, C-2/3), 119.6 (CH, C-2/3), 120.7 (CH, C-10), 122.0 
(CH, C-21), 123.8 (C, C-14), 124.6 (CH, C-4), 131.3 (CH, C-20), 134.3 (C, C-6/8/15), 138.8 
(C, C-6/8/15), 139.3 (C, C-6/8/15), 151.0 (C, C-12), 160.9 (C, C-17); HRMS (ESI
+
): Found: 
312.0983; C19H15NNaO2 (MNa
+
) Requires 312.0995 (3.7 ppm error), Found: 290.1164; 
C19H16NO2 (MH
+
) Requires 290.1176 (3.9 ppm error). 
Lab notebook reference: MJJ7/40 
 
1-(4-Fluorophenyl)-9H-carbazol-2-ol (200c) 
 
Synthesised using general procedure 3G with α-diazocarbonyl 188c (61 mg, 0.20 mmol), 
Cu(OTf)2 (14.5 mg, 40 µmol) and CHCl3 (4 mL). Purification by column chromatography 
(30→40% EtOAc in hexane) afforded the title compound 200c (43 mg, 78%) as a brown 
solid, mp 122–124 °C; vmax (cm
-1
) 3457, 1603, 1459, 1222, 1157, 840, 737; δH (400 MHz, 
CDCl3) 5.02 (1H, br s, H-13), 6.93 (1H, d, J = 8.5 Hz, H-11), 7.20–7.25 (1H, m, H-3), 7.30–
7.37 (4H, m, H-4,5,17), 7.56–7.62 (2H, m, H-16), 7.80 (1H, br s, H-7), 7.94 (1H, d,  J = 8.5 
Hz, H-10), 8.01 (1H, d,  J = 8.0 Hz, H-2); δC (100 MHz, CDCl3) 108.8 (CH, C-11), 109.5 (C, 
C-9), 110.4 (CH, C-5), 116.9 (2CH, d, J = 22.0 Hz, C-17), 117.2 (C, C-1), 119.5 (CH, C-
3/10), 119.7 (CH, C-3/10), 120.7 (CH, C-7), 123.8 (C, C-14), 124.7 (CH, C-4), 128.9 (C, d, J 
= 4.0 Hz, C-15), 131.9 (2CH, d, J = 8.5 Hz, C-16), 139.1 (C, C-6/8), 139.4 (C, C-6/8), 151.1 
(C, C-12), 162.6 (C, d, J = 248 Hz, C-18); δF (376 MHz, CDCl3) −112.5–−112.6 (1F, m); 
HRMS (ESI
+
): Found: 300.0810; C18H12FNNaO (MNa
+
) Requires 300.0795 (−4.9 ppm error), 
Found: 278.0971; C18H13FNO (MH
+
) Requires 278.0976 (1.6 ppm error). 
Lab notebook reference: MJJ7/60 
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7-Chloro-1-phenyl-9H-carbazol-2-ol (200d) 
 
Synthesised using general procedure 3G with α-diazocarbonyl 188d (65 mg, 0.20 mmol), 
Cu(OTf)2 (14.5 mg, 40 µmol) and CHCl3 (4 mL). Purification by column chromatography 
(20% EtOAc in hexane) afforded the title compound 200d (37 mg, 63%) as a pale yellow 
solid, mp 157–159 °C; vmax (cm
-1
) 3522, 3435, 1613, 1601, 1453, 1441, 1166, 911, 798, 734; 
δH (400 MHz, CDCl3) 5.19 (1H, br s, H-13), 6.96 (1H, d, J = 8.5 Hz, H-11), 7.19 (1H, dd, J = 
8.0, 2.0 Hz, H-3), 7.29 (1H, d, J = 2.0 Hz, H-5), 7.50–7.69 (5H, m, H-16,17,18), 7.86 (1H, br 
s, H-7), 7.87–7.92 (2H, m, H-2,10); δC (100 MHz, CDCl3) 109.3 (CH, C-11), 110.5 (CH, C-
5), 110.6 (C, C-9), 116.5 (C, C-1), 120.2 (CH, C-3), 120.3 (CH, C-2/10), 120.6 (CH, C-2/10), 
122.5 (C, C-14), 128.8 (CH, C-18), 130.0 (2CH, C-16), 130.15 (C, C-4/6/8/15), 130.19 (2CH, 
C-17), 132.6 (C, C-4/6/8/15), 139.2 (C, C-4/6/8/15), 139.8 (C, C-4/6/8/15), 151.3 (C, C-12); 
HRMS (ESI
+
): Found: 316.0499; C18H12
35
ClNNaO (MNa
+
) Requires 316.0500 (0.3 ppm 
error), Found: 294.0681; C18H13
35
ClNO (MH
+
) Requires 294.0680 (−0.2 ppm error). 
Lab notebook reference: MJJ7/69 
 
6-Methoxy-1-phenyl-9H-carbazol-2-ol (200e) 
 
Synthesised using general procedure 3G with α-diazocarbonyl 188e (64 mg, 0.20 mmol), 
Cu(OTf)2 (14.5 mg, 40 µmol) and CHCl3 (4 mL). Purification by column chromatography 
(30% EtOAc in hexane) afforded the title compound 200e (20 mg, 35%) as a brown oil; vmax 
(cm
-1
) 3415, 1612, 1483, 1288, 1165; δH (400 MHz, CDCl3) 3.93 (3H, s, H-4), 5.20 (1H, br s, 
H-14), 6.92 (1H, d, J = 8.5 Hz, H-12), 6.97 (1H, dd, J = 8.5, 2.5 Hz, H-5), 7.21 (1H, d, J = 8.5 
Hz, H-6), 7.48–7.55 (2H, m, H-2,19), 7.57–7.66 (4H, m, H-17,18), 7.74 (1H, br s, H-8), 7.89 
(1H, d, J = 8.5 Hz, H-11); δC (100 MHz, CDCl3) 56.0 (CH3, C-4), 102.7 (CH, C-2), 108.5 
(CH, C-12), 110.4 (C, C-9), 111.0 (CH, C-6), 113.4 (CH, C-5), 117.2 (C, C-1), 120.6 (CH, C-
11), 124.3 (C, C-15), 128.6 (CH, C-19), 130.0 (2CH, C-17/18), 130.1 (2CH, C-17/18), 133.0 
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(C, C-7/9/16), 134.2 (C, C-7/9/16), 139.8 (C, C-7/9/16), 151.0 (C, C-13), 154.0 (C, C-3); 
HRMS (ESI
+
): Found: 312.0994; C19H15NNaO2 (MNa
+
) Requires 312.0995 (0.2 ppm error). 
Lab notebook reference: MJJ7/82 
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5.5 Experimental for Chapter 4 
Methyl 3-(4-fluorophenyl)propiolate (269a) 
 
To a solution of 1-ethynyl-4-fluorobenzene (533 mg, 4.44 mmol) in THF (44 mL) at −78 °C 
was added n-BuLi (1.95 mL, 4.88 mmol, 2.5 M in hexanes) dropwise. The mixture was stirred 
at −78 °C for 30 min before methyl chloroformate (0.38 mL, 4.88 mmol) was added dropwise. 
The mixture was stirred at −78 °C for a further 2 h before being quenched by the careful 
addition of sat. NH4Cl(aq) (10 mL) and diluted with Et2O (20 mL). The organics were 
separated and the aqueous extracted with Et2O (3 × 30 mL). The organics were combined, 
washed with brine, dried (MgSO4), concentrated in vacuo and purified by column 
chromatography  (0 → 5% Et2O in hexane) to afford the title compound 269a (494 mg, 62%) 
as a white solid, mp 57–59 °C (lit.156 57–59 °C); vmax (cm
-1
) 2224, 1708, 1304, 1203, 833; δH 
(400 MHz, CDCl3) 3.85 (3H, s), 7.08 (2H, dd, J = 8.5, 8.0 Hz), 7.59 (2H, dd, J = 8.5, 5.5 Hz); 
δC (100 MHz, CDCl3) 52.8 (CH3), 80.2 (C), 85.4 (C), 115.6 (C, d, J = 4.0 Hz), 116.1 (2CH, d, 
J = 22.0 Hz), 135.3 (2CH, d, J = 8.5 Hz), 154.4 (C), 163.9 (C, d, J = 254.0 Hz); δF (376 MHz, 
CDCl3) −106.1–−106.2 (1F, m).  
Lab notebook reference: MJJ8/55 
Spectroscopic data matched those reported in the literature.
157
 
 
Methyl 3-(thiophen-2-yl)propiolate (269b) 
 
To a solution of 2-ethynylthiophene (0.5 mL, 4.99 mmol) in THF (50 mL) at −78 °C was 
added n-BuLi (2.20 mL, 5.49 mmol, 2.5 M in hexanes) dropwise. The mixture was stirred at 
−78 °C for 30 min before methyl chloroformate (0.42 mL, 5.49 mmol) was added dropwise. 
The mixture was stirred at −78 °C for a further 2 h before being quenched by the careful 
addition of sat. NH4Cl(aq) (10 mL) and diluted with EtOAc (20 mL). The organics were 
separated and the aqueous extracted with EtOAc (3 × 30 mL). The organics were combined, 
washed with brine, dried (MgSO4), concentrated in vacuo and purified by column 
chromatography  (5 → 10% EtOAc in hexane) to afford the title compound 269b (357 mg, 
43%) as a yellow solid, mp 49–51 °C (lit.156 54–55 °C); vmax (cm
-1
) 2207, 1709, 1269, 1221, 
1160; δH (400 MHz, CDCl3) 3.85 (3H, s), 7.07 (1H, dd, J = 5.0, 3.5 Hz), 7.48 (1H, dd, J = 5.0 
Hz), 7.50 (1H, dd, J = 3.5 Hz); δC (100 MHz, CDCl3) 52.8 (CH3), 80.5 (C), 84.6 (C), 119.3 
(C), 127.5 (CH), 131.2 (CH), 136.6 (CH), 154.3 (C). 
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Lab notebook reference: MJJ8/57 
Spectroscopic data matched those reported in the literature.
156
 
 
Methyl 3-(trimethylsilyl)propiolate (269c) 
 
To a solution of ethynyltrimethylsilane (0.5 mL, 3.62 mmol) in THF (36 mL) at −78 °C was 
added n-BuLi (1.59 mL, 3.98 mmol, 2.5 M in hexanes) dropwise. The mixture was stirred at 
−78 °C for 30 min before methyl chloroformate (0.31 mL, 3.98 mmol) was added dropwise. 
The mixture was stirred at −78 °C for a further 2 h before being quenched by the careful 
addition of sat. NH4Cl(aq) (10 mL) and diluted with EtOAc (20 mL). The organics were 
separated and the aqueous extracted with EtOAc (3 × 30 mL). The organics were combined, 
washed with brine, dried (MgSO4), concentrated in vacuo and purified by column 
chromatography  (0 → 5% EtOAc in hexane) to afford the title compound 269c (271 mg, 
48%) as a colourless oil; δH (400 MHz, CDCl3) 0.25 (9H, s), 3.78 (3H, s); δC (100 MHz, 
CDCl3) −0.9 (3CH3), 52.7 (CH3), 94.3 (C), 99.9 (C), 192.2 (C). 
Lab notebook reference: MJJ8/58 
Spectroscopic data matched those reported in the literature.
158
 
 
4-(2,2-dibromovinyl)-1,2-dimethoxybenzene (271) 
 
To a suspension of CBr4 (20.0 g, 60.2 mmol) in CH2Cl2 (100 mL) at 0 °C was added PPh3 
(31.6 g, 120.4 mmol) portionwise and the mixture was stirred at 0 °C for 30 min. 3,4-
dimethoxybenzaldehyde (10 g, 60.2 mmol) was then added and the reaction mixture was 
stirred at 0 °C for 1 h. The reaction mixture was poured into a 1:1 mixture of brine:water (100 
mL) and the organics were separated. The aqueous was further extracted with a 1:1 mixture of 
CH2Cl2:hexane (2 × 100 mL) and the organics were combined, dried (MgSO4) and 
concentrated in vacuo. The crude material was purified by column chromatography (hexane 
then 15% EtOAc in hexane) to afford the title compound 271 (15.3 g, 79%) as a yellow oil; δH 
(400 MHz, CDCl3) 3.88 (6H, s), 6.85 (1H, d, J = 8.0 Hz), 7.09 (1H, d, J = 8.0 Hz), 7.18 (1H, 
s), 7.40 (1H, s); δC (100 MHz, CDCl3) 55.9, 87.4, 110.7, 111.0, 121.9, 127.9, 136.4, 148.5, 
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149.3; HRMS (ESI
+
): Found: 342.8933; C10H10
79
Br2NNaO (MNa
+
) Requires 342.8940 (2.1 
ppm error). 
Lab notebook reference: MJJ5/49 
Spectroscopic data matched those reported in the literature.
125
 
 
Methyl 3-(3,4-dimethoxyphenyl)propiolate (269d) 
 
To a solution of dibromide 271 (15.3 g, 47.5 mmol) in THF (190 mL) at −78 °C was added n-
BuLi (62 mL, 99.8 mmol, 2.5 M in hexanes) dropwise and the mixture was stirred at −78 °C 
for 45 min then at 0 °C for 45 min. The mixture was then recooled to −78 °C and 
methylchloroformate (3.67 mL, 97.5 mmol) was added dropwise. The mixture was stirred at 0 
°C for 2h then quenched with sat. NH4Cl(aq) (100 mL) and the organics were separated. The 
aqueous was further extracted with Et2O (2 × 100 mL) and the organics were combined, dried 
(MgSO4) and concentrated in vacuo. The crude material was purified by successive 
recystallisations (EtOAc:hexane, washing with cold hexane and Et2O) to afford the title 
compound 269d (5.22 g, 50% after 2 crops) as a brown solid, mp 81–83 °C (lit.125 76–77 °C); 
vmax (cm
-1
) 2211, 1708, 1515, 1252, 1232, 1157, 1137, 1023; δH (400 MHz, CDCl3) 3.84 (3H, 
s), 3.89 (3H, s), 3.92 (3H, s), 6.85 (1H, d, J = 8.5 Hz), 7.08 (1H, d, J = 2.0 Hz), 7.24 (1H, dd, 
J = 8.5, 2.0 Hz); δC (100 MHz, CDCl3) 52.7, 56.0, 79.6, 87.5, 111.0, 111.3, 115.3, 127.3, 
148.8, 151.5, 154.7 
Lab notebook reference: MJJ5/50 
Spectroscopic data matched those reported in the literature.
125
 
 
4-Phenyl-1-(pyridin-2-yl)but-3-yn-2-one (228a) 
 
Synthesised using general procedure 4A with DIPA (0.60 mL, 4.26 mmol), n-BuLi (1.70 
mL, 4.26 mmol, 2.5 M in hexanes), 2-methylpyridine (0.20 mL, 2.03 mmol), methyl 
phenylpropiolate (0.31 mL, 2.13 mmol) and THF (30 mL). Purification by column 
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chromatography (10% EtOAc in hexane) afforded the title compound 228a (316 mg, 70%, 
85:15 enol:keto) as a yellow solid, mp 71–73 °C; vmax (cm
-1
) 1741, 1694, 1491, 1388, 1366, 
1160; δH (400 MHz, CDCl3) 4.19 (2H, s, H-6, keto), 5.90 (1H, s, H-6, enol), 6.97–7.06 (2H, 
m, H-2,4 enol), 7.24 (1H, dd, J = 7.5, 5.0 Hz, H-2 keto), 7.31–7.40 (6H, m, H-4,13,14, enol + 
keto), 7.41–7.50 (3H, m, H-12,14, keto), 7.51–7.59 (2H, m, H-12, enol), 7.64 (1H, ddd, J = 
8.0, 8.0, 2.0 Hz, H-3, enol), 7.71 (1H, ddd, J = 8.0, 8.0, 2.0 Hz, H-3, keto), 8.28 (1H, br d, J = 
5.0 Hz, H-1, enol), 8.64 (1H, br d, J = 4.5 Hz, H-1, keto), 15.02 (1H, br s, H-8, enol); 
13
C 
NMR data of enol tautomer δC (100 MHz, CDCl3) 86.4 (C, C-9), 89.6 (C, C-10), 103.7 (CH, 
C-6), 119.1 (CH, C-2/4), 121.4 (CH, C-2/4), 122.0 (C, C-11), 128.3 (2CH, C-13), 128.9 (CH, 
C-14), 131.9 (2CH, C-12), 137.4 (CH, C-3), 144.0 (CH, C-1), 149.5 (C, C-5), 157.6 (C, C-7); 
Characteristic 
13
C NMR data of keto tautomer δC (100 MHz, CDCl3) 54.3 (CH2, C-6); HRMS 
(ESI
+
): Found: 222.0915; C15H12NO (MH
+
) Requires 222.0913 (−0.7 ppm error). 
Lab notebook reference: MJJ8/50 
 
4-(3,4-Dimethoxyphenyl)-1-(pyridin-2-yl)but-3-yn-2-one (228b) 
 
Synthesised using general procedure 4A with DIPA (2.94 mL, 21.0 mmol), n-BuLi (8.4 mL, 
21.0 mmol, 2.5 M in hexanes), 2-methylpyridine (0.99 mL, 10.0 mmol) in THF (100 mL) and 
a solution of ester 269d (2.31 g, 10.5 mmol) in THF (50 mL). Purification by column 
chromatography (40% EtOAc in hexane) afforded the title compound 228b (2.11 g, 75%, 
77:23 enol:keto) as a yellow solid, mp 78–80 °C; vmax (cm
-1
) 2200, 1595, 113, 1252, 1023, 
808; δH (400 MHz, CDCl3) 3.87 (3H, s, H-14/16, keto), 3.89 (3H, s, H-14/16, enol), 3.91 (6H, 
s, H-14/16, enol + keto), 4.17 (2H, s, H-6, keto), 5.87 (1H, s, H-6, enol), 6.80 (1H, d, J = 8.5 
Hz, H-17, keto), 6.81 (1H, d, J = 8.5 Hz, H-17, enol), 6.95 (1H, d, J = 1.5 Hz, H-12, keto), 
6.97–7.04 (2H, m, H-2,4, enol), 7.06 (1H, d, J = 1.5 Hz, H-12, enol), 7.12 (1H, dd, J = 8.5, 1.5 
Hz, H-18, keto), 7.16 (1H, dd, J = 8.5, 1.5 Hz, H-18, enol) 7.24 (1H, d, J = 7.0, 5.5 Hz, H-2, 
keto), 7.33 (1H, d, J = 8.0 Hz, H-4, keto), 7.62 (1H, dd, J = 8.0, 7.5 Hz, H-3, enol), 7.71 (1H, 
dd, J = 7.5, 7.5 Hz, H-3, keto), 8.24–8.30 (1H, m, H-1, enol), 8.61–8.65 (1H, m, H-1, keto), 
15.03 (1H, br s, H-8, enol); 
13C NMR data of enol tautomer δC (100 MHz, CDCl3) 55.86 (CH3, 
C-14/16), 55.89 (CH3, C-14/16), 85.2 (C, C-9), 90.0 (C, C-10), 103.2 (CH, C-6), 110.9 (CH, 
C-17), 114.0 (C, C-11), 114.5 (CH, C-12), 118.9 (CH, C-2/4), 121.3 (CH, C-2/4), 125.5 (CH, 
C-18), 137.4 (CH, C-3), 143.9 (CH, C-1), 148.6 (C, C-5) 149.8 (C, C-13/15), 150.0 (C, C-
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13/15), 157.7 (C, C-7); Characteristic 
13C NMR data of keto tautomer δC (100 MHz, CDCl3) 
54.2 (CH2, C-6); HRMS (ESI
+
): Found: 304.0944; C17H15NNaO3 (MNa
+
) Requires 304.0944 
(−0.1 ppm error), Found: 282.1128; C17H16NO3 (MH
+
) Requires 282.1125 (−1.2 ppm error). 
Lab notebook reference: MJJ5/51 
 
4-(4-Fluorophenyl)-1-(pyridin-2-yl)but-3-yn-2-one (228c) 
 
Synthesised using general procedure 4A with DIPA (0.30 mL, 2.12 mmol), n-BuLi (0.85 
mL, 2.12 mmol, 2.5 M in hexanes), 2-methylpyridine (0.1 mL, 1.01 mmol) in THF (10 mL) 
and a solution of methyl ester 269a (189 mg, 1.06 mmol) in THF (5 mL). Purification by 
column chromatography (20% EtOAc in hexane) afforded the title compound 228c (209 mg, 
86%, 81:19 enol:keto) as a yellow solid, mp 74–76 °C; vmax (cm
-1
) 1620, 1597, 1507, 1374, 
1224, 834, 801; δH (400 MHz, CDCl3) 4.17 (2H, s, H-6, keto), 5.87 (1H, s, H-6, enol), 6.96–
7.12 (6H, m, H-2,4,13 enol + keto), 7.24 (1H, dd, J = 8.0, 5.0 Hz, H-2, keto), 7.32 (1H, d, J = 
8.0 Hz, H-4, keto), 7.44–7.50 (2H, m, H-12, keto), 7.50–7.57 (2H, m, H-12, enol), 7.63 (1H, 
ddd, J = 8.0, 8.0, 1.5 Hz, H-3, enol), 7.71 (1H, ddd, J = 8.0, 8.0, 1.5 Hz, H-3, keto), 8.27 (1H, 
d, J = 5.0 Hz, H-1, enol), 8.62 (1H, d, J = 4.5 Hz, H-1, keto), 15.04 (1H, br s, H-8, enol); 
13
C 
NMR data of enol tautomer δC (100 MHz, CDCl3) 86.1 (C, C-9), 88.5 (C, C-10), 103.6 (CH, 
C-6), 115.7 (2CH, d, J = 22.0 Hz, C-13), 118.1 (C, d, J = 4.0 Hz, C-11), 119.1 (CH, C-2/4), 
121.4 (CH, C-2/4), 133.9 (2CH, d, J = 7.5 Hz, C-12), 137.5 (CH, C-3), 144.0 (CH, C-1), 
149.5 (C, C-5), 157.5 (C, C-7), 162.9 (C, d, J = 250.0 Hz, C-14); Characteristic 
13
C NMR data 
of keto tautomer δC (100 MHz, CDCl3) 54.3 (CH2, C-6); δF (376 MHz, CDCl3) −105.7–−105.8 
(1F, m, keto), −109.4–−109.5 (1F, m, enol); HRMS (ESI+): Found: 240.0810; C15H11FNO 
(MH
+
) Requires 240.0819 (4.0 ppm error). 
Lab notebook reference: MJJ8/56 
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1-(Pyridin-2-yl)non-3-yn-2-one (228d) 
 
Synthesised using general procedure 4A with DIPA (0.30 mL, 2.12 mmol), n-BuLi (0.85 
mL, 2.12 mmol, 2.5 M in hexanes), 2-methylpyridine (0.1 mL, 1.01 mmol) in THF (15 mL) 
and methyl 2-octynoate (0.18 mL, 1.06 mmol). Purification by column chromatography (20% 
EtOAc in hexane) afforded the title compound 228d (154 mg, 71%, 67:37 enol:keto) as a 
yellow oil; vmax (cm
-1
) 2930, 2228, 1618, 1594, 1550, 1470, 1361, 1151, 805, 739; δH (400 
MHz, CDCl3) 0.89 (3H, t, J = 7.5 Hz, H-15, keto), 0.92 (3H, t, J = 7.5 Hz, H-15, enol), 1.24–
1.68 (12H, m, H-12,13,14, enol + keto), 2.31 (2H, t, J = 7.0 Hz, H-11, keto), 2.39 (2H, t, J = 
7.0 Hz, H-11, enol), 4.06 (2H, s, H-6, keto), 5.71 (1H, s, H-6, enol), 6.92–7.01 (2H, m, H-2,4, 
enol), 7.22 (1H, dd, J = 7.5, 5.5 Hz, H-2, keto), 7.24–7.28 (1H, m, H-4, keto), 7.60 (1H, ddd, J 
= 8.0, 8.0, 1.5 Hz, H-3, enol), 7.68 (1H, ddd, J = 8.0, 8.0, 1.5 Hz, H-3, keto), 8.25 (1H, br d, J 
= 5.5 Hz, H-1, enol), 8.59 (1H, br d, J = 4.5 Hz, H-1, keto), 14.87 (1H, br s, H-8, enol); 
13
C 
NMR data of enol tautomer δC (100 MHz, CDCl3) 13.9 (CH3, C-15), 19.2 (CH2, C-11), 22.2 
(CH2, C-12,13,14), 27.9 (CH2, C-12,13,14), 31.0 (CH2, C-12,13,14), 77.9 (C, C-9), 91.8 (C, 
C-10), 102.6 (CH, C-6), 118.7 (CH, C-2/4), 121.1 (CH, C-2/4), 137.2 (CH, C-3), 144.0 (CH, 
C-1), 149.7 (C, C-5), 157.8 (C, C-7); Characteristic 
13C NMR data of keto tautomer δC (100 
MHz, CDCl3) 54.4 (CH2, C-6); HRMS (ESI
+
): Found: 216.1385; C14H18NO (MH
+
) Requires 
216.1383 (−1.0 ppm error). 
Lab notebook reference: MJJ8/44 
 
1-(Pyridin-2-yl)-4-(thiophen-2-yl)but-3-yn-2-one (228e) 
 
Synthesised using general procedure 4A with DIPA (0.30 mL, 2.12 mmol), n-BuLi (0.85 
mL, 2.12 mmol, 2.5 M in hexanes), 2-methylpyridine (0.1 mL, 1.01 mmol) in THF (10 mL) 
and a solution of methyl ester 269b (176 mg, 1.06 mmol) in THF (5 mL). Purification by 
column chromatography (20% EtOAc in hexane) afforded the title compound 228e (96 mg, 
42%, 85:15 enol:keto) as a yellow oil. (Note: this compound degrades overnight when stored 
at room temperature.); vmax (cm
-1
) 2198, 1615, 1552, 1472, 705; δH (400 MHz, CDCl3) 4.17 
(2H, s, H-6, keto), 5.87 (1H, s, H-6, enol), 6.98–7.08 (4H, m, H-2,4,13, enol + keto), 7.21–
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7.28 (2H, m, H-2,4, keto), 7.33–7.36 (2H, m, H-12,14, enol), 7.41 (1H, d, J = 3.5 Hz, H-12, 
keto), 7.49 (1H, d, J = 5.5 Hz, H-14, keto), 7.63 (1H, ddd, J = 7.5, 7.5, 1.0 Hz, H-3, enol), 7.71 
(1H, ddd, J = 7.5, 7.5, 1.0 Hz, H-3, keto), 8.26 (1H, br d, J = 5.0 Hz, H-1, enol), 8.62 (1H, br 
d, J = 4.5 Hz, H-1, keto), 15.07 (1H, br s, H-8, enol); 
13
C NMR data of enol tautomer δC (100 
MHz, CDCl3) 83.1 (C, C-9), 90.1 (C, C-10), 103.5 (CH, C-6), 119.0 (CH, C-2/4), 121.5 (CH, 
C-2/4), 122.0 (C, C-11), 127.2 (CH, C-13), 128.4 (CH, C-12/14), 133.3 (CH, C-12/14), 137.5 
(CH, C-3), 143.8 (CH, C-1), 149.7 (C, C-5), 157.5 (C, C-7); Characteristic 
13
C NMR data of 
keto tautomer δC (100 MHz, CDCl3) 54.0 (CH2, C-6); HRMS (ESI
+
): Found: 228.0470; 
C13H10NOS (MH
+
) Requires 228.0478 (3.5 ppm error). 
Lab notebook reference: MJJ8/60 
 
1-Phenyl-4-(pyridin-2-yl)pent-1-yn-3-one (228f) 
 
Synthesised using general procedure 4A with DIPA (0.52 mL, 3.68 mmol), n-BuLi (1.47 
mL, 3.68 mmol, 2.5 M in hexanes), 2-ethylpyridine (0.20 mL, 1.75 mmol), methyl 
phenylpropiolate (0.27 mL, 1.84 mmol) and THF (26 mL). Purification by column 
chromatography (20% EtOAc in hexane) afforded the title compound 228f (138 mg, 33%, 
97:3 enol:keto) as a yellow/green oil. (Note: this compound degrades overnight when stored at 
room temperature.); vmax (cm
-1
) 1589, 1551, 1488, 1461, 755, 690; 
1
H NMR data of enol 
tautomer δH (400 MHz, CDCl3) 2.26 (3H, s, H-7), 7.11 (1H, d, J = 7.0, 5.5 Hz, H-2), 7.26 (1H, 
d, J = 8.0 Hz, H-4), 7.32–7.40 (3H, m, H-14,15), 7.54–7.61 (2H, m, H-13), 7.76 (1H, ddd, J = 
8.0, 8.0, 1.0 Hz, H-3), 8.39 (1H, br d, J = 5.5 Hz, H-1), 15.73 (1H, br s, H-9); 
13
C NMR data 
of enol tautomer δC (100 MHz, CDCl3) 15.4 (CH3), 85.6 (C, C-10), 94.4 (C, C-11), 108.3 (C, 
C-6), 119.4 (CH, C-4), 119.7 (CH, C-2), 122.4 (C, C-12), 128.3 (2CH, C-14), 128.8 (CH, C-
15), 131.7 (2CH, C-13), 137.6 (CH, C-3), 144.6 (CH, C-1), 145.1 (C, C-5), 159.2 (C, C-8); 
Characteristic 
13C NMR data of keto tautomer δC (100 MHz, CDCl3) 56.9 (CH, C-6); HRMS 
(ESI
+
): Found: 258.0887 C16H13NNaO (MNa
+
) Requires 258.0889 (0.7 ppm error), Found: 
236.1078; C16H14NO (MH
+
) Requires 236.1070 (−3.5 ppm error). 
Lab notebook reference: MJJ8/52 
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6-(2-Oxo-4-phenylbut-3-yn-1-yl)nicotinonitrile (228g) 
 
Synthesised using general procedure 4A with DIPA (0.29 mL, 2.1 mmol), n-BuLi (0.84 mL, 
2.1 mmol, 2.5 M in hexanes) in THF (10 mL), a solution of 5-Cyano-2-picoline (118 mg, 1.0 
mmol) in THF (5 mL) and methyl phenylpropiolate (0.16 mL, 1.1 mmol). Purification by 
column chromatography (10% EtOAc in hexane) afforded the title compound 228g (145 mg, 
59%, 96:4 enol:keto) as a yellow solid, mp 126–128 °C; vmax (cm
-1
) 2227, 2196, 1638, 1587, 
1521, 1162, 837, 749, 688, 551; 
1H NMR of enol tautomer δH (400 MHz, CDCl3) 5.97 (1H, s, 
H-7), 7.09 (1H, d, J = 9.0 Hz, H-5), 7.34–7.44 (3H, m, H-14,15), 7.53–7.60 (2H, m, H-13), 
7.83 (1H, dd, J = 9.0, 2.0 Hz, H-4), 8.63 (1H, d, J = 2.0 Hz, H-1), 14.03 (1H, br s, H-9); 
13
C 
NMR data of enol tautomer δC (100 MHz, CDCl3) 85.3 (C, C-10), 92.3 (C, C-11), 104.3 (CH, 
C-7), 104.5 (C, C-2), 116.7 (C, C-3), 121.18 (CH, C-4), 121.24 (C, C-12), 128.5 (2CH, C-14), 
129.6 (CH, C-15), 132.1 (2CH, C-13), 139.4 (CH, C-4), 149.3 (CH, C-1), 151.0 (C, C-6), 
160.6 (C, C-8); Characteristic 
13C NMR data of keto tautomer δC (100 MHz, CDCl3) 54.1 
(CH2, C-7); HRMS (ESI
+
): Found: 247.0869; C16H11N2O (MH
+) Requires 247.0866 (−1.2 
ppm error). 
Lab notebook reference: MJJ8/36 
 
1-(4-Bromopyridin-2-yl)-4-phenylbut-3-yn-2-one (228h) 
 
Synthesised using general procedure 4A with DIPA (0.25 mL, 1.76 mmol), n-BuLi (0.70 
mL, 1.76 mmol, 2.5 M in hexanes), 4-bromo-2-methylpyridine (0.10 mL, 0.84 mmol), methyl 
phenylpropiolate (0.14 mL, 0.92 mmol) and THF (13 mL). Purification by column 
chromatography (10% EtOAc in hexane) afforded the title compound 228h (221 mg, 88%, 
76:24 enol:keto) as a yellow solid, mp 93–95 °C; vmax (cm
-1
) 2202, 1616, 1573, 1531, 756, 
690; δH (400 MHz, CDCl3) 4.17 (2H, s, H-6, keto), 5.84 (1H, s, H-6, enol), 7.19–7.24 (2H, m, 
H-2,4 enol), 7.33–7.48 (7H, m, ArH, enol + keto), 7.50–7.59 (5H, m, ArH, enol + keto), 8.16 
(1H, d, J = 6.0 Hz, H-1, enol), 8.44 (1H, d, J = 5.5 Hz, H-1, keto), 14.46 (1H, br s, H-8, enol); 
13C NMR data of enol tautomer δC (100 MHz, CDCl3) 85.7 (C, C-9), 90.7 (C, C-10), 103.6 
(CH, C-6), 121.7 (C, C-11), 122.8 (CH, C-2/4), 124.1 (CH, C-2/4), 128.4 (2CH, C-13), 129.2 
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(CH, C-14), 132.0 (2CH, C-12), 133.8 (C, C-3), 145.8 (CH, C-1), 149.1 (C, C-5), 158.8 (C, C-
7); Characteristic 
13C NMR data of keto tautomer δC (100 MHz, CDCl3) 53.8 (CH2); HRMS 
(ESI
+
): Found: 300.0006; C15H11
79
BrNO (MH
+
) Requires 300.0019 (4.3 ppm error). 
Lab notebook reference: MJJ8/33 
 
1-(3-Methylpyridin-2-yl)-4-phenylbut-3-yn-2-one (228i) 
 
Synthesised using general procedure 4A with DIPA (0.26 mL, 1.85 mmol), n-BuLi (0.74 
mL, 1.85 mmol, 2.5 M in hexanes), 2,3-lutidine (0.10 mL, 0.88 mmol), methyl 
phenylpropiolate (0.14 mL, 0.92 mmol) and THF (13 mL). Purification by column 
chromatography (30% EtOAc in hexane) afforded the title compound 228i (165 mg, 80%, 
92:8 enol:keto) as a yellow solid, mp 76–78 °C; vmax (cm
-1
) 2202, 1589, 1562, 1435, 757, 690; 
δH (400 MHz, CDCl3) 2.28 (3H, s, H-5, enol), 2.34 (3H, s, H-5, keto), 4.22 (2H, s, H-7, keto), 
5.88 (1H, s, H-7, enol), 6.87 (1H, dd, J = 7.5, 5.5 Hz, H-2, enol), 7.17 (1H, dd, J = 7.5, 5.0 Hz, 
H-2, keto), 7.32–7.40 (6H, m, H-14,15, enol + keto), 7.42–7.48 (3H, m, H-3,13, enol + keto), 
7.52 (1H, d, J = 8.0 Hz, H-3, keto), 7.55–7.60 (2H, m, H-13, enol), 7.98 (1H, br d, J = 5.5 Hz, 
H-1, enol), 8.47 (1H, br d, J = 5.0 Hz, H-1, keto), 16.18 (1H, br s, H-9, enol); 
13
C NMR data 
of enol tautomer δC (100 MHz, CDCl3) 18.3 (CH3, C-5), 87.7 (C, C-10), 88.5 (C, C-11), 97.9 
(CH, C-7), 117.4 (CH, C-2), 122.1 (C, C-12), 128.3 (2CH, C-14), 128.9 (CH, C-15), 129.0 (C, 
C-4), 132.0 (2CH, C-13), 138.1 (CH, C-3), 138.5 (CH, C-1), 154.6 (C, C-6/8), 155.9 (C, C-
6/8); Characteristic 
13C NMR data of keto tautomer δC (100 MHz, CDCl3) 52.6 (CH2, C-7); 
HRMS (ESI
+
): Found: 236.1062; C16H14NO (MH
+
) Requires 236.1070 (3.3 ppm error). 
Lab notebook reference: MJJ8/64 
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1-(Isoquinolin-1-yl)-4-phenylbut-3-yn-2-one (228j) 
 
Synthesised using general procedure 4A with DIPA (0.22 mL, 1.58 mmol), n-BuLi (0.63 
mL, 1.58 mmol, 2.5 M in hexanes), 1-methylisoquinoline (0.10 mL, 0.75 mmol), methyl 
phenylpropiolate (0.12 mL, 0.79 mmol) and THF (11 mL). Purification by column 
chromatography (40% EtOAc in hexane) afforded the title compound 228j (166 mg, 81%, 
>99:1 enamine:imine) as a yellow solid, mp 123–125 °C; vmax (cm
-1
) 1588, 1550, 1493, 1250, 
1207, 1143; δH (400 MHz, CDCl3) 6.42 (1H, s, H-11), 6.90 (1H, d, J = 6.5 Hz, H-3), 7.33–
7.45 (4H, m, H-2,17,18), 7.56 (1H, dd, J = 8.5, 7.5 Hz, H-7), 7.58–7.65 (3H, m, H-5,16), 7.70 
(1H, dd, J = 7.5, 7.5 Hz, H-6), 8.14 (1H, d, J = 8.5 Hz, H-8), 15.67 (1H, br s, H-1); δC (100 
MHz, CDCl3) 86.6 (C, C-13), 90.2 (C, C-14), 92.6 (CH, C-11), 112.1 (CH, C-3), 121.8 (C, C-
15), 123.8 (C, C-4), 124.7 (CH, C-8), 127.1 (CH, C-5), 127.7 (CH, C-2/7/18), 127.8 (CH, C-
2/7/18), 128.3 (2CH, C-17), 129.2 (CH, C-2/7/18), 132.3 (CH, C-6), 132.4 (2CH, C-16), 
135.6 (C, C-9), 154.0 (C, C-10), 168.8 (C, C-12); HRMS (ESI
+
): Found: 294.0890; 
C19H13NNaO (MNa
+
) Requires 294.0889 (−0.1 ppm error), Found: 272.1069; C19H14NO 
(MH
+
) Requires 272.1070 (0.4 ppm error). 
Lab notebook reference: MJJ8/39 
 
4-Phenyl-1-(pyrazin-2-yl)but-3-yn-2-one (228k) 
 
Synthesised using general procedure 4A with DIPA (0.30 mL, 2.12 mmol), n-BuLi (0.85 
mL, 2.12 mmol, 2.5 M in hexanes), 2-methylpyrazine (0.09 mL, 1.01 mmol), methyl 
phenylpropiolate (0.16 mL, 1.06 mmol) and THF (15 mL) (Note: Reaction stirred at −78 °C 
for 1 h after the addition of the methyl ester). Purification by column chromatography (20 → 
40% EtOAc in hexane) afforded the title compound 228k (77 mg, 35%, 95:5 enol:keto) as a 
pale brown solid, mp 42–44 °C; vmax (cm
-1
) 1618, 1506, 1117, 755; 
1
H NMR data of enol 
tautomer δH (400 MHz, CDCl3) 6.00 (1H, s, H-5), 7.34–7.44 (3H, m, H-12,13), 7.53–7.61 
(2H, m, H-11), 8.30–8.34 (1H, m, H-2), 8.34–8.36 (1H, m, H-1), 8.42 (1H, d, J = 1.5 Hz, H-
3), 13.26 (1H, br s, H-7); 
13
C NMR data of enol tautomer δC (100 MHz, CDCl3) 85.1 (C, C-8), 
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91.5 (C, C-9), 102.3 (CH, C-5), 121.5 (C, C-10), 128.4 (2CH, C-12), 129.4 (CH, C-13), 132.0 
(2CH, C-11), 140.0 (CH, C-1/2), 140.4 (CH, C-1/2), 143.8 (CH, C-3), 148.5 (C, C-4), 153.3 
(C, C-6); Characteristic 
13C NMR data of keto tautomer δC (100 MHz, CDCl3) 51.5 (CH2, C-
5); HRMS (ESI
+
): Found: 245.0692; C14H10N2NaO (MNa
+) Requires 245.0685 (−2.6 ppm 
error). 
Lab notebook reference: MJJ8/43 
 
1-(Pyridin-2-yl)-4-(trimethylsilyl)but-3-yn-2-one (228l) 
 
Synthesised using general procedure 4A with DIPA (0.49 mL, 3.47 mmol), n-BuLi (1.39 
mL, 3.47 mmol, 2.5 M in hexanes), 2-methylpyridine (0.16 mL, 1.65 mmol) in THF (16.5 
mL) and a solution of methyl ester 269c (270 mg, 1.73 mmol) in THF (9 mL). Purification by 
column chromatography (15% EtOAc in hexane) afforded the title compound 228l (240 mg, 
67%, 91:9 enol:keto) as a yellow oil; vmax (cm
-1
) 1617, 1595, 1552, 1472, 1249, 1149, 932, 
843; δH (400 MHz, CDCl3) 0.18 (9H, s, H-11, keto), 0.25 (9H, s, H-11, enol), 4.07 (2H, s, H-
6, keto), 5.82 (1H, s, H-6, enol), 6.98 (1H, d, J = 8.0 Hz, H-4, enol), 7.02 (1H, dd, J = 7.5, 5.0 
Hz, H-2, enol), 7.22 (1H, dd, J = 7.5, 5.0 Hz, H-2, keto), 7.26 (1H, d, J = 8.0 Hz, H-4, keto), 
7.62 (1H, ddd, J = 8.0, 7.5, 1.5 Hz, H-3, enol), 7.68 (1H, ddd, J = 8.0, 7.5, 1.5 Hz, H-3, keto), 
8.28 (1H, br d, J = 5.0 Hz, H-1, enol), 8.59 (1H, br d, J = 5.0 Hz, H-1, keto), 14.78 (1H, br s, 
H-8, enol); 
13
C NMR data of enol tautomer δC (100 MHz, CDCl3) −0.4 (3CH3, C-11), 95.6 (C, 
C-10), 101.1 (C, C-9), 104.3 (CH, C-6), 119.3 (CH, C-2), 121.4 (CH, C-4), 137.4 (CH, C-3), 
144.4 (CH, C-1), 148.3 (C, C-5), 157.6 (C, C-7); Characteristic 
13
C NMR data of keto 
tautomer δC (100 MHz, CDCl3) 54.1 (CH2, C-6); HRMS (ESI
+
): Found: 218.0988; 
C12H16NOSi (MH
+
) Requires 218.0996 (3.6 ppm error). 
Lab notebook reference: MJJ8/62 
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4-Phenyl-2H-quinolizin-2-one (229a) 
 
Synthesised using general procedure 4B with pyridine-ynone 228a (66 mg, 0.3 mmol), 
AgNO3 (1.0 mg, 6.0 μmol) in DCE (1.5 mL) and EtOH (1.5 mL) for 2 h. Purification by 
column chromatography (5 → 20% MeOH in EtOAc) afforded the title compound 229a (64 
mg, 97%) as a pale brown solid, mp 174–176 °C; vmax (cm
-1
) 3378, 1620, 1576, 1505, 749, 
703; δH (400 MHz, CDCl3) 6.42 (1H, dd, J = 7.5, 6.5 Hz, H-2), 6.63 (1H, br s, H-6/8), 6.75 
(1H, br s, H-6/8), 7.06 (1H, dd, J = 8.5, 6.5 Hz, H-3), 7.19 (1H, d, J = 8.5 Hz, H-4), 7.37–7.45 
(2H, m, H-11/12), 7.50–7.59 (3H, m, H-11/12,13), 7.62 (1H, d, J = 7.5 Hz, H-1); δC (100 
MHz, CDCl3) 111.6 (CH, C-6/8), 111.9 (CH, C-2), 124.5 (CH, C-4/6/8), 124.7 (CH, C-4/6/8), 
128.4 (CH, C-3), 129.0 (2CH, C-11/12), 129.3 (CH, C-1/13), 129.5 (2CH, C-11/12), 130.1 
(CH, C-1/13), 132.9 (C, C-10), 144.8 (C, C-5/9), 145.8 (C, C-5/9), 175.5 (C, C-7); HRMS 
(ESI
+
): Found: 244.0738; C15H11NNaO (MNa
+
) Requires 244.0733 (−2.1 ppm error), Found: 
222.0923; C15H12NO (MH
+
) Requires 222.0913 (−4.5 ppm error). 
Lab notebook reference: MJJ8/51 
 
4-(3,4-Dimethoxyphenyl)-2H-quinolizin-2-one (229b) 
 
Synthesised using general procedure 4B with pyridine-ynone 228b (2.11 g, 7.50 mmol), 
AgNO3 (25.5 mg, 0.15 mmol) in DCE (37.5 mL) and EtOH (37.5 mL) for 4 h. Purification by 
column chromatography (5 → 20% MeOH in EtOAc) afforded the title compound 229b (2.09 
g, 99%) as a pale brown solid, mp 211–213 °C; vmax (cm
-1
) 3379, 1622, 1576, 1516, 1491, 
1263, 1022, 756; δH (400 MHz, CDCl3) 3.88 (3H, s, H-13/15), 3.95 (3H, s, H-13/15), 6.44 
(1H, ddd, J = 8.0, 6.5, 1.5 Hz, H-2), 6.62 (1H, d, J = 2.5 Hz, H-6/8), 6.77 (1H, d, J = 2.5 Hz, 
H-6/8), 6.89 (1H, d, J = 1.5 Hz, H-11), 6.96–7.03 (2H, m, H-16,17), 7.06 (1H, dd, J = 9.0, 6.5 
Hz, H-3), 7.20 (1H, br d, J = 9.0 Hz, H-4), 7.72 (1H, d, J = 8.0 Hz, H-1); δC (100 MHz, 
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CDCl3) 56.0 (CH3, C-13/15), 56.1 (CH3, C-13/15), 111.4 (CH, C-6/8/11/16), 111.6 (CH, C-
6/8/11/16), 111.8 (CH, C-6/8/11/16), 111.9 (CH, C-2), 121.9 (CH, C-17), 124.4 (CH, C-6/8), 
124.7 (CH, C-4), 125.2 (C, C-10), 128.4 (CH, C-3), 129.5 (CH, C-1), 144.8 (C, C-5/9), 145.7 
(C, C-5/9), 149.6 (C, C-12/14), 150.3 (C, C-12/14), 175.4 (C, C-7); HRMS (ESI
+
): Found: 
282.1121; C17H16NO3 (MH
+
) Requires 282.1125 (1.3 ppm error). 
Lab notebook reference: MJJ8/67 
 
4-(4-Fluorophenyl)-2H-quinolizin-2-one (229c) 
 
Synthesised using general procedure 4B with pyridine-ynone 228c (72 mg, 0.3 mmol), 
AgNO3 (1.0 mg, 6.0 μmol) in DCE (1.5 mL) and EtOH (1.5 mL) for 2 h. Purification by 
column chromatography (5 → 10% MeOH in EtOAc) afforded the title compound 229c (72 
mg, 100%) as a pale brown solid, mp 244–246 °C; vmax (cm
-1
) 3380, 1623, 1577, 1515, 1486; 
δH (400 MHz, CDCl3) 6.42 (1H, dd, J = 7.0, 7.0 Hz, H-2), 6.60 (1H, d, J = 2.5 Hz, H-6/8), 
6.71 (1H, d, J = 2.5 Hz, H-6/8), 7.05 (1H, dd, J = 9.0, 7.0 Hz, H-3), 7.18 (1H, d, J = 9.0 Hz, 
H-4), 7.21–7.29 (2H, m, H-12), 7.38–7.45 (2H, m, H-11), 7.57 (1H, br d, J = 7.0 Hz, H-1); δC 
(100 MHz, CDCl3) 111.8 (CH, C-6/8), 111.9 (CH, C-2), 116.8 (2CH, d, J = 22.0 Hz, C-12), 
124.7 (CH, C-4), 124.9 (CH, C-6/8), 128.3 (CH, C-3), 129.0 (C, d, J = 4.0 Hz, C-10), 129.1 
(CH, C-1), 131.2 (2CH, d, J = 8.5 Hz, C-11), 144.6 (C, C-5/9), 144.8 (C, C-5/9), 163.5 (C, d, 
J = 251.0 Hz, C-13), 175.5 (C, C-7); δF (376 MHz, CDCl3) −109.4–−109.5 (1F, m); HRMS 
(ESI
+
): Found: 240.0825; C15H11FNO (MH
+
) Requires 240.0819 (−2.2 ppm error). 
Lab notebook reference: MJJ8/59 
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4-Pentyl-2H-quinolizin-2-one (229d) 
 
Synthesised using general procedure 4B with pyridine-ynone 228d (153 mg, 0.711 mmol), 
AgNO3 (2.4 mg, 14.2 μmol) in DCE (3.6 mL) and EtOH (3.6 mL) for 3 h. Purification by 
column chromatography (5 → 10% MeOH in EtOAc) afforded the title compound 229d (149 
mg, 97%) as a pale brown solid, mp 69–71 °C; vmax (cm
-1
) 3369, 1622, 1574, 1489, 1177, 726; 
δH (400 MHz, CDCl3) 0.93 (3H, t, J = 7.0 Hz, H-14), 1.33–1.50 (4H, m, H-12,13), 1.74 (2H, 
tt, J = 8.0, 7.0 Hz, H-11), 2.84 (2H, t, J = 8.0 Hz, H-10), 6.58 (1H, d, J = 2.5 Hz, H-6/8), 6.64 
(1H, dd, J = 7.5, 7.5 Hz, H-2), 6.77 (1H, d, J = 2.5 Hz, H-6/8), 7.09 (1H, dd, J = 9.0, 7.5 Hz, 
H-3), 7.20 (1H, d, J = 9.0 Hz, H-4), 7.57 (1H, br d, J = 7.5 Hz, H-1); δC (100 MHz, CDCl3) 
13.8 (CH3, C-14), 22.3 (CH2, C-12/13), 26.2 (CH2, C-11), 31.3 (CH2, C-12/13), 32.4 (CH2, C-
10), 111.3 (CH, C-6/8), 112.4 (CH, C-2), 122.8 (CH, C-6/8), 125.2 (CH, C-4), 127.1 (CH, C-
1), 127.9 (CH, C-3), 145.0 (C, C-5/9), 145.1 (C, C-5/9), 175.9 (C, C-7); HRMS (ESI
+
): 
Found: 216.1381; C14H18NO (MH
+
) Requires 216.1383 (1.1 ppm error). 
Lab notebook reference: MJJ8/46 
 
4-(Thiophen-2-yl)-2H-quinolizin-2-one (229e) 
 
Synthesised using general procedure 4B with pyridine-ynone 228e (80 mg, 0.352 mmol), 
AgNO3 (1.2 mg, 7.0 μmol) in DCE (1.8 mL) and EtOH (1.8 mL) for 9 h. Purification by 
column chromatography (5 → 10% MeOH in EtOAc) afforded the title compound 229e (47 
mg, 59%) as a brown oil; vmax (cm
-1
) 3379, 1618, 1577, 1485, 754; δH (400 MHz, CDCl3) 6.49 
(1H, ddd, J = 7.0, 7.0, 1.5 Hz, H-2), 6.64 (1H, d, J = 2.5 Hz, H-6/8), 6.93 (1H, d, J = 2.5 Hz, 
H-6/8), 7.08 (1H, dd, J = 8.0, 7.0 Hz, H-3), 7.20 (1H, d, J = 8.0 Hz, H-4), 7.22 (1H, dd, J = 
5.0, 3.5 Hz, H-12); 7.29 (1H, dd, J = 3.5, 1.0 Hz, H-11), 7.60 (1H, dd, J = 5.0, 1.0 Hz, H-13), 
7.89 (1H, d, J  = 7.0 Hz, H-1); δC (100 MHz, CDCl3) 112.0 (CH, C-2/6/8), 112.2 (CH, C-
2/6/8), 124.6 (CH, C-4), 126.6 (CH, C-6/8), 127.9 (CH, C-12), 128.7 (CH, C-3), 129.1 (CH, 
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C-1/13), 129.3 (CH, C-1/13), 130.1 (CH, C-11), 132.7 (C, C-10), 138.7 (C, C-5/9), 145.1 (C, 
C-11), 175.2 (C, C-7); HRMS (ESI
+
): Found: 228.0474; C13H10NOS (MH
+
) Requires 
228.0478 (1.7 ppm error). 
Lab notebook reference: MJJ8/61 
 
1-Methyl-4-phenyl-2H-quinolizin-2-one (229f) 
 
Synthesised using general procedure 4B with pyridine-ynone 228f (42 mg, 0.178 mmol), 
AgNO3 (0.6 mg, 3.6 μmol) in DCE (0.9 mL) and EtOH (0.9 mL) for 18 h. Purification by 
column chromatography (5 → 10% MeOH in EtOAc) afforded the title compound 229f (19 
mg, 45%) as a brown oil; vmax (cm
-1
) 3401, 1622, 1560, 1508, 761, 703; δH (400 MHz, CDCl3) 
2.34 (3H, s, H-7), 6.41 (1H, ddd, J = 7.5, 7.0, 1.5 Hz, H-2), 6.80 (1H, s, H-9), 7.11 (1H, dd, J 
= 9.0, 7.0 Hz, H-3), 7.37–7.43 (2H, m, H-12/13), 7.47 (1H, d, J = 9.0 Hz, H-4), 7.51–7.57 
(3H, m, H-12/13,14), 7.68 (1H, d, J = 7.5 Hz, H-1); δC (100 MHz, CDCl3) 10.3 (CH3, C-7), 
111.0 (CH, C-2), 118.1 (C, C-6), 122.0 (CH, C-4), 122.5 (CH, C-9), 127.7 (CH, C-3), 129.1 
(2CH, C-12/13), 129.4 (2CH, C-12/13), 129.9 (CH, C-1/14), 130.0 (CH, C-1/14), 133.5 (C, C-
11), 141.6 (C, C-5/10), 144.3 (C, C-5/10), 174.4 (C, C-8); HRMS (ESI
+
): Found: 236.1071; 
C16H14NO (MH
+) Requires 236.1070 (−0.3 ppm error). 
Lab notebook reference: MJJ8/54 
 
2-Oxo-4-phenyl-2H-quinolizine-7-carbonitrile (229g) 
 
Synthesised using general procedure 4B with pyridine-ynone 228g (74 mg, 0.3 mmol), 
AgNO3 (1.0 mg, 6.0 μmol) in DCE (1.5 mL) and EtOH (1.5 mL) for 3 h. Purification by 
column chromatography (5 → 10% MeOH in EtOAc) afforded the title compound 229g (61 
mg, 82%) as a pale yellow solid, mp 243–245 °C; vmax (cm
-1
) 2230, 1628, 1602, 1585, 1519, 
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1306; δH (400 MHz, CDCl3) 6.58 (1H, d, J = 2.5 Hz, H-7/9), 6.74 (1H, d, J = 2.5 Hz, H-7/9), 
6.97 (1H, d, J = 9.5 Hz, H-5), 7.17 (1H, d, J = 9.5 Hz, H-4), 7.37–7.45 (2H, m, H-12/13), 
7.56–7.67 (3H, m, H-12/13,14), 7.97 (1H, s, H-1); δC (100 MHz, CDCl3) 97.4 (C, C-2), 113.4 
(CH, C-7/9), 115.6 (C, C-3), 125.4 (CH, C-7/9), 125.7 (CH, C-4), 125.9 (CH, C-5), 128.9 
(2CH, C-12/13), 130.0 (2CH, C-12/13), 131.0 (CH, C-14), 131.4 (C, C-11), 136.6 (CH, C-1), 
143.1 (C, C-6/10), 146.2 (C, C-6/10), 176.2 (C, C-8); HRMS (ESI
+
): Found: 269.0694 
C16H10N2NaO (MNa
+) Requires 269.0685 (−3.1 ppm error), Found: 247.0872; C16H11N2O 
(MH
+) Requires 247.0866 (−2.6 ppm error). 
Lab notebook reference: MJJ8/38 
 
8-Bromo-4-phenyl-2H-quinolizin-2-one (229h) 
 
Synthesised using general procedure 4B with pyridine-ynone 228h (90 mg, 0.3 mmol), 
AgNO3 (1.0 mg, 6.0 μmol) in DCE (1.5 mL) and EtOH (1.5 mL) for 3 h. Purification by 
column chromatography (5 → 10% MeOH in EtOAc) afforded the title compound 229g (90 
mg, 82%) as a yellow solid, mp >300 °C; vmax (cm
-1
) 1625, 1578, 1505, 752; δH (400 MHz, 
CDCl3) 6.44 (1H, dd, J = 8.0, 2.0 Hz, H-2), 6.51 (1H, d, J = 2.5 Hz, H-6/8), 6.71 (1H, d, J = 
2.5 Hz, H-6/8), 7.36 (1H, d, J = 2.0 Hz, H-4), 7.37–7.43 (2H, m, H-11/12), 7.46 (1H, d, J = 
8.0 Hz, H-1), 7.52–7.61 (3H, m, H-11/12,13); δC (100 MHz, CDCl3) 111.1 (CH, C-6/9), 115.4 
(CH, C-2), 123.2 (C, C-3), 124.7 (CH, C-6/9), 125.7 (CH, C-4), 129.0 (2CH, C-11/12), 129.6 
(2CH, C-11/12), 130.1 (CH, C-1/13), 130.4 (CH, C-1/13), 132.6 (C, C-10), 144.7 (C, C-5/9), 
145.8 (C, C-5/9), 175.7 (C, C-7); HRMS (ESI
+
): Found: 300.0022; C15H11
79
BrNO (MH
+
) 
Requires 300.0019 (−1.2 ppm error). 
Lab notebook reference: MJJ8/35 
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9-Methyl-4-phenyl-2H-quinolizin-2-one (229i) 
 
Synthesised using general procedure 4B with pyridine-ynone 228i (71 mg, 0.3 mmol), 
AgNO3 (1.0 mg, 6.0 μmol) in DCE (1.5 mL) and EtOH (1.5 mL) for 5 h. Purification by 
column chromatography (5 → 10% MeOH in EtOAc) afforded the title compound 229i (52 
mg, 73%) as a yellow oil; vmax (cm
-1
) 3391, 1625, 1586, 1524; δH (400 MHz, CDCl3) 2.37 (3H, 
s, H-5), 6.37 (1H, dd, J = 7.0, 7.0 Hz, H-2), 6.72–6.78 (2H, m, H-7,9), 6.96 (1H, d, J = 7.0 Hz, 
H-3), 7.37–7.45 (2H, m, H-12/13), 7.50–7.60 (4H, m, H-1,12/13,14); δC (100 MHz, CDCl3) 
19.6 (CH3, C-5), 109.0 (CH, C-7/9), 111.2 (CH, C-2), 124.1 (CH, C-7/9), 127.7 (CH, C-3), 
128.0 (CH, C-1/14), 129.1 (2CH, C-12/13), 129.4 (2CH, C-12/13), 130.0 (CH, C-1/14), 130.9 
(C, C-4), 133.6 (C, C-11), 145.2 (C, C-6/10), 146.4 (C, C-6/10), 175.8 (C, C-8); HRMS 
(ESI
+
): Found: 236.1065; C16H14NO (MH
+
) Requires 236.1070 (2.0 ppm error). 
Lab notebook reference: MJJ8/65 
 
4-Phenyl-2H-pyrido[2,1-a]isoquinolin-2-one (229j) 
 
Synthesised using general procedure 4B with ynone 228j (81 mg, 0.3 mmol), AgNO3 (1.0 
mg, 6.0 μmol) in DCE (1.5 mL) and EtOH (1.5 mL) for 20 h. Purification by column 
chromatography (5 → 10% MeOH in EtOAc) afforded the title compound 229j (58 mg, 70%) 
as a pale yellow solid, mp 139–141 °C; vmax (cm
-1
) 1626, 1601, 1572, 1582; δH (400 MHz, 
CDCl3) 6.64 (1H, d, J = 8.0 Hz, H-2), 6.72 (1H, d, J = 2.5 Hz, H-10/12) 7.40–7.69 (10H, 
ArH), 8.27 (1H, d, J = 7.5 Hz, H-7); δC (100 MHz, CDCl3) 109.9 (CH, C-10/12), 112.1 (CH, 
C-2), 122.5 (CH, C-10/12), 124.3 (CH, C-7), 125.3 (C, C-3/8), 125.7 (CH, ArC), 126.9 (CH, 
ArC), 128.9 (CH, ArC), 129.1 (2CH, C-15/16), 129.4 (2CH, C-15/16), 129.6 (C, C-3/8), 130.0 
Chapter 5. Experimental 
 
 
243 
(CH, ArC), 131.1 (CH), 133.7 (C, C-14), 143.5 (C, C-9/13), 147.8 (C, C-9/13), 176.7 (C, C-
11); HRMS (ESI
+
): Found: 272.1069; C19H14NO (MH
+
) Requires 272.1070 (0.2 ppm error). 
Lab notebook reference: MJJ8/40 
 
6-Phenyl-8H-pyrido[1,2-a]pyrazin-8-one (229k) 
 
Synthesised using general procedure 4B with pyridine-ynone 228k (66 mg, 0.3 mmol), 
AgNO3 (1.0 mg, 6.0 μmol) in DCE (1.5 mL) and EtOH (1.5 mL) for 5 h. Purification by 
column chromatography (5 → 20% MeOH in EtOAc) afforded the title compound 229k (56 
mg, 85%) as a yellow solid, mp 170–172 °C; vmax (cm
-1
) 3400, 1619, 1600, 1567, 1505; δH 
(400 MHz, CDCl3) 6.81 (1H, d, J = 2.5 Hz, H-5/7), 6.84 (1H, d, J = 2.5 Hz, H-5/7), 7.32–7.38 
(2H, m, H-1,2), 7.38–7.45 (2H, m, H-10/11), 7.52–7.63 (3H, m, H-10/11,12), 8.65 (1H, s, H-
3); δC (100 MHz, CDCl3) 114.1 (CH, C-5/7), 119.6 (CH, C-1/2), 126.3 (CH, C-5/7), 127.4 
(CH, C-1/2), 129.0 (2CH, C-10/11), 129.6 (2CH, C-10/11), 130.7 (CH, C-12), 131.3 (C, C-9), 
137.7 (C, C-4/8), 145.8 (C, C-4/8), 152.6 (CH, C-3), 176.5 (C, C-6); HRMS (ESI
+
): Found: 
245.0678; C14H10N2NaO (MNa
+
) Requires 245.0685 (2.9 ppm error), Found: 223.0865; 
C14H11N2O (MH
+
) Requires 223.0866 (0.4 ppm error). 
Lab notebook reference: MJJ8/45 
 
2H-Quinolizin-2-one (229l) 
 
To a solution of TMS-ynone 228l (98 mg, 0.451 mmol) in acetone (4.5 mL) was added 
AgNO3 (15.3 mg, 90.2 μmol). The reaction mixture was stirred at rt for 19 h then concentrated 
in vacuo. The crude product was dissolved in CH2Cl2 and purified by column chromatography 
(5 → 20% MeOH in EtOAc) to afford the title compound 229l (54 mg, 82%) as a brown solid, 
mp 38–40 °C; vmax (cm
-1
) 3301, 1649, 1571, 1513, 1486, 1427, 851; δH (400 MHz, CDCl3) 
6.53 (1H, d, J = 2.5 Hz, H-6), 6.56 (1H, ddd, J = 7.0, 6.5, 1.0 Hz, H-2), 6.78 (1H, dd, J = 7.5, 
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2.5 Hz, H-8), 7.05 (1H, d, J = 9.0, 6.5 Hz, H-3), 7.11 (1H, br d, J = 9.0 Hz, H-4), 7.61 (1H, d, 
J = 7.0 Hz, H-1), 7.79 (1H, d, J = 7.5 Hz, H-9); δC (100 MHz, CDCl3) 111.2 (CH, C-6), 112.2 
(CH, C-2), 123.0 (CH, C-8), 123.9 (CH, C-4), 128.5 (CH, C-3), 132.0 (CH, C-1), 135.1 (CH, 
C-9), 144.1 (C, C-5), 176.2 (C, C-7); HRMS (ESI
+
): Found: 146.0604; C9H8NO (MH
+
) 
Requires 146.0600 (−2.7 ppm error). 
Lab notebook reference: MJJ8/63 
 
6-(3,4-Dimethoxyphenyl)-3,4-dihydro-1H-quinolizin-8(2H)-one (273) 
 
To a solution of quinolizidine 229b (28 mg, 0.1 mmol) in MeOH (1 mL) was added Pd/C (14 
mg). The mixture was evacuated in vacuo and backfilled with argon three times then 
evacuated in vacuo and backfilled with hydrogen three times. The mixture was stirred at rt for 
16 h before being filtered through Celite®), eluting with EtOAc. The filtrate was then 
concentrated in vacuo to afford the title compound 273 (26 mg, 91%) as a pale yellow oil; vmax 
(cm
-1
) 3359, 2935, 1623, 1509, 1262, 1248, 1024, 729; δH (400 MHz, CDCl3) 1.78–1.90 (4H, 
m, H-2,3), 2.78 (2H, t, J = 6.5 Hz, H-1/4), 3.68 (2H, t, J = 5.5 Hz, H-1/4), 3.87 (3H, s, H-
13/15), 3.91 (3H, s, H-13/15), 6.27–6.29 (2H, m, H-6/8,11), 6.79 (1H, d, J = 1.5 Hz, H-6/8), 
6.86 (1H, dd, J = 8.0, 2.5 Hz, H-17), 6.92 (1H, d, J = 8.0 Hz, H-16); δC (100 MHz, CDCl3) 
18.3 (CH2, C-2/3) , 22.4 (CH2, C-2/3), 28.4 (CH2, C-1/4), 47.0 (CH2, C-1/4), 55.9 (CH3, C-
13/15), 56.0 (CH3, C-13/15), 111.0 (CH, C-16), 111.6 (CH, C-6/8), 116.5 (CH, C-6/8/11), 
119.1 (CH, C-6/8/11), 121.2 (CH, C-17), 126.9 (C, C-10), 149.0 (C, C-5/9), 149.8 (C, C-5/9), 
150.7 (C, C-12/14), 151.9 (C, C-12/14), 178.4 (C, C-7); HRMS (ESI
+
): Found: 308.1265; 
C17H19NNaO3 (MNa
+
) Requires 308.1257 (−2.5 ppm error), Found: 286.1447; C17H20NO3 
(MH
+
) Requires 286.1438 (−3.4 ppm error). 
Lab notebook reference: MJJ6/5 
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4-(3,4-Dimethoxyphenyl)hexahydro-1H-quinolizin-2(6H)-one (274) 
 
To a solution of quinolizidine 229b (1.05 g, 3.73 mmol) in AcOH (0.64 mL, 11.2 mmol) and 
EtOH (37 mL) was added PtO2 (254 mg, 1.12 mmol). The mixture was evacuated in vacuo 
and backfilled with nitrogen three times then evacuated in vacuo and backfilled with hydrogen 
three times. The mixture was stirred at rt for 4 days before being filtered through Celite®, 
eluting with EtOAc. The filtrate was poured into sat. NaCHO3 (aq) (30 mL) and diluted with 
EtOAc (50 mL). The organics were separated and the aqueous was extracted with EtOAc (4 × 
50 mL). The organics were combined, dried (MgSO4), and concentrated in vacuo to afford the 
crude hydrogenation product 230b, which was used in the next step without further 
purification. 
To a solution of dry DMSO (1.33 mL, 18.7 mmol) in CH2Cl2 (65 mL) at −78 °C under argon 
was added oxalyl chloride (0.80 mL, 9.33 mmol). The mixture was stirred at −78 °C for 1 h, 
then a solution of the above crude product in CH2Cl2 (19 mL) was added. The mixture was 
stirred at −78 °C for 1 h, then Et3N (5.72 mL, 41.0 mmol) was added, the mixture was then 
allowed to warm to room temperature and stirred for a further 2 h. The reaction mixture was 
quenched by the careful addition of 2 M NaOH(aq) (30 mL) and diluted with CH2Cl2 (20 mL). 
The organics were separated and the aqueous extracted with CH2Cl2 (3 × 60 mL). The 
organics were combined, dried (MgSO4), concentrated in vacuo and purified by column 
chromatography (0 → 2% MeOH in CH2Cl2) to afford the title compound 274 (730 mg, 68%) 
as a yellow oil; vmax (cm
-1
) 2932, 1722, 1516, 1263, 1028; δH (400 MHz, CDCl3) 1.19–1.35 
(1H, m), 1.38–1.81 (6H, m), 2.22–2.37 (2H, m), 2.41 (1H, ddd, J = 13.5, 3.0, 3.0 Hz), 2.51 
(1H, dd, J = 13.5, 13.0 Hz), 2.68 (1H, dd, J = 13.5, 12.5 Hz), 2.75–2.83 (1H m), 3.21 (1H, dd, 
J = 12.5, 3.0 Hz), 3.88 (3H, s), 3.91 (3H, s), 6.79–6.87 (2H, m), 6.91 (1H, br s); δC (100 MHz, 
CDCl3) 24.2 (CH2), 25.8 (CH2), 34.3 (CH2), 48.7 (CH2), 50.9 (CH2), 52.8 (CH2), 55.8 (CH3), 
56.0 (CH3), 62.4 (CH), 70.0 (CH), 109.6 (CH), 110.9 (CH), 119.5 (CH), 135.1 (C), 148.3 (C), 
149.3 (C), 208.0 (C); (ESI
+
): Found: 290.1752; C17H24NO3 (MH
+) Requires 290.1751 (−0.6 
ppm error). 
Lab notebook reference: MJJ8/68 + MJJ8/71 
Spectroscopic data matched those reported in the literature.
128,129,127
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(±)-Lasubine II (235) 
 
To a solution of ketone 274 (724 mg, 2.50 mmol) in THF (25 mL) at −78 °C was added L-
Selectride
®
 (5.0 mL, 5.00 mmol, 1.0 M in THF) dropwise. The mixture was stirred at −78 °C 
for 3 h then warmed to 0 °C before being quenched by the careful addition of sat. NaHCO3 (aq) 
(25 mL). The suspension was stirred at room temperature for 2 h and then diluted with EtOAc 
(40 mL). The organics were separated and the aqueous extracted with EtOAc (3 × 50 mL). 
The organics were combined, dried (MgSO4), concentrated in vacuo and purified by column 
chromatography  (10 → 20 → 30% MeOH in CH2Cl2) to afford the title compound 235 (527 
mg, 72%) as an off-white foam, mp 41–43 °C; vmax (cm
-1
) 2930, 1516, 1261, 1230, 1136, 
1028; δH (400 MHz, CDCl3) 1.20–2.00 (12H, m), 2.33–2.47 (1H, m), 2.70 (1H, br d, J = 11.0 
Hz), 3.32 (1H, br d, J = 10.5 Hz), 3.86 (3H, s), 3.89 (3H, s), 4.12–4.19 (1H, m), 6.79 (1H, d, J 
= 8.0 Hz), 6.82–7.00 (2H, m); δC (100 MHz, CDCl3) 24.8 (CH2), 26.1 (CH2), 33.6 (CH2), 40.3 
(CH2), 42.7 (CH2), 53.2 (CH2), 55.8 (CH3), 55.9 (CH3), 56.4 (CH), 63.4 (CH), 65.0 (CH), 
110.4 (CH), 110.8 (CH), 119.7 (CH), 137.1 (C), 147.7 (C), 148.9 (C); HRMS (ESI
+
): Found: 
292.1918; C17H26NO3 (MH
+
) Requires 292.1907 (−3.6 ppm error). 
Lab notebook reference: MJJ8/75 
Spectroscopic data matched those reported in the literature.
6 
 
Ethyl 2-(1H-pyrrol-2-yl)acetate (276) 
 
To a solution of pyrrole (13.9 mL, 200 mmol) in THF (300 mL) at ~−15 °C was slowly added 
MeMgCl (64 mL, 192 mmol, 3.0 M in THF). The reaction mixture was allowed to warm to 
RT and stirred for 30 min. The reaction mixture was then recooled to ~−10 °C and ethyl 
bromoacetate (8.85 mL, 80 mmol) was added. The reaction mixture was allowed to warm to 
RT and stirred for 30 min and then quenched with NH4Cl(aq) (200 mL). The organics were 
separated and the aqueous was extracted with Et2O (2 x 200 mL). The organics were 
combined, dried over MgSO4 and concentrated in vacuo. The crude material was purified by 
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fractional distillation in vacuo to afford the title compound 276 as a colourless oil (6.02 g, 
49%); νmax (cm
-1
) 3388, 2983, 1727, 1370, 1243, 1157, 1028, 720; δH (400 MHz, CDCl3) 1.30 
(3 H, t, J = 7.0 Hz), 3.68 (2 H, s), 4.19 (2 H, q, J = 7.0 Hz), 6.02–6.05 (1 H, m), 6.14–6.18 (1 
H, m), 6.76–6.79 (1 H, m), 8.76 (1 H, br s); δC (100 MHz, CDCl3) 14.1 (CH3), 33.2 (CH2), 
61.1 (CH2), 107.2 (CH), 108.2 (CH), 117.7 (CH), 123.3 (C), 171.2 (C). 
Lab notebook reference: MJJ7/86 
Spectroscopic data matched those previously reported in the literature.
159
 
 
2-(1H-Pyrrol-2-yl)acetic acid (277) 
 
To a solution of ethyl 2-(1H-pyrrol-2-yl)acetate 276 (804 mg, 5.25 mmol) in THF (37 mL) 
and MeOH (3.7 mL) at 0 °C was added 2 M NaOH(aq) (30 mL) dropwise. The reaction 
mixture was warmed to RT and stirred for 1 h 20 min. Water (20 mL) was added and the 
aqueous layer was washed with EtOAc (20 mL). The organic extract was discarded. The 
aqueous layer was acidified with 10% HCl(aq) (20 mL) until pH = 1 and then extracted with 
EtOAc (2 x 20 mL). The organics were combined, dried over MgSO4 and concentrated in 
vacuo to afford the title compound 277 without further purification as an off white solid (621 
mg, 95%); mp 77–79 °C;  νmax (cm
-1
) 3341, 3325, 3119, 2910, 1696, 1415, 1243, 1209, 745; 
δH (400 MHz, CDCl3) 3.74 (2 H, s), 6.07–6.11 (1 H, m), 6.17–6.20 (1 H, m), 6.77–6.80 (1 H, 
m), 8.57 (1 H, br s), 10.67 (1 H, br s); δC (100 MHz, CDCl3) 33.1 (CH2), 107.9 (CH), 108.5 
(CH), 118.1 (CH), 122.2 (C), 177.3 (C). 
Lab notebook reference: akc01-92 
Spectroscopic data matched those previously reported in the literature.
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N-Methoxy-N-methyl-2-(1H-pyrrol-2-yl)acetamide (278) 
 
Synthesised using general procedure 2A with 2-(1H-pyrrol-2-yl)acetic acid 277 (596 mg, 
4.76 mmol), T3P 50% in EtOAc (4.55 g, 7.14 mmol), DIPEA (2.49 mL, 14.3 mmol) and 
MeNH(OMe)·HCl (511 mg, 5.24 mmol) in CH2Cl2 (24 mL) at RT for 1.5 h. Afforded the title 
compound 278 without further purification as a pale brown solid (633 mg, 79%); mp 63–65 
°C;  νmax (cm
-1
) 3322, 2938, 1646, 1432, 1386, 1175, 1002, 723; δH (400 MHz, CDCl3) 3.22 (3 
H, s, H-8), 3.72 (3 H, s, H-9), 3.83 (2 H, s, H-6), 6.01–6.03 (1 H, m, H-4), 6.12–6.15 (1 H, m, 
H-2/3), 6.74–6.76 (1 H, m, H-2/3), 9.05 (1 H, br s, H-1); δC (100 MHz, CDCl3) 30.4 (CH2, C-
6), 32.0 (CH3, C-8), 61.5 (CH3, C-9), 107.0 (CH, C-4), 107.9 (CH, C-2/3), 117.5 (CH, C-2/3), 
124.3 (C, C-5), 171.6 (C, C-7); HRMS (ESI
+
): Found: 191.0791; C8H12N2NaO2 (MNa
+
) 
Requires 191.0791 (0.1 ppm error), Found: 169.0977; C8H13N2O2 (MH
+
) Requires 169.0972 
(−3.3 ppm error). 
Lab notebook reference: akc01-93 + WPU 
Spectroscopic data matched those previously reported in the literature.
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4-(4-Methoxyphenyl)-1-(1H-pyrrol-2-yl)but-3-yn-2-one (231a) 
 
Synthesised using general procedure 2B with 4-ethynylanisole (919 mg, 6.96 mmol), THF 
(15 + 10 mL), Weinreb amide 278 (390 mg, 2.32 mmol) and n-BuLi (2.32 mL, 5.80 mmol, 
2.5M in hexanes). Purification by column chromatography (10:1 hexane:EtOAc, then 2:1 
hexane:EtOAc) afforded the title compound 231a as a pale yellow solid (314 mg, 57%); mp 
112–114 °C; vmax (cm
-1
) 3337, 2198, 1655, 1597, 1508, 1253, 1089, 1023, 839, 798, 739; δH 
(400 MHz, CDCl3) 3.85 (3H, s, H-14), 4.00 (2H, s, H-6), 6.12 (1H, br s, H-3/4) 6.19–6.21 
(1H, H-3/4), 6.80 (1H, H-2), 6.88–6.92 (2H, m, H-12), 7.48–7.52 (2H, m, H-11); δC (100 
MHz, CDCl3) 43.6 (CH2, C-6), 55.4 (CH3, C-14), 87.7 (C, C-8), 94.2 (C, C-9), 108.1 (CH, C-
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2/3/4), 108.6 (CH, C-2/3/4), 111.4 (C, C-10), 114.4 (2CH, C-11), 118.1 (CH, C-2/3/4), 123.0 
(C, C-5), 135.3 (2CH, C-12), 161.9 (C, C-13), 184.7 (C, C-7); HRMS (ESI
+
): Found: 
262.0835; C15H13NNaO2 (MNa
+
) Requires 262.0838 (1.9 ppm error), Found: 240.1022; 
C15H14NO2 (MH
+
) Requires 240.1019 (−1.9 ppm error). 
Lab notebook reference: WPU 
 
4-(4-Methoxyphenyl)-1-(1H-pyrrol-2-yl)but-3-yn-2-ol (279a) 
 
Synthesised using general procedure 2I with pyrrole-ynone 231a (76 mg, 0.318 mmol), 
NaBH4 (48 mg, 1.27 mmol) and MeOH (13 mL). Purification by column chromatography (7:3 
hexane:EtOAc) afforded the title compound 279a (70 mg, 91%) as a pale brown oil; vmax (cm
-
1
) 3380, 1605, 1508, 1290, 1245, 1172, 1027, 831, 716; δH (400 MHz, CDCl3) 2.65 (1H, br s, 
H-8), 3.09 (1H, dd, J = 15.5, 7.0 Hz, H-6a), 3.15 (1H, dd, J = 15.5, 5.5 Hz, H-6b), 3.83 (1H, s, 
H-15), 4.77 (1H, dd, J = 7.0, 5.5 Hz, H-7), 6.08–6.13 (1H, m, H-4), 6.17–6.22 (1H, m, H-3), 
6.73–6.76 (1H, m, H-2), 6.83–6.89 (2H, m, H-13), 7.35–7.42 (2H, m, H-12), 8.63 (1H, br s, 
H-1); δC (100 MHz, CDCl3) 36.1 (CH2, C-6), 55.2 (CH3, C-15), 62.7 (CH, C-7), 85.3 (C, C-
10), 88.1 (C, C-9), 107.4 (CH, C-4), 108.1 (CH, C-3), 113.9 (2CH, C-13), 114.2 (C, C-11), 
117.4 (CH, C-2), 127.3 (C, C-5), 133.1 (2CH, C-12), 159.7 (C, C-14); HRMS (ESI
+
): Found: 
264.0985; C15H15NNaO2 (MNa
+
) Requires 264.0995 (3.8 ppm error), Found: 242.1168; 
C15H16NO2 (MH
+
) Requires 242.1176 (3.2 ppm error). 
Lab notebook reference: MJJ3/74 
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9-(4-Methoxyphenyl)-1-azaspiro[4.4]nona-1,3,8-trien-7-one (280a) 
 
To a solution of ynone 231a (23.9 mg, 0.100 mmol) in CH2Cl2 (1 mL) was added AgNO3 (1.7 
mg, 10.0 µmol), the mixture was stirred for 1 h at RT. The crude material was then purified by 
column chromatography (EtOAc) to afford the title compound 280a as a pale brown oil (23.8 
mg, 99%); vmax (cm
-1
) 3337, 2198, 1655, 1597, 1508, 1253, 1089, 1023, 839, 798, 739; δH 
(400 MHz, CDCl3) 2.65 (1H, d, J = 18.0 Hz, H-5a), 2.72 (1H, d, J = 18.0 Hz, H-5a), 3.81 (3H, 
s, H-13), 6.55 (1H, s, H-7), 6.77–6.81 (3H, m, H-2/3,11), 7.05–7.09 (2H, m, H-10), 7.65 (1H, 
d, J = 5.0 Hz, H-2/3), 8.66 (1H, s, H-1); δC (100 MHz, CDCl3) 40.8 (CH2, C-5), 55.4 (CH3, C-
13), 89.0 (C, C-4), 114.5 (2CH, C-11), 124.4 (C, C-9), 128.4 (CH, C-2/3), 128.6 (2CH, C-10), 
130.3 (CH, C-7), 159.4 (CH, C-2/3), 162.4 (C, C-12), 168.9 (C, C-8), 172.3 (CH, C-1), 201.1 
(C, C-6); HRMS (ESI
+
): Found: 262.0841; C15H13NNaO2 (MNa
+
) Requires 262.0838 (0.9 
ppm error), Found: 240.1024; C15H14NO2 (MH
+
) Requires 240.1019 (−1.8 ppm error). 
Lab notebook reference: WPU 
 
4-(4-Methoxyphenyl)-1H-indole (281a) 
 
Synthesised using general procedure 2L with alcohol 279a (47 mg, 0.195 mmol), AgNO3 
(3.3 mg, 19.5 µmol) and CH2Cl2 (2 mL). Purification by column chromatography (8:2 
hexane:EtOAc) afforded the title compound 281a (36 mg, 83%) as a colourless oil; vmax (cm
-1
) 
3412, 1608, 1518, 1492, 1244, 1178, 1031, 836, 753; δH (400 MHz, CDCl3) 3.91 (3H, s, H-
14), 6.76 (1H, br s, H-2), 7.04–7.10 (2H, H-12), 7.21 (1H, d, J = 7.5 Hz, H-6), 7.25 (1H, dd, J 
= 3.0, 3.0 Hz, H-3), 7.30 (1H, dd, J = 8.0, 7.5 Hz, H-7), 7.38 (1H, d, J = 8.0 Hz, H-8), 7.66–
7.73 (2H, m, H-11), 8.23 (1H, br s, H-4); δC (100 MHz, CDCl3) 55.3 (CH3, C-14), 102.1 (CH, 
C-2), 109.7 (CH, C-8), 113.9 (2CH, C-12), 119.4 (CH, C-6), 122.3 (CH, C-7), 124.3 (CH, C-
Chapter 5. Experimental 
 
 
251 
3), 126.0 (C, C-1), 129.7 (2CH, C-11), 133.8 (C, C-5/9/10), 134.1 (C, C-5/9/10), 136.2 (C, C-
5/9/10), 158.7 (C, C-13); HRMS (ESI
+
): Found: 246.0881; C15H13NNaO (MNa
+
) Requires 
246.0889 (3.3 ppm error). 
Lab notebook reference: MJJ3/80 
Spectroscopic data matched those reported in the literature.
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1-(3,4-Dihydro-2H-pyrrol-5-yl)-4-phenylbut-3-yn-2-one (283a) 
 
Synthesised using general procedure 4A with DIPA (0.31 mL, 2.23 mmol), n-BuLi (0.89 
mL, 2.23 mmol, 2.5 M in hexanes), 2-methyl-1-pyrroline (0.10 mL, 1.06 mmol), methyl 
phenylpropiolate (0.16 mL, 1.11 mmol) and THF (15 mL). Purification by column 
chromatography (60:40 EtOAc in hexane) afforded the title compound 283a (172 mg, 76%, 
>99:1 enamine:imine) as a pale yellow solid, mp 98–100 °C; vmax (cm
-1
) 1593, 1532, 1507, 
1295, 1270, 1134, 759, 691; δH (400 MHz, CDCl3) 2.03 (2H, tt, J = 7.5, 7.0 Hz, H-3), 2.68 
(2H, t, J = 7.5 Hz, H-4), 3.65 (2H, t, J = 7.0 Hz, H-2), 5.44 (1H, s, H-6), 7.30–7.39 (3H, m, H-
12,13), 7.51-7.56 (2H, m, H-11), 10.03 (1H, br s, H-1); δC (100 MHz, CDCl3) 21.1 (CH2, C-
3), 32.5 (CH2, C-4), 48.0 (CH2, C-2), 85.6 (C, C-8), 89.9 (C, C-9), 93.5 (CH, C-6), 121.7 (C, 
C-10), 128.3 (2CH, C-12), 129.2 (CH, C-13), 132.4 (2CH, C-11), 169.2 (C, C-5), 172.5 (C, C-
7); HRMS (ESI
+
): Found: 212.1067; C14H14NO (MH
+
) Requires 212.1070 (−1.4 ppm error). 
Lab notebook reference: MJJ9/33 
 
5-Phenyl-2,3-dihydroindolizin-7(1H)-one (284a) 
 
Synthesised using general procedure 4B with pyrroline-ynone 283a (21 mg, 0.1 mmol), 
AgNO3 (0.33 mg, 2.0 μmol) in DCE (0.5 mL) and EtOH (0.5 mL) at 80 °C for 3 h. 
Purification by column chromatography (20 → 30% MeOH in EtOAc) afforded the title 
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compound 284a (21 mg, 100%) as a white solid, mp 97–99 °C; vmax (cm
-1
) 1629, 1536; δH 
(400 MHz, CDCl3) 2.17 (2H, tt, J = 7.5, 7.0 Hz, H-3), 3.07 (2H, td, J = 7.5, 1.0 Hz, H-4), 3.89 
(2H, t, J = 7.0 Hz, H-2), 6.31 (1H, d, J = 3.0 Hz, H-8), 6.34–6.36 (1H, m, H-6), 7.35–7.40 
(2H, ArH), 7.44–7.48 (3H, ArH); δC (100 MHz, CDCl3) 22. 2 (CH2, C-3), 31.0 (CH2, C-4), 
52.7 (CH2, C-2), 112.5 (CH, C-8), 118.2 (CH, C-6), 128.1 (2CH, C-11/12), 128.8 (2CH, C-
11/12), 129.6 (CH, C-13), 134.3 (C, C-10), 149.0 (C, C-5/9), 153.6 (C, C-5/9), 179.8 (C, C-7); 
HRMS (ESI
+
): Found: 212.1074; C14H14NO (MH
+
) Requires 212.1070 (1.8 ppm error). 
Lab notebook reference: MJJ9/34 
Appendices 
 
 
253 
Appendices 
Appendix I. Synthesis of Spirocyclic Indolenines 
Appendices 
 
 
254 
Appendices 
 
 
255 
Appendices 
 
 
256 
Appendices 
 
 
257 
Appendices 
 
 
258 
Appendices 
 
 
259 
Appendices 
 
 
260 
Appendices 
 
 
261 
Appendices 
 
 
262 
Appendices 
 
 
263 
Appendices 
 
 
264 
Appendices 
 
 
265 
Appendices 
 
 
266 
Appendices 
 
 
267 
Appendices 
 
 
268 
Appendices 
 
 
269 
Appendices 
 
 
270 
Appendices 
 
 
271 
Appendices 
 
 
272 
Appendices 
 
 
273 
Appendices 
 
 
274 
Appendices 
 
 
275 
Appendices 
 
 
276 
Appendices 
 
 
277 
Appendices 
 
 
278 
 
  
Appendices 
 
 
279 
Appendix II. Silver(I)- or Copper(II)-Mediated Dearomatization of 
Aromatic Ynones: 
Appendices 
 
 
280 
Appendices 
 
 
281 
Appendices 
 
 
282 
 
  
Appendices 
 
 
283 
Appendix III. Silver(I)-Catalyzed Dearomatization of Alkyne-Tethered 
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Appendix IV. Silica-Supported Silver Nitrate as a Highly Active 
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Abbreviations 
Ac acetyl 
acac acetylacetone 
Ad adamantyl 
AIBN azobisisobutyronitrile 
APCI atmospheric pressure chemical ionisation 
aq aqueous 
BINOL 1,1'-bi-2-naphthol 
Bn benzyl 
Boc tert-butyloxycarbonyl 
BOX bisoxazoline 
br broad 
Bu butyl 
CADA catalytic asymmetric dearomatisation 
CCDC Cambridge crystallographic data centre 
CDI 1,1'-carbonyldiimidazole 
COD cyclooctadiene 
COSY correlation spectroscopy 
CPA chiral phosphoric acid 
CSA camphorsulfonic acid 
CSP chiral stationary phase 
d doublet 
dba dibenzylideneacetone 
DBU 1,8-diazabicyclo(5.4.0)undec-7-ene 
DCE 1,2-dichloroethane 
DEAD diethyl azodicarboxylate 
DEPT distortionless enhancement by polarisation transfer 
Abbreviations 
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DIPEA N,N-diisopropylethylamine 
DMAP 4-dimethylaminopyridine 
DMDO dimethyldioxirane 
DME dimethoxyethane 
DMF dimethylformamide 
DMP Dess–Martin periodinane 
DMSO dimethylsulfoxide 
dppp 1,3-bis(diphenylphosphino)propane 
DTBM-
SEGPHOS 
5,5′-bis[di(3,5-di-tert-butyl-4-methoxyphenyl)phosphino]-4,4′-bi-1,3-
benzodioxole 
EDG electron donating group 
ee enantiomeric excess 
ESI electrospray ionisation 
esp α,α,α′,α′-tetramethyl-1,3-benzenedipropionic acid 
Et ethyl 
EWG electron withdrawing group 
h hour(s) 
H8-BINOL 5,5′,6,6′,7,7′,8,8′-Octahydro-1,1′-2-naphthol 
HMBC heteronuclear multiple bond correlation 
HSQC heteronuclear single quantum coherence 
IBX 2-iodoxybenzoic acid 
Im imidazole 
IPr 1,3-bis(2,6-diisopropylphenyl)-1,3-dihydro-2H-imidazol-2-ylidene 
LA Lewis acid 
LDA lithium diisopropylamide 
LHMDS lithium bis(trimethylsilyl)amide 
m multiplet 
m-CPBA meta-Chloroperoxybenzoic acid 
Abbreviations 
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Me methyl 
MOM methoxymethyl ether 
Ms mesyl 
NBS N-bromosuccinimide 
NMO N-methylmorpholine N-oxide 
NMR nuclear magnetic resonance 
nOe nuclear Overhauser effect 
oct octanoate 
p-ABSA 4-acetamidobenzenesulfonyl azide 
Ph phenyl 
PMP para-methoxyphenyl 
PPA polyphosphoric acid 
PPTS pyridinium p-toluenesulfonate 
Pr propyl 
p-TSA para-toluenesulfonic acid 
Raney-Ni Raney nickel 
RT room temperature 
s singlet 
SPINOL 1,1′-spirobiindane-7,7′-diol 
t triplet 
T3P propylphosphonic anhydride 
TBAF tetrabutylammonium fluoride 
TBME methyl tert-butyl ether 
TBS tert-butyldimethylsilyl 
TES triethylsilyl 
Tf triflyl 
TFA trifluoroacetic acid 
Abbreviations 
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THF tetrahydrofuran 
TLC thin-layer chromatography 
TMS trimethylsilyl 
TPA triphenylacetate 
Ts tosyl 
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